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Abstract 
Children with the congenital heart defect TOF require surgical repair. Their 
myocardium is exposed to chronic hypoxia due to insufficiently oxygenated blood shunted 
from the right to the left side of the heart through the VSD, resulting in cyanosis. Such 
corrective surgery often requires the use of CPB. During these procedures the aortic clamp is 
applied to allow access to the heart for the surgical correction creating an ischemic 
environment. When the clamp is removed and blood flow returned, the heart is reperfused. 
This exposes the myocardium to IR injury. Super-high oxygen (O2) levels are often used in the 
bypass circuit after the cross-clamp is released. This means during reperfusion the 
myocardium is exposed to high levels of O2. This is thought to be harmful, especially to 
children with cyanosis pre-operatively. 
 
A growing body of evidence suggests that these high levels of O2 may be damaging to 
the infant myocardium but the mechanisms are not that well understood. The first aim of this 
project was to investigate the molecular changes that occur within the infant myocardium in 
the context of congenital heart disease by comparing myocardium from the cyanotic patient 
group (TOF patients) and acyanotic patient group (patients with sub-aortic stenosis or truncus 
arteriosus i.e. disorders requiring myocardial resection but where the myocardium is 
acyanotic) during the ischemic phase. This was performed to reflect as near to pre-operative 
gene expression levels as possible. This thesis focused on the expression of inflammatory 
mediators (TLRs) and stress proteins (HSPs). It was found that TLR4 (p=0.0303), TLR2 
(p=0.0177) and HSP27 (0.0303) mRNA expression were significantly higher in the 
myocardium from the cyanotic patient group compared to the acyanotic patient group. This 
could indicate a consequence of the hypoxic environment within such myocardium. 
 
HSPs are stress proteins, which are induced upon cellular stress. The Aplein receptor 
(APJ) is upregulated in the heart during ischemia and IR injury and thought to be cardio-
protective. Additional work was performed that investigated the protein expression of HSP27 
and APJ during the ischemic phase in cyanotic and non-cyanotic TOF myocardium. This 
expression was compared with various measurements of cardiac function. HSP27 protein 
expression was significantly elevated in cyanotic myocardium pre-operatively. It was also 
associated with improved right ventricle function and systemic perfusion. This supports a 
cardio-protective effect of HSP27 in cyanotic TOF. APJ was found to be associated with 
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improved systemic perfusion when both cyanotic and non-cyanotic patient data were 
combined. 
 
In order to determine if stress genes (HSPs) were inducible in the infant myocardium, 
they were exposed to classic heavy metal inducers sodium arsenite and cadmium chloride. Of 
the six HSPs investigated, all were shown to be present within the ischemic myocardium. 
Myocardial HSP32 (p=0.0156), HSP72 (p=0.0156) and HSP90 (p=0.0156) mRNA expression 
were significantly increased by exposure to heavy metals. Therefore, HSPs were shown to be 
inducible in infant myocardium. This was a good experimental control for the re-oxygenation 
experiment. 
 
The expressions of the same genes were also examined in vitro during an attempt to 
mimic re-oxygenation of the ischemic myocardium when the aortic-clamp is removed. Tissue 
was removed during the ischemic phase from both cyanotic and acyanotic patients and 
exposed to differential O2 levels. It was found exposure to 20% and 60% O2 for 4 hours 
induced mRNA expression of HSP32 (p=0.0391 and p=0.0078 respectively) and HSP72 
(p=0.0078 and p=0.0078 respectively). This could indicate cellular stress during re-
oxygenation of infant myocardium during surgical correction. No difference was indicated 
between the cyanotic and acyanotic patient group.  
 
The work of this thesis was focused on myocardial mRNA/ protein expression. 
Whether there is an alteration in circulating inflammatory mediators was not the focus of the 
present study but the results within this thesis highlighted the need for future studies to look at 
the effect of circulating factors on myocardial inflammation.  
 
This project is novel because it allowed a better understanding of the molecular 
mechanisms at work within infant myocardium and how they are influenced by re-
oxygenation injury. It also examined how they are affected by cyanosis. It has highlighted the 
best ways in which such investigations could be extended. It has contributed important 
molecular data to the area of research and could potentially help lead to an improvement in 
myocardial protection during cardiac surgery with CPB. 
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Abbreviations and Definitions 
 
ATF6 – activation of transcription factor 6 
AT1 – angiotensin receptor 
ADP – adenosine diphosphate 
Apoptosis – programmed cell death where biological signals within the cell deliberately cause 
cell death. 
APC – antigen presenting cells  
APJ – Apelin receptor 
APS – ammonium persulfate 
ASD – atrial septal defect 
ATP – adenosine triphosphate 
AVP – vasopressin 
BiP – binding immunoglobulin protein  
Bp – base pair 
BSA – bovine serum albumin 
Ca2+ – calcium    
CABG – coronary artery bypass grafting  
CdCl2 – cadmium chloride 
cDNA – complementary DNA 
CO2 – carbon dioxide 
CK – creatine kinase 
CPB – cardio-pulmonary bypass  
Chimeric – an organism that is made up of one or more different cells that are genetically 
distinct 
DAMP – danger-associated molecular patterns 
dH2O – distilled water 
DNA – deoxyribonucleic acid 
dNTPs – deoxynucleotide triphosphates 
Epicardium - outer protective layer of heart  
EGR-1 – early growth response protein 
Em – resting membrane potential 
ER – endoplasmic reticulum. 
EOR – ER overload response 
Eritoran – TLR4 antagonist that blocks activation of this receptor 
FV – Fallot variant 
GRP - glucose regulated proteins 
Heat shock – heat stress that can induce HSP expression 
Heterodimer – a protein made up of two different subunits  
HIF-1 – hypoxia-inducible factor 
Housekeeping genes – genes required for homeostasis of basic cell function 
H - hydrogen 
HO – heme-oxygenase 
HMGB – high mobility group box 
HSP –heat shock proteins 
Hyperkalemic solutions – solution with high potassium content 
iNOS – inducible nitric oxide synthase 
gDNA – genomic DNA 
GRP78 – 78 kDa glucose-regulated protein  
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GRP94 – 94 kDa glucose-regulated protein 
IL – Interleukin  
ICAM-1 – intercellular adhesion molecules  
IFN-β – interferon -β 
IRF3 – Interferon regulatory factor 3 
IR injury – Ischemic-reperfusion injury 
IVC – inferior vena cava 
K – potassium 
LA – left Atrium 
Ligand – molecular that binds to a specific receptor to initiate its downstream signalling 
LPS – lipopolysaccharides 
LV – left ventricle 
MAL – MYD88 adaptor-like protein 
MHC – major histo-compatibility complex  
MI – myocardial infarction 
MCP-1 – monocyte chemotactic protein-1  
mRNA – messenger RNA  
MYD88 – myeloid differentiation factor-88  
Myectomy – excision of a muscle 
Myocardial hibernation – prolonged inactive contractile function of the heart that can be 
reversed 
Myocardial stunning - contractile function stops briefly 
N2 – nitrogen  
NaOH – sodium hydroxide 
Na – sodium 
NaAsO2 – sodium arsenite 
Necrosis – premature death of a healthy living cell caused by external factors such as 
infection, toxins or trauma. In contrast to apoptosis (see above) 
NFkB – nuclear factor kappa B 
NKC – natural killer cell 
NO – nitric oxide 
O2 – oxygen 
Oxidative phosphorylation – process that produces ATP (energy) within the mitochondria  
PAMPs – pathogen associated molecular patterns  
PCR – polymerase chain reaction 
PaO2 – arterial oxygen tension 
POD1 – post-operative day one 
PRR – pattern recognition receptors 
PS – pulmonary stenosis 
qPCR – quantitative polymerase chain reaction 
rho – spearman rank correlation 
RLT buffer – buffer provided with RNeasy Fibrous Tissue Midi Kit (Qiagen cat. no. 75742) 
RNA – ribonucleic acid 
RT – reverse transcription 
RW1 buffer – buffer provided with RNeasy Fibrous Tissue Midi Kit (Qiagen cat. no. 75742) 
ROD – relative optical density 
ROS – reactive oxygen species 
RA – right atrium 
RQ – relative quantification 
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RV – right ventricle 
RVOT – axis RV outflow tract  
SaO2 – systemic arterial oxygen saturation 
SARM – sterile α- and armadillo-motif-containing protein 
SAS – sub-aortic stenosis 
sGC – soluble guanylate cyclase 
SIRS – systemic inflammatory response syndrome 
SDS - sodium dodecyl sulfate 
SNPs – single-nucleotide polymorphisms 
STD – stock standard 
SVC – superior vena cava 
SvO2 – mixed venous oxygen saturation  
TA – truncus arteriosus  
TEMED - Tetramethylethylenediamine 
TGF-β – transforming growth factor beta  
TIR – Toll/IL-1R/Resistance motif 
TLR – Toll Like receptors 
Tm – melting temperature of the primers 
TNF-α – tumor necrosis factor-alpha  
TOF – Tetralogy of Fallot 
TRAM – TRIF-related adaptor molecule 
TRIF – TIR domain-containing adaptor-inducing IFN-β 
VCAM-1 – vascular cell adhesion molecule-1 
VSD – ventricular septal defect 
UPR – unfolded protein response. 
Ubiquinone – part of the electron transport chain and is involved in aerobic respiration. 
Ubisemiquinone – an electron donor during oxidative phosphorylation. 
UV light – ultra-violet light 
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CHAPTER 1 – INTRODUCTION  
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1.1 The Heart 
1.1.1 Anatomy 
The heart is the main functioning part of the body’s circulatory system and is 
responsible for taking deoxygenated blood from the systemic circulation, where it is re-
oxygenated when it passes through the pulmonary circulation (lungs), and then transporting 
re-oxygenated blood back into the systemic circulation. Blood is transported throughout the 
body through various types of blood vessels, which include arteries and capillaries. This 
ensures that all the major organs of the body are provided with an adequate supply of 
oxygenated blood. Veins return the blood to the heart. The heart is positioned in the thorax, 
between the lungs and lies more to the left side of the body. 
 
The heart consists of three layers of tissue the first of which is the outer layer called the 
epicardium, which consists of mainly connective tissue acting as a protective barrier. The 
second layer is the myocardium that makes up the muscular middle layer of the heart i.e. the 
cardiac muscle. The third layer is called the endocardium and is a thin, smooth continuous 
membrane lining the interior of the chambers of the heart and is the equivalent to the 
endothelium that lines blood vessels. The space within the endocardium is known as the 
ventricular cavity and is where the blood flows. Enclosing the heart (and its 3 layer) is a 
membrane known as the pericardium. This membrane is made up of two layers, an inner 
double layer of serous membrane and an outer fibrous layer. The space between the 
pericardium and the epicardium is known as the pericardial cavity.  
 
The heart’s interior (which is shown in figure 1-1) is separated into the left and right 
side of the heart by the septum (A). Each side of the heart is further divided by the valves of 
the heart, resulting in four chambers. These are the left (B) and right (C) atria and the left (D) 
and right (E) ventricles. The valve that separates the right atrium (RA) and right ventricle 
(RV) is the tricuspid valve (F) and consists of 3 leaflets. The valve that separates the left 
atrium (LA) and left ventricle (LV) is the mitral valve (G) and consists of 2 leaflets. Changing 
pressure in the chambers of the heart results in the opening and closing of the valves. When 
the pressure in the ventricles increases to a higher level than in the atria, the valves close thus 
preventing backflow of blood and ensuring the flow is one way through the heart. The closure 
of the valves is supported by the chordae tendineae, which are muscular cords connected to the 
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valves and which continue down into muscle projections that line the interior wall of the 
ventricles and that are covered by endothelium. 
 
The flow of blood into the heart begins with de-oxygenated blood flowing into the RA 
from the superior and inferior venae cavae (H). The blood then travels from the RA through 
the tricuspid valve into the RV and then exits the heart entering the pulmonary circulation. 
This occurs via the pulmonary artery (I) (which contains the pulmonic valve (J)), which splits 
into the left and right pulmonary arteries. The pulmonary arteries carry blood to the lungs to 
be re-oxygenated. Re-oxygenated blood then re-enters the heart via the pulmonary veins (K), 
of which there are four, into the LA. Blood then goes through the mitral valve to the LV, 
where it exits the heart via the aorta (L) (which contains the aortic value (M)) which returns 
the oxygenated blood back to the systemic circulation.  
 
The blood supply of the heart itself is provided by the coronary arteries, which branch 
off from the aorta as blood initially leaves the heart. The pressure at which blood flows within 
the LV is higher than in the RV because the systemic circulation has a higher resistance than 
the pulmonary circulation.  
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Figure 1-1. The internal structure of the heart 
 
Figure shows the internal anatomy of the heart, including all the major chambers, blood 
vessels and valves (Modified from Chung and Rich, 1990). 
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1.1.2 Energy metabolism of the heart 
The main function of the heart is to pump oxygenated blood from the heart to the rest 
of the body and this requires a lot of energy. The majority of energy utilised by the heart is 
provided by adenosine triphosphate (ATP) produced in the mitochondria by oxidative 
phosphorylation making cardiac cell function highly dependent on oxygen (O2) availability 
(Ferrari, 1996).  The importance of this is highlighted by the fact there is such a high number 
of mitochondria within cardiac tissue compared to other tissue types (Page, 1973).  Also, the 
amount of energy used within the heart is tightly regulated therefore any interruption in blood 
supply would be highly detrimental (Grynberg et al., 1996). 
 
1.1.3 Tetralogy of Fallot 
Tetralogy of Fallot (TOF) is a congenital heart condition with an incidence of 1/3600 
births and this makes up about 3.5% of babies born with cardiac abnormalities (Shinebourne et 
al., 2006). This condition was first recognised as early as 1671, but like the majority of other 
congenital cardiac abnormalities the aetiology is not yet defined (Apitz et al., 2009). This 
condition requires surgical repair and such surgical procedures require the use of cardio-
pulmonary bypass (CPB). 
 
TOF is characterised by four separate defects. These are: (1) pulmonary stenosis (PS) 
that causes restricted blood flow to the lungs and results in inadequate oxygenation of the 
blood; (2) a ventricular septal defect (VSD) where there is a hole in the septum separating both 
ventricles of the heart; (3) an over-riding aorta which is positioned just above the VSD; (4) a 
thickened right ventricle (hypertrophy) caused by the high pressure caused by the pulmonary 
stenosis (reviewed in Bailliard and Anderson, 2009).  
 
Usually, the pressure within the LV is higher than within the RV. In the case of TOF, 
the pressure is actually equal in both the LV and RV. This is because the presence of the VSD 
causes the pressure within the two ventricles to equalise. Without the PS, this would make the 
volume of blood entering the pulmonary circulation too high causing pulmonary 
overcirculation and ultimately lead to heart failure. Thus the presence of the PS with the VSD 
helps maintains TOF patients until surgical repair can be performed.  
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Another consequence of the PS and VSD is that deoxygenated blood entering the heart 
is shunted from the RV to the LV through the VSD back into the systemic circulation. This 
recirculation of blood that has been poorly oxygenated results in an overall lower O2 blood 
saturation level (~70-80%) with a typical arterial O2 tension (PaO2) of 40mmHg (normally 
would be 75-100mmHg). This means that the heart is chronically exposed to low levels of O2, 
resulting in cyanotic damage (Apitz et al., 2009). This patient group is the primary source of 
cyanotic tissue used for experiments within this project. 
1.1.4 Sub-aortic stenosis (control) 
Sub-aortic stenosis (SAS) is a congenital heart defect that requires corrective heart 
surgery involving CPB. This condition is characterized by the presence of a fibrous ring in the 
left ventricular outflow tract located beneath the aortic valve (Gersony, 2001). The prevalence 
of this condition is 0.25 for every 1000 live births (Grech, 2001). This condition is not always 
apparent at birth and can also occur in conjunction or as a consequence of other congenital 
cardiac defects, for example, with a VSD (Gersony, 2001; Somerville et al., 1980).  
 
When investigating the effect cyanosis on the myocardium and the consequences of 
ischemic-reperfusion (IR) injury, this is a good control group for the TOF patient group. This 
is because these patients experience no cyanotic damage but still require corrective cardiac 
surgery with CPB. 
 
1.2 Cardiac surgery 
There are a high number of cardiovascular pathological conditions involving both 
children and adults that can occur and require surgical intervention. The extent of the surgical 
procedure will vary depending on the nature of the defect. For example, in this study we have 
a specific interest in the surgical correction of congenital heart defects such as TOF and SAS, 
both of which require open-heart surgery with the use of a CPB machine (Starr and 
Hovaguimian, 1994; Carrascal Hinojal et al., 2006; Hraska et al., 2007; reviewed in Bailliard 
and Anderson, 2009). 
1.2.1 Cardio-pulmonary Bypass (CPB) 
The time period between the initial proposition and the final development of the CPB 
machine, where the circulating blood of the body could be diverted, properly oxygenated and 
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anti-coagulated, occurred over several decades. Its concept would not have been possible if 
not for the discovery of heparin, an anti-coagulant, which was necessary due to the fact that 
blood clotted when it came into contact with non-endothelial type surfaces (reviewed in 
Stammers, 1997). The first successful cardiac surgical procedure that used a CPB machine 
was one in 1953 where an atrial septal defect (ASD) was repaired in an 18-year patient 
(Gibbon, 1954). This itself was not followed by consistent success and the process underwent 
many advances in last 10-20 years. Open-heart surgery is now thought of as a relatively 
routine procedure (reviewed in Stammers, 1997). 
 
The function of the CPB unit (which is highlighted in figure 1-2) is to temporarily 
replace and perform the basic functions of the heart and lungs i.e. to pump blood throughout 
the systemic circulation and to regulate both the levels of O2 and carbon dioxide (CO2) present 
within the bloodflow. It achieves this by diverting blood flow from the heart into the CPB unit 
(A), where gas exchange (B) occurs and energy of bloodflow (C) is provided via the pumps, 
then bloodflow returns to the arterial circulation (D). The coronary circulation within the heart 
is prevented and returned by the use of the cross-clamp (E) (reviewed in Paparella et al., 
2002). To better describe the different stages of CPB and the effect it has on the heart, the 
different phases of the process are shown in table 1. The use of cardioplegia and the cross 
clamp, which is used to artificially arrest the heart during bypass, is described in the next 
section.  
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Figure 1-2.  Cardio-pulmonary bypass unit 
 
Figure shows the CPB circuit. (SVC – superior vena cava, IVC – inferior vena cava) 
(Modified from Dunbar et al., 2001) (A – systemic blood flow diverted from the heart into the 
CPB unit, B – gas exchange, C – movement of bloodflow via pumps, D – bloodflow returns to 
the arterial circulation, E – application of aortic clamp to stop coronary circulation). 
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During the use of CPB (see table 1), the heart and the systemic tissues of patients are 
exposed to a high level of O2 primarily due to the re-oxygenation (B) of the blood within the 
extracorporeal unit of the CPB machine before it returns to the body. The level of O2 used 
during both paediatric and adult cardiac surgery with CPB will often involve hyperoxic levels 
(Ihnken et al., 1998; reviewed in Allen et al., 2001). The systemic tissues are exposed to the 
highly oxygenated blood throughout the entire surgical procedure (on bypass) and the heart is 
exposed to this hyper-oxygenated blood before and after the application of the cross-clamp. 
 
1.2.2 Protection of the myocardium from CPB 
 During repair of intra-cardiac defects (see figure 1-3 for an overview of the timeline of 
cardiac surgical repair with CPB) it is necessary to stop heart contraction. This is achieved by 
interrupting the myocardial blood flow (application of the cross-clamp) and infusing the heart 
with a myocardial paralysing solution (cardioplegia). This is done to prevent heart contraction 
in order reduce energy consumption and help prevent the exhaustion of metabolites. This is 
the mainstay of myocardial protection during cardiac surgery with CPB. Such protection is 
especially important for children with congenital heart defects such as TOF (see section 1.1.3) 
as they are thought to have more vulnerable myocardium (Merante et al., 1998; Najm et al., 
2000; Corno et al., 2002).  
 
1.2.2.1 Cardioplegia 
 Cardioplegia in its most basic form is a solution containing high potassium (K) content 
(20µMol/l) and the most common type is known as St. Thomas' Hospital cardioplegic 
solutions. These hyperkalemic (high K content) solutions result in depolarised cardiac arrest 
where the increased levels of K cause a change in the resting membrane potential (Em) across 
the plasma membrane of the myocytes that will ultimately reach a point where mechanical 
contraction is terminated in diastole (reviewed in Chambers, 2003). It should be noted that the 
level at which K is elevated to should be tightly monitored because if such levels were to 
increase exponentially, the end result would be calcium (Ca2+) overload causing potentially 
irreversible consequences (reviewed in Chambers, 2003). There are various types of 
cardioplegia, where it can be either crystalloid or blood based and where adenosine, instead of 
K, can be used as the paralysing agent. In whichever formulation, in the current era, 
essentially all paediatric cardiac surgery is conducting using cardioplegia.  
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As already stated, cardioplegia solution can be either crystalloid or blood based and 
over the years it had been found that blood-based cardioplegia has become the preferred type 
of transporter of hyperkalemic solution. Blood based cardioplegic solution was first suggested 
in 1979 as an alternative to crystalloid based hyperkalemic solution and there have been 
several studies to suggest it can provide better protection to the heart in comparison to 
crystalloid solutions but there is also data that shows there is no major clinical benefit of one 
over the other (Buckberg, 1979; Robinson et al., 1995; Mezzetti et al., 1995; Bolling et al., 
1997; Young et al., 1997; Feindel et al., 1984; Ferreira et al., 2003; Guru et al., 2006; Jacob et 
al., 2008). In relation to paediatric surgery specifically, there is some of evidence that blood 
cardioplegia provides better myocardial protection compared with crystalloid cardioplegia but 
overall the literature findings are inconclusive (Caputo et al., 2002; Amark et al., 2005).  
 
The type of cardioplegic hyperkalemic solution described so far is extracellular but 
there is an alternative intracellular solution known as cardioplegic solution HTK. It also causes 
depolarised arrest but does not cause it to the same degree and therefore could be a better 
alternative (Bretschneider, 1980; Krohn et al., 1989; reviewed in Fallouh et al., 2008).  
 
Despite the St. Thomas' Hospital cardioplegic solutions being the most widely used, 
they may not provide the most optimal method of myocardial protection during cardiac 
surgery with CPB, with them causing potential complications of their own (reviewed in 
Chambers and Fallouh, 2010). In fact, there was a study performed with infant hypertrophied 
rat hearts and it was shown that St. Thomas' Hospital cardioplegic solution provided no 
enhanced protection against ischemic exposure (Karck et al., 1996). Alternatives to St. 
Thomas' Hospital cardioplegic solution include the use of polarised cardiac arrest instead, 
where the Em across the membrane is kept closer to normal levels i.e. the resting potential. 
This can be done by various methods, including the use of sodium (Na) channel blockers and 
K channel openers (Snabaitis et al., 1997; Cohen et al., 1993; reviewed in Chambers, 2003; 
Dobson and Jones, 2004; reviewed in Fallouh and Chambers, 2008).  
 
1.2.2.2 Temperature of cardioplegic delivery to the heart 
Another consideration is the temperature at which the cardioplegic solution is 
delivered to the heart during cardiac surgery requiring CPB. Mild (32-34°C) and moderate 
(25°C) hypothermia is used fairly regularly in clinical practice (Belway et al., 2011; Stocker et 
 
 
31 
al., 2011). Deep hypothermia (<20°C) was used very early on during the first attempts at 
cardiac surgery. The heart and lungs can be protected at this temperature for about 15-20 
minutes. Such procedures were used to repair very basic cardiac defects, such as ASDs, which 
lasted only a few minutes but carried significant risk. Therefore, the use of such procedures 
was quickly discontinued. 
 
For both children and adults, there has been either slight or no difference found in post-
operative outcome between the use of mild and moderate hypothermia during cardiac surgery 
with CPB (Nathan et al., 2007; Eggum et al., 2008; Stocker et al., 2011; Ali Aydemir et al., 
2012; Leshnower et al., 2012). Despite the routine use of mild or moderate hypothermia, some 
evidence suggests that normothermic (37°C) cardiac surgery is as clinically beneficial 
(Durandy and Hulin, 2006; Durandy and Hulin, 2007; Poncelet et al., 2011; reviewed in 
Durandy et al., 2008). An interesting study was performed where several different methods of 
cardioplegia delivery were undertaken during surgical repair of congenital cardiac defects 
such as TOF. It was found that cold blood cardioplegia with hot shot (warm blood 
cardioplegia) was beneficial for cyanotic patients while for acyanotic paediatric patients it was 
found not to matter (Modi et al., 2004). These findings were confirmed by a later study by the 
same research group (Modi et al., 2006). This suggests that temperature is more of an issue for 
cyanotic patients over acyanotic patients, highlighting how much more vulnerable these 
patients could be to potential myocardial damage caused during heart surgery with CPB. 
 
There are 2 main reasons that hypothermia is used during CPB. The first is that the 
lower temperature is thought to lower the body’s metabolic rate and therefore reduce potential 
damage done by IR injury during cardiac surgery. In essence it is augmenting the protection 
given by cardioplegia, which artificially arrests the heart in order to help preserve metabolites 
within the heart needed for basic myocyte function. The second reason is the situation where 
bypass has to be temporarily delayed or stopped due to a complication; the lower temperature 
will provide some protection for the body, especially the brain, from the consequential low 
flow of blood.  
 
1.2.2.3 Oxygen tension used during CPB 
When on bypass, patients are often exposed to high levels of O2 (see table 1). This 
primarily occurs when the blood passing through the CPB machine, which is oxygenated to a 
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high O2 tension, is returned to the systemic circulation (Ihnken et al., 1998; reviewed in Allen 
et al., 2001). This ensures that all distal organs of the body, especially the brain, are properly 
protected during surgery by being adequately perfused. There are however some concerns 
about the use of such high levels of O2 in such a clinical setting (see section 1.3). 
 
1.2.2.4 Alternatives to surgery with CPB 
The combination of using CPB and cardioplegic arrest during cardiac surgery and all 
that is involved can contribute to post-operative myocardial dysfunction and low cardiac 
output state. This can be caused by a wide range of factors that are described in more detail 
elsewhere (see section 1.3) (Kirklin et al., 1983; Menasche, 1995; reviewed in Kozik and 
Tweddell, 2006).  
 
Alternatives to using cardiac surgery with CPB have been explored, such as the use of 
a minimal extracorporeal circulation system, which has been shown to reduce inflammation 
compared to use of more conventional CPB (Fromes et al., 2002). It has also been suggested 
that using ‘off pump’ surgery might be a viable option as it has been shown that there is less 
inflammation, oxidative stress and other post-operative damage than when compared with 
surgery using CPB (Brasil et al., 1998; Strüber et al., 1999; Matata et al., 2000). It should be 
noted that such a procedure would not be possible for the surgical repair of congenital cardiac 
defects. 
 
1.2.2.5 Conclusion 
Overall, the resulting gold standard of myocardial protection during open-heart surgery 
with CPB and the resultant ischemic period includes a combination of localised hypothermia 
and temporary paralysis of myocardial contraction by means of cardioplegia (crystalloid or 
blood), which will ensure the preservation of cardiac ATP reserves and help keep cardiac 
function normal post-operatively. This would not be possible without such measures, as the 
prolonged ischemia would cause severe myocardial damage (Bretschneider et al., 1975; 
reviewed in Reimer et al., 1983). Other important considerations are an adequate perfusion 
technique when the CPB is undertaken that often involves using hyperoxic levels of O2 
throughout surgery. Also, a good standard of surgical technique and proficiency in 
administration of anaesthetic drugs during the surgical procedure are important (reviewed in 
Durandy, 2008). Although such methods are adequate and widely used, alternative, better 
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methods of myocardial protection will always be beneficial as they would improve the success 
of surgery and enhance overall post-operative patient outcome. The question is: can 
investigating the molecular mechanisms involved in IR injury during paediatric cardiac 
surgery allow an improvement in current methods of myocardial protection? 
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1.2.3 Surgical correction of TOF 
One of the patient groups of interest in this study are patients suffering from the 
paediatric heart condition known as TOF (see section 1.1.3). Repair of this condition always 
involves open-heart surgery with CPB (reviewed in Kunes et al., 2007). The method of 
treatment depends on the severity of the defect. If the O2 blood saturation level is below 70% 
when the baby is born, palliation (to reduce severity of symptoms) i.e. a shunt procedure is 
performed. Then total repair of the defect is performed as a secondary procedure when the 
baby is about 3-6 months. If the baby’s blood saturation level is about or above 70% when 
born, then total repair is done as a primary procedure but not until the baby is 3-6 months.  
 
The shunt procedure involves using a piece of synthetic material to divert blood 
leaving the heart back to the lungs. This provides an adequate flow of blood to the pulmonary 
circulation allowing sufficient re-oxygenation of enough blood that will alleviate the 
symptoms of TOF. Total cardiac surgical repair of TOF requires CPB and aortic-clamping. In 
this surgical procedure the VSD is closed by the use of a patch and the PS is widened when 
the obstruction is severe enough (reviewed in Bailliard and Anderson, 2009).  
 
1.2.4 Surgical correction of sub-aortic stenosis (SAS) 
Surgical correction of this condition (see section 1.1.4) requires cardiac surgery with 
CPB. The fibrous tissue causing the obstruction is removed once identified, with care being 
taken not to damage the aortic valve. In addition, a myectomy (excision of muscle) is often 
performed in order to make the ventricular outflow track larger and in order to help reduce the 
likely hood of the SAS from returning, which would require additional repair (Starr and 
Hovaguimian, 1994; Carrascal Hinojal et al., 2006; Hraska et al., 2007). 
 
1.3 Consequences of open-heart surgery 
Many congenital cardiac defects, including TOF and SAS (both previously defined in 
sections 1.1.3 and 1.1.4 respectively), require surgical correction. Such procedures usually 
involve aortic-clamping and the use of CPB (see section 1.2.1). Due to its invasive nature and 
the inevitable ischemic changes that occur, open-heart surgery will result in various forms of 
insult, which are described in more detail in the present section. The 3 different sources of 
such damage include direct physical trauma, myocardial IR injury and systemic inflammation 
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caused by CPB. Such damage needs to be minimized in order to help protect the myocardium 
and promote post-operative survival of patients undergoing such procedures. Current 
protective methods have already been described (see section 1.2.2).  
 
1.3.1 Direct physical trauma 
The first type of insult is the physical damage caused by the surgery itself and its 
associated inflammation (Gu et al., 1999; Tárnok et al., 1999;	  Prondzinsky et al., 2005). Such 
damage will result from tissue being cut, stitched or retracted during surgery. This damage 
will universally affect a number of different cell types within the heart, including 
cardiomyocytes, endothelial cells, vascular smooth muscle cells and connective tissue cells. It 
will often result in necrotic cell death where the cellular damage is beyond repair and can 
result in an inflammatory response (reviewed in de Jong et al., 2009). 
 
1.3.2 Global myocardial IR injury 
Global myocardial IR damage is caused by the application and subsequent release of 
the aortic-clamp and will cause an associated inflammatory response (Zahler et al., 1999; 
reviewed in Kunes et al., 2007). The heart will be exposed to ischemia upon application of the 
aortic-clamp due to the removal of the coronary blood flow through the heart, the period of 
which will vary depending on the type of surgical correction being performed (Attia et al., 
1976; Nagashima, 1993; reviewed in de Jong et al., 2009). This will cause a reduction in the 
available O2 and associated nutrients that are essential for proper heart function. The most 
important nutrient required for heart function is ATP, which is produced by oxidative 
phosphorylation within the mitochondria. This process requires O2 therefore a deficiency of 
this will be severely detrimental to cardiac cell function (Ferrari, 1996).  Therefore, during 
total ischemia, the process of oxidative phosphorylation will be inhibited, preventing the 
production of ATP via this pathway (Lesnefsky et al., 1997). This will cause a shift from 
aerobic to anaerobic glycolysis, which allows a boost in ATP production to occur in the 
absence of O2 but with an adverse build up of lactic acid as well as hydrogen (H) ions 
(protons) from ATP hydrolysis (Allen and Orchard, 1987), a depletion of creatine kinase (CK) 
and an increase in inorganic phosphate levels (Allen et al., 1985). The majority of ATP 
produced from anaerobic glycolysis is used to preserve the functionality of ion pumps situated 
in the plasma membrane of cardiac cells (Weiss et al., 1985).  This is in contrast to what 
happens during normoxic conditions within the heart where the majority of energy is used for 
 
 
37 
muscle cell contraction, with only a small amount being used for the maintenance of ion 
pumps (reviewed in Solaini and Harris, 2005). 
 
Anaerobic glycolysis cannot be maintained for long due to the fact that the amount of 
ATP produced is insufficient to maintain cardiac cell function. Also, the accumulation of 
lactate and H ions, which causes a decrease in intracellular pH (acidosis) and an increase in 
the intracellular concentrations of Na+ and Ca2+, will also result in the inhibition of anaerobic 
glycolysis (Rovetto et al., 1975). This will cause an overall fall in available ATP, which 
combined with the other changes caused by anaerobic glycolysis will have the end result of 
inhibiting cardiac muscle contraction, which is the primary function of cardiac tissue (Hohl et 
al., 1982; Kingsley et al., 1991; reviewed in Doenst et al., 2008). This will eventually result in 
cardiac cell death if not reversed. During cardiac surgery, this problem is largely overcome by 
the use of cardioplegia and hypothermia to slow down cardiac cell metabolism in an effort to 
preserve ATP content (Opie et al., 1971). Although it has been shown that a fall in ATP is 
associated with loss of contraction in cardiac tissue during ischemia, it is not the sole cause 
(Kentish et al., 1986; Guth et al., 1993). Another cause of the ATP deficit is the continued 
functionality of mitochondrial ATPase during cardiac tissue ischemia that converts ATP to 
adenosine diphosphate (ADP) (Jennings et al., 1991).  
 
The duration of the ischemic period is very important to the extent of the damage done 
to the cardiac tissue. The duration of safe ischemia (without cardioplegia) at normothermia is 
very short being only a few minutes. This would be extended to about 20 minutes if the tissue 
was at 20°C (deep hypothermia) or below. During cardiovascular disease, an occlusion of 
blood flow within the heart can cause the formation myocardial infarct (MI) if the period of 
ischemia is prolonged. Cell integrity in the cardiac tissue will become severely compromised, 
causing full contracture and final necrotic cell death. The affected areas will eventually form 
scar tissue known as a MI through action of the immune system (Jennings et al., 1957; Porter 
et al., 1893; Bretschneider et al., 1975; reviewed in Doenst et al., 2008). This highlights the 
potential adverse effects of prolonged ischemic exposure. 
 
Ischemic exposure can result in contractile dysfunction within the heart. Specific 
consequences include a process known as myocardial stunning upon short-term ischemic 
exposure. This is where contractile function will stop briefly but can be reversed with no long 
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lasting side affects. Also, prolonged periods of partial ischemia or long term exposure to low 
blood flow can result in myocardial hibernation, where the inactive contractile function of the 
heart tissue is prolonged but can still be reversed (Lavallee et al., 1983; Darsee et al., 1981; 
Elsässer et al., 1997; reviewed in Doenst et al., 2008).  
 
Ischemic exposure does not always result in necrotic cell death of cardiac cells. 
Necrotic cell death is when an exogenous factor, such as physical trauma or infection, causes 
the early death of a healthy living cell. The alternative is apoptosis, which is programmed cell 
death. This is where biological signals within the cell deliberately cause cell death and this is 
usually beneficial to the organism (Fliss and Gattinger, 1996; McCully et al., 2004; reviewed 
in Doenst et al., 2008). In a study that used a rat animal model of MI, it was shown that the 
dominant type of cell death seen in cardiac cells after MI was apoptosis. Necrotic cell death 
did occur but not to the same magnitude. Necrotic cell death continued after apoptotic cell 
death and contributed to a progressive loss of cells over time after the MI (Kajstura et al., 
1996). This highlights that the avenue of cell death during ischemia is not straight forward. 
Another source of damage during ischemia is thought to be the production of reactive oxygen 
species (ROS) by the enzyme xanthine oxidase that is found in the cytoplasm of cardiac cells 
(Kevin et al., 2003; Pacher et al., 2006; reviewed in Suleiman et al 2008). Damage sustained 
by induced ischemia by the use of the aortic-clamp during cardiac surgery is protected against 
by several methods that have already been described (see section 1.2.2). 
 
Once the surgical corrective procedure has been completed, the aortic-clamp is 
removed, which will return coronary blood flow to the ischemic heart. Reperfusion is the only 
method upon which damage done by ischemia can be reversed, but the extent to which this 
can be done will depend on the length and severity of the ischemic period and can itself cause 
damage to the already fragile cardiac tissue (Chandra, et al., 1976; reviewed in Suleiman et 
al., 2008). The heart is usually exposed to high levels of O2 upon reperfusion (release of cross-
clamp) during cardiac surgery (Ihnken et al., 1998; reviewed in Allen et al., 2001). Upon 
reperfusion of the ischemic heart, the tissue is exposed to O2 and ATP synthesis by oxidative 
phosphorylation then resumes, as does normal ion channel function and therefore normal 
intracellular pH is restored and cardiac cell contraction is once again initialised. Despite this, 
there can still be further cell death by either necrosis or apoptosis (reviewed in Solaini and 
Harris, 2005).  
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Upon reperfusion of ischemic tissue, there is an even bigger rise in the intracellular 
Ca2+ concentration than that seen during the ischemic exposure of the tissue, with the end 
result being contractile impairment (Kusuoka et al. 1991; reviewed in Suleiman et al., 2001). 
This rise in intracellular Ca2+ can occur either via the myocardial Ca2+ channels (in the 
sarcolemma and the sarcoplasmic reticulum) or the reversal of the sarcolemmal Na+/ Ca2+ 
exchanger (Smart et al., 1997). Examples of such contractile impairment include myocardial 
stunning (described previously) and ventricular fibrillation. These are examples of reversible 
impairment of cardiac contraction (Smart et al., 1997). In more detail, myocardial stunning is 
caused by an abnormality in the function of both the myocardial Ca2+ channels and the reversal 
of the Na+/ Ca2+ exchanger. In comparison, ventricular fibrillation is caused via the abnormal 
function of the Na+/ Ca2+ exchanger (Smart et al., 1997). 
 
Another consequence of the large increase in intracellular Ca2+ during reperfusion is 
hypercontracture of the myocardium. This usually occurs after the reperfusion of tissue 
exposed to prolonged ischemia (Ladilov et al., 1995; Siegmund et al., 1997; Schäfer et al., 
2001).  There are 2 ways in which contracture occurs during reperfusion. This first is known 
as Ca2+ overload induced contracture. During ischemia there is an increase of intracellular 
Ca2+. Upon reperfusion, ATP production via oxidative phosphorylation restarts. This allows 
cellular contraction and intracellular ion levels (including Ca2+ concentration) to normalise. 
The recovery of contraction is more immediate than that of ion levels. Therefore due to the 
high levels of Ca2+ within the cell, a Ca2+ driven contraction is caused resulting in 
hypercontracture. The other method is known as rigor induced contracture. This usually occurs 
after prolonged ischemia where reperfusion of the cardiac tissue is low and repletion of ATP 
within the tissue is slow (reviewed in Piper et al., 2004). Hypercontracture has been linked as 
a cause of necrotic cell death during the early phase of reperfusion of ischemic tissue and 
therefore could potentially cause an immune response (Fujiwara et al., 1989; Garcia-Dorado et 
al., 1992).  
 
A rise in intracellular Ca2+ during reperfusion will also cause a noticeable rise in 
mitochondrial Ca2+ (Varadarajan et al., 2001). This has been linked to contributing to the 
cellular damage caused during reperfusion of ischemic tissue due to fact that when the influx 
of Ca2+ into the mitochondria is blocked, cellular damage is reduced, ATP production in 
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mitochondria is highly increased and contractile function that is impaired by the influx of 
mitochondrial Ca2+ is improved (Ferrari et al., 1982; Peng et al., 1980; Grover et al., 1990).  
 
ROS production during reperfusion has been described as another major source of 
cellular damage, which is thought to occur via the mitochondrial respiratory chain through the 
action of the electron transport chain (Vanden Hoek et al., 1997; reviewed in Solaini and 
Harris, 2005). The most probable source of this is ubiquinone that is reduced during ischemia 
to ubisemiquinone. During reperfusion, this will react with O2 to produce ROS (reviewed in 
Suleiman et al., 2001). It should be noted that xanthine oxidase has also been implicated in the 
production of ROS during reperfusion, but is thought less important in the heart during such 
injury (Thompson-Gorman et al., 1990; Xia et al., 1995; reviewed in Suleiman et al., 2001). 
 
Under normal physiological conditions, the action of antioxidants easily regulates ROS 
production during IR injury but during reperfusion, such systems are unable to cope due to 
their impairment during ischemia (reviewed in Turer et al., 2010). This causes an excess of 
ROS, which can cause damage to many cellular components including nucleic acids, lipids 
and proteins. Also, the combined effect of the large intracellular/ mitochondrial influx of Ca2+ 
and the production of ROS via the mitochondrial respiratory chain that causes oxidative stress 
can result in the mitochondrial permeability transition pore being opened (Haworth and 
Hunter, 1979; Sedlic et al., 2010; Kim et al., 2006; reviewed in Halestrap, 2009). If this occurs 
chronically it will result in irreversible mitochondrial injury, leading to complications such as 
the release of ROS into the cytosol from within the mitochondria and ultimately result in 
necrotic cell death (Griffiths et al., 1995; reviewed in Suleiman et al., 2008). Another 
implicated source of ROS production during reperfusion is nitric oxide (NO). This is produced 
by the endothelium and its production is increased during early reperfusion, where it reacts 
with O2 to create ROS that will cause tissue and cellular damage (Wang and Zweier, 1996). 
 
1.3.2.1 Level of O2 exposure during global myocardial IR injury 
As already stated, during both paediatric and adult cardiac surgery with CPB, high 
levels of O2 are often used (Ihnken et al., 1998; reviewed in Allen et al., 2001). This means 
that reperfusion of the heart during cardiac surgery will be at a high O2 tension. There are 
some concerns that such hyperoxic exposure could be a potential source of damage during 
such procedures. There are several studies within the literature that support this. A study 
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compared the use of hyperoxic (O2 tension (pO2)= 5400 mmHg) CPB to normoxic (pO2= 5140 
mmHg) CPB in adults undergoing coronary artery bypass grafting (CABG). Several 
measurements were taken within each group, including the levels of polymorphonuclear 
leukocyte elastase (secreted by neutrophils during inflammation), CK, antioxidants and nitrate. 
All of these were higher in the group exposed to hyperoxic CPB. This indicated hyperoxic 
CPB resulted in more oxidative myocardial damage compared to normoxic CPB (Ihnken et 
al., 1998). A similar comparison was performed during surgical correction of cyanotic 
congenital heart defects. Patients either had controlled normoxic CPB (PO2= 50–80 mmHg) or 
hyperoxic CPB (PO2=150–180 mmHg). Troponin I (marker of myocardial damage), 8-
isoprostane (marker of oxidative stress) and protein S100 (marker of inflammatory diseases) 
were all lower in the controlled normoxic CPB group. These findings along with other 
measurements taken indicated that hyperoxic CPB resulted in higher myocardial and oxidative 
stress than controlled CPB (Caputo et al., 2009). There is also some clinical evidence that the 
use of hyperoxic reperfusion after cardiac arrest was associated with higher in-hospital 
mortality when compared to the use of hypoxic or normoxic exposure (Kilgannon et al., 
2010). 
 
Surgical correction of congenital defects in patients with cyanosis is carried out on 
bypass at high levels of O2 (300 to 400 mm Hg) (reviewed in Morita, 2012). There are several 
studies that used a pig animal model, which indicated cyanotic infant myocardium (PaO2 of 
25mmHg) was highly susceptible to re-oxygenation injury when exposed to high levels of O2 
(PaO2 400mmHg) during reperfusion (Ihnken (i) et al., 1995; Ihnken (ii) et al., 1995; Morita 
(i) et al., 1995; Morita (ii) et al., 1995). This has also been shown in children with cyanotic 
damage undergoing corrective surgery on bypass for congenital heart defects (Modi et al., 
2002; Bulutcu et al., 2002). There has also been evidence that controlling re-oxygenation 
during the use of CPB for patients that have congenital defects with pre-operative cyanotic 
damage will reduce post-operative injury. One such study recruited 31 children with cyanotic 
damage, who were put into 2 different groups. In the first group, bypass was initiated with 
very low O2 levels that were gradually increased for 5 minutes until levelling out at about 200 
to 300 mmHg. In the other group, bypass was initiated at very high levels of O2 for 5 minutes 
then again lowered out to 200 to 300 mmHg. Patients that had controlled re-oxygenation 
experienced significantly lower levels of creatine-phosphokinase-MB (marker of cardiac 
injury) and ventilation time (Babu et al., 2012). This was shown in a similar study performed 
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by another research group (Zhu (i) et al., 2005). This is supporting evidence that hyperoxic O2 
exposure during CPB could be particularly harmful to the myocardium from children with 
cyanosis pre-operatively if not properly controlled. Therefore protecting such children during 
surgery on bypass is very important. 
 
Hyperoxia is associated with the production of ROS; therefore during hyperoxic 
reperfusion the damage caused by ROS would be more exaggerated than normally seen at 
normoxic levels (Jamieson et al., 1986). In the case of paediatric surgery, the infant 
myocardium has been shown to be more susceptible to damage due to ROS during reperfusion 
(Otani et al., 1987). In relation to children with cyanosis before surgical correction on bypass, 
damage caused by free radicals (shown by measurement of hydroxy conjugated dienes) was 
observed during TOF surgical correction before and after aortic clamping and during 
reperfusion (Del Nido et al., 1987). Also, in a study using a pig animal model, it was shown 
that exposing infant myocardium to mechanically ventilated hyperoxia (PaO2= 422 +/- 33 
mmHg) induced the production of ROS in the infant myocardium. Also, the ability to increase 
production of anti-oxidants to provide protection from such damage was reduced (Bandali et 
al., 2004). Such studies highlight the potential danger of using hyperoxic levels of O2 during 
cardiac surgery with CPB. Hyperoxic reperfusion has also been shown to exasperate impaired 
mitochondrial function within the heart. This could result in a detrimental post-operative 
clinical outcome as the loss of functional mitochondria would ultimately result in necrotic cell 
death (Angelos et al., 2011).  
 
There are some studies that show that the use of hyperoxia does not actually cause 
additional damage. For example, in a study using a rat model of IR injury, the animals were 
exposed to 40 minutes of ischemia then either ventilated with normoxic levels of O2 (40% O2) 
or with hyperoxic levels of O2 (95% O2). The size of MI produced was unaffected by the level 
of O2 exposure. This suggests that the level of O2 used during CPB does not affect the amount 
of damage caused by IR injury (Mariero et al., 2012). A study that investigated the use of 
hyperoxic exposure (>95% O2) before IR injury in a rat animal model showed that such pre-
treatment resulted in a reduction in MI formation and a reduction in the amount of apoptotic 
cell death. This highlighted a cardio-protective role of hyperoxia (Foadoddini et al., 2011). 
Despite all these examples, it is inconclusive whether the use of hyperoxia levels of O2 in the 
clinical setting is harmful enough to discontinue its use. This was shown in a retrospective 
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study of the use of hyperoxic exposure and its association to mortality after cardiac arrest. The 
study indicated that such a relationship was not highly supported and therefore cautioned 
preventing the use of hyperoxic exposure after cardiac arrest (Bellomo et al., 2011; 
Hoedemaekers and van der Hoeven, 2011). 
 
During cardiac surgery with CPB, it is important to keep the brain protected by 
keeping it properly perfused. This is another reason why such high levels of O2 are used 
during such procedures. It has been shown that hyperoxic exposure can cause apoptotic cell 
death within the white matter of the developing brain in a study using a rat animal model 
(Gerstner et al., 2008). The effect of hyperoxic reperfusion on cerebral outcome was 
investigated using a rat animal model of global cerebral ischemia. The rats were exposed to 
ischemia then resuscitated on a ventilator at either 21% O2 for 1 hour or 100% O2 for 1 hour. It 
was shown that hyperoxic (100% O2) reperfusion resulted in increased hippocampal neuronal 
death and more inflammation when compared to normoxic (21% O2) reperfusion (Hazelton et 
al., 2010). Another study using a canine cardiac arrest model illustrated that the use of 
hyperoxic reperfusion reduced hippocampal oxidative energy metabolism in the brain 
(Richards et al., 2007). Therefore cerebral damage could be a consequence of using high O2 
levels during CPB. 
 
1.3.2.2 Myocardial IR injury in cardiovascular disease compared to cardiac surgery 
It should be noted that there are some distinct differences in the IR injury characteristic 
of cardiovascular disease when compared to that seen during cardiac surgery, which is the 
situation that we are more concerned with. During cardiac surgery, the affect of IR injury (as 
described above) on the tissue is minimised due to the use of cardioplegic solution and 
hypothermia (refer to section 1.2.2). This combination slows down the metabolic rate of the 
heart tissue, conserving the stability of the cardiomyocytes during the ischemic period created 
by the application of the cross clamp (reviewed in Turer et al., 2010). Cardioplegia delivered 
at hypothermic temperature has been shown to improve the survival of the myocardium during 
cardiac surgery (Drescher et al., 2011). However, it has also been shown that the temperature 
used does not influence the extent of myocardial injury (Carrier et al., 1994). Reperfusion 
during cardiac surgery is caused when the aortic-clamp is released. The blood that is returned 
to the heart has gone through the CPB unit and is therefore artificially highly oxygenated and 
contains activated factors of the innate immune system due to the blood contact with the 
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extracorporeal circulation apparatus (described in section 1.3.1). Therefore the heart tissue in 
this case is exposed to a different version of IR injury than seen during cardiovascular disease, 
which lacks these factors. 
 
The physical trauma and exposure to chemicals such as anaesthetics and cardioplegia 
solution are absent during the occurrence of cardiovascular disease therefore the effects of 
these chemicals are exclusive to the model of cardiac surgery (reviewed in Turer et al., 2010). 
In the case of anaesthetics, it has been shown that their use during cardiac surgery with CPB 
could possibly prevent an inflammatory response instead of being a potential cause (Hambsch 
et al., 2002). For example, sevoflurane has been shown to reduce the inflammatory response 
produced by damage done during cardiac surgery by reducing the expression of pro-
inflammatory cytokines and inhibiting the number of activated neutrophils (Nader et al., 2004; 
Nader et al., 2006; Kawamura et al., 2006).  
 
Another major distinction when comparing cardiac surgery and cardiovascular disease 
is, that a MI, which is a consequence of IR injury during cardiovascular disease, is a singular 
localised occurance. It usually occurs in a single blood vessel and is pre-dominantly an 
ischemic event. Tissue is not necessarily reperfused at all and if it is this usually occurs by 
surgical intervention (angioplasty or CABG) or by lysis of the clot causing the occlusion 
within the blood vessel to be removed. As such, any reperfusion that occurs will not be for 
quite a while after the ischemic event. This combined with all the other differences described 
above makes the approach to protecting the heart from damage during cardiac surgery 
definitively different from what would be needed during cardiovascular disease.  
 
1.3.3 Localised myocardial inflammation 
The types of cellular insults described so far that occur as a result of cardiac surgery, 
such as the physical trauma and IR injury, can cause certain aspects of the innate immune 
system to be activated, which themselves can result in their own sources of cellular damage 
via the activation of an inflammatory response within the heart (Franke et al., 2005; 
Prondzinsky et al., 2005; reviewed in Suleiman, 2008). Also, the use of CPB during open-
heart surgery can contribute to the inflammation seen but this will be discussed in more detail 
later (see section 1.3.4) (Wan et al., 2004).  
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The activation of the innate immune system during cardiac surgery and its related 
insults is very much like what occurs when the body is infected by foreign pathogens such as 
Lipopolysaccharides (LPS), which are recognised by pattern recognition receptors (PRRs) 
such as Toll like receptors (TLRs) (reviewed in Akira et al., 2006). It is generally accepted 
that some type of cellular injury needs to occur in conjunction with activation of PRRs by 
foreign pathogens for the initiation of the immune system. However it has been shown that 
dendritic cells can be activated without any foreign pathogen detection but by cells dying due 
to viral infection or by necrosis. This shows that an immune reaction can occur without the 
presence of foreign pathogens (Gallucci et al., 1999). 
 
The activation of the immune system due to cell injury/death in the heart has been 
thought to be because of certain intracellular protein mediators and other products of IR injury 
that are released upon damage/ cell death. These will then interact with PRRs, such as TLRs. 
This will result in downstream activation of transcription factors such as nuclear factor kappa 
B (NF-κB) promoting a pro-inflammatory response involving both protein and cellular 
components of the immune system. These mediators are known as danger-associated 
molecular patterns (DAMPs) (Gallucci et al., 1999; Shi et al., 2000) and examples include 
ROS, heat shock proteins (HSPs), and fibronectin (reviewed in Turer et al., 2010).  
 
As already stated, during cardiac surgery a localised immune response in the heart is 
caused in part due to the physical injury of the procedure. This will cause unavoidable necrotic 
cell death when cells are damaged beyond repair. This will release intracellular mediators that 
will activate cellular and protein aspects of the immune system via receptors like TLRs. This 
will result in inflammation and an increase in pro-inflammatory cytokines (Gu et al., 1999; 
Tárnok et al., 1999; Prondzinsky et al., 2005). 
 
During cardiac surgery with CPB, the application and release of the aortic-clamp 
exposes the myocardium to both ischemia and reperfusion respectively. Both ischemia and 
reperfusion can cause damage both separately and combined (refer to section 1.3). An 
inflammatory response is triggered by the ischemic damage via pathways controlled by 
transcription factors such as hypoxia-inducible factor (HIF-1) and early growth response 
protein (EGR-1). When the aortic-clamp is released blood is returned to the heart. This blood 
will have been passed through the CPB machine and will be highly oxygenated and will 
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contain a high level of primed cellular and protein components of the innate immune system. 
Myocardial exposure to IR injury will cause damage and cell death, activating inflammatory 
cascades via receptors such as TLRs. With the addition of the primed immune system 
components in the blood from the CPB machine any immune response begun in the heart by 
IR injury will be exaggerated (reviewed in Kunes et al., 2007).  
 
Such activation of the immune system because of IR injury produces high levels of 
pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-
18 (IL-18) and tumor necrosis factor-alpha (TNF-α) (Sawa et al., 1998; Chandrasekar et al., 
1999; Pomerantz et al., 2001; Bennermo et al., 2004; reviewed in Kunes et al., 2007) and also 
chemokines such as interleukin-8 (IL-8) (reviewed in Suleiman et al., 2008). This will 
increase the activation of adhesion molecules on the surface of the endothelium such as 
intercellular adhesion molecules (ICAM-1) and vascular cell adhesion molecules (VCAM-1), 
which will already have been activated to an extent by direct damage done to the endothelium 
by physical damage and IR injury (Kalawski et al., 1998). The expression of these adhesion 
molecules means that interactions between them and leukocytes within the blood that are 
activated both by localised immune system activation and also activation due to the passage of 
blood through the CPB machine (described later in this section) is promoted. Vascular 
permeability is then increased, allowing the migration of primed leukocytes such as 
neutrophils and monocytes into the area of the reperfused heart tissue (reviewed in Kunes et 
al., 2007). One of the main dangers that are presented here is the large production of ROS by 
the activated neutrophils that is in addition to ROS already produced during IR injury itself. 
This will cause damage to tissue already vulnerable due to previous insult and will increase 
the amount of cell death (necrosis and apoptosis) (Palatianos et al., 2004). Anti-inflammatory 
cytokines like interleukin-10 (IL-10) are also expressed during IR injury, which has been 
shown to protect the heart against such damage (Jones et al., 2001).  
 
Other aspects of the immune system such as the complement system and the 
coagulation system are also activated due to IR injury and will contribute to the inflammatory 
response caused (Weiser, et al., 1996; Tanhehco et al., 1999; reviewed in Turer et al., 2010). 
 
As already stated, TLRs have been implicated in initiating an inflammatory response 
upon their activation by intracellular mediators released after necrotic cell death. Toll like 
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receptor 2 (TLR2) and Toll like receptor 4 (TLR4) have been shown using animal models to 
be involved in the inflammatory response caused by IR injury in the myocardium (Chong et 
al., 2004; Shimamoto et al., 2006; Hua et al., 2007; Sakata et al., 2007; Cha et al., 2008; Arslan 
et al., 2009; Ha et al., 2010). Also HSPs, which are thought to have extracellular 
immunological functions once released from cellular confinement, have been shown to be 
involved in TLR signalling that initiates inflammation in response to cardiac IR injury 
(Dybdahl et al., 2002; Zou et al., 2008; Ao et al., 2009). HSPs have been further shown to be 
cardio-protective against IR injury in the heart, specifically HSP20 (Fan et al., 2005; Zhu (ii) 
et al., 2005; Qian et al., 2009), HSP27 (Kwon et al., 2007; Lu et al., 2008) and HSP72 
(Nakamura et al., 2000; Kim et al., 2006; Liu et al., 2007). 
 
1.3.4 Inflammatory response caused by CPB 
The use of CPB during open-heart surgery is associated with the occurrence of a 
systemic inflammatory response that is in addition to the localised myocardial inflammation 
seen due to the other factors previously discussed (Butler et al., 1993). The CPB machine 
performs the functions of the heart and lungs during open-heart surgery (see section 1.2.1). 
This involves keeping the blood pumping around the body and keeping the blood sufficiently 
oxygenated (Warren et al, 2009).  Although the CPB machine does its job adequately, the 
blood of the body is exposed to an artificial environment when it passes through the 
extracorporeal circulation apparatus of the CPB machine and the blood re-oxygenation is 
being controlled by a non-biological mechanism. The end result is the activation of the 
immune system, which will cause a systemic inflammatory response. This can have a multi-
factorial affect on many organs of the body, especially the heart and lungs (Butler et al., 1993) 
and if severe enough this can manifest as systemic inflammatory response syndrome (SIRS) 
(Sablotzki et al., 2002). 
 
The immune response that occurs due to IR injury during cardiac surgical repair has 
been described as a more localised response in the heart itself. The activation of components 
of the innate immune system by the use of CPB has been shown to occur more in the systemic 
tissues of the body. This is mostly caused via the primed components of the immune system in 
the blood that have come into contact with the extracorporeal unit of the CPB machine while 
the patient is on bypass (Tomic et al., 2005). Normally the blood of the body comes into 
contact only with the endothelium, which has many regulatory elements that will keep 
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components of the immune system in check. The surface of the extracorporeal circulation 
apparatus of the CPB machine lacks these endogenous protective mechanisms. When the 
blood encounters such foreign material this will activate both cellular and protein components 
of the immune system within the blood. This will cause systemic inflammation when the 
blood encounters endothelium in the systemic tissues while the patient is on bypass. This will 
also increase the localised inflammation seen in the heart when the coronary blood flow is 
returned upon the removal of the aortic-clamp (reviewed in Warren et al., 2009). 
 
Cellular activation of immune components in the blood by CPB includes the activation 
of leukocytes, such as neutrophils and monocytes (Wachtfogel et al., 1987; Cameron et al., 
1996; el Habbal et al., 1995; el Habbal et al., 1997; reviewed in Warren et al., 2009), the 
activation of platelets (Rinder, 1991; Rinder et al., 1994) and an increase in leukocyte–platelet 
co-aggregates (Rinder et al., 1992; Rinder et al 1994; Rinder et al., 1996). There is also an 
increase in the level of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 and also a 
resultant increase in the level of chemokines such as IL-8 and monocyte chemotactic protein-1 
(MCP-1) (Wan et al., 1996; Zahler et al., 1999; Dreyer et al., 2000; Wan et al., 1999; 
Yamaguchi et al., 2005; Nesher et al., 2006; reviewed in de Jong et al., 2009). Activated 
monocytes are the source for pro-inflammatory cytokines like IL-6 and pro-inflammatory 
chemokines like IL-8 (reviewed in Warren et al., 2009). This increase in pro-inflammatory 
cytokines and chemokines causes the activation of the endothelium and results in an increase 
in the expression of adhesion molecules. This in turn will encourage the migration of 
leukocytes from the blood into the tissue, which itself can contribute to the systemic 
inflammation often associated with the use of CPB (Wei et al., 2003). Of all organs, in the 
context of cardiac surgery with CPB, the heart, lungs, kidney and the liver are normally the 
most severely affected by such systemic inflammation (Zahler et al., 1999; Hirai et al., 2001). 
It should also be noted that there is also an increase in the expression of anti-inflammatory 
cytokines, like IL-10, interleukin-4 (IL-4), interleukin-13 (IL-13) and transforming growth 
factor beta (TGF-β). This will usually correct and contain, via a negative feedback loop, the 
immediate increase in pro-inflammatory cytokines expression that occurs during an 
inflammatory response. During cardiac surgery with CPB, such regulation is not sufficient to 
regulate the expression of pro-inflammatory cytokines (McBride et al., 1996; Nathan et al., 
2000; reviewed in Kunes et al., 2007).  
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Activation of protein components of the immune system due to cardiac surgery with 
CPB includes the complement system, which is activated via both the alternative and classical 
pathways (Chenoweth et al., 1981; Kirklin et al., 1983; Kirklin et al., 1986; Steinberg et al., 
1993), the kallirenin-kinin system (Saatvedt et al., 1995; te Velthuis et al., 1997; Wachtfogel 
et al., 1998), the coagulation system that can function via the intrinsic and extrinsic 
coagulation pathways (Hunt et al., 1998; reviewed in Kunes et al., 2007) and the fibrinolytic 
system (Stibbe et al., 1984; Khalil et al., 2004). 
 
The blood that has been through the CPB and returned to the systemic circulation will 
have been exposed to very high levels of O2. Such exposure has also been shown to induce an 
inflammatory response. Such investigation usually involved studies that looked at damage 
caused within the lungs. A study was undertaken that involved patients undergoing cardiac 
surgery with CPB who underwent inter-operative exposure to either 50% or 100% O2. It was 
shown that exposure to 100% O2 resulted in an increase in the production of pro-inflammatory 
cytokines within the lungs (Pizov et al., 2000). Another study used both TLR4 null and wild 
type rats to investigate the effect of hyperoxia on the expression of pro-inflammatory 
mediators within in the lungs. The rats were exposed to 80% O2 for either 48 hours or 96 
hours. It was suggested that hyperoxic exposure caused inflammation within the lungs and that 
such inflammation was dependent on TLR4 expression and the activation of NFkB (Ogawa et 
al., 2007). TLR4 signalling was investigated in neutrophils in order to see if TLR4 activation 
was O2 dependent. It was shown that LPS induced TLR4 signalling was inhibited in the 
presence of antioxidants. The downstream production of cytokines was also prevented. This 
highlighted that inflammation caused by TLR4 signalling was inhibited by the absence of 
ROS, showing it to be linked to O2 exposure (Asehnoune et al., 2004). 
 
1.3.5 Other known complications of CPB 
Other known complications from the use of CPB during cardiac surgery include 
excessive bleeding, neurological complications, renal problems, pulmonary dysfunction or 
overall organ dysfunction (Khuri et al., 1992; Wessel et al., 1993; Bellinger et al., 1995; 
reviewed in Murphy et al., 2009). 
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1.3.6 Conclusion 
The outcome of the localized cardiac inflammation and the systemic inflammation 
described will escalate myocardial dysfunction and/ or cell death already caused by all the 
different avenues described above. Such inflammation is the body’s immune system trying to 
repair the damage caused. In the context of cardiac surgery, if the myocardial dysfunction 
caused occurs for an extensive period of time resulting in increased cell death this could have 
deleterious effects on the post ventricular function of patients who have undergone cardiac 
surgery with CPB. In children with congenital cardiac defects such as TOF, where the 
myocardium has already sustained some damage previous to the surgical correction due to the 
characteristic defects of the condition, it is even more important to minimize any potential 
inflammation that may occur during cardiac surgery. This would help minimize post-operative 
ventricular function complications once the surgical corrective procedure has been completed. 
Therefore, finding new and novel ways to protect the myocardium from such damage other 
than those used in the current clinical practice is an important avenue of investigation. In this 
project, observing the molecular mechanisms active within the myocardium and the 
expression of their key protein mediators during such damage was the focus in trying to 
illuminate such potential alternative protective mechanisms. Prime candidates include TLRs 
and HSPs, which have both been shown to be involved in the processes described above. 
 
1.4 Toll like receptors (TLRs) 
1.4.1 What are TLRs? 
TLRs are a highly conserved family of type 1 trans-membrane glycoproteins that were 
first discovered in the Drosophila fly, where the homologous gene Toll was shown to be 
involved in adult fly development. In more detail, it was shown to be involved in the 
differentiation of various tissues along the dorsal-ventral axis, but also in their immune 
response against fungal infection. The latter was discovered by showing that mutations in the 
TLR gene dramatically reduced survival after such infection (Lemaitre et al., 1996). A human 
homologue of this Drosophila gene was then identified in a subsequent study, characterized 
later as TLR4. This was shown to be involved in the mammalian inflammatory response, 
specifically involving the activation of NFkB and the resulting activation of pro-inflammatory 
cytokines. TLR4 has now become one of the best characterized TLRs overall (Medzhitov et 
al., 1997). This role of TLRs in the innate immune response was also shown in a study where 
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mutant TLR4 mice were more prone to LPS infection due to their presumed inability to detect 
the pathogen in comparison with control mice, again showing the role of TLRs in innate 
immunity (Poltorak et al., 1998). TLRs were soon being recognised as primary initiating 
elements of the innate immune response.  
 
TLRs are part of the Toll/interleukin-1 receptor superfamily. They all have similar 
methods of downstream signalling due to a universal Toll/IL-1R/Resistance (TIR) motif, 
which activate the same inflammatory signalling pathways (reviewed in Liew et al., 2005). So 
far 13 mammalian TLR have been identified (Nomura et al., 1994; Taguchi et al., 1995). Of 
these, TLR1-10 are functional in humans but TLR11-13 have been lost from the human 
genome. Twelve are functional in mice, except for TLR10, which has been rendered useless 
due to the insertion of a retrovirus (reviewed in Kawai and Akira, 2010).  
 
1.4.2 What do TLRs do? 
TLRs recognise their own unique ligands known as pathogen associated molecular 
patterns (PAMPs). These are summarised in table 2. This specificity of ligands for the 
different TLRs was originally highlighted by the fact that all responses of the mammalian 
immune system to LPS infection (pathogen) were affected by a mutation found at a single 
gene locus called Lps. This was later shown to encode the TLR4 protein (Watson and Riblet, 
1974; reviewed in Beutler et al., 2004). This was also highlighted (in a study already 
mentioned) by the fact that mice with a mutant TLR4 gene were more susceptible to LPS 
infection when compared with control mice, again showing the specificity of TLR4 for the 
detection of LPS (Poltorak et al., 1998). Based on such studies, TLR4 and its interaction with 
LPS soon became one of the best characterization of the ligand specificity of TLRs. Due to the 
diversity in the PAMPs that can be detected by TLRs, which include molecules from protozoa, 
bacteria, fungi and viruses, TLRs provide a wide ranging system of detection that make them 
indispensable to the ability of the innate immune system to recognise foreign pathogens. Due 
to their ability to detect these PAMPs, TLRs are known as PRRs and TLRs are the best 
characterized overall. 
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Table 2 – Human TLR microbial, viral and HSP ligands 
TLR Ligand References 
1 Triacylated lipopeptides (with TLR2) Jin et al., 2007 
2 Bacterial lipopeptides, glycans, 
glycolipids, HSP70 
Takeuchi et al., 1999; Gantner et al., 
2003; Campos et al., 2001; Asea et al., 
2002 
3 Viral double-stranded RNA Alexopoulou et al., 2001 
4 LPS, Respiratory Syncytial Virus, 
HSP60, 
Poltorak et al., 1998; Monick et al., 
2003; Ohashi et al., 2000; Asea et al., 
2002 
5 Flagellin Hayashi et al., 2001 
6 Lipotechoic acid and diacylated 
lipopeptides (with TLR2) 
Kang et al., 2009;  
7 Viral single stranded RNA Heil et al., 2004; Diebold et al., 2004; 
Lund et al., 2004 
8 Viral single stranded RNA Heil et al., 2004 
9 Unmethylated DNA (CpG motifs), 
viral genomic DNA 
Hemmi et al., 2000; Lund et al., 2003 
10 Yet to be identified  
 
 
The recognition of PAMPs was very much based on the theory that the body’s immune 
system operates solely on recognising ‘self’ from ‘non self’ (Janeway, 1989). This idea did not 
account for the initiation of the immune system by non-pathogenic insults such as ischemia or 
oxidative stress and so another explanation was proposed. It was thought that the innate 
immune system could recognise any threat to the body that would be characterized by danger 
signals produced upon cell or tissue injury/ death (Matzinger, 1994). In time some PPRs, 
including TLRs, were shown to recognise such danger signals that were endogenous ligands, 
which became known as DAMPs (Gallucci et al., 1999; Shi et al., 2000). For example, TLR4 
can recognise heat shock protein 22 (HSP22), heat shock protein 60 (HSP60) and heat shock 
protein 72 (HSP70). All 3 are released extracellularly as a direct result of tissue damage and 
initiate downstream signalling resulting in NFkB activation and a pro-inflammatory response 
(Asea et al., 2002; Dybdahl et al., 2002; Ohashi  et al., 2000; Roelofs et al., 2006; Vabulas et 
al., 2001; Vabulas et al., 2002; de Graaf et al., 2006; Galloway et al., 2008; Ao et al., 2009). 
TLR4 can also recognise fibrinogen and soluble heparan sulfate (Smiley et al., 2001; Johnson 
et al., 2002; Johnson et al., 2004). TLR2, another well-characterized TLR, can also recognise 
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HSP70, HSP60 but also hyaluronan fragments all of which will trigger an immune response 
(Asea et al., 2002; Vabulas et al., 2001; de Graaf et al., 2006; Galloway et al., 2008; 
Scheibner et al., 2006). HSPs are described elsewhere in more detail (see section 1.6) and they 
are known mainly for being induced by a cellular stress such as IR injury and their cardio-
protective properties (Jayakumar et al., 2001; Kirchhoff et al., 2002; Okubo et al., 2001). 
Another more recently discovered DAMP is high mobility group box (HMGB) 1, which can 
activate leukocytes once released from cells via necrotic cell death and can interact with TLR2 
and TLR4 (Scaffidi et al., 2002; Park et al., 2004). Based on this, TLRs are prime candidates 
of investigation for attenuating damage and inflammation caused during cardiac surgery with 
CPB. This is due to the fact that DAMPs released upon cellular injury can initiate TLR 
downstream signalling. The release of DAMPs has been thought to occur in a number of ways, 
which include the release from the cell upon necrotic cell death, cell secretion and release via 
enzymatic activity (reviewed in Gill et al., 2010). 
 
1.4.3 The role of TLRs in the immune system 
TLRs obviously play an integral role in the body’s immune system, predominately in 
the innate response but with some interaction with the adaptive. This is highlighted by the fact 
that the majority of TLRs are expressed on many components of both the innate and the 
adaptive immune system. For example, in a study that investigated TLR expression in 
leukocytes, Toll like receptor 1 (TLR1) was expressed on monocytes, polymorphonuclear 
leukocytes, T cells, B cells, and natural killer cells. TLR2, 4, and Toll like receptor 5 (TLR5) 
were expressed on myelomonocytic cells and Toll like receptor 3 (TLR3) was only expressed 
on dendritic cells (Muzio et al., 2000). Another study showed the differential expression of 
TLR1-5 on monocytes as they matured into infant dendritic cells and a marked increased in 
TLR3 expression was observed while the rest tended to have a reduced expression during this 
transition (Visintin et al., 2001). In another study it was shown that TLR2 was expressed on 
infant dendritic cells via which lipopetides could initiate their maturation (Hertz et al., 2001) 
and also TLR2 expression was shown to occur on macrophages (Underhill et al., 2000). In 
other studies, TLR2 expression was shown on T cells and TLR4 expression was shown on B 
cells (Mokuno et al., 2000; Ogata et al., 2000).  
 
 
 
54 
TLRs are not just expressed on components of the immune system but are also 
expressed in epithelial cells, for example TLR2, 3 and 4 have been shown to be expressed in 
intestinal epithelial (Cario et al., 2000). Also TLR2 and 4 were activated when interacting 
with their cognate ligands in human epithelial cells (Faure et al., 2001). Another important 
fact about TLR expression is that they have 2 different intracellular localities. TLR3, 7, 8, and 
9 are expressed in intracellular vesicles like endoplasmic reticulum (ER), endosomes and 
lysosomes and recognise mainly microbial nucleic acid. TLR1, 2, 4, 5, 6, and 10 are expressed 
on the plasma membrane where they usually detect, and are activated by, microbial membrane 
protein components (reviewed in Gill et al., 2010). The function and ligand detection of 
human TLR10 is still being investigated. In fact in a recent study it was shown to be able to 
dimerize with itself, TLR1 and TLR6. It also directly interacted with a TLR adapter protein 
called myeloid differentiation factor-88 (MYD88), described later, which is essential for TLR 
downstream signalling. It was also shown that there was no functional form of TLR10 in mice. 
This confirms previous finding, however a functional form was found in the rat genome where 
it was expressed on B cells and dendritic cells (Hasan et al., 2005). Another recent study 
showed that TLR10 directly interacted with TLR2. It was thought that this dimer’s ligand 
would likely be triacylated lipopeptides and other microbial ligands. This resulted in the 
recruitment of MYD88 but did not involve the typical downstream signalling seen with other 
TLRs that would usually result in NFkB activation (Guan et al., 2010). Also, another study 
indicated that TLR10 expression was induced by both hypoxia and ROS. This then initiated 
the NFkB cascade pathway in human monocytes, highlighting a possible role of TLR10 in 
inflammation, but such data as present is limited (Kim et al., 2010). TLRs have also been 
shown to have a role in apoptosis (Ward et al., 2005; Goyal et al., 2002; Lombardo et al., 
2007).  
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1.4.4 TLR signalling 
 
Figure 1-4. TLR signalling of membrane bound TLRs 
 
 
Figure showing the downstream signalling pathways of TLR1, 2 and 4, which involve 
the adapter proteins MYD88 and MAL. This results in the activation of NFkB signalling 
pathways. TLR1 and TLR2 form a heterodimer, while TLR4 forms a homodimer in 
order to initiate downstream signalling. This is the pathway relevant to work within this 
thesis. 
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 TLR signalling (shown in figure 1-4) is generally accepted to occur by TLR protein 
dimerization, either with the formation of homodimers or heterodimers. It is known that TLR1 
and 6 form heterodimers with TLR2 (Farhat et al., 2008). TLR4, 9, 3 and 5 are believed to 
form homodimers and recently TLR8 was shown to from heterodimers with TLR7 and 9 
(Wang et al., 2006; reviewed in O’Neil and Bowie, 2007). All TLRs, except TLR3, signal via 
an adapter protein known as MYD88, which itself has the TIR motif already described 
allowing it to interact with the TLRs themselves and enable downstream signalling (reviewed 
in Liew et al., 2005). MYD88 was initially indicated to be involved in TLR signalling in a 
study that involved MYD88 null mice being exposed to LPS, the microbial ligand of TLR4. 
This resulted in the failure of LPS induced gene expression indicating MYD88 as a mediator 
of TLR4 expression. It was also noticed in this study that this lack of LPS gene induction was 
only partial, suggesting that there were other adapter proteins involved with TLR4 signalling 
(Kawai et al., 1999). Four other well known adapter proteins have been identified, which also 
have the TIR motif. These are known as MYD88 adaptor-like protein (MAL) or Tirap, TIR 
domain-containing adaptor-inducing IFN-β (TRIF) and TRIF-related adaptor molecule 
(TRAM). They are all involved in TLR signaling to some degree, allowing more specific 
activation of downstream signaling depending on the TLR activated (reviewed in Beutler et 
al., 2004).  
 
The downstream signalling of TLR5, 7, 8, 9 and 11 solely involves the adapter protein 
MYD88 while MAL/ Tirap is required in the MYD88 signalling cascade produced by the 
activation of TLR1, 2, 6 and 4, which results in the activation of the transcription factor NFkB 
and the production of pro-inflammatory cytokines such as TNF and IL-6 (Libermann et al., 
1990; Horng et al., 2002; Yamamoto (i) et al., 2002; reviewed in Beutler et al., 2004). It is of 
no surprise that TLR1, 2 and 6 share the same signalling pathway as they all form 
herterodimers with each other in order to initiate downstream signalling (Farhat et al., 2008). 
TRIF is involved in both TLR3 and TLR4 signalling in a MYD88 independent signalling 
pathway, while TRAM is restricted to the TLR4 MYD88-independent signalling pathway and 
is in no way involved with TLR3 activation.  The MYD88 independent signalling pathway 
causes the activation of Interferon regulatory factor 3 (IRF3) and the resulting production of 
interferon-β (IFN-β) and its associated gene pathways (Fitzgerald et al., 2003; Yamamoto (ii) 
et al., 2002; reviewed in Chao et al., 2009). TLR4 therefore is shown to uniquely have two 
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different possible avenues of downstream signalling upon activation (reviewed in Beutler et 
al., 2004).  
 
A fifth TLR adapter protein has also been identified that is known as sterile α- and 
armadillo-motif-containing protein (SARM). This protein can inhibit TRIF signalling of 
TLRs, which is the signalling cascade that occurs independently of MYD88 (Carty et al., 
2006). This is a good example of how TLR signalling can be negatively regulated, which is 
very important in the case of the immune system, which if not tightly controlled can lead to 
the production of autoimmune and inflammatory conditions. 
 
TLR downstream signalling initiated by either PAMPs or DAMPs use the same 
pathways but the distinction between the outcomes of activation by each of these initiators is 
generally different. For example, PAMP activation generally occurs in response to pathogenic 
infection therefore activation of the immune system is done in order to recruit immune system 
cellular components to destroy the invader. The activation by DAMPs, which is caused by a 
cellular insult such as ischemia and/ or reperfusion will usually result in the body trying to 
actively heal itself from the damage produced (reviewed in Gill et al., 2010). For the same 
signalling pathways to be used for such different outcomes, other proteins will come into play. 
For example, in studies involving TLR4 signalling initiated by either PAMPs or DAMPs, it 
was shown that a protein known as MD2 was involved in TLR4 signalling in response to LPS 
detection but was not involved in the detection of DAMPs (necrotic cell death) (Kim (ii) et al., 
2007). Another protein known as CD14 was involved in the recognition of both PAMPs and 
DAMPs. Specifically CD14 initiated an inflammatory cascade in response to necrotic cell 
death (Chun et al., 2010). As such it is important to realise that there are many other proteins 
involved in such immune system gene signalling. 
 
1.4.5 TLR and cardiac surgery: the role of immune system and resulting inflammation 
There is much interest in the role of TLRs in the immune system and how they induce 
NFkB expression and the production of pro-inflammatory cytokines. One way in which this is 
highlighted is the current interest of TLR signalling in inflammatory and/ or autoimmune 
diseases, examples including irritable bowel disease (Hausmann et al., 2002), Behcet's disease 
(Kirino et al., 2008) and rheumatoid arthritis (Brentano et al., 2005; Kim (iii) et al., 2007). 
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Such examples shows what can happen when signal transduction in innate immune system 
cascades, which involve TLRs, are not kept in check. This highlights the role of TLRs within 
the inflammatory response. Consequently, TLRs are an attractive potential therapeutic tool 
that could help reduce potential damage caused by inflammation. The importance of such 
investigation can be shown by the fact TLR signalling is known to mediate NFkB gene signal 
transduction, which causes inflammation and the production of pro-inflammatory cytokines. 
Also, TLR signalling within in the heart has an affect on the amount of damage done by IR 
injury that can cause such inflammation (Jones et al., 2003; reviewed in Zhang and Ghosh, 
2001; Faure et al., 2000; Sawa et al., 1997).  
1.4.6 TLR response to cardiac surgery CPB 
Damage done during cardiac surgery with CPB has already been described. This 
includes the physical damage, the myocardial IR injury caused and the innate immune 
response initiated either locally within the heart or systemically (see section 1.3). Such 
inflammation can cause more exaggerated cardiac dysfunction by causing additional damage 
and if severe enough can cause myocardial cell death. Any reduction in this type of damage 
would therefore be beneficial in order to promote the best post-operational outcome of such 
invasive surgical procedures. 
 
As already stated there are two distinct sources of inflammation caused during cardiac 
surgery with CPB (see sections 1.3.3 and 1.3.4). These will contribute to either localised 
myocardial dysfunction and/ or cell death or in systemic organ dysfunction and/ or cell death 
due to the circulating inflammatory mediators activated in the blood that has been through the 
CPB machine. When this blood encounters the endothelial tissue within the systemic 
circulation, immune system cascades will be activated. This in turn will contribute to the 
localised myocardial inflammation already present and will also affect other multiple distal 
organs of the body. Therefore, there are two different avenues via which inflammation would 
need to be prevented. It should be noted that no matter the localisation or the reason for the 
inflammation induced, the downstream signalling cascades initiated would be the same. 
 
It has been demonstrated that TLRs are expressed in human endothelial tissue and it 
was found that TLR4 expression was significantly higher than the expression of TLR2 (Faure 
et al., 2000; Faure et al., 2001; Fan et al., 2003; Mullick et al., 2008). TLRs are also expressed 
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on cells of the immune system, for example, they have been found on leukocytes, lymphocytes 
and antigen presenting cells (Muzio et al., 2000; Xu et al., 2001; Hoshino et al., 2002; Dasari 
et al., 2005). Also, TLR expression, specifically TLR4, has been shown to be located in 
adventitial fibroblasts, which have been shown to be immunologically active by the fact that 
TLR4 signalling activation within these cells produced an inflammatory signalling cascade 
resulting in pro-inflammatory cytokine release (Vink et al., 2002). TLRs are also expressed in 
adult cardiac tissue, for example TLR2, TLR4 and TLR5 expression was shown in 
cardiomyocytes. When stimulated, this resulted in the activation of the transcription factor 
NFkB, resulting in a pro-inflammatory response (Boyd et al., 2006). TLR4 expression has also 
been characterized in both normal and failing human adult myocardium (Frantz et al., 1999).  
 
TLR expression is usually activated by pathogenic invasion. Such expression can also 
be caused by cellular insults such as IR injury. The activation of an inflammatory response due 
IR injury via TLR4 signalling has been shown to occur in the heart (Chong et al., 2004; Feng 
et al., 2008). It is likely that the damage caused by IR injury will result in cardiac dysfunction 
and/ or cell death in the myocardium. This will likely cause the release of DAMPs such as 
HSPs, which will initiate TLR downstream signalling. This is supported by a study that 
showed the release of HSP72 in plasma taken from patients who had undergone adult cardiac 
surgery with CPB. An additional experiment from the same study showed that monocytes 
from TLR4 mutant mice were unable to produce cytokine release upon exposure to HSP72. 
Such cytokine release was possible in the wild type mice showing that TLR4 expression was 
required. The use of a TLR4 antibody prevented such cytokine release caused by HSP72 and 
therefore an interaction between TLR4 and HSP72 was shown (Dybdahl et al., 2002).  
 
TLRs are expressed in the heart, in the endothelium and on cellular components of the 
immune system, which are all involved in the inflammation caused during cardiac surgery 
with CPB. The fact that TLR activation can be caused by IR injury means that the prevention 
of TLR signalling within the heart could potentially help stop the inflammatory cascades and 
the resulting cardiac dysfunction and cell death. This is supported by the fact that in TLR4 null 
mice, damage caused by IR injury was reduced, indicating preventing TLR4 activation and 
subsequent downstream signalling reduced damage caused by inflammation (Oyama et al., 
2004). The main question is which of the TLRs are of the most relevant for investigation in 
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order to prevent or limit the damage and/ or cell death escalated by inflammation caused 
during cardiac surgery with CPB? 
 
TLR2 and TLR4 are both the best characterized TLRs in the literature with regards to 
their expression in the heart and their role in inflammation. For example, it was shown in a 
study where both were expressed (along with TLR5) in adult human cardiomyocytes that upon 
their deliberate inducement a pro-inflammatory cascade was produced via NFkB. Therefore 
TLR4 and TL2 are good candidates for the investigation of how to reduce inflammation in the 
heart during IR injury caused by cardiac surgery (Boyd et al., 2006). Some more examples of 
studies that show the role played by TLR4 and TLR2 in the immune response and resultant 
inflammation caused in relation to IR injury and other insults are discussed below. MYD88, an 
adapter protein involved in the downstream signalling of both TLR4 and TLR2, will also be 
mentioned. 
 
In relation to TLR4 expression in the heart, a study was performed using mutant TLR4 
mice exposed to IR injury and a reduction in infarction size was observed in the TLR4 mutant 
mice when compared to wild type controls (Chong et al., 2004). Another study, already 
described, supported these findings (Oyama et al., 2004). A study that involved using the 
TLR4 inhibitor eritoran in a mouse animal model resulted in a reduced infarction size and a 
reduced inflammatory response in relation to IR injury (Shimamoto et al., 2006). In the same 
study, using TLR4 knockout mice it was shown that the reduction in infarct size was through a 
phosphoinositide 3-kinase-dependent pathway (Hua et al., 2007). A study conducted very 
recently showed that the pre-administration of LPS in mice before IR injury, which would 
induce TLR4 expression, could provide protection against damage. This protection was 
abolished in TLR4 knockout mice. This TLR4 signaling occurred via MYD88 and involved 
inducible nitric oxide synthase (iNOS) and soluble guanylate cyclase (sGC) (Wang et al., 
2011). An interesting study investigated TLR4 expression during heart transplants performed 
between TLR4 knockout and wild type mice strains. The mice were exposed to a 2 hour 
period of hypothermic ischemia and were then reperfused. Serum samples were taken and the 
levels of cytokines were determined. The mutant group had lower levels of cytokines when 
compared to wild type (Kaczorowski et al., 2007). The same group investigated which other 
proteins were involved in such TLR4 signalling during hypothermic IR injury. It was found 
 
 
61 
that CD14, MYD88, TRIF, and HMGB1 were all involved in the inflammation caused 
(Kaczorowski et al., 2009). 
 
In relation to cardiac function, a TLR4 expression study was performed using TLR4 
knockout mice compared to wild type mice that were exposed to IR injury. It was found that 
despite the knockout mice having a reduction in MI formation and cytokine release, it was 
found that left-ventricular developed pressure was reduced in the TLR4 knockout mice compared 
to wild type (Kim (i) et al., 2007). This was contradicted in another study. When knockout 
TLR4 mice were exposed to IR injury, it was demonstrated that there was a reduction in the 
amount of cardiac dysfunction and a reduction in the production of pro-inflammatory 
cytokines caused by IR injury when compared to appropriate controls (Cha et al., 2008).  
 
The majority of these animal studies indicate that a lack of TLR4 expression attenuates 
inflammation caused by IR injury. Most studies involve the use of TLR4 knockout mice, 
which usually results in a reduced MI or a decrease in the expression of pro-inflammatory 
cytokines. All except one study disagreed, where LPS induced TLR4 expression providing 
protection against IR injury (Wang et al., 2001). The fact that TLR4 expression was induced 
prior to IR injury could suggest a reason for the disagreement. Activation of the TLR4 
signalling pathway may in some way provide protection against the subsequent insult of IR 
injury. Also lack of TLR4 has been shown to reduce the incidence of cardiac dysfunction (Cha 
et al., 2008). As before, there was a study that indicated the opposite where the lack of TLR4 
expression did not prevent cardiac dysfunction (Kim (i) et al., 2007). Based on the evidence, 
TLR4 provides a good example of a gene worth investigating for its role in IR injury and 
inflammation. One distinction that should be made is that these animal studies do not involve 
exposure to activated components of the immune system that would be present within the 
systemic circulation during the use of CPB. Also, the mice used would not have undergone 
anaesthetics or cardioplegia. All these factors would likely effect TLR expression seen during 
cardiac surgery with CPB therefore the expression seen in these animal models may not be an 
appropriate comparison. 
 
TLR4 is expressed in cardiac tissue as well as on cellular components of the immune 
system. It was shown using both wild type and TLR4 knockout mice, treated with LPS in 
order to induce TLR4 expression, that a lack of leukocyte TLR4 expression was responsible 
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for a reduction in cardiac dysfunction. This was not seen for TLR4 expressed on cardiac 
myocytes. This could indicate it is the activation of TLR4 signalling in the cells of the immune 
system present in the blood being circulated by CPB that is responsible for cardiac 
inflammation and resulting cardiac dyfunction caused during cardiac surgery (Tavener et al., 
2004). These finding were contradicted in a study performed using TLR4 knockout, chimeric 
and wild type mice where it was indicated that it was cardiac myocardial TLR4 expression 
that caused dysfunction after MI rather than TLR4 expressed on cells of the immune system 
(Fallach et al., 2010). This role of cardiac TLR4 expression was again supported by a study 
that showed cardiac TLR4 expression induced by LPS was involved in impairment of cardiac 
function (Baumgarten et al., 2006). In another study it was found that removal of TLR4 
expression in both cardiac tissue and on cellular components of the immune system 
contributed to reduced contractile dysfunction (Binck et al., 2005). All these studies suggests 
that inhibiting TLR4 expression could potentially limit the consequences of cardiac surgery 
with CPB that can often lead to such cardiac dysfunction. However, there was some confusion 
over whether it was cardiac TLR4 expression or TLR4 expression on aspects of the immune 
system responsible for this. 
 
In relation to TLR2 expression it was recently shown that in TLR2 null mice that were 
exposed to IR injury, there was no difference in infarct size when compared to wild type 
controls. Despite this, the contractile ability of the wild type group after IR injury was 
sufficiently impaired when compared to the TLR2 null mice. This highlights the potential role 
of TLR2 in cardiac dysfunction that can be caused by IR injury during cardiac surgery (Sakata 
et al., 2007). In contradiction to this previous study, it was shown that the absence of TLR2 
expression in TLR2 mutant mice reduced MI size as a result of IR injury. Also, the number of 
neutrophils within the myocardium in response to IR injury was reduced in TLR2 mutant 
mice. Lack of TLR2 expression also provided protection against endothelial dysfunction due 
to IR injury and also resulted in a reduced number ROS in the cardiac tissue (Favre et al., 
2007). Using an antibody raised against circulating TLR2 that prevented its activation, it has 
been shown that infarction size in mice exposed to IR injury was reduced, again highlighting 
the role of TLR2 in myocardial IR injury and how the prevention of TLR2 induction could be 
beneficial in the setting of cardiac surgery (Arslan et al., 2010). In a study using wild type and 
TLR2 knockout mice, the activation of TLR2 signaling by administration of a TLR2 ligand 
before IR injury caused the activation of the phosphoinositide 3-kinase-dependent pathway. 
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This provided protection against IR injury. Such protection was lost in knockout TLR2 mice 
showing the phosphoinositide 3-kinase-dependent pathway was TLR2 dependent (Ha et al., 
2010).  
 
Again, all these animal studies that investigate TLR2 expression mostly involve the 
use of TLR2 knockout mice. Again, as with TLR4, most support the premise that a lack of 
TLR2 expression reduces MI formation and inflammation. There were again some studies that 
disagreed with this. One where TLR2 expression was induced prior to the IR injury suggested 
that the inducement of TLR2 expression prior to the IR insult provides protection against 
injury (Ha et al., 2010). This is similar to the study for TLR4 that disagreed with the majority 
of the other evidence for a similar reason (Wang et al., 2011). Also, there was one study that 
used TLR2 knockout mice that indicated that lack of functional TLR2 had no affect on MI 
formation (Sakata et al., 2007). 
 
It has already been discussed that there was some disagreement about if it was 
circulating TLR4 expressed on cells on the immune system or if it was TLR4 expressed in 
cardiac tissue that was responsible for cardiac dysfunction. This was also raised in relation to 
TLR2 in a few studies. In one study, where bone marrow transplantation between wild type 
and TLR2 mutant mice was performed, it was indicated that it was circulating TLR2 
responsible for a reduction in MI formation. This study was therefore more related to 
myocardial inflammation rather than cardiac dysfunction (Arslan et al., 2010). Another study 
that performed similar experiments while investigating endothelial dysfunction caused by IR 
injury suggested that both circulating TLR2 and TLR2 expressed within cardiac tissue was 
responsible for a reduction in damage done by IR injury (Favre et al., 2007). This again 
highlights the question of whether is it cardiac TLR expression or TLR expression on cells of 
the immune system that should be investigated. 
 
MYD88, a key adapter protein in TLR signalling (apart from TLR3), could also be a 
potential target in order to reduce the incidence of inflammation in relation to IR injury. 
Experiments have been performed in rats in which MYD88 expression was blocked by 
transfection and then the animals were exposed to IR injury. Infarct size was significantly 
smaller in the knockout mice compared to controls. NFkB expression was also reduced 
compared to controls, as was apoptosis due to cardiac IR injury (Hua et al., 2005). Using 
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MYD88 null mice in comparison to wild type controls it was shown that upon exposure to IR 
injury, the MYD88 null mice sustained less damage and less inflammation compared to 
controls. This study illustrates that attenuating MYD88 expression could be a potential benefit 
as it may reduce inflammation caused by IR injury that can be caused during cardiac surgery 
(Feng et al., 2008). MYD88 is a downstream adapter protein involved in both TLR2 and 
TLR4 signalling. These animal studies show that a lack of functional MYD88 attenuates MI 
formation and inflammation caused by IR injury. Therefore, MYD88 is a good candidate to 
investigate in relation to inflammation caused by IR injury during cardiac surgery, just like 
TLR2 and TLR4. 
 
In relation to evidence of TLR signalling during cardiac surgery, adult patients who 
underwent elective cardiac surgery with CPB had elevated circulating monocyte TLR2 and 
TLR4 expression post-operatively, with TLR4 being significantly increased (Dybdahl et al., 
2002). Another study investigated TLR4 signalling during cardiac surgery with CPB using a 
TLR4 inhibitor known as eritoran (previously mentioned). Patients were infused with the 
inhibitor or a placebo (control) 1 hour prior to the initiation of CPB and there were no obvious 
benefits seen. Specifically, no difference in inflammation or organ dysfunction was seen when 
comparing patients infused with eritoran to the control patient group (Bennett-Guerrero et al., 
2007). 
 
Patients who undergo cardiac surgery are often exposed to hyperoxic levels of O2 
during surgical procedures (Ihnken et al., 1998; reviewed in Allen et al., 2001). Such exposure 
can cause the induction of TLR expression and activation of the related downstream signalling 
pathways that lead to inflammation. This is usually more problematic for the lungs. For 
example, a study was performed which involved cultured alveolar epithelial cells. The study 
investigated the effect of acute lung injury on TLR signalling. It was shown that hyperoxic 
exposure for 2 hours caused an increase in the production of ROS within the cells. This caused 
an increase in the expression of both TLR2 and TLR4 and an increase in the production of 
pro-inflammatory cytokines (Huang et al., 2011). Another study using TLR4 null mice 
showed that prolonged exposure to hyperoxia (100% O2) caused a higher degree of damage to 
the lungs and a higher mortality rate in the null mice when compared to controls (Zhang et al., 
2005). Another study investigated the effect of hyperoxic exposure (80% O2 for either 48 
hours or 96 hours) on both TLR4 null and wild type rats. Such exposure caused the activation 
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of the NFkB pathway within the lungs, which occurred via the receptor TLR4. Such activation 
was reduced in the mutant mice (Ogawa et al., 2007). Hyperoxic exposure can cause apoptosis 
and in a study involving TLR4 inducible transgenic mice, it was shown that when exposed to 
hyperoxia (100% O2 for 72 hours), such mice that had TLR4 induced expression had a 
noticeable reduction in pulmonary apoptosis when compared with appropriate controls 
(Qureshi et al., 2006). Therefore, TLR4 has been shown to have a role in both inflammation 
and apoptotic cell death that is caused by exposure to hyperoxic levels of O2. 
 
Overall, there is an abundance of evidence involving animal studies that show that 
TLR4, TLR2 and MYD88 have an important role during IR injury and the resulting 
inflammation. There are a few examples of studies that promote TLR4 and TLR2 as being 
cardio-protective, but these studies suggested such protection was present due to the 
inducement of their expression prior to IR injury (Kim (i) et al., 2007; Wang et al., 2011). 
Also, there is some disagreement about whether it is cardiac TLR2/ 4 expression or the 
expression of TLR2/ 4 on cellular components of the immune system that should be focused 
on. Despite this, there is enough evidence cited that TLR4, TLR2 and MYD88 are valid 
indicators of inflammation and therefore valid genes to investigate in this project. Specifically, 
how their expression is affected by cardiac surgery with CPB and the resultant IR injury. 
 
1.5 What is Nuclear factor kappa B? 
TLRs have already been described in detail as PRRs that recognize PAMPs or 
DAMPs. Such activation of TLRs will facilitate downstream signalling that will result in the 
activation of the transcription factor NFkB (reviewed in Kawai and Akira, 2007). 
 
NFkB was first discovered in 1986 where it was shown to be a nuclear factor that 
bound DNA, specifically the immunoglobulin κB light chain promoter in B lymphocytes 
(Sen and Baltimore, 1986). NFkB is part of a protein family that contains 5 different but 
structurally similar subunits that will combine to make different homo and hetero-dimers in 
order to become functional transcription factors. In fact, dimerization is a requirement for 
DNA binding overall for this protein family (Logeat et la, 1991; Bressler et al., 1993). The 
most common dimer formed within this protein family is p50-p65. This is what is often 
referred to as “NFkB” and is the one most abundant in the heart. This dimer has been shown to 
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have a DNA binding function (Urban (i) and Baeuerle, 1991; Urban (ii) et al., 1991; Ganchi et 
al., 1993; reviewed in de Winther et al., 2005).  
1.5.1 NFkB and the heart 
NFkB plays a part in many different roles with the cardiovascular system. Of all NFkB 
dimers present in the heart, p50-p65 seems to be the most dominantly expressed (Norman et 
al., 1998).  In relation to TLRs, which are one of the main inflammatory mediators of interest 
in this project, NFkB can be activated by TLR signalling via both the MYD88 signalling 
pathway and also by the MYD88 (TRIF) independent signalling pathway. These have been 
described in more detail elsewhere but both result in the activation of NFkB and the 
production of pro-inflammatory cytokines, adhesion molecule activation and activation of 
leukocytes, all of which are aspects of an innate immune inflammatory response that can occur 
within the heart (reviewed in Kawai and Akira, 2007). Evidence that supports this is a study 
performed using knockout mice for MYD88 and TRIF. It showed that in mice that were 
deficient in both proteins, NFkB activity was completely stopped in relation to TLR4 
activation. Also in TRIF deficient mice, the activity of NFkB was severely reduced 
(Yamamoto et al., 2003).  
 
Evidence of NFkB expression in the heart includes a study that investigated 
myocardial infarction using p50 knockout mice. This study showed that when the subunit p50 
of the NFkB dimer was absent, cardiac dysfunction was reduced, showing the role of NFkB in 
promoting a more severe outcome during heart failure (Frantz et al., 2006). This is supported 
by another study involving heart failure that showed NFkB expression was upregulated within 
cardiac tissue obtained from patients with this condition (Frantz et al., 2003).  
 
In relation to damage done during cardiac surgery, such as IR injury, a study was 
performed using wild type and NFkB knockout mice. It was shown that the lack of the p50 
subunit reduced the damage caused by IR injury compared with the wild type controls (Frantz 
et al., 2007). Specific examples showing the expression of NFkB during the use of cardiac 
surgery with CPB includes a study involving left ventricular biopsies obtained from the adult 
heart during cardiac surgery with CPB. It demonstrated that NFkB promoted an inflammatory 
response (Valen et al., 2001). Another study showed that CPB induced the expression of 
NFkB and TNF in patients undergoing elective cardiac surgery (Meldrum et al., 2003).  
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The interest of NFkB in this project is because of its role as a transcription factor. It 
can activate an inflammatory response, which includes the production of pro-inflammatory 
cytokines (Libermann and Baltimore, 1990). Many more examples of the pro-inflammatory 
nature of NFkB have already been mentioned in previous sections. 
 
1.6 Heat Shock Proteins 
1.6.1 What are HSPs? 
In 1962, it was observed that exposing salivary gland cells of Drosophila busckii to 
heat shock caused the formation of visible “puffs” to form on the Drosophila’s polytene 
chromosomes (Ritossa, 1962). This indicated heat induced gene expression had occurred at 
these chromosomal sites and the resulting proteins of this expression became known as heat 
shock proteins (HSPs) (Tissières et al., 1974). These HSP genes are highly conserved, being 
found in both eukaryotes and prokaryotes (reviewed in Feder and Hofmann, 1999). They are 
ubiquitously expressed in all cell types and are highly expressed within intracellular 
compartments. These include the cytosol of prokaryotes and the cytosol, mitochondria, 
endoplasmic reticulum and nucleus/nucleolus of eukaryotes (reviewed in Kiang and Tsokos, 
1998; reviewed in Latchman, 2001; reviewed in Srivastava et al., 2002; reviewed in Pockley, 
2003). As different HSPs were identified they were differentiated and named based upon their 
molecular weight (kD) (reviewed in de Jong et al., 2009). About 10 different families of HSPs 
have been identified. Although proteins from a single family were related in structure and 
function, there was little homology found when members of different families were compared 
(reviewed in Srivastava et al., 2002).  
1.6.2 HSP families 
Examples of the main classes of mammalian HSPs, as these are most relevant to the 
present discussion, include HSP110, HSP90, HSP70, HSP60, HSP40, HSP32 (heme 
oxygenase-1), small HSP (sHSP) (e.g. HSP20, HSP27 and αB-crystallin) and ubiquitin 
(protease) (reviewed in Latchman, 2001; reviewed in Pockley, 2003; reviewed in Noble et al., 
2008). Only those families that have been the best characterised will be discussed in more 
detail. 
 
The HSP90 superfamily makes up the majority of cellular protein content (Jakob et al., 
1995). It is generally expressed in the nucleus and the cytoplasm and it functions as a 
 
 
68 
chaperone protein, helping intracellular proteins maintain their formation, especially during 
times of cellular stress (reviewed in Noble et al., 2008). It plays a key role in preventing the 
activation of HSP gene expression via its interaction with heat shock factor one (HSF1), the 
key regulator of HSP activation (Zou et al., 1998). It also influences the function of steroid 
receptors (reviewed in Pratt, 1998) and has been shown to be present in the extracellular space 
where it is thought to interact with the body’s immune system (reviewed in Schmitt et al., 
2007).  
 
The HSP70 superfamily is very large with at least 12 members. It is highly conserved 
in evolution (Hunt and Morimoto, 1985) and is the best characterised of all HSP families 
(reviewed in Daugaard et al., 2007). Of these members, the inducible form of HSP70 (HSP72) 
and its constitutive form HSC70 (HSP73) are both localised in the cytoplasm (Brown et al., 
1993) and the nucleus (reviewed in Noble et al., 2008). HSC70, unlike HSP70, is non 
inducible during cellular stress, with it undertaking important housekeeping functions, while 
HSP70 participates in cellular defense against insult (reviewed in Noble et al., 2008). HSP70/ 
HSC70 under normal conditions act as chaperones, assisting in protein folding and transport 
(Shi et al., 1992), but under stressful conditions, HSP70 is induced to help protect the cell 
against damage and also helps maintain cellular stability by being anti-apoptotic (reviewed in 
Schmitt et al., 2007). Other members of the family include HSP78 that is localised in the 
endoplasmic reticulum and HSP75 that is localised in the mitochondria. Both HSP78 and 
HSP75 function as chaperones (reviewed in Noble et al., 2008). As well as these intracellular 
roles, HSP70 has also been localised at the cellular membrane, specifically on mammalian 
tumour cells (Multhoff et al., 1995) and in the extracellular space where it is thought to 
interact with components of the immune system just like HSP90, which is described more in 
detail later (reviewed in Schmitt et al., 2007). 
 
The HSP60 family, also known as chaperonins, are mainly localised in the 
mitochondria of mammalian cells (reviewed in Horvath et al., 2008) where they chaperone the 
protein folding and transport of mitochondrial proteins, and their proteolysis when they are 
beyond repair (reviewed in Garrido et al., 2001). HSP60 is also found in the cytoplasm, where it 
functions as an anti-apoptotic protein (reviewed in Arya et al., 2007). HSP60 is regulated by 
its co-chaperone HSP10 when performing its functions (Shan (i) et al., 2003; Shan (ii) et al., 
2003). It was shown that both chaperonins functioned together to prevent cell death in the 
 
 
69 
mitochondrial membrane of rat cardiac myocytes (Lin et al., 2001). However, HSP60 can also 
be pro-apoptotic, as both HSP60 and HSP10 were shown to promote apoptosis in the 
mitochondria of Jurkat T cells. They did this by binding and promoting the function of 
caspase-3, which is activated by cytochrome C, resulting in the acceleration of apoptosis 
(Samali et al., 1999). HSP60 has been localised to the plasma membrane, been found in the 
plasma and also in the extracellular space where it is thought to interact with the immune 
system, all of which was shown in a study of heart failure using both rat and human models 
(Lin et al., 2007; reviewed in Horvath et al. 2008). 
 
 Hemeoxygenase (HO), which was first discovered by Tenhunen et al in 1968, is an 
enzyme that facilitates the degradation of heme. This reaction yields the by-products carbon 
monoxide, ferrous iron and biliverdin, which is then further converted into bilirubin by 
biliverdin reductase (Tenhunen et al., 1968; reviewed in Idriss et al., 2008). It exists in 3 
isoforms, the first of which is HO-1, which is known to be induced by a number of factors that 
include heavy metals and ROS (reviewed in Idriss et al., 2008) and which is also known as 
heat shock protein 32 (HSP32). The second isoform is HO-2, and although it is non-inducible, 
it is constitutively expressed in various tissues throughout the body. Its specific function is 
thought to be maintaining the basic homeostatic balance of haem within the body’s tissues 
(reviewed in Idriss et al., 2008). The third and final isoform HO-3 that was originally found in 
the rat is the least characterised within the literature and does not seem to have a major 
function. It has even been suggested that it is in fact a psudogene similar in structure to HO-2 
(McCoubrey et al., 1997; Hayashi et al., 2004). HO-1, which is also known as HSP32, is the 
one of greatest interest in relation to this project (Taketani et al., 1989).  
 
HSP27 (HSP25) is a member of the small HSP superfamily, the members of which 
range between 15 and 30 kDa (reviewed in Schmitt et al., 2007). HSP27 is localised mainly in 
the cytoplasm and the nucleus (reviewed in Noble et al., 2008) where it acts as a chaperone, 
primarily preventing protein aggregation (Ehrnsperger et al., 1997). The induction of HSP27 
expression is caused by heat shock and other types of cellular stress (Landry et al., 1989; 
reviewed in Salinthone et al., 2008). As well as other members of the sHSP family, HSP27 
can undergo phosphorylation and form large oligomers, the extent of which depends on the 
extent of cellular stress (Garrido, 2002). Such phosphorylation, which causes a conformational 
change in the oligomers formed by HSP27, have been shown to improve the stability of the 
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cytoskeleton under heat shock stress in stable Chinese hamster cells which either 
constitutively expressed wild-type HSP27 or an HSP27 isoform that was not able to be 
phosphorylated (Lavoie et al., 1995). HSP27 has also been shown to protect the cytoskeleton 
in neonatal cardiac cells (van de Klundert et al., 1998). HSP27 is also an anti-apoptotic 
protein. Its interaction with cytochrome c upon its release from the mitochondria negatively 
regulates apoptotic cell death by preventing cytochrome c activating caspases in the cytosol 
(Bruey et al., 2000).  Another well-characterised member of the sHSP family is αB-crystallin 
that is ubiquitously expressed, but has particularly high expression in the heart, eye lens and in 
muscles and like HSP27 is an anti-apoptotic protein (reviewed in Arya et al., 2007; reviewed 
in Noble et al., 2008). HSP27, just like HSP60, HSP70 and HSP90 has also been localised to 
the extracellular space (reviewed in Calderwood (i) et al., 2007).  
 
Heat shock protein 20 (HSP20) was first discovered in 1994 when it was isolated from 
rat and human skeletal muscle (Kato et al., 1994). This protein, also known as HspB6, is part 
of the small heat shock protein family, which is made up of a further 9 other proteins (Kappé 
et al., 2003). Another member of note is HSP27, which has already been described. A possible 
function for HSP20 was shown in a study involving vascular smooth muscle. It was suggested 
that phosphorylated HSP20 was able to cause vasorelaxation, which could be beneficial if 
cellular stress within the heart causes vasoconstriction (Flynn et al., 2003). Another study that 
investigated the vasorelaxation function of HSP20 involved sildenafil, where the application 
of sildenafil was associated with a rise in phosphorylation of HSP20, which was thought to be 
essential for its function. This resulted in an increase in the vasorelaxation of a pre-contracted 
porcine coronary artery, suggesting that HSP20 played a role is this physiological process 
(Tessier et al., 2004). 
1.6.3 Factors that induce HSP expression 
After the initial experimentation with heat shock, several studies undertaken provided 
evidence of other stimuli that induced HSP expression. These include hypoxia (Patel et al., 
1995), exercise (Locke and Noble, 1995), inflammation (reviewed in Horvath et al., 2008), 
hyperthermia (Slakey et al., 1993), ischemia (reviewed in Richard et al., 1996), viral infection 
(Collins and Hightower, 1982), bacterial infection (Zheng et al., 2004), ROS (oxidative stress) 
(Kukreja et al., 1994), sodium arsenite (Li et al., 1983), steroid hormones (Norton and 
Latchman, 1989) and ethanol (Plesset et al., 1982). Consequently, this superfamily of proteins 
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is also known as the “stress proteins”, as they are expressed in response to such a range of 
stresses in order to reduce, repair or remove any cellular damage caused (Madden et al., 
2008). 
1.6.4 Functions of HSPs 
 
1.6.4.1 Intra-cellular HSP 
The best known function of these proteins is when they are acting as molecular 
chaperones, although it should be noted that not all HSPs fall into this category (reviewed in 
Horvath et al., 2008). Molecular chaperones, which are families of unrelated proteins, assist in 
the correct conformational assembly of newly produced proteins, fixing incorrectly folded 
proteins (protein disaggregation) and the subsequent translocation of correctly folded proteins 
to intracellular or extracellular destinations (reviewed in de Jong et al., 2009; reviewed in 
Horvath et al., 2008; reviewed in Liberek et al., 2008; reviewed in Latchman, 2001). Such 
functions are active even under normal physiological conditions, with constitutively expressed 
HSPs accounting for 5-10% of total cellular protein content (reviewed in Pockley, 2003). 
When a cell is under stress the expression and the action of HSPs are of upmost importance as 
they ensure proteins within the cell maintain their correct conformation and help facilitate the 
proteolysis of proteins denatured beyond repair (reviewed in Latchman, 2001). Table 3 
highlights the intra-cellular roles of most well known HSPs 
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Table 3. Intracellular location and function of major mammalian HSP 
Major Mammalian HSP families Intracellular Location Intracellular function 
HSP 25/ 27 (Small HSP) Cytoplasm/ nucleus Molecular chaperone of anti- apoptotic 
death 
HSP32 (HO-1) Cytoplasm Indirect anti-oxidant via haem 
degradation 
HSP40 Cytoplasm/ nucleus Co-chaperone with HSP70 
HSP60 (chaperonins) Mitochondria/ cytoplasm Correct protein folding in 
mitochondria, anti/pro-apoptotic death, 
anti-inflammation. 
HSP70: 
HSP70/72 (inducible) 
 
HSC70/ HSP73 (constitutive)   
 
HSP75 
 
Cytoplasm/ nucleus 
 
Cytoplasm/ nucleus 
Mitochondria 
 
Molecular chaperone, anti-
inflammation. 
Molecular chaperone 
Mitochondrial chaperone of protein 
transport. 
HSP90 Cytoplasm/ nucleus Molecular chaperone (evolutionary 
modulator) 
HSP110 Nucleolus/ cytoplasm Molecular chaperone 
 
(reviewed in Pockley, 2003; reviewed in Calderwood (i) et al., 2007; reviewed in Noble 
et al., 2008) 
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HSP are also involved in the regulation of apoptosis and through this helps maintain 
overall cell survival, especially in deleterious conditions. For example, the intrinsic 
(mitochondrial/ caspase-9) apoptotic pathway is inhibited by HSP27 (Bruey et al., 2000), 
HSP90 (Pandey et al., 2000) and HSP70 (Beere et al., 2000) but promoted by HSP10 and 
HSP60 (Samali et al., 1999). The extrinsic (receptor mediated) apoptotic pathway is inhibited 
by HSP70 (Park et al., 2001), HSP90 (Sato et al., 2000) and HSP27 (Charrette et al., 2000). 
The fact that HSPs can regulate apoptosis means that they can help maintain cell stability, 
especially during times of cellular stress. 
 
1.6.4.2 Extra-cellular HSPs 
Originally, HSPs were believed to be solely intracellular, which is where their 
cytoprotective roles (maintenance of protein folding and regulation of apoptosis) are carried 
out. It has since been reported that some HSPs are not confined to the cytosol, with some also 
being extracellular. For example, HSP72 was expressed on the plasma membrane of human 
tumour cells (Botzler et al., 1998; Gastpar et al, 2004). Also, release of HSP70 was shown in 
neuronal cells (Robinson et al., 2005), human tumour cells (Barreto et al., 2003; Evdonin et 
al., 2004), systemic blood mononuclear cells (Hunter-Lavin et al., 2004) and vascular smooth 
muscle cells (Liao et al., 2000). HSP60 was observed at the mitochondrial plasma membrane 
(Gupta and Knowlton, 2002) and the plasma membrane of adult cardiac myocytes (Lin et al., 
2007). It was also demonstrated that HSP60 was released from human neuroblastoma cells 
(Bassan et al., 1998). B cells have been shown to release HSP27, HSP70 and HSP90 (Clayton 
et al., 2005). HSP60 and HSP70 have also been detected in patient serum samples (Pockley et 
al., 1998; reviewed in Pockley et al, 2008). All this evidence supports the extracellular 
location of HSPs. 
 
The method used by HSPs to become extracellular, with HSP70 being the most 
investigated, has long been a subject of controversy. The existence of extracellular HSPs has 
only been accepted in recent times (reviewed in Mambula et al., 2007). In order to investigate 
the method of HSP extracellular release, several studies were performed that involved HSP70. 
HSP70 secretion does not occur by the classical pathway, i.e. it does not encode a leader 
signal protein (reviewed in Calderwood (i) et al., 2007). There are several alternative 
pathways by which leaderless proteins can be secreted. The first is because of necrotic cell 
death, which was shown in a study where HSP70 was released from prostate carcinoma cells 
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when they become necrotic (Mambula (i) and Calrderwood, 2006). Another method of 
secretion was the release of proteins from the intracellular space via secretory vesicles, a 
method used for the release of Interlukin-1β (another leaderless protein) from activated 
monophages (MacKenzie et al., 2001). This method of release was shown to be available for 
the extracellular release of HSP90, HSP70, HSC70 and HSP27, which were excreted from 
heat shocked B-cells via exosomes (Clayton et al., 2005). Another pathway for the release of a 
leaderless protein such as HSP70 was shown to be via lysosomal endosomes that transfer 
intracellular proteins to the plasma membrane and release them into the extracellular space. 
This was shown to be the method by which HSP70 was released from tumour cells (Mambula 
and Calderwood, 2006).  
 
 
1.6.4.3 HSPs and the immune system  
The extracellular functions of HSPs have been extensively investigated and the 
majority of these functions include interaction with aspects of the immune system (table 4) 
(Calderwood (i) et al, 2007). 
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Table 4. Extracellular functions of mammalian HSPs 
Major Mammalian 
HSP families 
Extracellular 
Location 
Extracellular 
function 
References 
HSP20 (small HSP) Extracellular space Anti-inflammatory Wang et al., 2009 
HSP25/ 27 (small 
HSP) 
Extracellular space Anti-inflammatory Reviewed in Calderwood 
(i) et al., 2007) 
HSP32 (HO-1) Extracellular space Anti-inflammatory Yeh et al., 2009 
HSP60 (chaperonins) Plasma membrane 
Extracellular space 
Pro-inflammatory 
 
Lin et al., 2007 
Bassan et al., 1998 
Chen et al., 2000 
HSP70/ 72 (inducible) Plasma membrane 
Extracellular space 
Antigen-presentation 
Pro-inflammatory 
Interacts with NKC 
Botzler et al., 1998; 
Gastpar et al, 2004 
Liao et al., 2000 
Dybdahl et al., 2002 
Noessner et al., 2002 
Asea et al., 2000 
Multhoff et al., 2001 
HSP90 Extracellular space Pro-immune Reviewed in Calderwood 
(i) et al., 2007) 
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HSPs are thought to interact with aspects of the immune system in the extracellular 
space upon release (Basu et al., 2000; reviewed in Pockley et al., 2008). For example, HSP70, 
much like major histocompatibility complex (MHC) molecules, has been shown to bind 
antigenic peptides forming a HSP-peptide complex, which bind to receptors on the surface of 
antigen presenting cells (APC) and then are taken up by them (Noessner et al., 2002). This 
results in the major histocompatibility complex I (MHC I) presentation of these peptides on 
the surface of APC (antigen cross-presentation) (Arnold-Schild et al., 1999; Singh-Jasuia et 
al., 2000). This causes the activation and proliferation of cytotoxic (CD8+) T lymphocytes 
(Blachere et al., 1997).  
 
For HSP-peptide complexes to be taken up by APC, specific receptors need to be 
expressed on their surface (reviewed in Binder et al., 2004). Such examples include TLR2, 
TLR4 and the LPS receptor CD14 that are all specific for extracellular HSP70 (reviewed in 
Schmitt et al., 2007). Other examples of cell receptors that are thought to interact with 
extracellular HSPs and help facilitate their role in immunity include the oxidised LDL binding 
protein CD91/ LRP, the tumour necrosis factor CD40 and scavenger receptors (reviewed in 
Calderwood (ii) et al., 2007).  
 
HSPs can also interact with APC receptors and cause an immune response without 
being bound to antigenic peptides when released into the extracellular space in response to 
trauma. For example, HSP70 can induce the expression of the pro-inflammatory cytokines 
tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-6 in human monocytes 
(APCs) by utilising the receptors TLR2 and TLR4 (Asea et al., 2000). HSP70 can also prime 
dendritic cells (Asea et al., 2002) and macrophages (Basu et al., 2002) to initiate the 
production of pro-inflammatory cytokines. HSP60 has also been shown to induce the 
production of pro-inflammatory cytokines like TNF-α from macrophages, also known APCs 
(Chen et al., 2000). It was shown in a study that macrophages of C3H/ HeJ mice, which are 
characterised by a mutant TLR4 gene, were unable to respond to HSP60, which is known to 
induce the production of pro-inflammatory cytokines. This indicated that HSP60 utilises TLR4 
for interacting with macrophages (Ohashi et al., 2000). This release of pro-inflammatory 
cytokines is caused by the activation of the transcription factor NF-kB, whose downstream 
signaling is also responsible for increasing the production of enzymes such as nitric oxide 
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synthase (reviewed in Lee and Kim, 2007). All this evidence highlights the fact that HSPs are 
involved in causing a pro-inflammatory response by acting as DAMPs in the extracellular 
space. Therefore, they could be involved in the inflammation in the myocardium that occurs 
during cardiac surgery with CPB (reviewed in de Jong et al., 2009). 
 
HSPs can also cause an anti-inflammatory response. For example, in a study where 
HO-1 (HSP32) was overexpressed in endothelial cells, it was shown that this over-expression 
inhibited inflammatory and cell death cascades, including a reduction of NFkB activation 
(Zabalgoitia et al., 2008). Another study using a rabbit model that investigated the affect HO-1 
on damage done by CPB and cardioplegia showed that HO-1 was able to reduce the level of 
apoptosis of cardiomyocytes. There was also a reduction in the levels of pro-inflammatory 
cytokines produced by NFkB and transcription factor AP-1 activation during CPB and 
cardioplegia administration (Yeh et al., 2009). In relation to HSP20, its over-expression has 
been shown to be able to inhibit LPS induced NFkB expression, which results in the 
production of pro-inflammatory cytokines (Wang et al., 2009). HSP70 can be anti-
inflammatory when it is intracellular, where it can inhibit the initiation of the NF-kB signaling 
cascade within cells of the immune system by blocking the NF-kB promoter (reviewed in de 
Jong et al., 2009).  The fact that HSPs are shown to be anti-inflammatory highlights another 
way in which investigating their expression during myocardial IR injury could help limit 
damage during cardiac surgery. 
 
Another important component of the innate immune system are natural killer cells 
(NKC), which have also been shown to interact with HSPs, in particular HSP70 via the NKC 
receptor CD94 (Gross et al., 2003). This interaction is thought to provide an additional 
activating signal for NKC, which is of particular interest in cancer therapy as HSP70 is highly 
expressed on several types of cancer cells (reviewed in Schmitt et al., 2007). HSP70 
interaction with NKC can also cause them to have increased cytolytic activity (Multhoff et al., 
2001) and cause an increase in its chemotaxis (Gastpar et al., 2004).  
 
1.6.4.4 Pre-conditioning 
A novel trait of HSP gene expression is that an initial cellular insult that causes HSP 
expression can enhance cellular defense against subsequent insult. This is known as pre-
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conditioning. It was found that the level of cellular protection afforded was proportional to the 
level of HSP expression produced by the initial insult (reviewed in Latchman, 2001). This 
feature of HSPs became of particular interest for those in the cardiovascular field in relation to 
protection against IR injury, which is a consequence of cardiac surgery with CPB, a subject 
that has already been discussed (see section 1.3). 
1.6.5 Regulation 
Heat shock transcription factor 1 (HSF-1) is thought to be the overall regulator of 
stress-induced heat shock gene transcription in vertebrates (Sarge et al., 1993; reviewed in 
Shamovsky and Nudler, 2008). Upon stress, HSF-1 is phosphorylated from a monomer 
(inactive) to a trimer (activated) and then translocated from the cytosol to the nucleus (Sarge et 
al., 1993). This trimer has a high binding affinity for the promoter regions of HSP genes, 
known as heat shock elements. Once HSF-1 has undergone phosphorylation and the trimer 
binds, transcription of HSPs is activated (Sarge et al., 1993; reviewed in Pockley, 2003). The 
efficiency of HSF-1 to carry out its function seems to be age dependent, with it becoming less 
affective as age increased. This was shown in a study where the response of HSF-1 was 
decreased in the myocardium of aged rats compared to that of rats that were younger (Locke 
and Tanguay, 1996). 
 
1.6.6 HSPs, cardio-protection and cardiac surgery 
A consequence of cardiac corrective surgery with CPB is IR injury of the myocardium 
(reviewed in de Jong et al., 2009). There are many physical methods employed during cardiac 
surgery that protect the heart against IR injury that have already been described (see section 
1.2.2). 
 
 IR injury to the cardiac tissue during cardiac surgery using CPB is a type of cellular 
stress. Certain cardio-protective proteins are expressed under such stressful conditions. These 
would include HSPs, which are known molecular chaperones, whose function is to ensure that 
the proteins within the cytoplasm of a cell are maintained in the right conformation. They also 
help prevent apoptotic cell death and therefore helps maintain cellular stability. This is 
especially important during a stress such as IR injury that occurs during cardiac surgery. HSPs 
also provide subsequent protection against a subsequent insult in a process known as pre-
conditioning (reviewed in de Jong et al., 2009). 
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HSP70 is highly expressed in myocardial tissue under assault and provides cardiac 
protection against stress, including against IR injury (reviewed in Latchman, 2001). The 
ability of HSP70 and other HSPs to provide such protection after IR injury in cardiac tissue 
has been shown in several studies, which are listed below. It should be noted that most of the 
following examples that highlight the protection provided by HSPs in myocardial tissue 
includes pre-conditioning (reviewed in Latchman, 2001). Examples also include HSP 
overexpression studies. These were performed because the studies involving HSPs being 
induced by pre-conditioning did not necessarily demonstrate that HSP expression was the sole 
source of protection against cardiac stress. Therefore they did not exclude other possible 
contributing factors produced during the initial stress factor (reviewed in Latchman, 2001). 
 
1.6.6.1 HSPs cardiac expression studies using cardiac cells 
Specific examples of studies involving cardiac cells include a study where stress 
induced expression of HSP72 by heat shock was shown to restrict the degree of myocardial 
damage caused by ischemia in myogenic heart cells (Mestril et al., 1994). Another study was 
performed using liposome-mediated gene transfer of HSP72 into rat myocardium cells where 
over-expression of HSP72 provided protection against IR injury, again highlighting its cardio-
protective function (Liu et al., 2007). HSP27 has also been shown to provide protection 
against IR injury using cardiac cell studies. For example, HSP27 was transfected into rat 
myocytes, which provided protection against cellular stress (Kwon et al., 2007). Another study 
overexpressed HSP27 in rat cardiomyocytes that then underwent simulated IR injury. Such 
overexpression was shown to protect against insult (Lu et al., 2008). HSP20 has also been 
found to be cardio-protective in cardiac cells. There was a study performed using adult rat 
cardiomyocytes that were transfected with a mutant HSP20 gene. The cells were then exposed 
to IR injury and had reduced protective ability when compared to the rat cardiomyocytes 
containing the normal HSP20 gene (Nicolaou et al., 2008). A study using adult rat 
cardiomyocytes that overexpressed HSP20 showed that these cells were protected against 
apoptosis induced by a β-agonist, highlighting a potential cardio-protective role for HSP20 
(Fan et al., 2004). All of these examples show that induction or the overexpression of HSPs 
can provide protection against IR injury, one of the main sources of damage to the 
myocardium during cardiac surgery with CPB.  
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1.6.6.2 HSPs cardiac expression studies using animal models 
There have been several studies using animal models that have shown the cardio-
protective effects of HSPs against IR injury. In one study, the induction of HSP27 and HSP70 
by simulated MI reduced the amount of damage afflicted by IR injury (Pantos et al., 2007). 
Another study used mice with HSP72 null mutations that were exposed to IR injury. These 
knockout mice were shown to be more susceptible to damage caused by IR injury (Kim et al., 
2006). When HSP27 was induced into rats using a protein delivery system, it was successfully 
expressed in the heart and resulted in a reduction in damage caused by IR injury (Kwon et al., 
2007). Another study using a rat animal model showed that overexpression of HSP27 provided 
such mice with enhanced protection against damage caused by IR injury  (Lu et al., 2008).  
 
In relation to HSP20, this protein was over-expressed in a transgenic mouse model. 
These mice were exposed to IR injury and it was shown that this over-expression contributed 
to better contractile function after the insult. There was also a reduction in apoptosis and in MI 
formation (Fan et al., 2005). Interestingly, it was shown that it is the C-terminus of HSP20 that 
is responsible for its cardio-protective ability (Islamovic et al., 2007). A specific substitution 
mutation within the HSP20 gene completely knocked out this cardio-protective ability due the 
fact it reduced the degree of HSP20 phosphorylation (Nicolaou et al., 2008). This blockage of 
HSP20 phosphorylation has also been shown to stop the cardio-protective nature of HSP20 in 
the incidence of IR injury (Qian et al., 2009).  
 
HO-1 (HSP32) was shown to be cardio-protective in a study performed using mice 
with impaired HO-1 gene expression that were exposed to IR injury in comparison to wild 
type controls. It was shown that mice with reduced HO-1 expression sustained more damage 
when compared to wild type controls (Yoshida et al., 2001). Such protection was also seen in 
a study using transgenic mice that had variable overexpression of HO-1 that were exposed to 
IR injury (Yet et al., 2001). Another study used a rat model where HO-1, conjugated into a 
viral vector, was introduced into the heart tissue prior to IR injury. It was found that there was 
a significant reduction in MI formation and inflammation when compared to wild type 
controls (Melo et al., 2002). A similar study involved a rat animal model of recurrent IR 
injury. An over-expression of HO-1 was induced by the use of viral vector delivery in the rat 
myocardium 5 weeks before exposure to the IR injury. This resulted in reduced inflammation, 
apoptosis and cardiac dysfunction (Pachori et al., 2006).  
 
 
81 
As with the studies involving the use of cardiac cell, all these studies using animal 
models again show that the induction and over-expression of HSPs can provide protection 
against IR injury. Also, as was often shown with the studies that investigated TLR expression, 
knockout mice were also used to investigate HSP expression. For both HSP72 and HSP32, a 
lack of functional protein seemed to make the animals more vulnerable to IR damage. All of 
this evidence again highlights the value of investigating the expression of HSPs in order to 
provide myocardial protection against IR injury. 
 
1.6.6.3 HSPs expression studies during cardiac surgery 
As well as the various studies described above to show the cardio-protective nature of 
HSPs in cardiac cells and animal models, other studies were carried out in order to show the 
benefit of HSPs in actual cases of cardiac surgical procedures.  For example, a study was 
undertaken that investigated the expression of HSP27, HSP60, HSP70 and HSC70 in pediatric 
patients undergoing cardiac surgery with CPB. The levels of HSPs were measured in tissue 
from the RA removed before and after aortic clamping during the surgical corrective 
procedure. The use of cardioplegic arrest did not cause any significant differences in the 
expression of HSPs. However, it was shown that on average 40% of patients had an increase 
in HSP70 expression and 28% had an increase in the rest of the HSPs investigated after 
cardioplegic arrest. These patients were associated with a lower level of biomarkers that 
indicate the level of cardiac injury. This highlighted an association between HSP70 and other 
HSPs with a better post-operative outcome. Therefore HSPs were shown to be potentially 
cardio-protective (Giannessi et al., 2003). Another study was performed that investigated the 
expression of HSP72 in tissue from the RA from patients undergoing surgical repair of 
congenital heart defects before and after aortic clamping. There was no significant difference 
seen in the expression of HSP72 suggesting that ischemic insult alone does not induce an 
increase in HSP expression (Storti et al., 2001). Overall, all the evidence listed generally 
supports the fact that HSPs are cardio-protective, that they are present in the myocardium and 
that they are beneficial during and after cardiac surgery. Hence, investigating their expression 
could be beneficial for finding new methods of myocardial protection. There are other 
examples of HSP expression during cardiac surgery, which will be discussed later, that are 
related to extracellular HSPs (see section 1.6.6.5). 
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During cardiac surgery with CPB, patients are often exposed to hyperoxic levels of O2. 
Such exposure can cause damage to the patients, in particular within the lungs. It has been 
shown that HSP expression can provide protection against such insult. For example, in a study 
where cultured human respiratory epithelial cells were exposed to hyperoxia (95% O2), it was 
shown that overexpression of HSP70 resulted in increased cellular survival. This indicated that 
HSP expression was protective against oxidative damage sustained in the lungs during cardiac 
surgery with CPB (Wong et al., 1998). HSP27 expression has also been shown to be 
protective within the lungs. Lung epithelial cells were exposed to hyperoxia (95% O2). 
Knockdown of HSP27 expression increased apoptotic cell death upon exposure to hyperoxia 
and overexpression of HSP27 decreased apoptotic cell death by exposure to hyperoxia. This 
study highlighted the protective role of HSP27 within the lungs when exposed to hyperoxia 
(Shao et al., 2009). Also, overexpression of HSP32 (HO-1) in human pulmonary epithelial 
cells was shown to provide enhance resistance against hyperoxic exposure (Lee et al., 1996). 
 
1.6.6.4 HSPs expression and cardiac repair of congenital heart defects 
Only a few studies have been carried out to investigate the expression of HSPs in 
relation to congenital heart defects such as TOF. For example, a study was undertaken where 
the level of HSP70 was investigated in muscle samples taken from the RV of patients that had 
undergone different types of corrective congenital heart surgery. HSP70 protein expression 
was demonstrated to some degree in all samples by the use of western blotting and 
immunohistochemistry. The cause of this expression was unclear and could have been caused 
by cellular stress, such as the trauma of the surgery itself, the hypoxic environment in the RV 
of such patients or by the hypertrophy seen in all samples used in the study (Nakamura et al., 
2000).  In a study which investigated HSP levels in hypertrophic cardiac muscle samples taken 
from the RV from patients undergoing congenital heart surgery, specifically the messenger 
RNA (mRNA) levels of HSP70 and HSP32, it was observed that all samples expressed 
significant levels of both. This upregulation of expression may be due to the trauma of the 
surgery itself, the hypoxic environment in the RV or by the hypertrophic nature of the tissue 
used (Takeuchi et al., 2003). Both these studies show the presence of HSP70, and some others, 
in the myocardium of children undergoing corrective cardiac surgery with CPB. Due to the 
fact that HSPs are known to be cardio-protective this is very important. This is because such 
children are especially vulnerable to the IR injury they are exposed to during corrective 
surgery. This is because they have cyanotic damage before surgery due to the chronic 
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exposure to hypoxia within the RV. Therefore, the investigation into the myocardial 
expression of HSPs in such vulnerable patients could potentially improve methods of 
myocardial protection employed during cardiac surgery. 
 
1.6.6.5 Extra-cellular HSP expression during cardiac surgery  
HSPs are beneficial due to their function as chaperones, which is their intracellular 
function. HSPs, as already stated, are also extracellular (Calderwood (i) et al, 2007). It has 
been shown that HSP70 and other HSPs are released into the extracellular space after cardiac 
surgery. For example, release of HSP70 was detected in the serum of patients who had 
undergone CABG surgery (with CPB) in adults (Dybdahl et al., 2002). During cardiac surgery 
with CPB and cardioplegic arrest in adult patients, a more exaggerated systemic release of 
HSP70 in patient serum was caused when compared to that seen during cardiac surgery 
without bypass (Dybdahl et al., 2004). This was most likely due to a higher degree of cellular 
damage caused during the cardiac surgery with CPB. Another study compared HSP70 
expression in the plasma of adult patients undergoing surgery with and without CPB. HSP70 
expression was significantly lower in patients that had not gone on bypass when compared to 
patients that had. This suggested that on pump surgery caused more stress and a more 
exaggerated increase in HSP72 expression. It also showed the extracellular location of HSP70 
(Lin et al., 2010). An increase in HSP27, HSP60, HSP70 and HSP90α was found in the serum 
of adult patients undergoing cardiac surgery with CPB when compared to the levels seen in 
the serum from patients who had surgery without CPB. This highlighted the extracellular 
location of several HSPs during cardiac surgery and again demonstrated that the use of CPB 
increased the expression of HSPs (Szerafin et al., 2008). Overall, HSP70 and other HSPs have 
been demonstrated to be in the extracellular place following cardiac surgery with CPB. It has 
already been described (see section 1.6.4.2) that extracellular HSPs interact with aspects of the 
immune system. Therefore, HSPs could have a role in the myocardial and systemic 
inflammation caused during cardiac surgery with CPB and could therefore be used in order to 
find a way in which to prevent it. 
 
1.6.7 Conclusion 
Overall, it can be seen that IR injury is a complex process of response and protection to 
the insults, often mediated by the same proteins (e.g. HSP72). It can also be seen that the 
manipulation of these systems might help to reduce the initial injury as well as providing 
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protection from damage caused. This could have beneficial outcomes when used in the context 
of cardiac surgery in order to discover new or improved methods of cardio-protection during 
cardiac surgery with CPB. This is of even greater importance in pediatric heart surgery, as this 
often involves children with congenital heart defects causing them to have abnormal, cyanotic 
myocardium. This could involve the investigation of both intracellular and extracellular HSPs. 
 
1.7 78 kDa glucose-regulated protein (GRP78) 
 
78 kDa glucose-regulated protein (GRP78), which is also known as binding 
immunoglobulin protein (BiP) or heat shock 70 kDa protein 5 (HSPA5) is a stress protein that 
is expressed in response to cellular insult in order to either maintain or refold protein 
structures that have been disrupted due to damage caused (Shiu et al., 1977; Haas and Wabl, 
1983; reviewed in Lee, 1992; reviewed in Lee, 2001). Stress proteins are generally known as 
either HSPs (see section 1.6) or glucose regulated proteins (GRP). Unlike HSPs, which are 
usually localised within the nucleus or the cytoplasm, GRPs are generally located within the 
endoplasmic reticulum (ER) (Munro and Pelham, 1987; reviewed in Lee, 1992; reviewed in 
Lee, 2001). The function of the ER within the cell is very diverse and includes being the site 
of protein folding and protein post translational modification, the maintenance of intracellular 
Ca2+ homeostasis, lipid synthesis and a site for the initiation of apoptotic pathways (Bush and 
Sze, 1986; Helenius et al., 1992; Cox et al., 1997; Wu et al., 2000; reviewed in Breckenridge 
et al., 2003). 
 
The GRPs were initially discovered by experiments carried out involving glucose 
starvation, specifically, a cell culture experiment involving chick embryo fibroblasts was 
carried out that showed the induction of these genes in response to a deficit of glucose. The 
genes identified within this study were then named based on their apparent function and 
molecular weight and were therefore named GRP78 and GRP94 (Shiu et al., 1977). GRP78 is 
the one of interest in this project. 
 
When cells undergo stress such as nutrient starvation, chronic exposure to ethanol, 
prevention of glycosylation or a reduction in intracellular Ca2+, it can result in the upregulation 
of ER stress chaperones such as GRP78 due to the accumulation of misfolded proteins within 
the ER (Shiu et al., 1977; Li et al., 1993; Miles et al., 1994; reviewed in Lee, 2001). This 
process is known as the unfolded protein response (UPR) and is one of the ways in which the 
 
 
85 
cell returns protein homeostasis within the ER back to normal (Patil and Walter, 2001; Ma and 
Hendershot, 2001). In fact, measurements of GRP78 expression have been used as an indicator 
of ER stress (Mao et al., 2004; reviewed in Lee, 2005). An alternative to the UPR pathway is 
the ER overload response (EOR) pathway, where the accumulation of proteins (not misfolded) 
within the ER induces the expression of the transcription factor NFkB that will result in an 
inflammatory response (Pahl and Baeuerle, 1995; Pahl et al., 1996; Pahl and Baeuerle, 1997). 
The EOR pathway does not induce the expression of GRP ER chaperones (reviewed in Rapp 
and Kaufmann, 2003). 
 
GRP78 is expressed in the heart. This was demonstrated in a study using a mouse 
model that showed that GRP78 is expressed at high levels within the heart during early stages 
of embryonic development, with GRP78 expression being mainly localized within cardiac 
myocytes (Barnes and Smoak, 2000). GRP78 expression within these cells was also increased 
after a 24 hour period of hypoglycaemia again highlighting how nutrient starvation can induce 
the expression of these stress proteins (Barnes and Smoak, 2000). 
 
Studies involving cellular stress within the heart that investigated the expression of 
GRP78 include a study that used cultured rat ventricular myocytes to determine if 16 hours of 
hypoxia could induce the UPR and the induction of GRP78. This insult successfully caused an 
increase in GRP78 expression suggesting hypoxia is detrimental to the stability of proteins 
within the ER (Thuerauf et al., 2006). This increase in GRP78 expression was not observed 
during reoxygenation after the hypoxic insult (Thuerauf et al., 2006). Another study 
investigated the role of GRP78 in apoptosis caused by ischemic insult in cardiac cells. 
Specifically, GRP78 was expressed on the surface of cardiac myocytes. When these cells were 
exposed to ischemic insult, GRP78 expression was increased, as was the incidence of 
apoptosis (Hardy and Raiter, 2010). The introduction of a GRP78 specific peptide reduced the 
amount of apoptosis caused by the ischemic insult by binding GRP78. This highlighted 
GRP78 as a potential target for reducing damage done by hypoxia, which is a cellular insult 
that occurs during cardiac surgery with CPB (Hardy and Raiter, 2010). In a pig animal model 
of chronic myocardial ischemia that resulted in heart failure, it was shown that both mRNA 
and protein GRP78 expression was increased in the myocardial tissue from these animals as 
were apoptotic activation pathways, again indicating that GRP78 expression is induced by 
ischemic insult with the heart (Xin et al., 2011). 
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Another study investigated hypertension by using a rat animal model with diastolic 
heart failure. It showed that the mRNA and protein expression of GRP78 was increased in 
these animals, along with capsase-12, indicating that in a model of cardiac stress, GRP78 
expression is increased along with the incidence of apoptosis (Sun et al., 2008). In relation to 
IR injury, a study using mouse hearts that were exposed to IR injury showed that the 
expression of GRP78 and GRP94 and therefore the UPR were increased due to this type of 
injury (Martindale et al., 2006). This same study used a transgenic mouse model that had 
specific cardiac expression of a protein called Activation of Transcription Factor 6 (ATF6). 
This expression was only activated upon exposure to tamoxifen. It showed that the UPR and 
the expression of GRP78 and GRP94 were higher in mice with tamoxifen induced ATF6 
expression when compared to appropriate controls, showing that ATF6 was involved in 
activating the UFR and GRP78 expression during IR injury (Martindale et al., 2006). The 
mice with activated ATF6 expression also sustained less damage due to IR injury suggesting 
both ATF6 and GRP78 as having a protective role in the heart against IR injury (Martindale et 
al., 2006). All of these studies show that GRP78 is a potential candidate for investigation into 
how to protect the myocardium from injury during cardiac surgery with CPB other than the 
present methods used. 
 
1.8 Apelin receptor (APJ) and it endogenous ligand Apelin 
Apelin is a peptide that was discovered in 1998 (Tatemoto et al., 1998) as the 
endogenous peptide ligand of the G protein-coupled APJ receptor, the previously orphaned 
receptor isolated in 1993 (O’Dowd et al., 1993). Apelin is the only identified ligand for the 
APJ receptor. Apelin exists as several biologically active forms; Apelin-36, 17, 16, 13 and 12 
have been found and are named by the number of amino acids in the COOH-terminal coding 
region (Berry et al., 2004). These different forms of the ligand are present due to the multiple 
cleavage sites on the precursor molecule, preproApelin (Habata et al., 1999). In 2009 it was 
found that [Pyr1] Apelin-13 was the predominant form of the peptide but showed comparative 
functional status to the other two main isoforms, Apelin-13 and Apelin-36 (Maguire et al,. 
2009).  
The APJ receptor shares 31% of its structural sequence to that of the angiotensin II 
type-1A receptor (O’Dowd et al., 1993) and has been shown to counteract damaging effects of 
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angiotensin II (Siddiquee et al., 2011), suggesting a role of Apelin as a complementary 
mechanism to the effects of angiotensin II.  
1.8.1 Function of Apelin/ APJ 
The APJ receptor is expressed in endothelial cells, vascular smooth muscle cells and 
cardiomyocytes (Kleinz et al., 2005) and the primary function of Apelin-APJ is thought to be 
in the cardiovascular system (reviewed in Japp and Newby, 2008). However, Apelin also has a 
role in many different processes in several systems throughout the body.  
Apelin is classed as an adipokine as it is produced by adipocytes and regulates glucose 
utilization in insulin resistant mice (Dray et al., 2008). Injection of the animals with Apelin 
reduced plasma levels of glucose, revealing Apelin as an endocrine regulator of glucose 
metabolism.  
Apelin also plays a role in fluid homeostasis by counteracting the action of vasopressin 
(Galanth et al., 2012). Apelin, expressed in the supraoptic and the paraventricular nuclei, 
inhibits release of arginine vasopressin (AVP) by the AVP neuron (De Mota et al., 2004). This 
displays how Apelin interacts with AVP to act as a diuretic. 
The main source of Apelin expression, however, is in the heart (Chandrasekaran et al., 
2010), and its primary effect is thought to be in the cardiovascular system. Within the 
myocardium itself, Apelin-APJ activation causes an increase in contractility of the 
myocardiocytes and is one of the most powerful positive inotropes known (Farkasfalvi et al., 
2007).  Apelin acts as an inotrope through modulation of Na+/ H+ and Na+/ Ca2+ transporters 
(Szokodi et al., 2002). This potent inotropic effect is thought to be through both autocrine and 
paracrine signalling, due to the expression of Apelin both in the endocardium and myocardium 
(reviewed in Falcão-Pires et al., 2010). This was found to be the case as Apelin-APJ 
stimulation still occurs after the removal of the endocardium (the main source of Apelin) in 
vitro (Charo et al., 2009). Apelin is also expressed in the smooth muscle cells of the 
vasculature throughout the body (Chandrasekaran et al., 2010). Apelin was found to function 
as a potent vasodilator in both arterial and venous vessels from studies in rodent models 
(Charo et al., 2009) and in clinical trials (Japp et al., 2010). It elicits this effect by inducing 
NO dependent pathways of vasodilatation (Tatemoto et al., 2001). Thus, by reducing both 
afterload and preload, Apelin function in the vasculature has protective effects on the heart. 
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The overall effect of Apelin-APJ action is therefore potentially particularly beneficial in heart 
failure; when considering it functions as an inotrope, a vasodilator and a diuretic (Japp and 
Newby, 2008). As a result of the theoretical advantageous effects of Apelin-APJ function, 
much of the research into Apelin has been focussing on heart failure. It is known that 
expression of Apelin and APJ in the myocardium is increased in response to heart failure in 
rats (Atluri et al., 2007) and it is thought that this may be part of a compensatory mechanism 
in an attempt to restore normal cardiac output. Also, evidence has suggested that Apelin 
protects the heart against fibrotic remodelling (Pchejetski et al., 2012), an important process in 
the pathogenesis of heart failure. There have been positive results from one of the few human 
studies as infusion of Apelin to heart failure patients improved cardiac output and caused 
peripheral and coronary vasodilation (Japp et al., 2010). Also, as heart failure progresses and 
ventricular dysfunction worsens, myocardial Apelin production is reduced (Chandrasekaran et 
al., 2010).  
1.8.2 Protection against ischemia 
The Apelin-APJ axis has been shown to reduce tissue damage in times of ischemic 
stress. Apelin infusion in rodents reduced the infarct size after coronary artery occlusion in 
rodents (Kleinz and Baxter, 2008). APJ is expressed in higher levels in mature coronary 
vessels after prolonged periods of ischemia (Tycinska et al., 2012) suggesting that the APJ 
receptor is produced and expressed in higher levels in response to hypoxia. Apelin production 
is also mediated through hypoxia; expression of the ligand is increased in times of hypoxia 
through the hypoxia-inducible factor 1α pathway (Ronkainen et al., 2007). Apelin has been 
shown to directly counteract the damaging effects of ischemia on the myocardium (Kleinz and 
Baxter, 2008). Rodent models have shown direct protection against IR injury by Apelin 
administration (Simpkin et al., 2007; Zeng et al., 2009) and it has been proven that Apelin 
reduces this damage by reducing ER stress and therefore attenuating ER-dependent apoptosis 
(Tao et al., 2011).  
The function of Apelin-APJ may therefore be beneficial during surgical procedures 
involving a CPB machine, which results in a motionless bloodless field and leaves the heart in 
ischemic conditions.  
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1.8.3 The characterization of Apelin-APJ 
TOF is a common cyanotic congenital heart defect (see section 1.1.3) that requires 
surgical correction with CPB. Complete surgical repair of TOF is usually performed in the 
first year of life with a mortality rate of <2% (Starr, 2010). Although surgical repair is the best 
intervention option, patients are often left with side effects as a result of the procedure, most 
notably a deficiency in RV function as a result of CPB (Allen et al., 1997). This adverse effect 
has been attributed to the insult of IR injury (reviewed in Murphy and Steenbergen, 2008), 
which is a known adverse effect of this surgical procedure and studies have been undertaken 
to assess ways in which this damage can be avoided, such as ischemic post-conditioning, 
which was shown to provide some protection for the myocardium during surgery (Ji et al., 
2011). Remote pre-conditioning is another more commonly studied method which attempts to 
reduce intra-operative myocardial damage and has been shown to decrease the effect of IR 
injury in a rodent study (Chiu et al., 2012) which involves pre-conditioning with HSPs. HSPs 
are peptides which are induced during times of ischemia to be produced as part of a cardio-
protective mechanism (see section 1.6). It has also been found that HSPs can protect the 
myocardium of patients undergoing surgical repair of TOF (Peng et al., 2011). The role of 
Apelin-APJ function has not been investigated in this area. This is therefore a field with much 
promise for Apelin-APJ, as HSPs have been found to be beneficial in cardio-protection during 
paediatric cardiac surgery and the functions of Apelin and HSPs are very similar. To date, 
Apelin and the APJ receptor have never been identified in the infant myocardium. Therefore, 
looking at the presence of the APJ receptors and therefore Apelin activity in the infant heart 
would be an intriguing line of investigation 
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1.9 Aims and hypothesis  
1) Experiment: Screening of differential gene expression in ventricular myocardium 
excised from cyanotic and control (acyanotic) patient groups. 
a. Aims: investigate the differential mRNA expression of inflammatory mediators 
and stress proteins within the myocardium from cyanotic and acyanotic patient 
groups and see how they differ.  
b. Hypothesis: Cyanotic patients have a different mRNA expression profile than 
acyanotic patients pre-operatively. 
2) Experiment: Induction of HSP gene expression in excised ventricular myocardium: 
mRNA and protein level analysis of HSP gene expression induced by heavy metal 
chemical inducers. 
a. Aims: to determine the effect of exposure to heavy metals on the expression 
(mRNA and protein) of genes of interest within infant myocardium. 
b. Hypothesis: HSP expression (mRNA and protein) can be induced in infant 
myocardium using classic heavy metal inducers. 
3) Experiment: Differential gene expression in RV myocardium excised from TOF and 
control patient groups exposed to differential oxygen levels. 
a. Aims: to expose ischemic infant myocardium to hyperoxic levels of O2 to see 
its effect on the differential mRNA expression of genes of interest within such 
tissue.  
b. Hypothesis: reperfusion of ischemic infant myocardial tissue in vitro will cause 
an inflammatory/ stress response, which will be elevated in cyanotic patients 
who are more vulnerable to injury. 
4) Experiment: The differential mRNA expression of GRP78 and APJ within infant 
myocardium 
a. Aims: to determine the differential expression of both genes within cyanotic 
patient myocardium compared to the acyanotic patient myocardium and how 
such expression is effected by re-oxygenation injury. 
b. Hypothesis: Cyanotic patients have a different mRNA expression profile than 
cyanotic patients pre-operatively and also after exposure of the infant 
myocardium to re-oxygenation injury. 
5) Experiment: Protein expression of HSP27 and APJ within cyanotic and acyanotic TOF 
myocardium over ischemic time during cardiac surgery in comparison to cardiac 
output and contraction. 
a. Aims: to investigate the differential protein expression of both genes within 
cyanotic and acyanotic TOF myocardium over ischemic time and compare this 
to cardiac clinical data. 
b. Hypothesis: The expression of both genes will increase over ischemic time. 
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CHAPTER 2 – MATERIALS AND 
METHODS 
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2.1 Consenting of patients 
2.1.1 Identifying suitable patients 
Children who underwent elective cardiac surgery for a Fallot type physiology 
(cyanotic) were identified as potential participants. Potential participants were identified by 
review of the cardiac surgical waiting list and clinical presentations at the multi-disciplinary 
weekly team meeting. Those attending included the health care team and Mr Mark Danton 
(consulting surgeon) who had overall responsibility co-ordinating the clinical team process 
and identifying potential patients. The control patient group, which includes children 
undergoing cardiac surgery in order to repair SAS (acyanotic), were identified by the same 
method as described above. 
2.1.2 Patient recruitment  
Parents were approached when they were attending the outpatient clinic. The 
consultant surgeon in charge would meet the parents and child and introduce the study for 
their consideration. If the parents were interested in participating in the study, Mr Danton 
would discuss the study and answer any questions the parents might have. The parents were 
also given an information sheet (as shown in appendix 1.1) and given appropriate time to read 
it and consider their child’s participation before consenting. There was a period of 
approximately 1-2 weeks from the first introduction of the project until written consent was 
required. If the parents agreed for the patient to take part in the study, they were asked to sign 
a study consent form (as shown in appendix 2) on the day their child was admitted to hospital, 
usually 24/ 48 hours prior to surgery. All consent forms were filed in the clinical notes of the 
patient and a copy was kept in the study file. It was made very clear that the parents still held 
the right to withdraw from the study at any point, even when written consent had been given. 
Control group participants were approached in the same way (for information sheet for control 
patient goup see appendix 1.2). 
 
The only instance when this method of approach would vary was for families who 
were unable to attend the outpatient clinic. In such cases, the child (patient) was admitted to 
hospital at least 48 hours prior to surgery and it was then that the parents of these children 
were approached for their potential participation in this study. If these parents were interested 
in their child participating in the study, Mr Danton would discuss the study with the parents 
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and answer any questions they might have. The parents were also given an information sheet 
and given an appropriate amount of time to read it to allow them to be able to consider their 
child’s participation before consenting. If the parents agreed, they were asked to sign a study 
consent form on the day their child underwent surgery. 
 
2.1.3 Ethical approval 
Full ethical approval (see appendix 3.2) for this project was given by the Greater 
Glasgow and Clyde Health Board with the relevant R and D approval (shown in appendix 
3.1). This process from start to finish took several months to complete. 
 
2.2 Collection and processing of heart tissue frozen immediately following 
resection for protein and mRNA analysis 
2.2.1 Tissue collected for protein analysis 
All equipment used for processing the tissue was cleaned with 70% ethanol to sterilise 
them before use. A number of 1.5ml eppendorf tubes equal to the number of samples to be 
collected were put on dry ice to ensure they were at a low temperature. This is because they 
would be used for storage of snap frozen tissue samples. Liquid nitrogen (N2) was collected in 
a suitable container and as it is very corrosive correct safety attire was worn. 
 
Tissue was collected in theatre and the time point at which each sample was collected 
was noted. The hospital number (anonymous identifier), time of aortic-clamping, age and 
gender of the patient were also recorded. Tissue samples were collected in plastic galley pots 
then immediately snap frozen in liquid N2. Snap frozen tissue was then brought back to the 
laboratory and then put into the pre-chilled 1.5ml eppendorf tubes that were kept on dry ice to 
ensure they remained cold. The tissue was then kept in -80°C storage until needed. 
 
 
2.2.2 Tissue collected for molecular analysis  
 
The method of tissue collection is as described in 2.1.1 except for the following 
differences. No liquid N2 or dry ice was used. Using sterile barrier tips and Gilson pipettes, 
1.2ml of RNAlater® solution (Sigma-Aldrich, cat. no. R0901) was put into each pre-collected 
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1.5ml eppendorf tube (10µl of RNAlater® solution is required per 1mg of tissue). Most pieces 
of tissue collected were approximately 100mg therefore 1.2ml was an adequate volume. 
 
Tissue collected in theatre was immediately put into the 1.5ml eppendorfs containing 
the RNAlater® solution. All eppendorf tubes were labelled appropriately. Once completed, the 
tissue samples in RNAlater® solution were brought back to the laboratory and stored in the 
fridge, at least overnight, before being used for RNA extraction.  
 
2.3 Reperfusion Experiments 
Two sets of experiments were undertaken in order to investigate the effect of exposing 
ischemic myocardium from both the cyanotic and acyanotic patient groups to 2% (hypoxia), 
20% (normoxia) and 60% (hyperoxia) O2. This was done in order to recreate reperfusion of 
the myocardium that occurs in the clinical setting of paediatric open-heart surgery with CPB 
and to investigate the effect this had on the differential gene expression of genes of interest 
within myocardium from the acyanotic and cyanotic patient groups. 
 
The first experimental model undertaken (figure 2-1) involved exposing tissue to 2% 
(hypoxia) and 20% (normoxia) O2. It was initially not possible to expose tissue to 60% 
(hyperoxia) O2 as such a high O2 concentration required an incubator which could allow O2 
levels of 60%. The incubator purchased from Biospherix for this purpose was faulty and not fit 
for purpose. Thus a second incubator was sourced (New Brunswick® 48R carbon dioxide 
(CO2) incubator). Upon receiving this incubator a second experimental model (figure 2-2) was 
designed and the tissue from each patient group was then exposed to 2% (hypoxia), 20% 
(normoxia) and 60% (hyperoxia) O2. Both experiments are outlined in figure 2-1 and figure 2-
2. The steps 1 to 5 in the diagrams correspond with steps 1 to 5 described within the text. 
 
2.3.1 Experiment 1: exposing myocardial tissue to 2% (hypoxia) and 20% (normoxia) 
O2 
 
Step 1: two NuAire® incubators were set to 2% (hypoxia) and 20% (normoxia) O2 
(figure 2-1). 10ml of supplemented media (see appendix 4) was added to two sterile T5 culture 
flasks and 1ml of supplemented media was added to 6 wells of two sterile 24 well culture 
plates (6ml in total). One of each was put into each incubator that was set to the desired O2% 
for at least 24 hours prior to tissue collection. 
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Step 2: When tissue was ready for processing, the T5 culture flasks were removed 
from the incubators. The first piece of tissue removed was put into RNAlater® solution that 
would act as the baseline reference (A) (figure 2-1). For the rest of the tissue collected, each 
piece was cut in half and then each half was put into the 2% or 20% O2 T5 culture flasks.  
 
Step 3: The tissue was transported back to the laboratory in the 2% and 20% O2 T5 
culture flasks.  
 
Step 4: Once back in the laboratory, the tissue was quickly removed from each of the 
T5 culture flasks (each done separately). All tissue was cut up into equal sized pieces and a 
small amount of tissue was removed from each flask to give the next reference points i.e. 
tissue collected in the 2% O2 flask (B) and tissue collected in the 20% O2 flask (C).  
 
Step 5: After this, for each flask (separately), the 24 well culture plates were removed 
from their relevant incubators and the tissue was distributed into an equal number of wells in 
each plate that contained supplemented media. Once done, both 24 well culture plates were 
then put back into their relevant incubators and left for 1.5 hours. 1.5 hours was chosen as this 
is this length of time the myocardium is exposed to re-oxygenation in the clinical setting of 
such surgery i.e. upon removal of the aortic clamp. After the 1.5 hour incubation, the culture 
plates were removed and tissue in each 24 well culture plate was removed and put into 
RNAlater® solution, representing the final two tissue collection points i.e. tissue incubated at 
2% O2 (D) and tissue incubated at 20% O2 (E) (figure 2-1).  
 
RNA was then extracted from the tissue (see section 2.5) that had been stabilised in 
RNAlater® solution and this was later reverse transcribed into complementary DNA (cDNA) 
(see section 2.6), which was used in quantitative real time polymerase chain reactions (qPCR) 
using primers designed for the noted genes of interest (see section 2.8.3). Any observed 
differences in gene expression was analysed. 
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Figure 2-1. Diagram showing the first reperfusion experimental model  
 
 
 
Figure showing the time course of experiment 1. Labelling on the diagrams refers to the 
following: A – collection of first reference samples, B – collection in flask containing 
2% O2, C – collection in flask containing 20% O2, D – after 2% incubation and E – after 
20% incubation. 
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2.3.2 Experiment 2: exposing myocardial tissue to 2% (hypoxia), 20% (normoxia) and 
60% (hyperoxia) O2 
 
This set of experiments incorporated the new incubator, which could reach hyperoxic 
O2 concentrations (60%). The set up for experiment 2 (figure 2-2) was the same as experiment 
1 except for the following differences.  
 
Step 1: The New Brunswick® 48R incubator was set up at 60% (hyperoxia) O2 in 
additional to the other 2 incubators which were set up as before. Three 25 well culture plates 
and only one T5 culture flask were used during the experiment. The three 24 well culture 
plates were required as three different O2 concentrations were being used instead of only two. 
Only one T5 culture flask was required as all tissue collected in theatre was being put into 
media incubated at 2% O2 for at least 24 hours prior to tissue collection in order to keep the 
tissue in hypoxic conditions for transport over to the laboratory.	  
 
Step 2: When it was time for tissue collection in theatre, the T5 culture flask (incubated 
at 2% O2 for 24 hours) was removed from its incubator and taken to theatre. The first tissue 
sample was put into RNAlater® solution i.e. baseline reference (A) (figure 2-2). All other 
tissue samples were collected into the 2% O2 T5 culture flask. 
 
Step 3: Tissue was transported back to laboratory in the 2% O2 T5 culture flask. 
 
Step 4: Once back in the laboratory, the tissue transported in the T5 culture flask was 
removed and cut up into equally sized pieces. Some tissue was removed at this point giving 
the second reference point i.e. expression at start of incubation (B).   
 
Step 5: The three 24 well culture plates were removed from their relevant incubators 
and the rest of the tissue was processed as already described except this was done over three 
plates instead of two. The plates were incubated for 4 hours in the second experiment instead 
of 1.5 hours. 4 hours was chosen in order to cause an exaggerated effect on any changes in 
gene expression due to changes in O2 concentrations that might not have been apparent during 
only 1.5 hours. Also, 4 hours was indicated in the literature to be an appropriate length of time 
to imitate reperfusion (Hua et al., 2007; Ha et al., 2010). After incubation, the culture plates 
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were removed and the tissue from each plate was put into RNAlater® solution (tissue 
collection points C (2%), D (20%) and E (60%)). 
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Figure 2-2. Diagram showing the set-up of tissue processing during hyperoxic reperfusion model 
 
 
Figure showing the time course of experiment 1. Labelling on the diagrams refers to the 
following: A – collection of first reference samples, B – collection in flask containing 
2% O2, C – after 2% incubation, D – after 20% incubation and E – after 60% incubation. 
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2.4 HSP induction experiments: mRNA and protein level analysis of HSP gene 
expression induced by heavy metal chemical inducers 
 
The aim of these experiments was to determine if heavy metals, known to be able to 
induce HSPs in other cell types, could induce HSPs in infant myocardium taken from both the 
cyanotic and acyanotic patient groups. This investigation into HSP expression was performed 
at both the mRNA and protein level. The expression of several inflammatory mediators was 
also investigated but only at the mRNA level. The methodology for the experiments described 
in sections 2.4.1 and 2.4.2 are summarised in figure 2-3. 
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Figure 2-3. Diagram showing the set-up of tissue processing during HSP chemical induction 
experiments. 
 
 
 
 
 
Figure showing the time course of HSP induction experiment. Labelling on the diagrams 
refers to the following: A – start of incubation, B – after incubation with chemical 
inducer for 6 hours, C – after incubation with media only for 6 hours (control). 
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2.4.1 mRNA level analysis of HSP gene expression induced by heavy metal chemical 
inducers 
 
Myocardium collected in theatre was incubated for 6 hours in media containing a 
chemical inducer, either sodium arsenite (NaAsO2) or cadmium chloride (CdCl2), or in media 
only that would act as a comparable experimental control. Based on previous experiments 
performed within the laboratory using placental tissue, 6 hours was agreed as an appropriate 
length of time for incubation (Barber et al., 1999).  
 
Two medium sized petri dishes were retrieved and labelled appropriately depending on 
the chemical inducer being used (one with either ‘6 hour CdCl2’ or ‘6 hour NaAsO2’ and one 
with ‘6 hour control’). 10ml of media was added to the correct petri dish. For each dish, the 
medium contained either the relevant concentration of the chemical inducer (CdCl2 or NaAsO2 
at 100 µM) (refer to appendix 4) or with supplemented media only (refer to appendix 4) that 
was the experimental control. A separate amount of supplemented media only was also 
prepared in a universal container, which was to be used for tissue collection. Once prepared 
the petri dishes and universal container were put into a NuAire® CO2 incubator set at 20% O2 
and at 37°C. 
 
When tissue was ready to be collected the universal container was removed from the 
incubator and taken to theatre and all tissue that was collected was put into it. The samples 
were brought back to laboratory and then all tissue was removed and cut into equal sized 
pieces. In order to show expression levels at the start of the 6 hour incubation period a piece of 
tissue was removed at this point and put into 3ml of RNAlater® solution. This sample was 
used as an experimental baseline reference sample (A). Then the 2 petri dishes (with or 
without the chemical inducer) were removed from the incubator and half of the tissue prepared 
was put into each. The petri dishes were then put back into the incubator and left for 6 hours. 
 
Once the incubation period was complete, the tissue was removed from the 2 petri 
dishes and put into 3ml of RNAlater® solution. Tissue that had been incubated in media with 
the chemical inducer (CdCl2 or NaAsO2) would act as the second tissue reference sample (B) 
and tissue incubated in media only would act as the third tissue reference sample (C). 
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The tissue was left in RNAlater® solution overnight at 4°C and then mRNA was 
extracted from the myocardium (see section 2.5) and then reverse transcribed (see section 2.6) 
into cDNA to be used in qPCR using primers designed for the genes of interest (see sections 
2.9 and 2.7.3 respectively). Any differences in gene expression caused by the chemical 
inducers compared to the appropriate controls were analysed. 
 
2.4.2 Protein level analysis of HSP gene expression induced by heavy metal chemical 
inducers 
 
The method of protein level analysis of induced HSP gene expression is as described in 
2.4.1 except for the following differences. A piece of tissue was not removed at the start of 
incubation therefore no experimental baseline reference sample (A) was collected. This is 
because investigating differential expression at the protein level requires larger amounts of 
tissue and there was insufficient tissue to perform all the steps as for the qPCR experiments, 
which require less tissue. Instead all tissue collected was split and either incubated for 6 hours 
in media with the chemical inducer (CdCl2 or NaAsO2 at 100 µM) that gave the sample 
reference sample B or incubated in media only (experimental control) that gave the sample 
reference sample C.  
 
After the 6 hour incubation was complete, all samples were snap frozen in liquid N2 
and then stored at -80 °C until needed. This tissue was then homogenised (see section 2.11.1) 
and the concentration of each sample was calculated using a Bradford assay (see section 
2.11.2). The samples were then used to perform Western blotting (see section 2.12) in order to 
investigate any differences in gene expression caused by the chemical inducers compared to 
the appropriate controls at the protein level and any differences observed were analysed. 
 
2.4.3 Protein level analysis of HSP gene expression induced by heavy metal chemical 
inducers with recovery time 
An additional experiment was performed after further investigation of the literature. 
Some studies show that in order to see differential expression of HSP at the protein level, the 
tissue should be allowed to recover for a certain period of time after exposure to a cellular 
stress (Kim et al., 2001; Rossi et al., 2002; Somji et al., 2002). After treatment, all aspects of 
the experimental set up are as in section 2.4.2, except that when the tissue was spilt, half of it 
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was exposed to NaAsO2 for 4 hours instead of 6 hours then allowed to recover for 20 hours in 
media only. The other half of the tissue was in media only for the entire 24 hours that acted as 
the experimental control. 
 
2.5 RNA extraction from heart tissue 
Right ventricle myocardium tissue samples were stored overnight at 4°C in RNAlater® 
solution to stabilize the RNA (as recommended by manufacturer) in preparation for extraction 
using the RNeasy® Fibrous Tissue Midi Kit (Qiagen, cat. no. 75742). Recovery of RNA from 
snap frozen tissue stored at -80°C storage was also attempted on initial samples collected but 
poor yields of RNA were obtained therefore all subsequent samples were put into RNAlater® 
solution.  
 
When RNA extraction was carried out the tissue was removed from the RNAlater® 
solution and placed in a pre-weighed container, which contained 2ml RLT buffer (buffer 
provided with kit) supplemented with beta-mercaptoethanol (ß-ME) (10 µl ß-ME per 1 ml 
buffer RLT). The tissue was then homogenised using a Polytron PT1600E homogeniser 
(Kinematica) at setting full speed for 3x20 seconds, then RNA was extracted from the 
homogenate as follows. 
 
After homogenising, each sample (2ml) was mixed with 4ml RNase free water 
(provided in kit) and 65µl proteinase K solution (provided in kit) then incubated at 52°C for 
20 minutes. The mixture was then spun in the centrifuge (4000xg, 25°C for 5 minutes). The 
supernatant was removed and put into new sterile 15ml Falcon tubes (Sigma-Aldrich, cat. no. 
Z617849) (typically 6ml of supernatant is retrieved) and a half volume of 100% ethanol 
(typically 3ml ethanol per 6ml of supernatant) was then added to the supernatant and mixed 
well by pipetting. An appropriate number of RNasey® Midi kit spin columns already contained 
within the 15ml collection tubes (provided in kit) were retrieved and 3 ml of the mixed 
supernatant (ethanol and supernatant) was added to the column which was then spun in the 
centrifuge (4000xg, 25°C for 5 minutes). This was repeated twice until all the mixed 
supernatant had gone through the column. 2ml of RW1 buffer (provided with kit) was then 
added to each spin column then spun down in the centrifuge (4000xg, 25°C for 5 minutes). 
DNase I solution (140µl of RDD buffer and 20µl of DNase I stock solution both provided in 
kit) was made and was then added to the membrane of all spin columns for 15 minutes to 
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ensure there was no genomic DNA (gDNA) contamination. Once completed, 2ml of RW1 
buffer was added to each spin column and left to stand for 5 minutes then spun down in the 
centrifuge (4000xg, 25°C for 5 minutes). 2.5ml of RPE buffer (provided in kit) was added to 
each spin column then spun down in the centrifuge (4000xg, 25°C for 2 minutes). Another 
2.5ml of RPE buffer was added to each spin column then again spun down in the centrifuge 
(4000xg, 25°C for 5 minutes). The spin columns were removed from their original collection 
tubes and put in new ones to ensure no ethanol in the RPE buffer in the flow through from the 
last step of centrifugation was present on the spin column.  
 
For RNA elution, 150µl of RNase free water was added directly to the membrane of 
the spin columns and then left on the bench for 1 minute. After this they were spun down in 
the centrifuge (4000xg, 25°C for 3 minutes) and then this step was repeated. Once RNA was 
successfully eluted in RNase free water, the RNA concentration (ng/µl) was then determined 
using a NanoDrop® (Thermo Scientific) to find the concentration of the RNA (either in a final 
volume of 150µl or 300µl), which once determined was entered into the appropriate database. 
The RNA was then separated into 50µl aliquots then put into -80°C storage.  
 
The concentration (ng/ ul) of RNA was determined on a NanoDrop® (see figure 2-4). 
The ratio of absorbance at 260 nm and 280 nm gives an indication of RNA purity. A value 
between 1.8 and 2.1 indicates optimal purity. Using high purity RNA during reverse 
transcription (RT) ensures optimal quality cDNA is used in the subsequent PCR/ qPCR. 
  
The issue of tissue viability is complex. Even if end stage markers of death are 
unaltered it is very likely for any tissue removed from the body that the events leading to death 
will begin. This could cause subtle changes in signalling molecules such as caspases and other 
apoptotic events. It would be useful in future work to examine tissue viability using the lactate 
dehydrogenase assay. However the RNA stability was examined in tissues and was shown to 
be non-degraded. Since cell death would result in RNA degradation, this as least suggests the 
tissue was viable. 
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Figure 2-4. NanoDrop® measurement of mRNA concentration for patient sample	  
 
Figure shows the RNA concentration of a sample 4.1 in ng/ul (554.9). The ratio of 
absorbance at 260 nm and 280 nm (260/ 280) gives an indication of RNA purity.  
 
 
2.6 Reverse transcription (RT) of mRNA 
mRNA was removed from -80°C storage and kept on wet ice at all times (4°C). Using 
the QuantiTect® Reverse transcription Kit (Qiagen, cat. no. 205310) and GoScript™	   reverse 
transcriptase (Promega, cat. no. A5003) the RNA was reverse transcribed into cDNA. The 
amount of RNA required for 100ng total RNA is calculated for each RNA sample. 
Experimental variation was minimized by using a standardized amount of RNA (100ng). This 
assumes almost 100% efficiency of the RT reaction.	  
The first step of this reaction using the QuantiTect® RT kit was the gDNA elimination 
reaction that was carried out on wet ice in PCR tubes (Thistle Scientific, cat. no. AX-PCR-02-
C). For each DNA elimination reaction in each PCR tube: 
o Wipeout buffer – 2µl 
o Template RNA (100ng) – Xµl and RNase free water – Yµl (X+Y=12µl) 
o Total reaction volume – 14µl 
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Once the reaction was set up, using a thermal cycler (DNA Engine®, Bio-Rad) the tubes were 
put through the ‘GOUT’ program: 
o 3 minutes at 42°C 
Once the program was complete, the PCR tubes were removed and a master mix was made up 
for the RT reaction (GoScript™ reverse transcriptase (not from QuantiTect® kit), RT buffer 
and RT primer mix) and 6µl of master mix was then added to each tube containing the RNA 
that had gone through the gDNA wipeout reaction. In each tube there was now the following: 
o DNA wipeout reaction - 14µl (already in tube) 
o GoScript™ reverse transcriptase – 1µl (from Promega, cat. no. A5003) 
o RT Buffer - 4µl 
o RT Primer Mix - 1µl 
o Total reaction volume - 20µl 
Once the RT reactions were step up they were again put into the thermal cycler using the 
‘RT4’ program: 
o 30 minutes at 42°C 
o 5 minutes at 95°C (enzyme deactivation) 
Once the reaction was completed, the newly made cDNA was put into -20°C storage. 
 
The GoScript™ reverse transcriptase was used instead of the one in the QuantiTect® kit 
because during the optimisation of the RT reaction, it was shown, having compared both, that 
the GoScript™ reverse transcriptase produced better quality cDNA. The quality of cDNA was 
checked using the Human cDNAOK!	  ® kit (Microzone, cat. no. 2HCDOK-150). This involved 
a PCR reaction containing 5 different primers pairs. Better quality cDNA will be able to 
amplify all 5 amplicons of up to 600 base pairs (bp). If there is no cDNA, only the positive 
PCR control should be visible (500 bp). This method was also used to periodically check the 
integrity of cDNA using the following reaction in each tube: 
o Human cDNAOK!	  ® kit mix – 7.5µl 
o MasterMix Gold – 12.5µl 
o H20 - 4µl 
o cDNA - 1µl 
o Total reaction vol. – 25µl 
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A mastermix of Human cDNAOK!	  ® kit mix, MasterMix gold and H20 was made and 24µl of 
this was added to suitably labelled PCR tubes, to which 1µl of cDNA was added. Once 
completed, the tubes were put into a thermal cycler using the program ‘cDNA-OK’: 
o 95°C for 5 minutes. 
o For 35 cycles: 
§ 95°C for 30 sec. 
§ 59°C for 20 sec. 
§ 72°C for 45 sec. 
Once completed, the products of this PCR reaction were separated on a 2% agarose gel at 50 
volts constant voltage (see section 2.10). An example of this is shown below (figure 2-5). 
 
 
Figure 2-5. Human cDNAOK!	  ® kit PCR products  
 
Figure showing a PCR experiment using the Human cDNAOK!	   ® kit (Microzone, cat. no. 
2HCDOK-150. The cDNA used was from samples 13A, 13B AND 13C. The negative control 
(C-) only contained distilled water and only the positive PCR control is visible at 500 bp. 
cDNA was made using the Quantitect® kit and GoScript™ reverse transcriptase. Products are 
run on a 2% agarose gel using a 100 bp ladder (Sigma-Aldrich, cat. no.  P1473). 6µl of DNA 
ladder and 10µl of PCR product were loaded into the gel. 
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 As already stated, in order to check the quality of the cDNA produced the Human 
cDNAOK!	  ® kit was used. This demonstrated that the cDNA made was of optimal quality as it 
allows amplification of amplicons of up to 600bp.  It was not possible to calculate the 
concentration of cDNA after the RT reaction was complete on the NanoDrop®. This is because 
there are Deoxynucleotide Triphosphates (dNTPs) left over within the cDNA from the RT 
reaction that would affect any reading on the NanoDrop®. Therefore any concentration 
obtained would not be exclusively for the cDNA produced. 
 
2.7 Primers 
2.7.1 Design 
In order to design primers the website ensembl (http://www.ensembl.org/index.html) 
was used to look up the gene of interest (name or symbol) in order for the sequence of the 
gene, including the position of exons and introns to be determined. Once a suitable DNA 
sequence was selected, primer 3 plus (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) was used to try and design suitable primers. Specific 
requirements were as followed: 
o A product size of between 100-200bp. 
o Primer size minimum 18bp, optimum 20bp, maximum 22bp. 
o Tm of primers to – optimum 61°C (–/+ 1°C). 
o Primer GC% - minimum 40%, optimum 50%, maximum 60%. 
o Select ‘advanced setting’ tab: 
§ Set the no. of GC clamps to 2 (preferable one at either end of primer). 
o Press the ‘pick primers’ button. 
o Hopefully a selection of possible primer pairs will be generated. 
Once potential primers were selected, they were checked for single-nucleotide 
polymorphisms (SNP) (https://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm). If no SNP 
were detected, using the website reverse ePCR (http://www.ncbi.nlm.nih.gov/projects/e-
pcr/reverse.cgi) the primers were checked to ensure they would bind specifically within the 
gene of interest only and not in multiple areas of the transcriptome. The website DNA 
calculator (http://www.sigma-genosys.com/calc/DNACalc.asp) was then used to check the 
secondary structure of the primers to ensure they would not likely create primer dimers. If the 
chosen primers pass all the checks were then ready to be ordered. 
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2.7.2 Primer preparation (Sigma-Aldrich) 
Before preparation, the workspace and all relevant equipment were cleaned with 100% 
ethanol and appropriate protective clothing was worn. Primers ordered from Sigma-Aldrich 
arrived as lyophilised primers labelled with the name given to the primers when they were 
designed and ordered.  
 
A primer stock solution was made as stated on the data sheet that arrived with the 
primers to give a 100µM primer stock solution.  From this, a 5µM working solution of each 
primer was made, by performing a 1/20 dilution using sterile RNase free water (380µl of 
RNase free H2O to 20µl of each primer). This concentration of working primer stock was 
based on optimisation experiments for the endpoint and qPCR machine used in the laboratory. 
Both the stock and primer stock solution were stored at -20°C. 
 
2.7.3 Primer sequences used for genes of interest 
Beta Actin (β-Actin) (designed by A. Fletcher) 
– F – GCGGGAAATCGTGCGTGACATT 
– R – GATGGAGTTGAAGGTAGTTTCGTG 
– Amplicon size – 232bp 
HSP20 (self-designed) 
– F – ACGAGGAGCGCCCGGATGAG 
– R – CTGGTGCGGCCTGGATGGAC 
– Amplicon size – 138bp 
HSP27 (Oba et al., 2008) 
– F – CAGTCTCATCGGATTTTGCAGC  
– R – TGTCCCTGGATGTCAACCACTT  
– Amplicon size – 318bp 
HSP32 (Shokawa et al., 2006) 
– F – GAGGCCAAGACTGCGTTCC  
– R – GGTGTCATGGGTCAGCAGC  
– Amplicon size - 72bp 
HSP60 (self-designed) 
– F – AAGGCATGAAGTTTGATCGAG  
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– R – CATTGGCAATTTCAAGAGCA    
– Amplicon - 153bp 
HSP72 (self-designed) 
– F – GGTGCAGGTGAGCTACAAGG  
– R – TGCGAGTCGTTGAAGTAGGC  
– Amplicon – 156bp 
HSP90 (self-designed) 
– F – TTTGTGGAGAAGGAACGTGA  
– R – CAGGTTTGTCTTCCGACTCTTT  
– Amplicon – 109bp 
4th TLR4 (self-designed primer 3 plus) 
– F – AGTTGAACGAATGGAATGTGC  
– R – ACACTGAGGACCGACACACC  
– Amplicon size – 114bp 
MYD88 (Isnardi et al., 2008) 
–  F – GACGACGTGCTGCTGGAGCTG  
– R – GATGAAGGCATCGAAACGCTCAG  
– Amplicon size – 201bp 
TLR2 (self-designed with primer 3 plus) 
–  F – GCCTCTCCAAGGAAGAATCC  
– R – TGTTGTTGGACAGGTCAAGG  
– Amplicon size – 141bp 
Apelin receptor (APJ) (Melgar-Lesmes et al., 2011) 
– F – CTATCCTGTTTTCTGAGTGTGAGG  
– R – CTAAGGGCTGGAGCACTAATTATC  
– Amplicon size – 89bp 
GRP78 (HSPA5) 
– Solaris® qPCR Gene Expression Assays for (Thermo Scientific, cat. no. AX-008198-
00-0100) 
β-Actin 
– Solaris® qPCR Gene Expression Assays for (Thermo scientific, cat. no. AX-003451-
00-0100) 
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There was a long optimisation period of several months involved with TLR4 primers 
ordered from Sigma-Aldrich used in the work herein. The first 3 TLR4 primer pairs used were 
tried and discarded until the fourth set used was finally optimised under the standard qPCR 
assay conditions. After this, no more problems were encountered. 
 
2.8 Polymerase Chain reaction (PCR)  
 
Before PCR was carried out all equipment was cleaned with 70% ethanol. Blue 
MegaMix-Double® (Microzone, cat. no. 2MMBD-5) was used for all endpoint PCR reactions. 
Primers suitable to analyze the genes of interest were ordered from Sigma-Aldrich (usually 
working stock of 5µM). A mastermix of relevant reagents was made up and 1µl of cDNA was 
used. A typical reaction in a single tube contained: 
o 12.5 µl Blue MegaMix Double®. 
o 2.5µl Forward primer (5µM). 
o 2.5µl Reverse primer (5µM). 
o 6.5µl RNAse water. 
o 1µl sample cDNA/ positive control cDNA/ distilled water (dH2O) negative 
control 
o 25µl total reaction volume. 
Once all reactions were set up they were placed into a thermal cycler (DNA Engine®, Bio-
Rad) and then run with the standard program ‘SAN1’: 
o 95°C for 5 minutes. 
o For 35 cycles: 
§ 94°C for 30seconds. 
§ 61°C for 30seconds. 
§ 72°C for 30seconds. 
o 72°C for 10 minutes. 
Once the reaction was complete the PCR products were placed in the fridge until gel 
electrophoresis was performed (see section 2.10). 
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2.8.1 Toll like receptor (TLR) screening with endpoint PCR 
The aim of these experiments was to screen ischemic myocardial tissue from cyanotic 
and control patients, collected in theatre, that had not been exposed to any type of 
experimental conditions in order to establish their expression profile for all known human 10 
TLRs and demonstrate if there were any identifiable differences between cyanotic and 
acyanotic patient groups. This was done using the TLR-RT Primer Set® (Invivogen, cat. no. 
rts-htlrs) that contained primers for all 10 human TLRs (figure 2-6). The sizes of the primers 
used were unknown as they were part of the kit. 
 
 
Figure 2-6. Primers for 1-10 TLR from the TLR-RT Primer Set® 
 
 
 
Figure shows an endpoint PCR reaction using the Invivogen kit control cDNA with all 
10 TLR primers. 100bp DNA ladder (Sigma-Aldrich, cat. no. P1473-1VL) was used 
despite the primer sizes being unknown. 6µl of the DNA ladder and 10µl of PCR 
product were loaded. 
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RNA was extracted from the heart tissue (see section 2.5) and then the RNA was used 
for RT to make cDNA. This cDNA was used to run a series of PCR experiments using primer 
pairs for all 10 human TLRs. The method of PCR mentioned in 2.8 was used but the reagents 
and the PCR program used were slightly different. The primers used were provided in the kit 
but their sequence and precise size was not given. A reaction in a single tube contained: 
o 12.5 µl Blue MegaMix Double®. 
o 1µl TLR primer pair (from kit). 
o 10µl RNase water. 
o 1.5µl sample cDNA/ positive control cDNA/ dH2O negative control or  
o 25µl total reaction volume. 
 
The following conditions (program ‘TLR’) were used for the PCR reaction on the thermal 
cycler: 
o 95°C for 2 minutes. 
o For 35 cycles: 
§ 95°C for 30 seconds. 
§ 60°C for 30 seconds. 
§ 72°C for 2 minutes. 
o 72°C for 5 minutes. 
 
A period of optimization was carried out when this kit was initially used. It was found 
it would only work with the positive control provided with the kit. It was discovered that the 
original PCR protocol provided by Invivogen was not correct and upon correction the 
problems encountered were solved. 
 
2.9 Quantitative real time polymerase chain reaction (qPCR) 
Before this method was undertaken all work space and equipment to be used was 
sterilized with 70% ethanol. Disposable sterile plastic consumables were used as bought or 
were sterilized under ultra-violet (UV) light. cDNA was removed from -20°C storage and 
allowed to thaw on wet ice. The GoTaq® qPCR Master Mix (Promega, cat. no. A6001) was 
used to undertake mRNA level investigation of differential gene expression using the 
StepOnePlus® qPCR machine (Applied Biosystems). The GoTaq® qPCR Master Mix contains 
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an intercalating dye that binds to double stranded DNA between adjacent base pairs. Once 
bound it emits a fluorescent signal. As the PCR amplification proceeds and more double 
stranded product is made, the fluorescent signal will increase.   
 
Primers used were ordered from Sigma-Aldrich and the endogenous control used was 
β-Actin. The choice of endogenous control is important. If its expression is not uniform in all 
samples then it does not account for intra sample variation. For this work the endogenous 
control was β-Actin, which has previously been demonstrated as a suitable endogenous control 
in this laboratory. 
 
Sample and reference sample (for correction of expression data and positive control) 
cDNA were diluted at 1/5 (2µl cDNA + 8µl dH2O). A mastermix was made for every primer 
used within a single experiment. A typical master mix plus cDNA per number of wells would 
be as follows: 
o 12 µl GoTaq® master mix (provided in kit). 
o 1.25µl Forward primer (5µM). 
o 1.25µl Reverse primer (5µM). 
o 5.25µl RNase water. 
o 0.25 CRX reference dye (provided in kit) 
o 5µl cDNA (1/5 dilution) 
o 25µl total volume. 
The experiment would be set up in Microamp® fast optical 96 well plates (Applied 
Biosystems, cat. no. 4346906). Once the plate was set up, a plastic cover was placed and 
sealed on top of the plate. The plate was then spun in a centrifuge (1500xg for 1 minute) to 
remove any bubbles and then it was put into the qPCR machine and the run was started. The 
following qPCR programme was used: 
o Holding stage - 95°C for 20seconds 
o Cycling stage - 95°C for 3 seconds, 60°C for 30 seconds - 50 cycles 
o Melt curve – 95°C for 15 seconds, 60°C for 1 minute, 95°C for 15seconds. 
Once the reaction was complete, the plate was removed from machine and kept in the fridge. 
The PCR products were run on a standard agarose gel (see section 2.10) to check size and 
confirm a single discreet product. 
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The disadvantage with GoTaq® qPCR Master Mix is that the dye it contains binds 
indiscriminately to any double stranded product. Therefore, to ensure a single discreet qPCR 
product is amplified during the reaction, melting curve analysis is used. This is where the 
qPCR products are exposed to a temperature gradient. The point at which 50% of the product 
denatures is measured i.e. when the double stranded PCR product separates to become single 
stranded DNA. If only one single discreet peak is present then there should only be one 
product.  Great care was taken when the primers were designed. It was ensured they did not 
contain any self-complementary sequence and that they did not form primer dimers. This 
ensured that the primers did not form secondary structures or result in non-specific primer 
binding that would result in undesired application. If any amplification occurs after 35 cycles 
during a qPCR reaction it is caused by non-specific primer binding and any results were 
discarded. 
 
The correct size (bp) of amplicon is known for each primer pair when they are 
designed (see section 2.7.1). Therefore the size of a PCR product can be established by gel 
electrophoresis (see section 2.10).  
 
It should be noted that the sensitivity of the GoTaq® assay used in all the qPCR 
reactions in this project was optimised by the use of copy number serial dilutions; a sample 
with a known copy number was serially diluted by 1/10 down to one copy number 
(demonstrated by Mr Alexander Fletcher).  
 
Biological replicates instead of technical replicates were used for these experiments. 
Specifically, tissue samples from the same patient group were grouped together and used as 
replicates of each other. Such variability between biological replicates is normal.  
 
Differential gene expression was then calculated using the Comparative Ct method to 
give relative quantification (RQ) of gene expression using the StepOne Software® v2.1 
(Applied Biosystems). 
 
2.9.1 qPCR with Solaris® qPCR gene expression assays (GRP78) 
These assays are an alternative to TaqMan® Gene Expression Assays (Applied 
Biosystems). They contain fluorescently labelled probes as well as primers for a gene of 
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interest that bind within the amplicon. These probes have fluorescent labels and a quencher 
molecule. The presence of the quencher prevents the fluorescent label from emitting a signal. 
During a successful qPCR reaction, the fluorescent label on the probe is successfully cleaved 
from the quencher by the activity of the Taq polymerase during the reaction, allowing the 
signal to be detected. This means a fluorescent signal will only be detected when the primers 
and probes bind together and amplify the target i.e. the gene of interest. 
 
Before this method was undertaken all work space and equipment to be used was 
sterilized with 70% ethanol. Disposable sterile plastic consumables were used as bought or 
were sterilized under UV light. cDNA was removed from -20°C storage and allowed to thaw 
on wet ice. Solaris© qPCR Gene Expression Assays for HSPA5 (GRP78) (Thermo Scientific, 
cat. no. AX-008198-00-0100) and β-Actin (Thermo Scientific, cat. no. AX-003451-00-0100) 
were used to undertake mRNA level investigation of differential gene expression using the 
StepOnePlus® qPCR machine (Applied Biosystems). The endogenous control used was β-
Actin.  
 
Sample and reference sample (for correction of expression data and positive) cDNA 
were not diluted. A mastermix was made for every Solaris® qPCR Gene Expression Assay 
used within a single experiment. A typical master mix plus cDNA per number of wells would 
be as follows: 
o 12.5 µl Solaris® qPCR master mix (provided in kit). 
o 1.25µl probe/ primer (provided in kit) 
o 10.25µl RNAse water (provided in kit) 
o 1µl cDNA  (provided in kit) 
o 25µl total volume. 
The experiment would be set up in a Thermo-fast® 96 PCR plate (Thermo Scientific, cat. no. 
AB-1900/W). Once the plate was setup, a plastic cover was placed and sealed on top of the 
plate. The plate was then spun in a centrifuge (1500xg for 1 minute) to remove any bubbles 
and then it was put into the qPCR machine and the run was started. Once the reaction was 
complete, the plate was removed from the machine and kept in the fridge if products were to 
be separated on an agarose gel (see section 2.10) to ensure the produced qPCR product was of 
the expected size. Differential gene expression was then calculated using the Comparative Ct 
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method to give RQ of gene expression using the StepOne Software® v2.1 (Applied 
Biosystems).  
 
2.9.2 Calculation of gene expression by comparative Ct method 
Differential gene expression of all the genes of interest was determined using the 
comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). This method is a relative 
quantification (RQ) method used to assess changes in mRNA levels of a gene of interest in 
one sample relative to the mRNA levels in other samples. It is not necessary for the exact 
amount of mRNA of the gene of interest in each sample to be known. This RQ of gene 
expression in all samples is determined against the level of expression of the gene of interest 
found in an arbitrary reference sample (described below). The resulting RQ or fold change of 
gene expression is expressed as arbitrary values with no units.  
 
The resulting RQ values were calculated using the StepOne® Software v2.1 (Applied 
Biosystems). The RQ value was calculated using the following equations: 
• ΔCt = Ct [Gene of interest] - Ct [Endogenous control] 
• ΔΔCt = ΔCt [sample]- ΔCt [reference sample] 
• RQ = 2 –ΔΔCt (normalised against reference sample) 
 
The Ct is the cycle number at the threshold chosen by the StepOne® Software v2.1 at 
which to measure and compare the level of transcript found in each sample. This is the point at 
which PCR product amplification is optimal. As amplification proceeds, the dye in the 
GoTaq® qPCR Master Mix intercalates into the double stranded PCR product and a 
fluorescent signal is emitted. This signal therefore indicates the degree of product 
amplification in each sample. 
  
The endogenous control is a housekeeping gene, whose mRNA expressions levels are 
fairly constant in all cell types. In these experiments the endogenous control used was β-Actin. 
In any sample you measure the known expression of a gene (β-Actin) against the unknown 
expression of a gene of interest. This is performed in order to account for intra sample 
variation. In this project, such variation is also accounted for by the fact that the concentration 
of RNA used in all RT reactions (see section 2.6) is standardised (100ng). Therefore, the level 
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of expression i.e. Ct of the endogenous control in each sample is substracted from the Ct of the 
gene of interest in each sample. This provides the ΔCt value. This is done for an arbitrary 
reference sample as well. The level of expression in this reference sample is what is used to 
calculate the RQ of gene expression of the gene of interest in all other samples. The ΔCt of 
each sample has the ΔCt of the reference sample subtracted from it, which gives the ΔΔCt for 
each sample. The RQ value is then calculated as shown above.  
 
The reference samples used were myocardial tissue samples obtained from 1) a TOF 
patient exposed to a chemical inducer that was used for the HSP primer set (13B) and 2) a 
control sample exposed to 2% O2 (18B). These references samples were tested to ensure they 
were appropriate for all the primers they were for (shown in figure 2.7 and figure 2.8). The 
fact this reference sample is known to work with all primers used and has been through the 
same procedure as all other samples means it also acts as a positive control for this assay.  
 
The fact the same references samples were used for all qPCR experiments allows the 
RQ results from one qPCR experiment to be compared to the results from another therefore it 
helped minimize inter experimental variation. Any inter experimental variation experienced in 
different reactions will affect the RQ value produced for the reference sample the same as it 
would affect the RQ values produced for all other samples. Therefore any variability in RQ 
values is minimized by its use in every reaction. 
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Figure 2-7. Reference sample 13B with HSP primer set 
 
Figure shows a PCR experiment using patient 13B cDNA with primers for HSP20, 
HSP27, HSP32, HSP60, HSP72 and HSP90. Products are separated on a 2% agarose 
gel. 50 base pair ladder was used (Bio-­‐Rad, cat. no. N32365). 6µl of DNA ladder and 
10µl of PCR product were loaded. 
 
 
Figure 2.8. Reference sample 18B with inflammatory mediator primer set 
 
Figure shows a PCR experiment using patient 18B cDNA with primers for TLR2 
(141bp), TLR4 (114bp) and MYD88 (201bp). Products are separated on a 2% agarose 
gel. 50 base pair ladder was used (New England Biolabs, cat. no. N04735). 6µl of DNA 
ladder and 10µl of PCR product were loaded. MYD88 has a known secondary product, 
which is apparent in the figure. 
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2.10 Gel electrophoresis for cDNA after endpoint PCR/ qPCR 
 
PCR/ qPCR products were separated by size in a 2%, 50ml agarose gel. 1.0g of 
agarose (Sigma-Aldrich, cat. no. 05066-50G) was mixed with 50ml of Tris-Acetate EDTA 
(TAE) buffer (Flowgen Bioscience, cat. no. H19109) (1x buffer diluted from a 50x stock) and 
thoroughly mixed. This was heated in the microwave at full power for 1minute and then 7.5µl 
of SYBR safe (Invitrogen, cat. no. S33102) was added before the gel was poured in order to 
make the cDNA in the gel visible under UV light. The gel was allowed to polymerise for up to 
1 hour, then once ready samples and a suitable molecular ladder (100bp DNA ladder from 
Sigma-Aldrich, cat. no. P1473-1VL) were prepared for loading. When reagents used did not 
have a dye already present within them, 2µl of gel loading dye (Sigma-Aldrich, cat. no. 
G2526-5ML) was added. Once loaded, the gel was run at 50 volts at constant voltage. Usually 
after running for about 20 minutes the gel was observed under a UV trans-illuminator in order 
to visualise the bands. 
 
2.11 Heart tissue preparation for protein expression analysis using Western 
blotting 
2.11.1 Homogenisation 
Tissue samples were removed from -80°C storage and ground to a fine powder in 
liquid N2 with a mortar and pestle and were added to an appropriate volume of homogenising 
buffer (see appendix 4) supplemented with protease inhibitor cocktail. Using a Polytron 
PT1600E homogeniser (Kinematica) set at setting 10, the sample containers were surrounded 
by ice and homogenized for 3x10s intervals with a 1 minute cool down at 4°C in between. The 
homogenate was spun in a centrifuge (5000xg for 10 minute at 4°C) to remove debris and the 
resultant supernatant containing the total cell protein (both particulate and cytosolic fractions) 
was extracted. 
 
2.11.2 Bradford assay for protein estimation 
The Bradford protein assay (Bradford, 1976) was used to quantify total protein 
concentration. A stock standard (STD) solution of Bovine Serum Albumin (BSA) (1mg per 
ml) (see appendix 4) was used to create the standard curve using the following standards: 
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Table 5. Standards (µg/ml) used for Bradford Assay 
STD concentration (µg/ml) Vol. stock std (µl) Vol. of dH2O (µl) 
0 n/a 50 
200 10 40 
400 20 30 
600 30 20 
800 40 10 
1000 50 n/a 
 
Samples were diluted by 1/40 (39µl of dH2O and 1µl of homogenate) or by an 
applicable dilution factor (e.g. 1/20). Measurement of concentrations was prepared using a 
BioPhotometer® (Eppendorf). 
 
2.12 Western Blotting 
2.12.1 Sample and gel preparation  
Samples were mixed 1:1 with loading buffer (see appendix 4) and boiled for 5 minutes 
at 95°C before loading. Samples were separated on a 10% sodium dodecyl sulfate-
polyacrylamide resolving gel with a 4% stacking gel (see appendix 4 for buffers used and for 
the composition of resolving and stacking gels) using the Protean II® xi Cell System (Bio-Rad, 
Hemelhempstead, U.K.) at 200 volts for a maximum of 4 hours (see appendix 4 for 
composition of running buffer). Each well was loaded with 50µg of protein unless otherwise 
stated. Pre-stained SDS-PAGE Standards (Low range, Bio-Rad, cat. no. 161-0305) were 
loaded beside the samples to demonstrate the size of proteins identified. Homogenised term 
placental villous tissue (50µg), known to express HSP27 and HSP72, were loaded and used as 
a reference sample and positive control. Although loading controls are not shown, they were 
performed to ensure the amount of protein being loading was equal for all samples. This was 
done using a β-actin antibody (see section 2.12.4). 
2.12.2 Transfer of proteins to Nitrocellulose 
 Transfer of proteins to Whatman Protran® nitrocellulose transfer membranes (Sigma-
Aldrich, cat. no. Z61360) in transfer buffer (see appendix 4) was carried out using the Trans-
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Blot SD Semi-Dry® Electrophoretic Transfer Cell (Bio-Rad, cat. no. 170-3940) at 22 volts and 
a variable constant current (2.5 x membrane area) for 30 minutes.   
2.12.3 Immuno-detection of proteins (Immuno-blotting) 
 Filters were blocked in 5% donkey serum (Serotec, cat. no. CO6SBZ) in TBSTB (see 
appendix 4) for 1 hour at room temperature unless otherwise stated. Primary antibodies were 
pre-absorbed (minimum of 30 minutes) in 5% human serum (Sera Laboratories International, 
cat. no. S-123-H) in TBSTB at room temperature during the blocking process. Filters were 
rinsed in TBSTB and incubated for 1 hour at room temperature with appropriate primary 
antibody solution (e.g. HSP27, New England Biolabs, cat. no 2402, mouse monoclonal, 
1:1000 concentration). Filters were rinsed and washed in TBSTB (3x5 minutes) and then 
incubated for 1 hour at room temperature with an appropriate horseradish peroxidase 
conjugated secondary antibody (e.g. Donkey anti mouse, Abcam,, cat. no. ab6820, 1:1000) 
diluted in TBSTB. Filters were rinsed again and washed with TBSTB (3x5 minutes) and then 
washed once for 5 minutes with dH2O. Immunologically reactive proteins were visualised 
using the Amersham ECL® Western Blot detection system (Amersham Pharmacia Biotech, 
GE healthcare, cat. no. RPN2106). Bands on the exposed films were scanned using a Bio-Rad 
GS-700® imaging densitometer connected to a Macintosh computer using Bio-Rad 
MultiAnalyst® software. Band densities were expressed relative to the density of the internal 
placental control sample included on every gel i.e. as relative optical density (ROD). 
 
2.12.4 Antibodies  
Primary antibodies: 
• HSP27 
o Cell signaling technology, cat. no. #2402 
o Mouse monoclonal 
o 1/1000 concentration 
• HSP32 (HO-1) 
o Enzo Life Sciences, cat. no. ADI-SPA-896 
o Rabbit polyclonal 
o 1/1000 concentration 
• HSP72 
o Enzo Life Sciences, cat. no. ADI-SPA-812 
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o Rabbit polyclonal 
o 1/1000 concentration 
• APJ  
o Novus Biologicals, cat. no NBP1-30869 
o Rabbit polyclonal 
o 1/1000 concentration 
• β-actin 
o Sigma Aldrich, cat. no. WH0000060M1 
o Mouse monoclonal 
o 1/3000 concentration 
 
Secondary antibodies: 
• Donkey polyclonal Secondary Antibody to Mouse IgG - H&L (HRP)  
o Abcam, cat. no. ab6820  
o 1/1000 concentration 
• Donkey anti-Rabbit IgG H&L (HRP) secondary antibody  
o Abcam, cat. no. ab7083 
o 1/3000 concentration 
 
2.13 Decay curve experiments 
 
The aim of this experiment (figure 2-9) was to determine if the expression pattern of 
the genes of interest seen during the qPCR experiments within the excised myocardium from 
both the acyanotic group and the cyanotic group was influenced by the conditions of the 
experiments performed on the myocardial tissue or if it was due to degradation of RNA during 
the time period of incubation. The steps 1 to 5 in the diagrams correspond with steps 1 to 5 
described within the text. 
 
Step 1: In preparation for tissue collection 1ml of supplemented media (see appendix 
4) was added to 4 wells of a sterile 24 well culture plate (4ml in total). A separate amount of 
supplemented media was also prepared in a universal container, which was to be used for 
tissue collection. Once prepared, the 24 well culture plate and universal container were put 
into a NuAire® CO2 incubator set at 20% O2 and at 37°C. Also 6 bijous were prepared, each 
containing 3ml of RNAlater® solution. 
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Step 2: When tissue was ready to be collected, the universal container was removed 
from the incubator and taken to theatre and all tissue that was collected was put into it. A bijou 
containing 3ml of RNAlater® solution was also taken over to theatre and a piece of tissue was 
removed at this point and put into it. This sample was used as an experimental baseline 
reference sample (A).  
 
Step 3: The samples within the universal container and the reference sample within the 
bijou were brought back to the laboratory. 
 
Step 4: When back in the laboratory, all tissue was removed from the universal and cut 
into equal sized pieces. Another piece of tissue was removed at this point and was put into 
another bijou containing 3ml of RNAlater® solution that would act as a second baseline 
reference (B).  
 
Step 5: When tissue was ready for further processing, the 24 well culture plate was 
removed from the incubator. The rest of the tissue was then distributed into the four wells of 
the 24 well plate that contained supplemented media. Once done, the 24 well culture plate was 
then put back into the incubator. Tissue was removed after 1.5 hours (C), 3 hours (D), 4 hours 
(E) and 6 hours (F) of incubation. These times were chosen as they represented the incubation 
times used in both the HSP induction (see section 2.4) and reperfusion experiments (see 
section 2.3). At each stage that tissue was removed, the culture plate was removed from the 
incubator and tissue in the relevant well of the 24 well culture plate was removed and put into 
a bijou containing 3 ml of RNAlater® solution. 
 
The tissue was left in RNAlater® solution overnight at 4°C and then RNA was 
extracted from the tissue (see section 2.5) and then reversed transcribed (see section 2.6) into 
cDNA to be used in qPCR reactions using primers designed for the genes of interest (see 
sections 2.7.3). Any differences in gene expression seen were analysed using qPCR (see 
section 2.9). 
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Figure 2-9 Decay curve experiment 
 
Figure 2.9 showing the time course of decay curve experiment. Labelling on the 
diagrams refers to the following: A – collection of first reference samples, B – collection 
in flask containing 20% O2, C – after 1.5 hours incubation, D – after 3 hours incubation, 
E – after 4 hours incubation, F – after 6 hours incubation. 
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3.1 Screening of differential gene expression in ventricular myocardium 
excised from cyanotic and control (acyanotic) patient groups 
 
3.1.1 Introduction 
 
Children with congenital heart defects such as TOF (see section 1.1.3) and SAS (see 
section 1.1.4) require surgical correction that involves cardiac surgery with CPB (Bailliard and 
Anderson, 2009). The major difference between these patient groups is that pre-operatively, 
TOF patient myocardium is cyanotic due to chronic exposure to insufficiently oxygenated 
blood shunted from the right to the left side of the heart through the VSD while SAS patient 
myocardium is acyanotic. It is thought that patients that are cyanotic pre-operatively are more 
vulnerable to damage sustained during cardiac surgery, for example, to IR injury (Merante et 
al., 1998; Najm et al., 2000; Corno et al., 2002). 
 
3.1.2 Methods and Results 
The aim was to investigate the differential expression of several genes of interest in 
myocardium excised from children undergoing corrective heart surgery in both cyanotic and 
acyanotic patients. 12 patients were recruited (table 6). Seven patients were cyanotic and were 
comprised of TOF and fallot variant (FV) patients. Five were control (acyanotic) patients, 
comprising of SAS and truncus arteriosus (TA) patients. There are 2 experiments described in 
this section and they both used the same sample set shown below in table 6. 
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Table 6. Patients recruited for cyanotic and acyanotic patients groups 
 
Patient Type Group Gender Age 
3(1) TOF Cyanotic Female 1 year 1 month 
4(1) TOF Cyanotic Male 1 year 2 months 
9(1) TOF Cyanotic Male 1 year 2 months 
10(1) TOF Cyanotic Male 0 years 11 months 
11A TOF Cyanotic Female 1 year 0 months 
16A TOF Cyanotic Male 0 year 11 months 
23A FV Cyanotic Female 1 year 1 month 
5(1) SAS Acyanotic Male 0 years 7 months 
6(1) SAS Acyanotic Female 12 years 4 months 
7(1) SAS Acyanotic Male 2 years 8 months 
8(1) TA Acyanotic Male 0 years 1 month 
18A SAS Acyanotic Female 0 years 11 months 
 
 
 
3.1.2.1 Experiment 1: Toll Like Receptor (TLR) screening by endpoint PCR 
  
Myocardial tissue (ischemic) samples collected (LV and RV) from acyanotic and 
cyanotic patients respectively that have not been exposed to any type of experimental 
conditions were screened in order to establish their expression profile for human TLRs 1-10 
using a specialised kit (Invivogen, cat. no. rts-htlrs). This was done in order to see if there 
were any identifiable differences of TLR expression within the myocardium from the cyanotic 
and acyanotic patient groups using endpoint PCR (see section 2.8.1). To date it is not known 
which TLRs are expressed in infant myocardium. The PCR products were separated on an 
agarose gel for size analysis (see section 2.10). It should be noted that the size of primers was 
unknown, as the company did not provide this information. 
 
In the cyanotic patient group (figure 3-1) TLR2-8 were expressed to some degree. 
TLR1 was not expressed in any patients. TLR9 and TLR10 were expressed at very low levels. 
TLR4 is expressed highly in all cyanotic patients. For the acyanotic group (figure 3-2), the 
observations were the same except for sample 6(1) where TLR8 was highly expressed. Also 
for sample 18A, TLR9 and TLR10 were highly expressed. There was no obvious noticeable 
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difference in the TLR gene expression profile of cyanotic patients compared to control 
patients. These observations are not quantitative and statistical analysis in this case is not 
appropriate. Overall TLRs, including TLR4 and TLR2 that became the main TLRs of interest 
in this thesis, are expressed in infant myocardial tissue. Such expression was found in 
myocardium from both the cyanotic and acyanotic patient groups. 
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Figure 3-1. TLR1-10 expression of 7 cyanotic patients 
 
 
Figure showing TLR1-10 expression profile of 7 cyanotic patients. Products are 
separated a 2% agarose gel using a 100bp DNA ladder (Sigma-Aldrich, cat. no. P1473-
1VL) despite the primer sizes being unknown. The numbers on each gel correspond to 
each of the 10 human TLRs. Positive control (C+) is provided for in kit and negative 
control (C-) is dH2O. 
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Figure 3-2. TLR1-10 expression of 5 acyanotic patients 
 
 
Figure showing TLR1-10 expression profile of 5 acyanotic patients. Products are 
separated on a 2% agarose gel using a 100bp DNA ladder (Sigma-Aldrich, cat. no. 
P1473-1VL) despite the primer sizes being unknown. The numbers on each gel 
correspond to each of the 10 human TLRs. Positive control (C+) is provided for in kit 
and negative control (C-) is dH2O. 
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3.1.2.2 Experiment 2:  Screening the differential expression of several genes of 
interest by qPCR 
Ischemic myocardial tissue samples (LV and RV) excised from cyanotic and control 
patients that had not been exposed to any type of experimental conditions were collected. The 
samples were screened in order to establish if there were any differences in expression seen 
for the genes of interest within the myocardium from both the cyanotic and control patient 
groups. This was done using qPCR (see section 2.9). The genes of interest include the 
inflammatory markers TLR2, TLR4, MYD88 and the stress genes HSP20, HSP27, HSP32 
(HO-1), HSP60, HSP70 and HSP90 (for primer sequences see section 2.7.3).  
 
qPCR (see section 2.9) was used to investigate changes in expression and any 
differences seen in gene expression were calculated using the Comparative Ct method (see 
section 2.9.2) to give relative quantification (RQ) of gene expression using the StepOne 
Software® v2.1 (Applied Biosystems). 
 
Statistical analysis was performed using GraphPad	   Prism 6	   Software©. Due to its 
biological variation the data did not follow a normal distribution therefore non-parametric 
statistical analysis was undertaken. Therefore the test used was the Mann-Whitney U test 
where data was expressed by the median and the interquartile range. A p-value of <0.05 (two-
tailed) is considered as statistically significant.	  
Inflammatory mediators:  
 The mRNA expression of TLR4, TLR2, and MYD88 was investigated (figure 3-3). 
TLR2 expression was significantly higher in the cyanotic group compared to the acyanotic 
group (1.23 vs. 0.68; p=0.0177). TLR4 expression was significantly higher in the cyanotic 
group compared to the acyanotic group (0.51 vs. 0.35; p=0.0303). MYD88 did not show a 
significant difference between the two groups. 
 
Stress proteins: 
The mRNA expression of HSP20, HSP27, HSP32, HSP60, HSP72 and HSP90 were 
investigated (see figure 3-4). Only HSP27 showed significantly higher expression in the 
cyanotic group compared to the acyanotic group (0.12 vs. 0.05; p=0.0303). HSP20. HSP32, 
HSP60, HSP70 and HSP90 showed no significant differences in expression between the two 
groups. 
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Figure 3-3. Figure shows the expression of inflammatory mediators in both the cyanotic and 
acyanotic patient groups. 
 
 
 
 
Figure shows comparison in the expression of TLR4 (A), TLR2 (B) and MYD88 (C) in 
both the cyanotic (n=7) and acyanotic (n=5) patient groups. Data is shown as box and 
whiskers plots (median, interquartile ranges). Expression was calculated using the 
Comparative Ct method to give relative quantification (RQ) of gene expression using the 
StepOne Software® v2.1 (Applied Biosystems). Statistical analysis was done using the 
Mann-Whitney U test and a p-value of <0.05 (two-tailed) is considered as statistically 
significant.  
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Figure 3-4. Figure shows the expression of stress proteins in both the cyanotic and acyanotic 
patient groups. A show HSP20 and HSP27, B shows HSP32 and HSP60 and C shows HSP72 
and HSP90. 
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Figure shows comparison in the expression of HSP20 and HSP27 (A), HSP32 and 
HSP60 (B), HSP72 and HSP90 (C) in both the cyanotic (n=7) and acyanotic (n=5) 
patient groups. Data is shown as box and whiskers plots (median, interquartile ranges). 
Expression was calculated using the Comparative Ct method to give RQ of gene 
expression using the StepOne® Software v2.1 (Applied Biosystems). Statistical analysis 
was done using the Mann-Whitney U test and a p-value of <0.05 (two-tailed) is 
considered as statistically significant.  
 
 
Summary of main findings: 
• Experiment 1: 
o TLR4 mRNA expression was the highest in both patient groups. 
o No difference in expression between cyanotic and acyanotic patient groups. 
• Experiment 2: 
o TLR4 (p=0.0303), TLR2 (p=0.0177) and HSP27 (0.0303) mRNA expression is 
significantly higher in the cyanotic patient group compared to the acyanotic 
group. 
	  
	  
 
 
 
 
C 
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3.2 Induction of HSP gene expression in excised ventricular myocardium:  
mRNA and protein level analysis of HSP gene expression induced by heavy 
metal chemical inducers 
 
3.2.1 Introduction 
HSPs are a highly conserved and ubiquitously expressed protein family. Expression of 
many HSPs is increased by a variety of different cellular insults. Consequently, HSPs are also 
known as “stress proteins” as they are expressed in response to a range of such stresses in 
order to repair or prevent any intracellular damage caused (Madden et al., 2008). 
 
The types of cellular insult that increase HSP expression have been mentioned before 
but some examples include hypoxia (Patel et al., 1995), inflammation (reviewed in Horvath et 
al., 2008), ischemia (Richard et al., 1996), bacterial infection (Zheng et al., 2004), ROS 
(oxidative stress) (Kukreja et al., 1994) and sodium arsenite (NaAsO2) (Li et al., 1983). The 
one of note here would be NaAsO2, which is one of the classical inducers of HSP expression 
used in this investigation. 
 
There are several examples of studies that have shown that heavy metal exposure can 
lead to increased expression of HSPs. For example, in a study involving the exposure of post-
implantation rat embryos in vitro to different levels of several different chemical teratogens, 
including cadmium chloride (CdCl2) and NaAsO2, HSP72 expression levels were measured 
using western blotting and immunohistochemistry. NaAsO2 was shown to cause a measurable 
increase of HSP72 while CdCl2 was not (Mirkes et al., 1994). Another study involved the 
exposure of various types of human endothelial cell types to CdCl2 and other chemical 
stressors. The results showed that cellular CdCl2 exposure for 3 hours caused the induction of 
HSP70, HSP60, HSP32 and HSP27 mRNA and protein expression. The most noticeable 
differences were seen for HSP32 and HSP72 in cadmium treated cells compared to untreated 
controls (Wagner et al., 1999). A more recent study used a transgenic mouse model, in which 
the firefly luciferase reporter gene was under the control of the murine hsp70-1 promoter. 
When the mice were exposed to CdCl2, HSP-70 gene expression was increased, the level of 
which was at maximum after 10 hours. This was indicated by the elevated activity of the 
reporter gene controlled by the hsp70-1 promoter and the elevated level of endogenous HSP70 
protein found in tissue samples taken from the transgenic mice after exposure (Wirth et al., 
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2002). Another similar study involving HSP32 (HO-1) was performed. This involved 
transgenic mice where the ho-1 promoter controlled the luciferase gene. The mice were 
exposed to acute levels of various chemical inducers, including CdCl2. The level of HSP32 
activation and expression, which was indicated by the level of the reporter gene, was used as 
an induction of the amount of induced HSP expression by the chemical inducers. In the case of 
CdCl2, HSP32 induction was seen in various tissues but the liver had the highest level of 
activity of the reporter gene and therefore the highest level of HSP32 induced expression 
(Malstrom et al., 2004).  
 
Other studies more specific for HSP induction due to NaAsO2 exposure include one 
involving the use of the cultured human urothelial cell line UROtsa, which were exposed to 
NaAsO2. The affect this had on the expression of HSP27, HSP60, HSC70, and HSP70 was 
investigated by qPCR and Western blotting in order to determine any changes in both mRNA 
and protein expressions levels. Only HSP70 showed significantly induced expression due to 
NaAsO2 exposure at both the mRNA and protein level (Rossi et al., 2002). Another study was 
performed that looked at the expression of HSP 32, HSP 72, HSP 60, and HSP 90 in precision-
cut rat lung slices when exposed to various concentrations NaAsO2. Only HSP32 and HSP72 
were induced upon NaAsO2 exposure (Wijeweera et al., 2001). 
 
Despite this wide literature on HSP induction by heavy metals, there is a distinct lack 
of evidence in the literature of this action in the heart. As HSP are potential mediators of 
protection in the heart from insults like IR injury that occurs during cardiac surgery, the ability 
to induce HSPs in cardiac tissue is of obvious benefit. This is especially important in children 
undergoing cardiac surgery for the correction of congenital cardiac defects, as such children 
often are associated with pre-operative cyantoic damage that results in apoptosis, meaning 
such children are much more vulnerable to additional damage.  
 
There have been studies that show that the induction of HSPs by the use of heavy 
metals has provided protection against IR injury in other tissues. One such study involved 
hepatic IR injury in mice, which investigated the role of HSP70 in such injury. HSP70 
expression was induced by the direct administration of NaAsO2 into the liver tissue before the 
liver was exposed to IR injury and it was found that there was a 50% reduction in liver injury 
sustained determined by western blotting analysis (Kuboki et al., 2007). Also, HSP70 null 
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mice also pre-exposed to NaAsO2 in the same manner did not acquire the same protection. 
This highlighted it was the expression of HSP70 that provided the protection against the IR 
injury (Kuboki et al., 2007).  
 
Thus in this project it was of interest to determine whether it is actually possible to 
induce HSPs in human infant myocardium using heavy metals. If so, this might open the 
pathway to seek ‘non-toxic’ ways of inducing HSPs in the heart. This set of experiments also 
acted as a control for the reperfusion experiments (see section 3.3) by investigating if it was 
actually possible to induce HSPs in the neonatal heart. 
3.2.2 Methods and Results 
 
The aim of these experiments was to determine the effect of heavy metal chemical 
inducers on the gene expression within infant myocardial tissue taken from the ventricle of 
children undergoing corrective surgery from both the cyanotic and acyanotic patient groups 
(see section 2.4). This investigation was done at both the mRNA and protein level. These 
experiments were undertaken while the hyperoxic reperfusion set up was being established. 
 
3.2.2.1 mRNA level gene expression in response to heavy metal exposure 
 
Differential gene expression was investigated in infant myocardial tissue taken from 
the ventricle of children undergoing corrective surgery from both the cyanotic and acyanotic 
patient groups. This tissue was exposed to heavy metal chemical inducers for 6 hours (see 
section 2.4.1). The two heavy metal chemical inducers used were NaAsO2 and CdCl2. The 
genes of interest were the stress genes HSP20, HSP27, HSP32 (HO-1), HSP60, HSP70 and 
HSP90. The inflammatory markers TLR2, TLR4, MYD88 were also investigated.  
 
In order to investigate the differential gene expression of the genes of interest, the 
method of qPCR (see section 2.9) was used and RQ of gene expression was calculated using 
the comparative Ct method (see section 2.9.2). Differential expression statistical analysis was 
investigated by looking at both chemical inducers separately and also with both inducers 
together. 
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Statistical analysis was performed using GraphPad	  Prism 6	  Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. The 
Wilcoxon matched-pairs signed rank test was used to look for any statistical differences in 
expression for all genes of interest seen due to the exposure to heavy metal chemical inducers. 
A p-value of <0.05 (two-tailed) is considered as statistically significant for these experiments. 
Seven patients (table 7) were recruited, comprising of TOF and TA patients. These patients 
were used for the mRNA gene expression analysis only. 
	  
Table 7. Patients recruited for mRNA level gene expression in response to heavy metals 
 
Patient Type Group Inducer Gender Age 
13 TOF Cyanotic Na Male 1 year 3 months 
15 TOF Cyanotic Cd Female 1 year 2 months 
19 TOF Cyanotic Na Female 0 years 9 months 
20 TOF Cyanotic Cd Female 1 year 2 months 
21 TOF Cyanotic Na Female 0 years 8 months 
22 TOF Cyanotic Cd Male 1 year 8 months 
28 TA Acyanotic Na Male 0 years 2 months 
(Na = Sodium aresenite, Cd = Cadmium Chloride) 
 
 
 
Analysis of data from induction by the heavy metal inducers separately: 
When looking at the differential mRNA expression of all HSPs and inflammatory 
mediators when exposed to either NaAsO2 or CdCl2 separately, there were no statistically 
significant differences observed in the expression (see table 8) of any of the HSPs or the 
inflammatory mediators. One possibility is that due to the low number of patient samples 
exposed to each chemical inducer (3 patients exposed to CdCl2 and 4 exposed to NaAsO2) 
may have meant that any significant difference in expression that may have been present was 
not identified. 
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Table 8. Statistical analysis of chemical inducers when analysed separately using the 
Wilcoxon matched-pairs signed rank test (p-value of <0.05 is considered as statistically 
significant). The p values are shown. 
 
 
Condition	   HSP20	   HSP27	   HSP32	   HSP60	   HSP72	   HSP90	   TLR4	   TLR2	   MYD88	  
NaAsO2	  baseline	  vs.	  NaAsO2	  
induction	   0.125 0.125 0.125 0.125 0.125 0.125 0.88 0.13 0.875 
NaAsO2	  baseline	  vs.	  NaAsO2	  
control	   0.125 0.875 0.125 0.625 0.125 0.125 0.13 0.63 0.125 
NaAsO2	  induction	  vs.	  NaAsO2	  
Control	   0.25 0.25 0.125 0.125 0.125 0.125 0.38 0.88 0.125 
CdCl2	  Baseline	  vs.	  CdCl2	  
induction	   0.25 0.25 0.25 0.75 0.25 0.25 1 0.75 0.25 
CdCl2	  Baseline	  vs.	  CdCl2	  
control	   1 0.75 0.25 0.25 0.25 0.25 0.75 1 0.25 
CdCl2	  induction	  vs.	  
CdCl2Control	   0.25 0.5 0.25 0.25 0.5 0.25 0.75 1 0.25 
 
 
 
Analysis of data from induction by the heavy metal inducers combined: 
 
Inflammatory mediators: 
The mRNA expression of TLR4, TLR2 and MYD88 were investigated (figure 3-5). 
There was no significant difference in the expression of TLR2, TLR4 and MYD88 upon 
exposure to heavy metal chemical induction after 6 hours. This was also true for TLR2 and 
TLR4 expression in the tissue incubated in media only for 6 hours. MYD88 expression was 
significantly decreased (p=0.0156) in the tissue incubated in media only for 6 hours.  
 
Stress proteins: 
The mRNA expression of HSP20, HSP27, HSP32 (figure 3-6) and the expression of 
HSP60, HSP72 and HSP90 (figure 3-7) were investigated. HSP27 and HSP60 had no 
significant differences when exposed to chemical inducers for 6 hours. This was the same for 
the tissue exposed to media only for 6 hours (control). HSP20 showed a significant decrease 
(p=0.0156) in expression when exposed to heavy metal chemical inducers for 6 hours but this 
was not shown in tissue exposed to media only for 6 hours (control). HSP32 (p=0.0156), 
HSP72 (p=0.0156) and HSP90 (p=0.0156) all showed a significant increase in expression 
when exposed to heavy metal inducers for 6 hours. This was also true for tissue exposed to 
media only for 6 hours (control).  
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The increase in expression due to exposure to the chemical inducer for 6 hours for 
HSP32, HSP72 and HSP90 was significantly higher (figure 3-8) when compared to the 
increase in the expression due to exposure to media only for 6 hours. Therefore the increase 
due to the chemical inducer was greater.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
Figure 3-5. Figure showing the differential mRNA expression of inflammatory mediators upon 
exposure to heavy metal chemical inducers or media only (control). 
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Figure showing the differential mRNA expression of TLR4 (A), TLR2 (B) and MYD88 
(C) in tissue exposed to heavy metals for 6 hours or tissue exposed to media only for 6 
hours (control). Samples taken from each patient (n=7) were used in both groups. Data is 
shown as line and symbol graphs (each sample’s data is plotted separately). The graphs 
(from left to right) show the expression from the start of incubation (baseline) and 
expression after 6 hours of incubation (with chemicals or control). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was done using the Wilcoxon matched-pairs signed rank test and a p-value of 
<0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-6. Figure showing the differential mRNA expression of the stress genes HSP20, 
HSP27 and HSP32 upon exposure to heavy metal chemical inducers or media only (control). 
 
 
 
 
 
 
 
 
 
 
146 
 
 
 
Figure showing the differential mRNA expression of HSP20 (A), HSP27 (B) and HSP32 
(C) in tissue exposed to heavy metals for 6 hours or tissue exposed to media only for 6 
hours (control). Samples taken from each patient (n=7) were used in both groups. Data is 
shown as line and symbol graphs (each sample’s data is plotted separately).  The graphs 
(from left to right) show the expression from the start of incubation (baseline) and 
expression after 6 hours of incubation (with chemicals or control). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was done using the Wilcoxon matched-pairs signed rank test and a p-value of 
<0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-7. Figure showing the differential mRNA expression of the stress genes HSP60, 
HSP72 and HSP90 upon exposure to heavy metal chemical inducers or media only (control). 
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Figure showing the differential mRNA expression of HSP60 (A), HSP72 (B) and HSP90 
(C) in tissue exposed to heavy metals for 6 hours or tissue exposed to media only for 6 
hours (control). Samples taken from each patient (n=7) were used in both groups. Data is 
shown as line and symbol graphs (each sample’s data is plotted separately). The graphs 
(from left to right) show the expression from the start of incubation (baseline) and 
expression after 6 hours of incubation (with chemicals or control). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was done using the Wilcoxon matched-pairs signed rank test and a p-value of 
<0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-8. Figure shows the differential mRNA expression of the stress genes HSP32, HSP72 
and HSP90 in tissue exposed to chemical inducers compared to media only (controls). 
 
 
 
 
Figure showing the differential mRNA expression of the stress proteins HSP32 (A), 
HSP72 (C) and HSP90 (C) of tissue exposed to chemical inducers for 6 hours compared 
to tissue exposed to media only for 6 hours (control). Samples taken from each patient 
(n=7) were used in both groups.  Data is shown as box and whiskers plots (median, 
interquartile ranges). Expression was calculated using the Comparative Ct method to 
give RQ of gene expression. Statistical analysis was done using the Wilcoxon matched-
pairs signed rank test and a p-value of <0.05 (two-tailed) is considered as statistically 
significant. 
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3.2.2.2 Protein level gene expression in response to heavy metal exposure 
 
The expression of HSPs in response to heavy metal exposure was also investigated at 
the protein level (see section 2.4.2) in infant myocardial tissue taken from the ventricle of 
children undergoing corrective surgery from the cyanotic patient group. Tissue was exposed to 
either 100µM NaAsO2 or 100µM CdCL2 for 6 hours at 37°C and then compared to appropriate 
controls. Differential expression at the protein level was performed using Western blotting 
(see section 2.12). The expression of HSP27, HSP72 and HSP32 were investigated. To see the 
relevant antibodies used see section 2.12.4. Five cyanotic patients (table 9) were recruited for 
this experiment, consisting of TOF and double outlet right ventricle (DORV) patients. These 
patients were used for protein gene expression analysis only. 
 
 
 
Table 9. Patients recruited for protein level gene expression in response to heavy metals 
Patient Type A or C Inducer Gender Age 
26 TOF C Na M 2 years 11 months 
27 TOF C Cd F 0 years 9 months 
30 DORV C Na F 4 years 1 months 
31 TOF C Cd M 0 years 10 months 
44 TOF C Na M 0 years 8 months 
(Na = Sodium arsenite, Cd = Cadmium Chloride) 
 
 
 
Differential expression of HSP32: 
Investigation of the differential expression of HSP32 was attempted but there did not 
seem to be any HSP32 expression present in the heart tissue samples being used for the 
experiments. To ensure this was not because of the antibody, we used an appropriate positive 
control (Microsome extract, Sigma-Aldrich, cat. no. MO317 (20mg/ul)). An example of this is 
shown below in figure 3-9. There was no expression observed in the heart tissue but there was 
expression seen for the positive control. 
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Figure 3-9. Results of Western blotting that shows the differential expression of HSP32 when 
induced by chemical inducers. 
 
 
 
 
Figure shows an autoradiograph representing the differential expression of HSP32 with 
placental tissue, heart tissue and a positive control. Lane 1 – SDS pre-stained standards 
(Bio-rad, cat. no. 161-0305), lane 2 - heart control, lane 3 –, placental control, lane 4 – 
NaAsO2 4 hour induction with 20 hour recovery, lane 5 – NaAsO2 control 24 hour 
induction, lane 6 – Microsome extract (C+). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
Differential expression of HSP72 and HSP27:  
The expression of HSP72 (figure 3-10) and HSP27 (figure 3-11) were investigated by 
Western blotting. Upon completion of HSP gene expression analysis by Western blotting, 
densitometry was then applied to the resulting autoradiographs shown below using Quality 
One® software and then used to calculate the ROD. The Wilcoxon matched-pairs signed rank 
test was used to look for any statistical differences in the expression HSP72 and HSP27 due to 
the exposure to heavy metals compared to the appropriate controls (media only). All data was 
analysed by combining the tissue exposed to both NaAsO2 and CdCl2.  
 
There was no significant difference in the expression of HSP27 and HSP72 (figure 3-
12) seen between tissue that had been incubated with a chemical inducer for 6 hours and tissue 
that had been incubated in media only for 6 hours.  
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Figure 3-10. Results of Western blotting that shows the differential expression of HSP72 in 
tissue exposed to chemical inducers. 
 
 
 
 
 
 
 
A: Autoradiograph representing the differential protein expression of HSP72 when 
induced by NaAsO2 and CdCl2. Lane 1 – SDS pre-stained standards (Bio-Rad), lane 2 – 
heart control sample, lanes 3 and 7 - NaAsO2 6 hour induction, lanes 4 and 8 - NaAsO2 
control 6 hour induction, lanes 5 and 9 - CdCl2 6 hour induction, lanes 6 and 10 - CdCl2 
control 6 hour induction, lane 2 – heart control, lane 11 – placental control.  
B: Autoradiograph representing the differential protein expression of HSP72 when 
induced by NaAsO2. Lane 1 – SDS pre-stained standards (Bio-Rad), lane 2 – start of 
incubation, lane 3 - NaAsO2 6 hour induction, lane 4 - NaAsO2 control 6 hour induction, 
lane 5 - placental control, lane 6 - heart control. 
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Figure 3-11. Results of Western blotting that shows the differential expression of HSP27 in 
tissue exposed to chemical inducers. 
 
 
 
 
 
A: Autoradiograph representing the differential protein expression of HSP27 when 
induced by NaAsO2 and CdCl2. Lane 1 – SDS pre-stained standards (Bio-Rad), lane 2 – 
heart control sample, lanes 3 and 7 - NaAsO2 6 hour induction, lanes 4 and 8 - NaAsO2 
control 6 hour induction, lanes 5 and 9 - CdCl2 6 hour induction, lanes 6 and 10 - CdCl2 
control 6 hour induction, lane 2 – heart control, lane 11 – placental control.  
B: Autoradiograph representing the differential protein expression of HSP27 when 
induced by NaAsO2. Lane 1 – SDS pre-stained standards (Bio-Rad), lane 2 – start of 
incubation, lane 3 - NaAsO2 6 hour induction, lane 4 - NaAsO2 control 6 hour induction, 
lane 5 - placental control, lane 6 - heart control. 
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Figure 3-12 Differential expression of HSP27 (A) and HSP72 (B) seen in tissue that had been 
incubated in tissue with a chemical inducer compared to tissue incubated in media only for 6 
hours (control). 
 
 
 
 
Figure showing the differential protein expression of HSP27 (A) and HSP72 (B) seen in 
tissue that had been incubated in tissue with a chemical inducer for 6 hours compared to 
tissue incubated in media only for 6 hours (control). Samples taken from each patient 
(n=5) were used in both groups. Data is shown as box and whiskers plots (median, 
interquartile ranges). Expression is shown as ROD. The Wilcoxon matched-pairs signed 
rank test was used to look for any statistical differences in expression. 
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Heavy metal exposure with recovery period: 
An additional experiment was performed where there was a period of recovery allowed 
after the initial exposure to the chemical inducer (see section 2.4.3). Specifically, tissue from a 
TOF patient (patient 40: TOF, cyanotic, male) was exposed to NaAsO2 for 4 hours then 
allowed to recover in media only for 20 hours. Part of the tissue was exposed to media only 
for 24 hours in order to act as an appropriate experimental control. There was no obvious 
difference in the expression of HSP27 (figure 3-13A) and HSP72 (figure 3-13B) in the tissue 
exposed to heavy metals with a recovery period when compared to tissue exposed to media 
only (control).  
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Figure 3-13. Figure showing the results of Western blotting that shows the differential 
expression of HSP27 (A) and HSP72 (B) when induced by NaAsO2 for 4 hours with 20 hours 
recovery. 
 
 
 
A: Autoradiograph representing the differential protein expression of HSP27 when 
exposed to NaAsO2 for 4 hours with 20 hours recovery and appropriate controls. Lane 1 
– SDS pre-stained standards (Bio-rad, cat. no. 161-0305), lane 2 - placental control, lane 
3 – heart control, lane 4 – NaAsO2 4 hour induction with 20 hour recovery, lane 5 – 
NaAsO2 control 24 hour induction.  
B: Autoradiograph representing the differential expression of HSP72 when exposed to 
NaAsO2 for 4 hours with 20 hours recovery and appropriate controls. Lane 6 - placental 
control, lane 7 – heart control, lane 8 – NaAsO2 4 hour induction with 20 hour recovery, 
lane 9 – NaAsO2 control 24 hour induction. 
 
Summary of main findings: 
 
• Experiment 1: 
o No difference in mRNA expression seen for any genes when heavy metal 
inducers analysed separately. 
o mRNA expression of HSP32 (p=0.0156), HSP72 (p=0.0156) and HSP90 
(p=0.0156) were significantly increased by heavy metals (analysis of both 
inducers combined. 
• Experiment 2: 
o HSP27 and HSP72 protein expression was not induced by heavy metal 
exposure (separate or combined analysis). 
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3.3 Differential gene expression in RV myocardium excised from TOF and control 
patient groups exposed to differential O2 levels 
 
3.3.1 Introduction 
Surgical correction of congenital heart defects on bypass can have adverse effects on 
post-operative cardiac output. During such procedures, the myocardium is exposed to high O2 
tensions (Ihnken et al., 1998; reviewed in Allen et al., 2001; reviewed in Morita, 2012). There 
are some concerns that this re-oxygenation of ischemic tissue (IR injury) could cause adverse 
post-operative complications. Patients with TOF have chronic ischemic damage results in 
cyanosis in the RV.  Such children are thought to be more vulnerable to re-oxygenation injury 
(Modi et al., 2002; Bulutcu et al., 2002). 
 
The molecular mechanisms involved in the myocardial response to IR injury have been 
investigated extensively. These investigations have shown that myocardium exposed to IR 
injury is prone to an inflammatory response that is regulated by varying factors, for example, 
by TLR4 (Chong et al., 2004; Cha et al., 2008). High level O2 exposure can also result in TLR 
downstream signalling that will result in an inflammatory response, primarily in the lungs 
(Zhang et al., 2005; Ogawa et al., 2007; Qureshi et al., 2006; Huang et al., 2011). 
 
HSPs, which are well known stress proteins, have been shown to provide protection 
against IR injury in rat myocardial tissue. In particular, HSP72 and HSP27 were shown to 
provide enhanced protection for rat myocardium against IR injury (Pantos et al., 2007). HSPs 
have also been shown be provide protection against damage done by hyperoxic O2 exposure 
(Wong et al., 1998; Shao et al., 2009). 
 
HSP70 has been shown to interact with TLR4, specifically when HSP72 was 
unregulated it was shown to modulate the inflammatory response and subsequent myocardial 
dysfunction caused by IR injury using TLR4 (Zou et al., 2008). This shows an interaction 
between HSPs and TLRs, both of which are of major interest in this project. 
 
Investigating the expression of the genes discussed herein, within the myocardium of 
patients undergoing cardiac surgery with CPB, could help improve the current knowledge of 
the molecular mechanisms active within the myocardium during heart surgery. This could 
allow us to discover new and novel methods of preventing such damage by reducing 
 
 
159 
inflammation caused by IR injury and other forms of insult or providing enhanced myocardial 
protection against such cellular insult. This would be of greater benefit for paediatric heart 
surgery for cyanotic patients, who are more vulnerable to re-oxygenation injury (Merante et 
al., 1998; Najm et al., 2000; Corno et al., 2002). 
 
3.3.2 Methods and Results 
The aim of these experiments was to investigate the effect of exposing ischemic heart 
tissue, taken from patients undergoing corrective cardiac surgery with CPB for congenital 
heart defects, to 2% O2 (hypoxia) representing the surgical state of myocardium, 20% O2 
(normoxia) representing what would happen if the child’s myocardium were exposed to 
normal O2 during surgery and 60% (hyperoxia) O2 representing what actually happens to 
myocardium during surgery i.e. exposed to hyperoxia. The aim was to investigate the effect 
this had on the differential gene expression of genes of interest within such tissue. A level of 
60% O2 was chosen as the highest level of O2 exposure because this was the highest that could 
be achieved in vitro. The genes of interest include both the inflammatory markers TLR2, 
TLR4, MYD88 and the stress genes HSP20, HSP27, HSP32 (HO-1), HSP60, HSP70 and 
HSP90. 
 
3.3.2.1 Experiment 1: exposing myocardial tissue to 2% (hypoxia) and 20% 
(normoxia) O2 
 
The first experimental model undertaken involved exposing myocardial tissue to 2% 
(hypoxia) and 20% (normoxia) O2 (outlined in section 2.3.1) for 1.5 hours. This first 
experiment was undertaken due to initial problems encountered establishing a model for 
hyperoxic reperfusion (60%) (see section 2.3.2). The tissues were exposed to either O2 
concentration for a period of 1.5 hours as this is this length of time the myocardium is exposed 
to re-oxygenation in the clinical setting of such surgery i.e. upon removal of the aortic clamp. 
Five patients (table 10) were recruited for this experiment, consisting of TOF, SAS and FV 
patients. These patients were used for the mRNA gene expression analysis upon exposure to 
2% and 20% O2 for 1.5 hours only. 
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Table 10. Patients recruited for exposure to 2% (hypoxia) and 20% (normoxia) O2 
 
Patient	   Type	   Group	   Gender	   Age	  
11	   TOF	   Cyanotic	   Female	   1	  year	  0	  months	  
16	   TOF	   Cyanotic	   Male	   0	  years	  11	  months	  
17	   TOF	   Cyanotic	   Female	   1	  year	  9	  months	  
18	   SAS Acyanotic	   Female	   0	  years	  11	  months	  
23	   FV	   Cyanotic	   Female	   1	  year	  1	  month	  
 
In order to investigate the gene expression of the inflammatory mediators and stress 
proteins mentioned above, the method of qPCR (see section 2.9) was used and RQ of gene 
expression was calculated using the comparative Ct method (see section 2.9.2). 
 
Statistical analysis was performed using GraphPad Prism 6 Software©. Due to 
biological variation the data did not follow a normal distribution therefore non-parametric 
statistical analysis was undertaken. Therefore the Wilcoxon matched-pairs signed rank test 
was used to look for any statistical differences in expression for all genes of interest seen due 
to the exposure to differential O2 levels. A p-value of <0.05 (two-tailed) is considered as 
statistically significant. 
 
It should be noted that the RQ values for the 20% baseline (C) sample for patient 18 
was disregarded due to poor quality of RNA and the resulting anomalous results. This study is 
an explorative study and is therefore observational in it nature. Due to limited patient numbers, 
all patients recruited for this study were taken as one group therefore a comparison of cyanotic 
and acyanotic patients was not possible. 
 
Inflammatory markers: 
The differential mRNA expression of TLR2, TLR4 and MYD88 (figure 3-14) were 
investigated. None of these genes showed any significant differences in gene expression upon 
exposure to either hypoxia or normoxia for 1.5 hours. Due to the low patient number, any 
potential trends may not be apparent therefore this would require further investigation. 
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Stress proteins: 
The differential mRNA expression of HSP20, HSP27, HSP32 (figure 3-15), HSP60, 
HSP72 and HSP90 (figure 3-16) were investigated. None of these genes showed any 
significant differences in gene expression upon exposure to either hypoxia or normoxia for 1.5 
hours. Due to the low patient number, any potential trends may not be apparent therefore this 
would require further investigation. 
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Figure 3-14. Figure showing the differential expression of inflammatory mediators upon 
exposure to 2% O2 and 20% O2 for 1.5 hours. A shows TLR4, B shows TLR2 and C shows 
MYD88. 
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Figure showing the differential expression of TLR4 (A), TLR2 (B) and MYD88 (C) 
when myocardium exposed to 2% O2 and 20% O2 for 1.5 hours. Samples taken from 
each patient (n=5) were used in each group. Data is shown as line and symbol graphs 
(each sample’s data is plotted separately). The graphs show the expression seen at the 
time of collection in theatre (theatre), at the time of the start of the incubation back in the 
laboratory (2/ 20% baseline) and after the 1.5 hour incubation (2/ 20% 1.5 hour). 
Expression was calculated using the Comparative Ct method to give RQ of gene 
expression. Statistical analysis was done using the Wilcoxon matched-pairs signed rank 
test and a p-value of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-15. Figure showing the differential expression the stress proteins HSP20, HSP27 and 
HSP32 upon exposure to 2% O2 and 20% O2 for 1.5 hours. A shows HSP20, B shows HSP27 
and C shows HSP32. 
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Figure showing the differential expression of HSP20 (A), HSP27 (B) and HSP32 (C) 
when exposed to 2% O2 and 20% O2 for 1.5 hours. Samples taken from each patient 
(n=5) were used in each group. Data is shown as line and symbol graphs (each sample’s 
data is plotted separately). The graphs show the expression seen at the time of collection 
in theatre (theatre), at the time of the start of the incubation back in the laboratory (2/ 
20% baseline) and after the 1.5 hour incubation (2/ 20% 1.5 hour). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was done using the Wilcoxon matched-pairs signed rank test and a p-value of 
<0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-16. Figure showing the differential expression the stress proteins HSP60, HSP72 and 
HSP90 upon exposure to 2% O2 and 20% O2 for 1.5 hours. A shows HSP60, B shows HSP72 
and C shows HSP90. 
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Figure showing the differential expression of HSP60 (A), HSP72 (B) and HSP90 (C) 
when exposed to 2% O2 and 20% O2 for 1.5 hours. Samples taken from each patient 
(n=5) were used in each group. Data is shown as line and symbol graphs (each sample’s 
data is plotted separately).  The graphs show the expression seen at the time of collection 
in theatre (theatre), at the time of the start of the incubation back in the laboratory (2/ 
20% baseline) and after the 1.5 hour incubation (2/ 20% 1.5 hour). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was done using the Wilcoxon matched-pairs signed rank test and a p-value of 
<0.05 (two-tailed) is considered as statistically significant. 
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3.3.2.2 Experiment 2: exposing myocardial tissue to 2% (hypoxia), 20% (normoxia) 
and 60% (hyperoxia) O2 
 
The second experimental model involved exposing ischemic infant myocardial tissue 
to 2% (hypoxia), 20% (normoxia) and 60% (hyperoxia) O2 (outlined in section 2.3.2) for 4 
hours. It was then determined whether or not such exposure caused any differences to occur in 
the expression of both inflammatory mediators and stress proteins. Hyperoxic exposure of the 
myocardium is the most clinically relevant due to its use in the clinical setting. The tissue was 
exposed for 4 hours rather 1.5 hours in order to determine if a longer exposure would result in 
enhanced gene expression. Ten patients (table 11) were recruited for this study, consisting of 
TOF, aortic obstruction and VSD patients. These patients were used for the mRNA gene 
expression analysis upon exposure to 2%, 20% and 60% O2 for 4 hours only. 
 
Table 11. Patients recruited for exposure to 2% (hypoxia), 20% (normoxia) and 60% 
(hyperoxia) O2 
 
Patient Type Group Gender Age 
32 PREV TOF Cyanotic Male 6 years 0 months 
33 TOF Cyanotic Male 0 years 10 months 
34 TOF Cyanotic Female 1 year 4 months 
35 TOF Cyanotic Female 0 years 6 months 
36 REDO TOF (FULLY 
SATURATED) 
Acyanotic Female 6 years 5 months 
37 TOF Cyanotic Male 0 years 11 months 
38 AORTIC OBSTRUCTION 
(CTL) 
Acyanotic Male 1 year 3 months 
39 TA (CTL) Acyanotic Male 0 years 1 month 
41 COMPLEX TOF Cyanotic Male 5 years 0 months 
45 VSD (FULLY SATURATED) Acyanotic Female 1 year 2 months 
 
 It should be noted that patients 38 and 39 do not have samples collected in theatre (A) 
or baseline (B) (sample time point on return to laboratory) due to limited tissue availability, 
therefore because paired statistical analysis was carried out the results for these samples were 
not included. Due to limited patient numbers, all patients recruited for this study were taken as 
one group. 
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In order to investigate the gene expression of the inflammatory mediators and stress 
proteins mentioned above, the method of qPCR (see section 2.9) was used and RQ of gene 
expression was calculated using the comparative Ct method (see section 2.9.2). Statistical 
analysis was performed as described in experiment 1. 
 
Inflammatory markers: 
The differential mRNA expression of TLR4 (figure 3-17A), TLR2 (figure 3-17B) and 
MYD88 (figure 3-17B) were investigated. None showed any significant differences in 
expression when exposed to 2% (hypoxia), 20% (normoxia) or 60% (hyperoxia) O2 for 4 
hours. Due to the low patient number, any potential trends may not be apparent therefore this 
would require further investigation. 
 
Stress proteins: 
The differential mRNA expression of HSP20, HSP27, HSP32 (figure 3-18), HSP60, 
HSP72 and HSP90 (figure 3-19) were investigated. HSP20 and HSP27 expression showed no 
significant differences in expression when exposed to any differential O2 level. HSP32 showed 
a significant increase in expression when exposed to normoxia (p=0.0391) and hyperoxia 
(p=0.0078) for 4 hours. HSP60 showed no significant differences in expression when exposed 
to any differential O2 level. HSP72 showed a significant increase in expression when exposed 
to normoxia (p=0.0078) and hyperoxia (p=0.0078) for 4 hours. HSP90 showed a trend of an 
increase in expression when exposed to normoxia (p=0.0547) and hyperoxia (p=0.0547) but 
this did not make statistical significance. There was no change in HSP32, HSP72 and HSP90 
expression after exposure to hypoxia for 4 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
170 
Figure 3-17A. Figure showing the differential expression of TLR4 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours 
 
 
 
The three points on the x-axis show TLR4 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-17B. Figure showing the differential expression of TLR2 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
The three points on the x-axis show TLR2 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give relative quantification (RQ) of gene 
expression. Statistical analysis was performed using the Wilcoxon matched-pairs signed 
rank test and a p-value of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-17C. Figure showing the differential expression of MYD88 upon exposure to 
hypoxia (2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
The three points on the x-axis show MYD88 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-18A. Figure showing the differential expression of HSP20 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
 
The three points on the x-axis show HSP20 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-18B. Figure showing the differential expression of HSP27 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
 
The three points on the x-axis show HSP27 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-18C. Figure showing the differential expression of HSP32 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
The three points on the x-axis show HSP32 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours Samples taken from each patient (n=8) were used in each group. Data is shown as 
line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-19A. Figure showing the differential expression of HSP60 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
 
The three points on the x-axis show HSP60 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-19B. Figure showing the differential expression of HSP72 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
 
The three points on the x-axis show HSP72 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Figure 3-19C. Figure showing the differential expression of HSP90 upon exposure to hypoxia 
(2% O2), normoxia (20% O2) and hyperoxia (60% O2) for 4 hours. 
 
 
 
The three points on the x-axis show HSP90 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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The expression of both HSP32 and HSP72 mRNA were increased during 4 hours of 
normoxic (20% 4 hours) and 4 hours of hyperoxic (60% 4 hours) exposure compared to 
baseline (baseline 2%). When comparing these two groups for HSP32 (figure 3-20A) using the 
Wilcoxon matched-pairs signed rank test a significant difference was not found (p=0.0781). 
For HSP72 (figure 3-20B), there was a significant difference found (p=0.0391) indicating that 
exposure to 20% O2 produced a bigger increase in HSP72 expression than 60% O2 after a 
period of 4 hours 
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Figure 3-20 Differential expression of HSP32 (A) and HSP72 (B) in tissue exposed to 4 hours 
of normoxic (20% 4 hours) and 4 hours of hyperoxic (60% 4 hours). 
 
Figure showing the differential mRNA expression of the stress proteins HSP32 (A) and 
HSP72 (B) in tissue exposed to 4 hours of normoxia (20% 4 hours) compared to tissue 
exposed to hyperoxia (60% 4 hours). Samples taken from each patient (n=8) were used 
in each group. Data is shown as box and whiskers plots (median, interquartile ranges). 
Expression was calculated using the Comparative Ct method to give RQ of gene 
expression. Statistical analysis was done using the Wilcoxon matched-pairs signed rank 
test and a p-value of <0.05 (two-tailed) is considered as statistically significant. 
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Comparison of cyanotic and acyanotic patients: 
So far the data from patients 38 and 39 has not been used in the analysis because they 
had no baseline values (see section 3.3.2.2). This has meant that cyanotic and acyanotic 
patients groups were unable to be compared. There is a full data set for the time points C (2% 
4 hours), D (20% 4 hours) and E (60% 4 hours) (see figure 2.2) for patients 38 and 39. It is 
therefore possible to compare these three groups in cyanotic patients compared to acyanotic 
patients. The patients recruited were grouped into cyanotic and acyanotic group (table 12).  
Table 12. Cyanotic and acyanotic patients exposed to 2%, 20% and E 60% O2 4 hours. 
Patient Type Group Gender Age 
32 PREV TOF Cyanotic Male  6 years 0 months 
33 TOF Cyanotic Male  0 years 10 months 
34 TOF Cyanotic Female  1 year 4 months 
35 TOF Cyanotic Female  0 years 6 months 
37 TOF Cyanotic Male  0 years 11 months 
41 COMPLEX TOF Cyanotic Male  5 years 0 months 
36 REDO TOF (FULLY SATURATED) Acyanotic Female  6 years 5 months 
38 AORTIC OBSTRUCTION (CTL) Acyanotic Male  1 year 3 months 
39 TA (CTL) Acyanotic Male  0 years 1 month 
45 VSD (FULLY SATURATED) Acyanotic Female  1 year 2 months 
 
Statistical analysis was performed using GraphPad Prism 6 Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. 
Therefore the test used was the Mann-Whitney U test where data was expressed by the median 
and interquartile range. A p-value of <0.05 (two-tailed) is considered as statistically 
significant. This comparison was done for the inflammatory mediators TLR4, TLR2 and 
MYD88 (figure 3-21) and the stress proteins HSP20, HSP27, HSP32 (figure 3-22), HSP60, 
HSP72 and HSP90 (figure 3-23). There was no statistically significant difference seen for any 
genes upon exposure to hypoxia (2% 4 hours), normoxia (20% 4 hours) and hyperoxia (60% 4 
hours) when comparing the cyanotic group with the acyanotic group. 
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Figure 3-21A. Differential expression of TLR4 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show TLR4 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-21B. Differential expression of TLR2 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show TLR2 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-21C. Differential expression of MYD88 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show MYD88 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-22A. Differential expression of HSP20 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show HSP20 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-22B. Differential expression of HSP27 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show HSP27 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-22C. Differential expression of HSP32 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
 
The two points on the x-axis show HSP32 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-23A. Differential expression of HSP60 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
 
The two points on the x-axis show HSP60 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-23B. Differential expression of HSP72 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show HSP72 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Figure 3-23C. Differential expression of HSP90 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show HSP90 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
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Summary of main findings: 
• Experiment 1: 
o No significant difference in mRNA expression seen for any genes when 
exposed to 20% O2 for 1.5 hours. 
• Experiment 2: 
o HSP32 mRNA expression is significantly increased after exposure to 20% 
(p=0.0391) or 60 % (p=0.0078) O2 for 4 hours 
o HSP72 mRNA expression is significantly increased after exposure to 20% 
(p=0.0078) or 60 %(p=0.0078) O2 for 4 hours 
o No significant differences in mRNA expression were seen for any genes of 
interest during 4 hours differential O2 exposure between the cyanotic and 
acyanotic patient groups. 
 
3.4 The differential expression of GRP78  
3.4.1 Introduction 
GRP78 (see section 1.7) is a stress protein that is expressed in response to damage to 
the cell to either maintain or refold protein structures (Shiu et al., 1977; Haas and Wabl, 1983; 
reviewed in Lee, 1992; reviewed in Lee, 2001). GRP78 is a part of the glucose regulated 
protein (GRP) family, which are generally located within the ER (Munro and Pelham, 1987; 
reviewed in Lee, 1992; reviewed in Lee, 2001). When a cell undergoes, for example, nutrient 
deprivation, the expression of ER regulated stress proteins such as GRP78 are upregulated due 
to the accumulation of misfolded proteins within the ER (Shiu et al., 1977; Li et al., 1993; 
Miles et al., 1994; reviewed in Lee, 2001) in a process known as the UPR, which if severe 
enough can result in apoptosis (Patil and Walter, 2001; Ma and Hendershot, 2001). 
 
There are several studies that show that GRP78 is expressed in the heart under cellular 
insults such as hypoxic insult and IR injury (Sun et al., 2008; Hardy and Raiter, 2010; Xin et 
al., 2011; Martindale et al., 2006). Therefore looking at its expression within cardiac tissue in 
order to investigate if it can protect the myocardium from injury during cardiac surgery with 
CPB could be beneficial. 
 
3.4.2. Materials and Methods 
3.4.2.1 Experiment 1: Screening of differential gene expression in ventricular 
myocardium excised from cyanotic and control (acyanotic) patient groups. 
Ischemic myocardial tissue samples (LV and RV) excisied from cyanotic and control 
patients that have not been exposed to any type of experimental conditions were screened in 
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order to establish any differential expression of GRP78 within the myocardium (for primer 
sequences see section 2.7.3) in both the cyanotic and control patient groups.  12 patients were 
recruited (please see table 6 in section 3.1.2). Seven patients were cyanotic and were 
comprised of TOF and FV patients. Five were control (acyanotic) patients, comprising of SAS 
and TA patients.  
 
qPCR (see section 2.9) was used to investigate changes in expression and any 
differences seen in gene expression were calculated using the Comparative Ct method (see 
section 2.9.2) to give RQ of gene expression using the Stepone Software® v2.1 (Applied 
Biosystems).  
 
Statistical analysis was performed using GraphPad Prism 6 Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. 
Therefore the test used was the Mann-Whitney U test where data was expressed by the median 
and the interquartile range. A p-value of <0.05 (two-tailed) is considered as statistically 
significant.  
 
There was no significant difference in GRP78 expression when comparing cyanotic 
and acyanotic patients (figure 3-24) 
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Figure 3-24. Figure shows the expression of GRP78 in both the cyanotic and acyanotic patient 
groups. 
 
 
Figure shows comparison in the expression of GRP78 in both the cyanotic (n=7) and 
acyanotic (n=5) patient groups. Data is shown as box and whiskers plots (median, 
interquartile ranges). Expression was calculated using the Comparative Ct method to 
give RQ of gene expression using the StepOne Software® v2.1 (Applied Biosystems). 
Statistical analysis was done using the Mann-Whitney U test and a p-value of <0.05 
(two-tailed) is considered as statistically significant. 
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3.4.2.2 Experiment 2: Reperfusion Experiment - exposing myocardial tissue to 2% 
(hypoxia), 20% (normoxia) and 60% (hyperoxia) O2 
 
The aim of this experiment was to investigate the effect of exposing ischemic heart 
tissue, taken from patients undergoing corrective cardiac surgery with CPB for congenital 
heart defects, to 2% (hypoxia), 20% (normoxia) and 60% (hyperoxia) O2 (see section 2.3) in 
order to recreate reperfusion that occurs in the clinical setting of paediatric open-heart surgery. 
This was done in order to investigate the effect this had on the differential gene expression of 
GRP78 using qPCR (see section 2.9). RQ of gene expression was calculated using the 
comparative Ct method (see section 2.9.2). Ten patients (please see table 11 in section 3.3.2.2) 
were recruited for this study, consisting of TOF, aortic obstruction and VSD patients. 
 
It should be noted that patients 38 and 39 do not have a theatre (A) or baseline (B) RQ 
value due to limited tissue availability therefore because paired statistical analysis was carried 
out, these patient values were not included. All patients recruited for this study were taken as 
one group. 
 
Statistical analysis was performed using GraphPad Prism 6 Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. 
Therefore the Wilcoxon matched-pairs signed rank test was used to look for any statistical 
differences in expression for GRP78 due to the exposure to differential O2 levels. A p-value of 
<0.05 (two-tailed) is considered as statistically significant. 
 
There was no significant change in the expression of GRP78 upon exposure to 2% 
(hypoxia), 20% (normoxia) or 60% (hyperoxia) O2 (figure 3-25).  
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Figure 3-25. Figure showing the differential expression of GRP78 upon exposure to 2% O2, 
20% O2 and 60% O2 for 4 hours. 
 
 
The three points on the x-axis show GRP78 expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
 
 
 
 
196 
Comparison of cyanotic and acyanotic patients: 
Data from patients 38 and 39 has not currently been used in the analysis because they 
have no baseline values (see section 3.3.2.2). This has meant that cyanotic and acyanotic 
patients groups were unable to be compared. There is a full data set for the time points C (2% 
4 hours), D (20% 4 hours) and E (60% 4 hours) (see section 2.2) for patients 38 and 39. It is 
therefore possible to compare these 3 groups in cyanotic patients compared to cyanotic 
patients. The patients recruited have been grouped into the cyanotic and acyanotic group (see 
table 12 in section 3.3.2.2).  
Statistical analysis was performed using GraphPad Prism 6 Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. 
Therefore the test used was the Mann-Whitney U test where data was expressed by the median 
and the interquartile range. A p-value of <0.05 (two-tailed) is considered as statistically 
significant. This comparison was done for GRP78 (figure 3-26). There was no statistically 
significant difference seen for GRP78 upon exposure to hypoxia (2% 4 hours), normoxia (20% 
4 hours) and hyperoxia (60% 4 hours) when comparing the cyanotic group with the acyanotic 
group. 
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Figure 3-26. Differential expression of GRP78 seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
 
	  
The two points on the x-axis show GRP78 expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges).  Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Mann-Whitney U test (p-value of <0.05 is considered 
as statistically significant) and p values are shown. 
 
 
 
198 
Summary of main findings: 
• Experiment 1: 
o No significant difference in GRP78 mRNA expression between the cyanotic 
and acyanotic patient groups. 
• Experiment 2: 
o No significant difference in GRP78 mRNA expression seen when exposed to 
20% or 60% O2 for 4 hours. 
o No significant differences in GRP78 mRNA expression seen during 4 hours 
differential O2 exposure between the cyanotic and acyanotic patient groups. 
 
3.5 The differential expression of APJ and its endogenous ligand Apelin  
3.5.1 Introduction  
APJ (see section 1.8) is part of the trans-membrane G protein-coupled receptor protein 
family and its cognate ligand is known as Apelin (O'Dowd et al., 1993; Tatemoto et al., 1998). 
There have been some studies that have supported the role of aplein and APJ as vasodilators 
(Lee et al., 2000; Tatemoto et al., 2001; Cheng et al., 2003). Other studies implicated a 
hypothalamic role for Apelin (De Mota et al., 2000; Reaux et al., 2001; Taheri et al., 2002; De 
Mota et al., 2004; Reaux-Le Goazigo et al., 2004). 
 
 APJ and Apelin are expressed in cardiac tissue (Kleinz and Davenport, 2004; Kleinz et 
al., 2005). In relation to cardiac function several studies have been shown them both to help 
improve cardiac contractibility (Szokodi et al., 2002; Berry et al., 2004; Ashley et al., 2005). 
This could be beneficial during times of stress that can be caused during cardiac surgery with 
CPB. Also, there have been several studies that have shown both APJ and Apelin expression 
play a role in the heart’s response to cellular stress and also that they can be cardio-protective 
(Sheikh et al., 2007; Jia et al., 2006; Atluri et al., 2007). All of this evidence from the 
literature highlights the fact that APJ was a suitable candidate for investigation in order to help 
improve the protection of the heart during cardiac surgery with CPB.  
 
3.5.2 Methods and Results 
3.5.2.1 Experiment 1: Screening of differential gene expression in ventricular 
myocardium excised from cyanotic and control (acyanotic) patient groups 
 
Ischemic myocardial tissue samples (LV and RV) excised from cyanotic and control 
patients that have not been exposed to any type of experimental conditions were screened in 
order to establish any differential expression of APJ in the myocardium (for primer sequences 
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see section 2.7.3) in both the cyanotic and control patient groups.  12 patients were recruited 
(please see table 6 in section 3.1.2). Seven patients were cyanotic and were comprised of TOF 
and FV patients. Five were control (acyanotic) patients, comprising of SAS and TA patients. 
 
qPCR (see section 2.9) was used to investigate changes in expression and any 
differences seen in gene expression was calculated using the Comparative Ct method (see 
section 2.9.2) to give RQ of gene expression using the Stepone Software® v2.1 (Applied 
Biosystems).  
 
Statistical analysis was performed using GraphPad Prism 6 Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. 
Therefore the test used was the Mann-Whitney U test where data was expressed by the median 
and the interquartile range. A p-value of <0.05 (two-tailed) is considered as statistically 
significant. 
 
There was no significant difference in APJ expression when comparing cyanotic and 
acyanotic patients (figure 3-27) 
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Figure 3-27. Figure shows the expression of APJ in both the cyanotic and acyanotic patient 
groups. 
 
 
Figure shows comparison in the expression of APJ in both the cyanotic (n=7) and 
acyanotic (n=5) patient groups. Data is shown as box and whiskers plots (median, 
interquartile ranges). Expression was calculated using the Comparative Ct method to 
give RQ of gene expression using the StepOne Software® v2.1 (Applied Biosystems). 
Statistical analysis was done using the Mann-Whitney U test and a p-value of <0.05 
(two-tailed) is considered as statistically significant. 
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3.5.2.2 Experiment 2: Reperfusion Experiment - exposing myocardial tissue to 2% 
(hypoxia), 20% (normoxia) and 60% (hyperoxia) O2 
 
The aim of this experiment was to investigate the effect of exposing ischemic heart 
tissue, taken from patients undergoing corrective cardiac surgery with CPB for congenital 
heart defects, to 2% (hypoxia), 20% (normoxia) and 60% (hyperoxia) O2 (see section 2.3) in 
order to recreate reperfusion that occurs in the clinical setting of paediatric open-heart surgery. 
This was done in order to investigate the effect this had on the differential gene expression of 
APJ using qPCR (see section 2.9). RQ of gene expression was calculated using the 
comparative Ct method (see section 2.9.2). Ten patients (please see table 11 in section 3.3.2.2) 
were recruited for this study, consisting of TOF, aortic obstruction and VSD patients. 
 
It should be noted that patients 38 and 39 do not have a theatre (A) or baseline (B) RQ 
value due to limited tissue availability therefore because paired statistical analysis was carried 
out, these patient values were not included. All patients recruited for this study were taken as 
one group. 
 
Statistical analysis was performed using GraphPad Prism 6 Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. 
Therefore the Wilcoxon matched-pairs signed rank test was used to look for any statistical 
differences in expression for APJ due to the exposure to differential O2 levels. A p-value of 
<0.05 (two-tailed) is considered as statistically significant. 
 
There was no significant change in the expression of APJ upon exposure to 2% 
(hypoxia), 20% (normoxia) or 60% (hyperoxia) O2 (figure 3-28). 
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Figure 3-28. Figure showing the differential expression of APJ upon exposure to 2% O2, 20% 
O2 and 60% O2 for 4 hours. 
 
 
The three points on the x-axis show APJ expression seen through from collection in 
theatre, in the 2% O2 media used for transport of tissue from theatre to the laboratory 
(baseline 2%) and the expression seen after the 4 hour incubation period (2/ 20/ 60% 4 
hours). Samples taken from each patient (n=8) were used in each group. Data is shown 
as line and symbol graphs (each sample’s data is plotted separately).  Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and a p-value 
of <0.05 (two-tailed) is considered as statistically significant. 
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Comparison of cyanotic and acyanotic patients: 
Data from patients 38 and 39 has not currently been used in the analysis because they 
did not have baseline values (see section 3.3.2.2). This has meant that cyanotic and acyanotic 
patients groups were unable to be compared. There is a full data set for the time points C (2% 
4 hours), D (20% 4 hours) and E (60% 4 hours) (see figure 2.2) for patients 38 and 39. It is 
therefore possible to compare these 3 groups in cyanotic patients compared to cyanotic 
patients. The patients recruited have been grouped into the cyanotic and acyanotic group (see 
table 12 in section 3.3.2.2).  
Statistical analysis was performed using GraphPad Prism 6 Software©. The data did not 
follow a normal distribution therefore non-parametric statistical analysis was undertaken. 
Therefore the test used was the Mann-Whitney U test where data was expressed by the median 
and the interquartile range. A p-value of <0.05 (two-tailed) is considered as statistically 
significant. This comparison was done for APJ (figure 3-29). There was no statistically 
significant difference seen for APJ upon exposure to hypoxia (2% 4 hours), normoxia (20% 4 
hours) and hyperoxia (60% 4 hours) when comparing the cyanotic group with the acyanotic 
group. 
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Figure 3-29. Differential expression of APJ seen in cyanotic patients compared to the 
acyanotic patients when exposed to hypoxia (2% 4 hours), normoxia (20% 4 hours) and 
hyperoxia (60% 4 hours).	  
	  
The two points on the x-axis show APJ expression seen in cyanotic patients (n=6) 
compared to the acyanotic patients (n=4) group when exposed to hypoxia (2% 4 hours) 
(top left), normoxia (20% 4 hours) (top right) and hyperoxia (60% 4 hours) (bottom). 
Data is shown as box and whiskers plots (median, interquartile ranges). Expression was 
calculated using the Comparative Ct method to give relative quantification (RQ) of gene 
expression. Statistical analysis was performed using the Mann-Whitney U test (p-value 
of <0.05 is considered as statistically significant) and p values are shown. 
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Summary of main findings: 
• Experiment 1: 
o No significant difference in APJ mRNA expression between the cyanotic and 
acyanotic patient groups. 
• Experiment 2: 
o No significant difference in APL mRNA expression seen when exposed to 20% 
or 60% O2 for 4 hours. 
o No significant differences in APJ mRNA expression seen during 4 hours 
differential O2 exposure between the cyanotic and acyanotic patient groups. 
 
3.6 Decay curve experiments 
3.6.1 Introduction 
The aim of these experiments was to investigate how the expression patterns of certain 
genes of interest within the infant myocardium were affected by varying incubations times. 
This was performed in order to illustrate whether changes of expression seen in the results 
were from the conditions of the experiments or if it was due to the time period of incubation. 
 
3.6.2 Methods and Results 
Myocardial tissue (ischemic) samples collected from three cyanotic patients (table 13) 
were incubated for 1.5 hours, 3 hours, 4 hours and 6 hours at 20% O2 at 37°C (see section 
2.14). In order to establish any differential expression due to incubation time only, the type of 
patient and O2 exposure were kept the same. Also, changes in expression were quantified by 
using qPCR (see section 2.9). RQ of gene expression was calculated using the comparative Ct 
method (see section 2.9.2). The genes of interest are the inflammatory mediators TLR4, TLR2 
and MYD88 and the stress proteins HSP20, HSP27, HSP32, HSP60, HSP72 and HSP90. It 
was not possible to do statistical analysis for this experiment. It should be noted that for 
patient 43, there was no 4 hour timepoint because RNA extraction was unsuccessful for this 
sample. Also, for patient 47 there was no baseline and 3 hour timepoint as there was less tissue 
available for this patient. Therefore the most important timepoints were chosen, specifically 
1.5 hours, 4 hours and 6 hours. 
 
Table 13. Patients recruited for decay curve experiment 
Patient Type Group Gender Age 
42 TOF Cyanotic  Male  1 year 7 months 
43 TOF Cyanotic  Male  2 years 5 months 
47 TOF Cyanotic  Female  0 years 8 months 
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Inflammatory mediators: 
The expression of TLR4, TLR2 and MYD88 were investigated (figure 3-30). There 
was no obvious pattern in expression over time in the incubator of any of these genes. 
 
Stress proteins: 
The expression of HSP20, HSP27, HSP32 (figure 3-31), HSP60, HSP72 and HSP90 
were investigated (figure 3-32). HSP20 and HSP27 did not have any particular trends in 
expression over time. HSP32 appeared to have an increase in expression at about 4-6 hours of 
incubation. HSP72, HSP72 and HSP90 all appeared to have slight trend of increase as time of 
incubation increased. Such changes seen did not appear to be significant. The observational 
nature of these results and the fact only 3 patients were used, some of which had absent time 
points, means statistical analysis was not possible. 
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Figure 3-30. Figure showing the differential expression of inflammatory mediators during 
differential incubation times. A shows TLR4, B shows TLR2 and C shows MYD88. 
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Figure showing the differential expression of TLR4 (A), TLR2 (B) and MYD88 (C) 
when infant myocardium (n=3) is exposed to differential incubation times. Data is 
shown as bar graphs. The graphs show the expression seen at the time of collection in 
theatre (theatre), at the time of the start of the incubation back in the laboratory 
(baseline), after 1.5 hours incubation (1.5 hours), after 3 hours incubation (3 hours), after 
4 hours incubation (4 hours) and after 6 hours incubation (6 hours). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. 
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Figure 3-31. Figure showing the differential expression of stress proteins during differential 
incubation times. A shows HSP20, B shows HSP27 and C shows HSP32. 
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Figure showing the differential expression of HSP20 (A), HSP27 (B) and HSP32 (C) 
when infant myocardium (n=3) is exposed to differential incubation times. Data is 
shown as bar graphs. The graphs show the expression seen at the time of collection in 
theatre (theatre), at the time of the start of the incubation back in the laboratory 
(baseline), after 1.5 hours incubation (1.5 hours), after 3 hours incubation (3 hours), after 
4 hours incubation (4 hours) and after 6 hours incubation (6 hours). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. 
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Figure 3-32. Figure showing the differential expression of stress proteins during differential 
incubation times. A shows HSP60, B shows HSP72 and C shows HSP90. 
 
 
 
 
 
 
 
 
 
212 
 
 
Figure showing the differential expression of HSP20 (A), HSP27 (B) and HSP32 (C) 
when infant myocardium (n=3) is exposed to differential incubation times. Data is 
shown as bar graphs. The graphs show the expression seen at the time of collection in 
theatre (theatre), at the time of the start of the incubation back in the laboratory 
(baseline), after 1.5 hours incubation (1.5 hours), after 3 hours incubation (3 hours), after 
4 hours incubation (4 hours) and after 6 hours incubation (6 hours). Expression was 
calculated using the Comparative Ct method to give RQ of gene expression. 
 
Summary of main findings: 
• Experiment 1: 
o Only mRNA expression pattern of note was seen for HSP32, but this was not 
significant enough to cause a problem. 
 
 
3.7 Association of HSP-27 expression with improved right ventricle function 
suggests a protective effect in cyanotic Tetralogy of Fallot. 
 
3.7.1 Introduction 
 TOF (see section 1.1.3) is the most common cyanotic congenital heart disease with an 
incidence of 4 per 10,000 live births.  Complete repair can be performed with a low mortality 
risk (<2%) (Starr, 2010). Early outcome can be determined by RV function in the immediate 
post-operative period. In the 20 years after repair, 10% to 15% of patients will require a further 
operation on their RV outflow tract, most for limited exercise capacity, ventricular 
dysrhythmias or more severe symptoms of heart failure (Nollert et al., 1997). TOF is an 
example of a congenital heart condition in which the RV is exposed to chronic ischemia and 
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pressure overload.  Patients have an increased risk of RV dysfunction following corrective 
surgery. The causes include residual haemodynamic load from PS or regurgitation, conduction 
abnormalities, residual RV outflow tract obstruction and direct surgical trauma.  How 
adequate the myocardium is protected during surgical repair has been an area of concern. Pre-
operatively the ventricle is exposed to increased systemic pressure. Furthermore CPB exposes 
the myocardium to ischemic stress/ hypoxia (during bypass) and potential reperfusion injury 
when O2 is restored at super-physiological levels. Whether the chronically hypoxic (cyanotic) 
myocardium is more or less tolerant of injury compared to normoxic (non-cyanotic) patients is 
unclear. Free radical injury has been reported during surgery as well as a non-homegeneous 
distribution of cardioplegia in what is a hypertrophied RV mass (Imura et al. 2001).  
 
 The heart adapts to an adverse physiological environment by altering gene expression 
(Ghorbel et al. 2010). Cyanotic TOF is associated with higher mRNA expression of genes 
associated with apoptosis and remodeling and reduced expression of genes associated with 
myocardium contractility and function as well as genes that protect against re-oxygenation 
injury compared with non-cyanotic TOF (Willis and Patterson, 2010)	  and this could limit the 
ability of the RV to protect itself against ischemic injury. An increase in ventricular mass will 
increase the susceptibility to IR injury further. In TOF, very young patients are subjected to 
complex open-heart surgery along with CPB.  The ability of this “infant” myocardium to 
protect itself against ischemic (and reperfusion) injury during aortic cross-clamping will 
determine post-operative outcome. 
 
  HSPs (see section 1.6) are a family of proteins that can be constitutively expressed in 
cells or induced by a variety of stress stimuli such as hypoxia, ischemia and pressure 
overloading (Willis and Patterson, 2010). The best described role for HSPs is maintaining the 
correct folding of proteins (Willis and Patterson, 2010). Although studied in other fields of 
medicine, the role of HSPs before, and following pediatric cardiac surgery, is not well 
understood. However, it is becoming clear from adult human and animal studies that HSPs 
may have an important role in protecting the damaged heart, which accumulates misfolded 
proteins (Schmitt et al., 2002; Taggart et al., 1997; Jayakumar et al., 2001; Hollander et al., 
2004; Yet et al., 2001; Aloy et al., 2008; Franklin et al., 2005; Efthymiou et al., 2004 and 
(Knowlton et al., 1998).  
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Only a few of the smaller HSPs, including HSP27 (see section 1.6), are increased in 
cells subjected to stress (Efthymiou et al., 2004). HSP27 is involved in protein folding and in 
the apoptotic/ programmed cell death pathway. Only a small number of studies on HSP27 
have been performed on the heart. These have been restricted mainly to animal studies and a 
few to adult disease. They do suggest that HSP27 is protective for the heart (Vander Heide, 
2002). 
 
 The role of HSP27 in the infant heart in TOF or during CPB, which itself is an IR 
insult, is not known. Thus the aim of this study was to determine the expression of HSP27 
protein in myocardium resected from both cyanotic and non-cyanotic TOF patients during 
surgical repair and to determine its relationship to RV function and clinical outcome. 
3.7.2 Materials and Methods  
3.7.2.1 Patients recruited 
20 patients with TOF who underwent surgical repair at Royal Hospital for Sick 
Children, Glasgow were recruited for the study. Patients were divided into a cyanotic group 
(n=10) and non-cyanotic group (n=10) based on preoperative saturations at rest <90% and 
>90% at room air respectively. A separate control group of age-matched children (n=15) 
presenting with an innocent murmur (median age 27.1, interquartile range 4.0-47.2 months 
versus TOF patients, p=0.62) was recruited to obtain normal reference values for tissue 
Doppler myocardial velocities. Glasgow West Research Ethics Committee approved this 
study. Parental consent was obtained for all patients.  
 
3.7.2.2 Peri-operative tissue Doppler Echocardiography  
Tissue Doppler echocardiography was performed under general anesthesia as 
described previously (Peng et al., 2011) before skin incision and repeated on post-operative 
day one (POD1) in the intensive care unit (ICU) and then one week later. Pulsed-wave tissue 
Doppler velocity measurements at tricuspid annulus, basal septum and mitral annulus were 
obtained from apical 4-chamber view to quantify systolic myocardial velocity (Sm cms-1). 
Three or more loops were stored for subsequent offline analysis. The presence of restrictive 
RV physiology was defined as antegrade flow across the pulmonary artery coincident with 
atrial systole in all respiratory cycles (parasternal short axis RV outflow tract (RVOT) view) 
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(Cullen et al., 1995). 
 
3.7.2.3 Surgical repair and Myocardial Protection  
Standard repair was performed as described previously (Peng et al., 2011) by VSD 
closure and resection of RV infundibular muscle via trans-tricuspid and trans-pulmonary 
routes using moderate hypothermia and blood cardioplegia. Prior to CPB, all patients received 
O2 supplementation and fractional inspired O2 was adjusted to maintain adequate oxygenation 
whilst avoiding hyperoxia (median PaO2 8.0kPa in the cyanotic group versus 12.1kPa in the 
non-cyanotic group (p=0.2). Epicardial echo was routinely performed to exclude any residual 
lesion at the end of the procedure. Direct RV and LV pressures were measured intra-
operatively post-repair. 
 
3.7.2.4 Western Blot Analysis  
All myocardium resected from the RV outflow tract, as part of the repair, was collected 
for protein analysis. Muscle was snap-frozen immediately in liquid N2 following resection and 
stored at -70°C until required. Pieces of muscle were grouped according to the ischemic time 
point at collection. Protein concentrations of all samples collected were calculated using the 
Bradford protein assay described in section 2.10.2 and differential protein expression analysis 
of HSP27 was done by Western blot analysis as described in section 2.11. The primary 
antibody (HSP 27, New England Biolabs, number 2402, mouse monoclonal) was used at 
1:1000). The secondary antibody was horseradish peroxidase conjugated donkey anti-mouse 
secondary antibody (Abcam, cat. no. ab6820, 1:1000). 
 
The beginning of ischemic time was defined as the time when aortic cross-clamping 
was initiated. The ischemic baseline period was defined as 0-15 minutes after aortic cross-
clamp and before repeat cardioplegia administration. Baseline HSP27 protein density was 
calculated from mean HSP27 expression in the RV myocardium resected during this period. 
This was considered to represent as close to the pre-operative HSP27 expression in the 
myocardium as possible. Subsequent muscle resected after this period was grouped together to 
determine any effect of ischemic time on HSP 27 expression. 
3.7.2.5 Post-operative monitoring 
Post-operatively, serum lactate level, mixed venous oxygen saturation (SvO2,%) and 
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Troponin-I were measured concurrently with echocardiography. SvO2 is a function of systemic 
arterial oxygen saturation (SaO2), which can be affected by various factors including right-to-
left intra-cardiac shunt, lung pathology therefore oxygen extraction ratio [OER=(SaO2-
SvO2)/SaO2] represents a better indicator of systemic perfusion (Martin and Shekerdemian, 
2009]. O2 saturation was measured from concurrent blood sampling taken from the peripheral 
arterial line and the central venous catheter in the superior vena cava (Martin and 
Shekerdemian, 2009). Inotrope score was calculated (Davouros et al., 2006) and duration of 
ventilation and length of ICU stay were recorded. 
 
3.7.2.6 Statistical Analysis 
Statistical analysis was performed following advice from a professional statistician 
using the Minitab® Statistical Software Release 14.2 (MinitabInc, Pennsylvania, US). Non-
parametric data (expressed in median + interquartile range, Q1-Q3) was analysed using the 
Mann-Whitney U-test, Wilcoxon Matched Pair or Kruskal-Wallis test for continuous variables 
and Fisher exact test for categorical variables. The strength of relationship between two 
variables was tested using Spearman rank correlation (rho). p <0.05 was considered to be 
statistically significant. 
 
3.7.3 Results 
Table 14 summarises the peri-operative characteristics of the two groups. There were 
no significant differences between the cyanotic and the non-cyanotic group with regard to age, 
gender and body weight. The cyanotic group had a significantly increased haematocrit level, 
lower O2 saturation and thicker interventricular septal wall thickness.  Cross-clamp time and 
bypass time were significantly increased in the cyanotic group however ventilation time and 
length of stay in critical care were similar.  
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Table 14. Peri-operative characteristics between Cyanotic and non-Cyanotic group. 
 
 Cyanotic group 
(n=10) 
Non-cyanotic 
group (n=10) 
p-value 95% CI of 
median 
difference 
PRE-OPERATIVE FACTORS 
Age (months) 22.1 (11.8-24.3) 16.4 (6.8-23.4) 0.36 (-3.8,16.3) 
Gender (n, %) 6 males (60%) 5 males (50%) 1.00 - 
Weight (kg) 9.2 (8.6-12.2) 10.5 (7.9-11.0) 0.94 (-2.2,3.2) 
Haematocrit level % 47.0 (40.8-50.0) 38.1 (37.0-40.9) 0.01 (1.9,11.3) 
O2 saturation % 76 (68-86) 93 (91-97) 0.0002 (-26,-10) 
BT shunt - BTS (n, %) 6, 60% 2, 20% 0.17 - 
RV wall thickness (cm) 0.70 (0.58-0.83) 0.65 (0.57-0.82) 0.91 (-0.13,0.16) 
IVS wall thickness (cm) 0.85 (0.70-0.94) 0.66 (0.54-0.75) 0.01 (0.08,0.34) 
Sm - tricuspid annulus, cm/s 10.01 (7.28-11.55) 7.85 (7.49-10.13) 0.31 (-1.12,3.64) 
Sm - basal septum, cm/s 4.93 (4.18-6.03) 4.69 (3.73-6.10) 0.53 (-1.52,0.82) 
Sm - mitral annulus, cm/s 4.90 (3.33-6.23) 4.83 (3.95-5.63) 0.96 (-1.47,1.72) 
INTRA-OPERATIVE FACTORS     
Cross-clamp time, minute 100.0 (75.0-
130.0) 
67.5 (61.8-76.0) 0.004 (-58.0,-8.0) 
Bypass time, minute 218.5 (180.8-
310.0) 
114.5 (98.8-
130.3) 
0.003 (63.0,182.0) 
Transannular Patch use (n, %) 6.60% 4. 40% 0.67 - 
Subvalvar patch (n, %) 5.50% 2.20% 0.35 - 
RV to systemic pressure ratio 
HSP 27  VALUES 
0.79 (0.69-1.11) 0.72 (0.62-0.88) 0.41 (-0.12,0.35) 
 
Median HSP 27 in baseline first  
15 minute period (R.O.D.) 
0.79(0.68-1.6) 0.71 (0.5-0.85) 0.03  
Median HSP 27 after the first15 
 minute period (R.O.D.) 
0.83 (0.7-1.0) 0.72 (0.53-0.88) 0.48  
Median HSP 27i from XC 
 period (R.O.D.) (<15+>15min) 
0.82 (0.68-1.4) 0.72 (0.5-0.85) 0.01  
 
POST-OPERATIVE FACTORS (DAY 1) 
 
Troponin-I (ng/ml) 16.5(11.7-51.0) 11.1 (7.6-13.5) 0.04 (0.1,37.6) 
     
Inotrope score 14.0 (9.5-16.3) 6.5 (0.8-14.9) 0.05 (0.0,13.0) 
Haemoglobin (g/dl) 12.2 (11.4-14.0) 11.5 (10.4-13.6) 0.41 (-1.2,2.1) 
SvO2 % 65.4 (55.5-71.3) 66.5 (61.8-68.3) 0.91 (-9.0,7.0) 
Oxygen extraction ratio, OER 0.33 (0.28-0.42) 0.32 (0.27-0.35) 0.68 (-0.1, 0.1) 
Oxygen excess factor, Ω 3.1 (2.4-3.6) 3.1 (2.9-3.7) 0.68 (-0.9, 0.6) 
Lactate 1.6 (0.9-1.9) 1.2 (0.88-1.35) 0.26 (-0.2,0.9) 
Sm - tricuspid annulus, cm/s 3.60 (2.50-4.60) 4.08 (2.87-4.77) 0.85 (-1.56,0.93) 
Sm - basal septum, cm/s 3.21 (2.39-4.48) 2.71 (2.13-4.66) 0.52 (-0.83,1.53) 
Sm - mitral annulus, cm/s 5.21 (3.94-6.46) 3.98 (3.61-5.15) 0.10 (-0.24,2.46) 
Restrictive RV physiology 2, 20% 3, 30% 1.00 - 
Ventilation time hours 141.0 (58.7-195.2) 82.0 (19.1-121.3) 0.14 (-7.7,122.7) 
Critical care stay days 7.8 (5.0-11.2) 5.0 (3.5-8.3) 0.27 (-2.3,6.1) 
 
All data expressed in median (interquartile range). BTS (Blalock-Taussig shunt), RV 
(right ventricle), IVS (interventricular septum), Sm (systolic myocardial velocity, XC 
(cross clamp), SvO2 (mixed venous oxygen saturation), ROD (relative optical density).  
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 When compared to the control group with innocent murmur, TOF patients had 
significantly reduced systolic annular velocity pre-operatively at tricuspid (8.13 v 12.67 cms-1 
p<0.0001), septum (4.80 v 7.58 cms-1 p<0.001) and mitral (4.83 v 7.52 cms-1 p<0.001).  Pre-
operative annular velocities were similar in the cyanotic and non-cyanotic TOF groups.  At 
post-operative day 1, systolic myocardial velocity was reduced further in the tricuspid and 
basal septum in both the cyanotic group (p<0.001 and p=0.02 respectively) and non-cyanotic 
group (p<0.001 and p=0.02 respectively) compared to pre-operative velocities. No differences 
in post-operative annular velocities or the presence of restrictive RV physiology were found 
between the cyanotic and non-cyanotic group.  No association was found between post-
operative RV velocities (tricuspid and septal) and pre-operative O2 saturation, haematocrit, 
cardiopulmonary bypass time, troponin release, surgical method, degree of pulmonary 
regurgitation and residual right ventricle outflow tract obstruction.   
 
 All TOF patient annular velocities improved one week after surgery compared to day 1 
(tricuspid p=0.01, septum p=0.004, mitral p=0.02) but remained below the baseline velocities 
of healthy children.  
 
3.7.3.1 Postoperative Troponin-I release and HSP-27. 
The cyanotic group released significantly more Troponin-I on post-operative day 1 
compared to the non-cyanotic group (Table 14).  Higher Troponin-I release was associated 
with a higher pre-operative haematocrit level (p=0.003), longer aortic cross-clamp time 
(p=0.02) and CPB time (p=0.02). There was no correlation between Troponin I and HSP27 or 
the weight of the total muscle harvested from each group.  
 
3.7.3.2 HSP27 expression in tissue resected from RV outflow tract obstruction.  
 There was no statistical difference between the amount of ventricle muscle resected 
from the cyanotic compared with the non-cyanotic group (748.7 mg versus 583.6 mg) 
(p=0.08). Figure 3-33 is a Western blot showing HSP27 expression in samples resected from 
two patients (numbered 9 and 19) at different times following initiation of cross-clamp 
(patient 9 (lanes 1-7) and patient 19 (lanes 9-12). All muscle samples collected during the 
aortic cross-clamp period expressed HSP27.  Also shown is the internal control and the 
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molecular weight markers used to confirm the HSP27 protein molecular weight was the 
expected 27 kDa. 
 
Figure 3-33. Representative Western blot showing HSP27 expression in 2 different patients   
 
Western blot showing HSP27 expression in 2 different patients (patient 9 (lanes 1-7) and 
patient 19 (lanes 9-12) at time intervals from the start of cross-clamping. Patient 9 lane: 
1, 10-15 minutes; 2, 15-20 minutes; 3, 20-25 minutes; 4, 30-35 minutes; 5, 35-40 
minutes; 6, 40-45 minutes; 7, 45-50 minutes). Patient 19 lanes: 9, 5-10 minutes; 10, 10-
15 minutes; 11, 15-20 minutes; 12, 20-25 minutes. IC (internal control human placenta 
tissue known to express HSP27). Molecular weight markers are shown on the left. 
31.25µg total myocardial protein was loaded per lane. 
 
 When both cyanotic and non-cyanotic groups were combined and analysed for HSP27 
levels before 15 minutes (baseline) or after 15 minutes there were no differences between any 
groups (Figure 3-34). The results for median and interquartile range for HSP27 expression 
were as follows: (i) for all samples collected during the first 15 minutes of aortic cross-clamp 
time were 0.75 (0.64-0.93), for samples collected after the first 15 minutes were 0.74 (0.58-
0.93) and for all time points together 0.74 (0.61-0.93).   
 
Next a separate analysis was performed for the cyanotic and non-cyanotic groups 
separately. The results are shown in Table 14 and Figure 3-35. There was a significant 
increase in HSP27 levels in the combined <15 minutes and >15 minutes cyanotic groups 
compared to the combined <15 minutes and >15 minutes non-cyanotic groups (p=0.01). When 
the <15 minutes and >15 minutes time points were analysed separately there was a significant 
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increase in HSP27 levels in the <15 minutes cyanotic compared to the <15 minutes non-
cyanotic group (p=0.03). In the cyanotic group, HSP27 expression <15 minutes was 
significantly lower when compared to HSP27 experssion > 15 minutes (p<0.05). This was not 
seen in the non-cyantoic group. There was no significant relationship between baseline HSP27 
levels and pre-operative variables i.e. age, weight, oxygen saturation, haematocrit and right 
ventricular wall thickness. 
 
Figure 3-34. HSP27 expression (ROD) expression in all patients (cyanotic and non-cyanotic) 
 
Box and whiskers plot (median, interquartile-range) of HSP27 (ROD) expression in all 
patients (cyanotic and non-cyanotic) grouped by time interval collected during aortic 
cross-clamping time (p>0.05). 
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Figure 3-35. HSP27 expression (ROD) expression in the cyanotic (left panel) and non-
cyanotic patients (right panel) 
 
 
Box and Box and whiskers plot (median, interquartile-range) of HSP27 (ROD) 
expression in the cyanotic (left panel) and non-cyanotic patients (right panel) grouped by 
time interval collected during aortic cross-clamping time. (*p<0.05) 
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 In the cyanotic group baseline HSP27 levels (tissue collected during the first 15 
minutes of aortic cross clamp (and the closest representation of pre-operative status) correlated 
highly with oxygen extraction ratio. The results are shown in Figure 3-36 (p=0.028).  In 
contrast this relationship was not seen in the non-cyanotic group (p=0.34). In the cyanotic 
group baseline HSP27 levels also significantly correlated with post-operative basal septal 
velocity (Figure 3-37, p=0.036) and again this relationship was not seen in the non-cyanotic 
group (p=0.93). There was no correlation of HSP27 with tricupsid or mitral annular velocity. 
Figure 3-38 shows that HSP27 also significantly correlated with better mixed venous oxygen 
saturation in the cyanotic group (p=0.02) but not the non-cyanotic group (p=0.93). None of the 
above associations were found when the analyses were performed on tissues collected after 15 
minutes from the start of cross-clamping time. No other associations were found. 
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Figure 3-36. Oxygen extraction ration and baseline HSP27 expression 
 
Scatter plot of oxygen extraction ration and baseline HSP 27 in cyanotic patients (left) 
and non-cyanotic (right). 
 
Figure 3-37. Post-operative (Day 1) basal septal velocity and baseline HSP27 expression 
 
Scatter plot of Post-operative (Day 1) basal septal velocity and baseline HSP 27 in 
cyanotic patients (left) and non-cyanotic (right). 
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Figure 3-38. Mixed venous oxygen saturation and baseline HSP27 expression 
 
Scatter plot of mixed venous oxygen saturation and baseline HSP 27 in cyanotic patients (left) 
and non-cyanotic (right). 
 
 
Summary of main findings: 
• There was a significant increase in HSP27 protein expression levels in the combined 
<15 minutes and >15 minutes cyanotic groups compared to the combined  <15 minutes 
and >15 minutes non-cyanotic groups (p=0.01). 
• When the <15 minutes and >15 minutes time points were analysed separately there 
was a significant increase in HSP27 protein expression levels in the <15 minutes 
cyanotic compared to the <15 minutes non-cyanotic group (p=0.03).    
• In the cyanotic group, HSP27 baseline protein expression (<15 minutes) was 
significantly lower when compared to HSP27 protein expression after 15 minutes 
(p<0.05). 
• In the cyanotic group baseline HSP27 protein expression levels (tissue collected during 
the first 15 minutes of aortic cross clamp (and the closest representation of pre-
operative status) correlated highly with oxygen extraction ratio (p=0.028). 
• In the cyanotic group baseline HSP27 protein expression levels also significantly 
correlated with post-operative basal septal velocity (Figure 3-36, p=0.036). 
• HSP27 also significantly correlated with better mixed venous oxygen saturation in the 
cyanotic group (p=0.02). 
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3.8 Association of APJ expression with improved right ventricle function 
suggests a protective effect in cyanotic TOF 
 
3.8.1 Introduction 
 The APJ receptor and its cognate ligand and their function within the heart have been 
discussed previous (see section 1.8). To date, Apelin and the APJ receptor have never been 
identified in the infant myocardium. The aim was to look for the presence of the APJ receptors 
and therefore Apelin activity in the infant heart. A further aim was to determine whether the 
ischemic stress of surgery for correction of TOF, involving CPB, results in an increase in the 
expression of the Apelin APJ receptor in the infant myocardium as part of a cardio-protective 
mechanism. A further aim was to establish if a relationship existed between levels of APJ 
receptor expression in the infant myocardium in relation to clinical outcome both pre and post-
operatively. The function of Apelin-APJ could be advantageous in the post-operative 
myocardium for two reasons. The well-established functions of Apelin (intropy, vasodilation, 
diuretic) reduce physiological strain of the recovering post-operative heart and the molecular 
protection of the cardiomyocytes to ischemic stress can limit the damage inflicted by the use 
of CPB and reduce IR injury.  
 
3.8.2 Materials and Methods 
 A similar study was performed for the differential protein expression of HSP27 (see 
section 3.7). Patient recruitment (section 2.7.2.1), Tissue Doppler echocardiography (section 
3.7.2.2), surgical repair (section 3.7.2.3), post-operative monitoring (section 3.7.2.5) and 
statistical analysis (section 3.7.2.6) were performed as described in section 3.7.2. Western 
blotting was used to assess APJ differential protein expression. This was performed as 
previously described (section 3.7.2.4) except for the following factors: The primary antibody 
used was rabbit polyclonal anti-APJ (Phoenix Pharmaceuticals) at a concentration of 1/1000 
after this was deemed suitable after antibody optimisation. The secondary antibody used was 
Donkey anti-rabbit (Abcam, 1/3000). 
 
For the purposes of analysis, the samples were grouped by time according to how long 
after the initiation of surgery the tissue was taken i.e. after application of the aortic clamp. The 
samples near the start of the surgery (taken during first 10 minutes) were taken as the closest 
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possible indicator of preoperative expression, as the myocardium would not have been subject 
to high levels of ischemic damage due to the short time of cardioplegia. All samples taken 
after 10 minutes until surgical resection was complete were combined and grouped 
separately (>10 minutes) and represent samples with increasing exposure to ischemic injury. 
 
3.8.3 Results 
Table 14 (see section 3.7) summarises the peri-operative characteristics of the two 
groups. Comparisons of these traits between the cyanotic, non-cyanotic group and the separate 
control group are already described (see section 3.7.3). 
 
Samples were placed into two groups depending on how long after the initiation of 
surgery the tissue was taken. The samples near the start of the surgery (taken during first 10 
minutes) were taken as the closest possible indicator of preoperative expression.  All samples 
taken after 10 minutes until surgical resection was complete were grouped separately (>10 
minutes).  
 
Western blot analysis showed phosphorylated APJ receptor expression in all the 
samples examined although the level varied between patients. Figure 3-39 shows a typical 
Western blot.  A separate analysis with β-Actin antibody (see figure 3-33) showed that the 
amount of protein loaded was consistent between each sample. 
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Figure 3-39 Representative Western blot showing APJ expression in different patients   
 
 
 
Western blot showing the Apelin receptor (APJ) in different patient samples. APJ 
receptor antibody NBP1-30869. All samples showed APJ receptor expression with 
variable amounts of expression between different patients. 
 
When comparing expression levels using the parameters described above, a significant 
difference was found when all of the samples were analysed together (cyanotic group and non-
cyanotic group combined) (figure 3-40): expression of phosphorylated APJ was found to be 
increased after 10 minutes when compared to values in the first 10 minutes of surgery 
(p<0.05), therefore as time of cardioplegia and ischemia increased, expression of 
phosphorylated APJ receptor increased.  
 
When the cyanotic and non-cyanotic groups were analysed separately, no statistical 
difference was found between the groups before or after 10 minutes (data not shown, p>0.05). 
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Figure 3-40. APJ expression (R.O.D) expression in all patients (cyanotic and non-cyanotic) 
 
 
Box and whiskers plot (median, interquartile-range) of APJ (relative optical density 
(R.O.D) expression in all patients (cyanotic and non-cyanotic) grouped by time interval 
collected during aortic cross-clamping time (p<0.05). 
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Troponin is a standard serum marker of cardiac damage. Expression levels 
of phosphorylated APJ were also correlated to serum troponin levels (measured post-operative 
day 1). In both the cyanotic and non-cyanotic patient groups, whether analysed separately or 
combined, levels of APJ expression did not significantly correlate to post-operative troponin 
levels before or after the 10 minute time point or in all time points combined (data not shown, 
p>0.05).   
 
Mixed venous oxygen saturation (SvO2) is a measure of the O2 saturation of the venous 
blood taken from one of the pulmonary arteries and therefore is representative of O2 saturation 
for the entire venous circulation. This figure can be a measure of O2 uptake from tissues in the 
periphery as well as arterial O2 and cardiac output. Phosphorylated APJ receptor expression 
(in samples collected from the cyanotic and acyanotic patient group after 10 minutes) 
positively correlated with SvO2 measured post operatively on day 1 (p<0.05) (figure 3-41). 
This association was not present when the APJ receptor expression was correlated with 
samples collected <10 minutes (data not shown, p>0.05). 
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Figure 3-41. Mixed venous oxygen saturation and APJ expression 
 
 
Scatter plot of mixed venous oxygen saturation and APJ expression in in samples 
collected from the cyanotic and acyanotic patient group after 10 minutes 
 
 
Summary of main findings: 
• The protein expression of phosphorylated APJ was found to be increased after 10 
minutes when compared to values in the first 10 minutes of surgery (p<0.05). 
• Phosphorylated APJ receptor protein expression (in samples collected from the 
cyanotic and acyanotic patient group after 10 minutes) positively correlated with SvO2 
measured post operatively on day 1 (p<0.05). 
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CHAPTER 4 – DISCUSSION  
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4.1 Introduction  
Despite the various measures employed to protect the myocardium during CPB (see 
section 1.2.2) during surgical repair of congenital heart defects there is still an increased 
incidence of post-operative low cardiac output (Babu et al., 2012). Children with TOF often 
have cyanotic damage due to the chronic exposure of the RV myocardium to insufficiently 
oxygenated blood shunted from the right to the left side of the heart through the VSD (see 
section 1.1.3). Such myocardium is thought to be more vulnerable to injury (Merante et al., 
1998; Najm et al., 2000; Corno et al., 2002).  
 
 The use of bypass is associated with various forms of insult (see section 1.3). In this 
thesis, the main one of interest is localized myocardial ischemic-reperfusion (IR) injury 
(1.3.2). During both paediatric and adult cardiac surgery with CPB, high levels of O2 are often 
used. Therefore, the systemic systems of the body are exposed to high O2 tensions throughout 
the procedure. The myocardium is exposed to ischemia upon application of the cross-clamp 
and is then reperfused (aortic-clamp release) with these high O2 levels resulting in myocardial 
IR injury (Ihnken et al., 1998; reviewed in Allen et al., 2001; reviewed in Morita, 2012). 
  
Surgical correction of congenital defects accompanied by cyanosis is, as already 
described, carried out on bypass using hyperoxic levels of O2 (usually 250 to 400 mm Hg) 
(reviewed in Morita, 2012). A collection of studies performed using a pig animal model 
illustrated that cyanotic myocardium (PaO2 of 25mmHg) is especially vulnerable to re-
oxygenation injury at high levels of O2 (PaO2 400mmHg). Such damage is characterized by 
oxidative damage (ROS), a reduction in antioxidant reserve, oxidative degradation of lipids, 
cardiac contractile impairment and a reduction in cardiac output (Ihnken (i) et al., 1995; 
Ihnken (ii) et al., 1995; Morita (i) et al., 1995; Morita (ii) et al., 1995). This has also been 
shown in children with cyanotic damage who are undergoing corrective surgery on bypass. 
Hyperoxic re-oxygenation caused an increase in the level of troponin (marker of cardiac 
dysfunction), oxidative damage (ROS), depletion in antioxidants and a rise in pro-
inflammatory cytokines (Modi et al., 2002; Bulutcu et al., 2002). This topic has been very 
recently reviewed (reviewed in Morita, 2012). 
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 There have been several different methods employed in order to protect cyanotic 
myocardium from hyperoxic re-oxygenation injury. The first is the use of a lower O2 tension. 
Using normoxic levels during bypass is known to produce less damage than hyperoxic re-
oxygenation during adult heart surgery (Ihnken et al., 1998; reviewed in Morita, 2012).  In 
relation to paediatric corrective heart surgery, several studies noted above, which used a pig 
animal model of re-oxygenation injury of cyanotic myocardium (about 25 mm Hg), 
demonstrated that using a moderate O2 tension (100 mmHg) rather than hyperoxic O2 levels 
(400 mmHg) reduced levels of ROS, reduced CK levels (marker of tissue damage), 
maintained antioxidant levels and improved cardiac dysfunction (Morita (i) et al., 1995). This 
reduction in damage by using a lower O2 tension using a pig animal model was demonstrated 
in various ways in other studies (Ihnken (i) et al., 1995; Ihnken (ii) et al., 1995). The 
protective effects of using moderate O2 levels during surgery on bypass were also shown in 
studies involving cyanotic patients undergoing paediatric corrective heart surgery (Bulutcu et 
al., 2002; Caputo et al., 2009). 
 
There is also evidence that controlling re-oxygenation during CPB for patients that 
have congenital defects with pre-operative cyanotic damage will reduce post-operative injury. 
This was also demonstrated using a pig animal model. Cyanotic myocardium (about 25 
mmHg) was either exposed to hyperoxic O2 tension (400 mmHg) immediately upon initiation 
of bypass or exposed to a gradual increase of O2 tension from ambient O2 levels up to 
hyperoxic levels (400 mmHg). Controlling the O2 level resulted in a reduction in oxidative 
damage, the maintenance of antioxidant reserve, less oxidative degradation of lipids, and an 
improvement of cardiac output (Morita (ii) et al., 1995). Similar findings were found in 
another study (Ihnken (ii) et al., 1995). This was also demonstrated during paediatric cardiac 
surgery, where 31 children with cyanotic damage were recruited and put into 2 different 
groups. In the first group, bypass was initiated with very low O2 levels that were gradually 
increased for 5 minutes until levelling out at about 200 to 300 mmHg. In the other group, 
bypass was initiated at very high levels of O2 for 5 minutes then again levelled out to 200 to 
300 mmHg. Patients that had controlled re-oxygenation experienced significantly lower levels 
of creatine-phosphokinase-MB (marker of cardiac damage) and ventilation time (Babu et al., 
2012). This was shown in a similar study by another research group (Zhu (i) et al., 2005). 
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 The molecular mechanism at work within in the myocardium in adults undergoing 
corrective heart surgery has been investigated. Such investigation into children undergoing 
corrective heart surgery for congenital heart defects is limited. Some genes of interest that 
have been investigated include aspects of the immune system, such as TLRs, and cardio-
protective proteins such as HSPs. By looking at the differential expression of such genes and 
how they behave in the myocardium under such stresses as IR injury could allow new and 
novel protective methods to be highlighted. As such, this was one of the main aims of this 
project. Another aim was to determine if there was any difference in the molecular 
mechanisms that occurs in the myocardium of children with pre-operative cyanotic damage 
during insult when compared to appropriate controls. 
 
A novel aspect of this project was the fact that the tissue being used to analyse these 
molecular mechanisms involved using human tissue from paediatric patients undergoing 
surgery for congenial heart defects. This type of clinical investigation has not yet been 
undertaken. 
 
4.2 Screening of differential gene expression in ventricular myocardium 
excised from TOF and control patient groups 
The main aim of these experiments (see section 3.3) was to investigate the differential 
expression of inflammatory markers and stress proteins within ventricular myocardium 
excised from both cyanotic and acyanotic patients. Such patients undergo corrective surgery 
with CPB in order to repair a congenital cardiac defect. Patients who are cyanotic due to 
chronic exposure of ischemia include those with TOF (see section 1.1.3) and patients who are 
acyanotic include those with SAS (see section 1.1.4). 
 
Damage done to the myocardium and the systemic organs of the body by cardiac 
surgery with CPB has already been discussed (see section 1.3) (Kirklin et al., 1983; Menasche, 
1995; reviewed in Kozik and Tweddell, 2006). The protection of the myocardium during such 
procedures is very important. This is thought to be even more important for patients with pre-
operative cyanosis, who are thought to be more vulnerable to further insult (Merante et al., 
1998; Najm et al., 2000; Corno et al., 2002). 
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By looking at the expression of various genes at the molecular level, it is possible 
cyanotic patients have a different expression profile than the acyanotic patients. Such 
differences could help improve the knowledge of the molecular mechanisms at work within 
the myocardium under cyanosis. Therefore the first experimental investigation carried in this 
thesis was to look at the difference in the expression of inflammatory mediators (TLRs) and 
stress proteins (HSPs) in the myocardium from cyanotic and acyanotic patients.  
 
4.2.1 Experiment 1: TLR screening by endpoint PCR 
The aim of this experiment (see section 2.8.1) was to look at the expression profile of 
all 10 human TLRs (inflammatory mediators) and secondly to determine if there was any 
difference in their expression between the acyanotic and cyanotic patient groups. This helped 
to determine which TLRs were expressed in the tissue being used in this work but also to see 
if cyanosis had an affect on their expression. RNA was extracted from the ventricular 
myocardium and a kit that had primers for all 10 human TLRs (Invivogen) was used to 
investigate mRNA gene expression using PCR in all relevant patients from both groups (see 
section 3.1.2.1). 
 
In the cyanotic group (figure 3-1), TLR4 was the most highly expressed. TLR1 was not 
expressed in any of these patients. The rest of the TLRs were all expressed to varying degrees 
in all 7 cyanotic patients. In the acyanotic group (figure 3-2), TLR4 was expressed at the 
highest level, except for sample 6(1) where TLR8 was also highly expressed. Also, for sample 
18A, TLR9 and TLR10 were highly expressed. TLR1 was not expressed at all. The other 
TLRs were expressed in all 5 acyanotic patients to varying degrees. There was no noticeable 
difference in the TLR gene expression profile of cyanotic patients compared to control 
patients.  
 
The initial reason this experiment was performed was to provide evidence of TLR 
expression, with emphasise on TLR2 and TLR4, within the infant ventricular myocardial 
tissue that was being used for all the analysis within this project. Some examples of relevant 
evidence of TLR expression within the literature is described below, but the expression of 
TLRs within the infant myocardium has not been widely investigated. 
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The expression of TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9 was demonstrated in 
both adult human and mice cardiomyocytes. However, only TLR2, TLR4 and TLR5, when 
induced with their cognate ligand, produced pro-inflammatory cytokines (Boyd et al., 2006). 
Another study demonstrated the expression of TLR4 in both normal and abnormal 
myocardium from human and mice (Frantz et al., 1999). Most other studies within the 
literature only investigate the expression of one TLR, usually TLR4, and some examples are 
noted later in this section. This thesis, for the first time, both looked at and demonstrated the 
expression profile of all 10 human TLRs in infant myocardium.  
 
TLR4 is one of the best characterized TLRs in the literature in relation to both the 
innate immune system and the heart. The fact that there are so many studies that demonstrate 
the role of TLR4 in inflammation caused by IR injury could suggest that TLR4 is the most 
important to cardiac function (for examples see section 1.4). This could suggest why it is the 
most highly expressed in both the cyanotic and acyanotic group.  
 
TLR4 is expressed on the plasma membrane and can be activated by extracellular 
signals such as PAMPs and DAMPs. Cardiac surgery can result in various forms of injury. 
This can cause both cell damage and/ or cell death that can cause the release of DAMPs, such 
as HSPs. TLR4 was the most highly expressed TLR in both patient groups. All patients had 
gone through cardiac surgery with CPB. Therefore all patients would have been exposed to 
cellular insult, which could have initiated an inflammatory response. This could have caused 
the high TLR4 expression in both patient groups. Also, most of the studies in the literature that 
look at the activation of TLRs by DAMPs mostly focus on TLR4 and to some extent TLR2 
(see section 1.4). Therefore it may be that these TLRs are the ones mostly activated by 
extracellular DAMPs and the reason why TLR4 was the most highly expressed within the two 
groups. 
 
On the premise that cyanotic patients have the potential for pre-operative myocardial 
injury because of exposure to chronic hypoxia, it may be expected that the expression of TLRs 
would be higher in the cyanotic group, in particular TLR4. This is because TLRs are activated 
by DAMPs and can initiate an inflammatory response (see section 1.4). The work in this thesis 
indicated that there was no difference in TLR expression between the two patient groups.  
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TLR1 was not apparent in any patient samples from either of the patient groups. This 
may be because it is expressed at very low levels and was therefore not detectable by the 
assay. The primers used in the kit resulted in PCR products of unknown sizes. Despite this, it 
was apparent that the PCR product produced by the TLR1 primer pair was the largest.  
 
This experiment had some limitations. The first was the use of endpoint PCR that is 
only semi-quantitative and therefore any observations on the differential expression of the 
genes of interested will be limited. Also, the commercial kit used for this experiment presented 
some obstacles. Initially, only the positive control provided within the kit produced a PCR 
product with all 10 TLR primer pairs. No PCR products were produced with the mRNA 
extracted from the myocardial tissue. After weeks of troubleshooting, it was discovered that 
the PCR protocol given by the company was incorrect. The elongation step during each cycle 
of the PCR reaction should have been 2 minutes. The original protocol had stated 30 seconds. 
After this was rectified through the trouble shooting system, the PCR worked correctly. 
 
If there had been time, it would have been ideal to have more patient samples. The 
nature of the patient groups that tissue was obtained from is not common. Therefore, although 
limited in the number of samples I could obtain, this study is unique in being the first to 
attempt to do investigative work of this nature. 
 
 The expression of all 10 human TLRs (except TLR1) was demonstrated in this 
experiment. This allowed for the TLRs of most interest to be identified for further 
investigation. TLR2 and TLR4 were chosen. Based on the fact qPCR allows a more 
quantitative analysis of differential expression, it was used in the next experiment of this 
section to further the observations described above. 
 
4.2.2 Experiment 2: Screening the differential expression of several genes of interest 
by qPCR 
 
The aim of this experiment was to look at the differential expression of inflammatory 
mediators and stress proteins and to determine if there were any differences in their expression 
between the acyanotic and cyanotic patient groups. The last experiment only looked TLRs. 
TLR4 and TLR2 were selected for experiment 2 based on the observations highlighted. 
MYD88 is involved in the downstream signalling of both these TLRs therefore was also 
 
 
238 
selected. HSPs were not investigated in experiment 1 and are known stress proteins and were 
thought good candidates for investigation. Using RNA extracted from the ventricular 
myocardium and appropriate primers, mRNA gene expression was therefore investigated for 
all genes of interest using qPCR in all relevant patients from both groups. 
 
Inflammatory mediators: 
The expression of TLR4, TLR2 and MYD88 were investigated (figure 3-3). It was 
found that both TLR4 (0.51 vs. 0.35; p=0.0303) and TLR2 (1.23 vs. 0.68; p=0.0177) had 
significantly higher expression in the cyanotic group when compared to the acyanotic patient 
group. There was no such difference seen for MYD88. 
 
 A direct comparison of the expression of TLR4, TLR2 and MYD88 between cyanotic 
and acyanotic myocardium has not been performed before in either adult or infant hearts. That 
makes this experiment novel. No change in TLR2 and TLR4 expression was seen between the 
2 patient groups in experiment 1. This contradicts findings in experiment 2. Endpoint PCR is 
only semi quantitative, while qPCR (see section 2.9) looks at the differential expression within 
every sample being tested in real time, allowing for a more accurate and informative 
assessment of the differential expression of the gene being investigated. Therefore the 
differences observed in experiment 1 and experiment 2 could be explained because qPCR is 
more sensitive. 
 
Both TLR4 and TLR2 are expressed on the plasma membrane and can cause an 
inflammatory response when activated by DAMPs (danger signals released during times of 
cell damage and/ or death) (Gallucci et al., 1999; Shi et al., 2000; Asea et al., 2002). Patients 
with cyanotic heart disease are known to have pre-operative hypoxic injury. Therefore, it is 
possible that this could have resulted in the elevated levels of both TLR2 and TLR4 seen in 
the cyanotic patient group. 
 
MYD88 is an adapter protein that is involved with the downstream signalling of both 
TLR4 and TLR2. It would have been expected that the mRNA for this gene would also be 
higher in the cyanotic patient group. Looking at the expression of MYD88 (figure 3.3), a trend 
can be seen where its expression in the cyanotic group is higher than in the acyanotic group 
but this did not reach statistical significance. 
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TLR4 can also result in the activation of the IRF3 via a MYD88 (TRIF) independent 
pathway. This results in the production of IFN-β and the activation of its associated pathways 
(Fitzgerald et al., 2003; Yamamoto (ii) et al., 2002; reviewed in Chao et al., 2009). Therefore 
an increase in the expression of TLR4 would not necessarily result in an increase in the 
expression of MYD88 at the same time. This would not be applicable for TLR2 since it only 
works through the MYD88 pathway. Another possibility for an elevation in TLR4 expression 
could be its involvement in apoptosis (Ward et al., 2005; Goyal et al., 2002; Lombardo et al., 
2007).  
 
Stress proteins: 
The expression of HSP20, HSP27, HSP32, HSP60, HSP72 and HSP90 was 
investigated (figure 3-4). Of the six HSPs, only HSP27 showed a significant difference i.e. 
HSP27 expression was significantly higher (0.12 vs. 0.05; p=0.0303) in the cyanotic group 
when compared to the acyanotic group. When looking at the expression of the other HSPs 
(figure 3-4), especially at HSP20, HSP60 and HSP90, there is a trend for higher expression in 
the cyanotic group when compared to the acyanotic group but these did not reach statistical 
significance. 
 
HSP27, like other HSPs, is a stress protein and its expression is induced by cellular 
stress (Landry et al., 1989; reviewed in Salinthone et al., 2008). HSP27 is mainly intracellular 
where it will carry out its function as a protein chaperone. This ensures the maintenance or 
restoration of the structure of damaged cellular proteins (reviewed in Noble et al., 2008; 
reviewed in de Jong et al., 2009; reviewed in Horvath et al., 2008; reviewed in Liberek et al., 
2008; reviewed in Latchman, 2001). Cyanotic patients that suffer from congenital defects such 
as TOF have pre-operative hypoxic damage, which is a cellular insult. This could explain the 
elevated expression of HSP27 in these patients. Also, HSP gene expression has a novel trait 
known as pre-conditioning (reviewed in Latchman, 2001). This is where an initial cellular 
insult increases HSP expression that protects against a subsequent insult. This could be an 
adaptive measure used by the body to try and protect itself again the ischemic damage caused 
by such congenial defects. HSP27 is also known to be involved in the regulation of the 
apoptotic pathway (Bruey et al., 2000; Charette et al., 2000). If the elevation in the expression 
of HSP27 was because of this pathway, it could also potentially be beneficial for patients with 
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cyanosis. This is because it could help prevent cell death and maintain cellular integrity within 
the heart under such ischemic stress. 
 
It has also been shown that HSPs, including HSP27, can be found outside the cell 
where they interact with cells of the immune system. (Bassan et al., 1998; Basu et al., 2000; 
reviewed in Calderwood (i) et al., 2007; reviewed in Horvath et al., 2008). Such interaction 
can also involve the use of receptors such as TLR4 (Asea et al., 2000). Perhaps both TLR4 
and HSP27 expression were elevated in the cyanotic group because they were involved in 
inflammation caused by the chronic ischemic exposure sustained in the cyanotic group. Such 
an interaction has been shown in a study that investigated the expression of HSPs in skin in 
relation to occurrence of allergies (Yusuf et al., 2009).  
 
HSP32, HSP72 and HSP90 are well known stress proteins and are well characterized 
in the literature (see section 1.6). They are known to be induced by cellular stress therefore it 
might have been expected that a change in their expression would have been observed 
between the two patient groups but this was not the case. 
 
The majority of work within this thesis used qPCR. Its use has many benefits but as 
with most methods in science there are some limitations. The type of qPCR assay I used was 
the GoTaq® qPCR Master Mix with appropriate primers. The dye this assay contains binds 
indiscriminately to any double stranded DNA. In order to ensure a single discreet product is 
detected, great care was taken with primer design and melt curve analysis was used (see 
section 2.9 for more detail). Also, because the correct size (bp) of amplicon is known for each 
primer pair when they are designed (see section 2.7.1), the size (bp) of a qPCR product can be 
established by gel electrophoresis (see section 2.10) (reviewed in Smith and Osborn, 2009). 
All these steps ensured the results obtained were a true reflection of change in expression of 
the genes of interest. 
 
The comparative Ct method (see section 2.9.2) was used to look at the differential 
expression of all genes of interest in all samples. This method is a RQ method (for more detail 
see section 2.9.2). Many methods are used to minimise intra experimental variation that could 
affect resulting RQ values. It is ensured that the expression of the endogenous control is 
uniform in all samples. For this work the endogenous control was β-Actin, which has been 
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demonstrated as a suitable endogenous control in this laboratory. Also, a standard amount of 
RNA (100ng) is used for each sample in every RT reaction (see section 2.6), standardising the 
amount of cDNA used in the subsequent PCR/ qPCR. The concentration (ng/ µl) of RNA is 
determined on a NanoDrop®. The ratio of absorbance at 260 nm and 280 nm gives a 
measurement of RNA purity (see section 2.5). A value of 1.8-2.1 indicates optimal purity. 
Using high purity RNA during RT helps ensure good quality cDNA is used in the subsequent 
PCR/ qPCR. The use of the same arbitrary reference sample in all qPCR reactions helps 
minimised inter experimental variation and allows RQ values produced from various different 
qPCR reactions to be compared (see section 2.9.2 for more detail). This reference sample 
works with all primers used and goes through all procedures experienced by other samples 
therefore it also acts as a positive control for this assay. All these checks helped ensure the 
results obtained herein reflected true differences in gene expression for all qPCR experiments 
carried out for this thesis. 
 
The overall results of experiment 1 and 2 provided evidence that the genes of interest 
in this study were expressed in the myocardium. Also, it was found that several of them had 
differential expression between the 2 patient groups: these were TLR4, TLR2 and HSP27. 
This demonstrated that molecular mechanisms within the myocardium are affected by the 
presence of pre-operative ischemic damage present in the cyanotic patient group. Therefore, 
further investigation of the expression these genes could lead to better methods of protection 
of the myocardium. This is especially important for the cyanotic patient group, which was 
shown to have elevated expression of both inflammatory mediators and stress protein in this 
thesis. 
 
 The expression of both inflammatory mediators and stress proteins has been 
demonstrated in the myocardium of both patient groups. The next important step was to see if 
the stress proteins could be induced in the tissue used for the work within this thesis. 
 
4.3 HSP induction experiments  
The aim of these experiments (see section 2.4) was to investigate whether or not HSPs 
could be induced within infant myocardium. Induction was attempted using heavy metals, 
which are classic inducers of stress proteins. Therefore the myocardial tissue was exposed to 
NaAsO2 and CdCl2 and any differential HSP expression was investigated. This investigation 
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was performed at both the mRNA (see section 3.2.2.1) and the protein level (see section 
3.2.2.2). The inflammatory mediators were also investigated but only at the mRNA level. 
These findings are discussed in the following sections. 
 
4.3.1 mRNA level gene expression in response to heavy metal exposure 
 
The aim of this experiment (see section 3.2.2.1) was to look at the differential 
expression of stress proteins in infant myocardium exposed to heavy metals. This was to see if 
these proteins could be induced in this tissue under cellular stress. Inflammatory mediators 
were also investigated. Using RNA extracted from the ventricular myocardium of patients 
undergoing corrective surgery for congenital defects and appropriate primers, mRNA gene 
expression was investigated using qPCR in all relevant patients for all the genes of interest. 
 
Stress proteins: 
The expression of HSP20, HSP27, HSP32, HSP60, HSP72 and HSP90 were 
investigated. When looking at the differential expression of all six HSPs when exposed to 
either NaAsO2 or CdCl2, no statistically significant differences were observed (see table 8). It 
is possible that the low patient numbers for each chemical inducer (only 3 patients) meant that 
any significant difference in expression present was not identified. This is unlikely because 
previous studies have shown that if heavy metals are effective then the response is usually 
very large (Barber et al., 1999).  
 
The differential expression of HSPs induced by both the heavy metal inducers 
combined was then analysed. HSP27 (figure 3-6B) and HSP60 (figure 3-7A) showed no 
significant differences when exposed to heavy metals for 6 hours. There are several examples 
of heavy metal exposure inducing the expression of HSP27 and HSP60. For example, 
exposure of various types of human endothelial cell types to CdCl2 for 3 hours caused an 
increase in the expression of both these HSPs (Wagner et al., 1999). However, another study 
that investigated the effect of NaAsO2 exposure on cultured human urothelial cell line UROtsa 
showed that the expression of HSP27 and HSP60 were unaffected at the mRNA level by such 
exposure (Rossi et al., 2002). 6 hour induction with heavy metals was chosen based on 
previous work performed in this laboratory (Barber et al., 1999). Induction of HSP27 and 
HSP60 mRNA expression might have occurred before the 6 hour timepoint because our 
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published studies looked at HSP protein levels only. However, the fact some other HSP 
mRNAs increased (see later) suggested it is not the time of incubation that is the reason. Also, 
the studies mentioned above do not look at their expression within the heart; therefore it is 
possible that their expression is not inducible in this tissue.  
 
HSP20 (figure 3-6A) showed a significant decrease in expression upon exposure to 
heavy metals. This was not seen in the control (media only). There is very little mention of 
HSP20 expression in relation to heavy metal exposure in the literature. One study involving 
HSP20 expression in airway smooth muscle indicated that exposure to 20 µM NaAsO2 did not 
affect the expression of HSP20 (Ba et al., 2009). The decrease in expression of HSP20 seen 
during this experiment could have been because exposure to heavy metals for 6 hours caused 
damage to RNA within the tissue that encodes for HSP20 or somehow inhibited steady state 
synthesis. The fact that the tissue in media only did not produce the same result supports the 
fact it was the heavy metal and not the 6 hour incubation period that caused the potential 
deterioration of RNA. Interestingly, this was not observed for the expression of other HSPs. 
Therefore, it is likely something specific about HSP20 and its RNA transcript that was 
affected by the heavy metal exposure. In future experiments it would be interesting to look at 
other time points to investigate this further. 
 
HSP32 (figure 3-6A), HSP72 (figure 3-7B) and HSP90 (figure 3-7C) all showed a 
significant increase in expression when exposed to heavy metals for 6 hours. This was also 
true for the tissue exposed to media only for 6 hours (control).  The increase in expression due 
to exposure to heavy metals for 6 hours was significantly higher (figure 3-8) when compared 
to the increase in the expression seen for the controls. Therefore the increase due to heavy 
metals was greater. There are many examples of HSP72 expression being induced by both 
NaAsO2 and CdCl2 (Mirkes et al., 1994; Wagner et al., 1999; Wirth et al., 2002; Rossi et al., 
2002). This is not surprising as HSP72 is the best characterized HSP in the literature. HSP32 
has also been shown to be induced by these heavy metal inducers (Wagner et al., 1999; 
Malstrom et al., 2004; Wijeweera et al., 2001). Studies that focused on HSP90 expression 
upon heavy metal exposure are fairly limited (Rossi et al., 2002). Of those it was shown that 
exposure to NaAsO2 did not significantly affect HSP90 expression (Rossi et al., 2002). 
Therefore the work in this thesis for HSP32 and HSP72 is supported. For HSP90, this thesis 
shows it can be induced by heavy metals in infant myocardium. 
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All these studies generally show that HSPs can be induced by heavy metals. No 
previous studies looked at their expression in infant myocardium. Therefore the demonstration 
of the inducement of the expression HSP32, HSP 72 and HSP90 in this tissue by heavy metals 
is a novel finding. The fact that all 3 HSPs were also induced significantly in the control after 
6 hours is also worth noting. This suggests that tissue being in the incubator itself caused a 
degree of cellular stress, therefore inducing their expression. 
 
Inflammatory mediators: 
The expression of TLR2, TLR4 and MYD88 was investigated. When looking at the 
differential expression of all inflammatory mediators when exposed to either NaAsO2 or 
CdCl2, there were no statistically significant differences observed (see table 8).  
 
The differential expression of these genes induced by both the heavy metal inducers 
combined was then analysed. TLR2 and TLR4 (figure 3-5) showed no significant differences 
in expression when exposed to heavy metals for 6 hours. This was the same for the controls. 
MYD88 (figure 3-5C) also did not show a change in expression upon exposure to heavy 
metals for 6 hours, but showed a significant decrease in the control for 6 hours. Perhaps when 
tissue was left in media only, the RNA encoding for MYD88 was especially vulnerable to 
degradation by being in the incubator for 6 hours. This seems unlikely due to the fact that this 
same decrease in expression was not seen for the tissue exposed to heavy metals. Based on 
these results, heavy metals seem to not induce an inflammatory response. This can only be 
said for exposure of these genes within the myocardium and for the 6 hour time point used in 
the experiment. 
 
Although heavy metals have been used in the literature as classic inducers of HSPs, 
there have not been studies showing them as inducers of inflammatory mediators. However, 
since we are interested in inflammatory mediators as well as HSPs, and we also had sufficient 
cDNA available it was possible to easily investigate whether heavy metals also induced 
inflammatory mediators in this context. Also, exposure to heavy metals will cause cellular 
stress, which may result in inflammation. The lack of expression caused by heavy metals in 
the work of this thesis and the lack of studies on the subject suggest that heavy metals are not 
appropriate inducers of the inflammatory mediators. There was one study that indicated that 
NaAsO2 exposure inhibited NFkB activation, suggesting it could inhibit an inflammatory 
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response in beta-stimulated Caco-2 cells (Hershko et al., 2002). However, this study did not 
look at TLR2, TLR4 or MYD88 and did not involve the myocardium. 
 
Overall, heavy metal induction of HSPs has been well documented. Such induction in 
the heart however has not. This study clearly demonstrates that HSPs are expressed in the 
infant myocardium and that several of them can be induced within these tissues by classic 
HSP inducers. Therefore, this experiment acted as a control for the reperfusion experiments as 
it showed that HSPs were expressed but also that they could be induced upon cellular stress in 
infant myocardium. While investigating mRNA HSP expression, we also investigated HSP 
expression at the protein level. This is described in the next section. 
 
4.3.2 Protein level gene expression in response to heavy metal exposure 
The aim of this experiment (see section 3.2.2.2) was to look at the differential protein 
expression of HSPs in infant myocardium exposed to heavy metals taken from patients in the 
cyanotic patient group. This was to supplement the mRNA HSP expression data just 
discussed. 
 
Using protein extracted from the ventricular myocardium and appropriate antibodies, 
protein expression of HSP27, HSP32 and HSP72 were investigated using Western blotting. It 
should be noted that due to small patient samples used for this experiment, analysis was 
performed by looking at expression caused by the combination of both heavy metals. It was 
therefore not possible to look at the differential expression caused by both heavy metals 
separately with valid statistical analysis. Also, as protein level expression analysis required 
more tissue from each patient than mRNA gene expression analysis, there are no baseline 
samples (except for patient 44) in this dataset. Therefore the only comparison possible for this 
part of this work of the thesis was to compare the level of HSP expression produced in tissue 
exposed to heavy metals for 6 hours to the expression in tissue kept in media only for 6 hours 
(control). 
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Differential expression of HSP32: 
HSP32 expression was investigated in infant myocardium but no detectable levels of 
the protein were demonstrated within this tissue using the chosen antibody (see section 
2.12.4). To ensure it was not the assay at fault, an appropriate positive control was used. This 
produced a positive result for HSP32 (see figure 3-9). It could be that HSP32 was not 
detectable within the limits of the assay or that it was not detectable in the tissue being used 
for the experiment. HSP32 was shown in this tissue at the mRNA level, therefore it was 
expected that it would be detectable at the protein level as well. As such, due to time 
constraints it was decided to limit the optimisation period for this protein and no further 
investigation was performed. 
 
Differential expression of HSP72 and HSP27: 
The expression of HSP72 (figure 3-10) and HSP27 (figure 3-11) were investigated by 
Western blotting (see section 2.12). There was no significant difference in the expression of 
HSP27 and HSP72 (figure 3-12) seen between tissue that had been incubated with a chemical 
inducer for 6 hours and tissue that had been incubated in media only for 6 hours (control).  
 
At the mRNA level, there was no difference in HSP27 expression (figure 3-5A) when 
exposed to heavy metals. This is agreed upon at the protein level. HSP27 expression has been 
shown to be unaffected by exposure to heavy metals, which supports these findings (Rossi et 
al., 2002). Whether other time points would have produced a change is not known but 6 hours 
is the normal time one might expect any indication to occur based on previously published 
studies on HSP induction (Barber et al., 1999). 
 
For patient 44, a baseline sample was collected as this patient yielded more tissue than 
expected. This patient’s tissue was exposed to NaAsO2. It appeared that expression of HSP27 
at the start of incubation was higher than that seen in samples exposed to heavy metals or 
media only (control) for 6 hours (figure 3-11). A heart control sample is also included in these 
experiments (patient 1, TOF). This patient sample was not exposed to any experimental 
conditions. The expression of HSP27 in this sample is higher than that seen in the samples 
exposed to 6 hours in the incubator.  This is also seen for the placenta control sample used. It 
suggests that protein stability of HSP27 in the incubator after 6 hours is severely reduced, 
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resulting in reduced HSP27 expression. There was only one baseline sample from one patient 
exposed to one heavy metal. Therefore such a suggestion is only observational.  
 
HSP72 mRNA expression (figure 3-7B) was induced by heavy metal exposure after 6 
hours compared to tissue in media only (control). This was not repeated at the protein level 
(figure 3-10) where no statistical difference was observed (figure 3-12). The elevated 
expression of HSP27 in the baseline (patient 44) and heart/ placental control samples when 
compared to the tissue exposed to 6 hours incubation (heavy metals or media only) was not 
seen for HSP72. There are several studies that show that HSP72 is induced by heavy metals at 
both the mRNA and protein level (Mirkes et al., 1994; Wagner et al., 1999; Wirth et al., 2002; 
Rossi et al., 2002; Kuboki et al., 2007). This means induced HSP72 expression by heavy 
metals may have been expected. These studies did not investigate HSP72 expression within 
the myocadium. Therefore, it may be that such changes in HSP72 expression by heavy metals 
is not seen in the infant myocardium at the protein level. Or it may be that such change would 
be apparent at a different time point than 6 hours, so although unlikely, it might be beneficial 
for future studies to examine other time intervals. 
  
Heavy metal exposure with recovery period: 
An additional experiment was performed where tissue from a TOF patient (patient 40: 
TOF, cyanotic, male) was exposed to NaAsO2 for 4 hours then allowed to recover in media 
only for 20 hours (see section 2.4.3). Control tissue was incubated in media only for 24 hours. 
This was performed because a number of other published studies that examined induced HSP 
expression allowed for a period of recovery to determine if HSP expression was caused after 
an initial exposure to heavy metals (Kim et al., 2001; Rossi et al., 2002; Somji et al., 2002). 
The expression seen for HSP27 and HSP72 in this one patient seemed to follow all the trends 
seen in the tissue exposed to heavy metal exposure without a period of recovery. HSP27 
expression (see figure 3-13) was again reduced within the tissue that had been incubated when 
compared to controls. There was no difference seen between heavy metal tissue exposure (4 
hour exposure with 20 hour recovery) and media only tissue exposure (control for 24 hours). 
HSP72 expression (see figure 3-13) was not different for any of the samples either. Although 
this small investigation only used one patient and one type of heavy metal inducer, a recovery 
period did not seem to make a difference. 
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Overall, HSP32 and HSP72 protein expression has been demonstrated in the infant 
myocardium but such expression seems unaffected by exposure to heavy metals. This is in 
contradiction to mRNA level expression seen in similar tissue, which did increase. Reasons 
for this have already been described.  
 
The number of clinical samples used in both the molecular and protein analysis of this 
experiment was limited. This is because the types of sample used were rare and hard to obtain. 
Also, due to the problems encountered setting up the hyperoxic reperfusion system, other 
avenues of investigation were followed in order to help to establish the experimental system 
used throughout this project. Despite this, the study does provide pilot data from which future 
studies can be based. 
 
 HSPs are induced at the mRNA level in the myocardium by classic inducers. They are 
also present at the protein level despite not being chemically induced. Also, mRNA TLR 
expression within the myocardium was shown in earlier work within this thesis. The presence 
of the genes of interest has been demonstrated in the tissue used for all experimental work 
herein. Therefore, it was now possible to investigate the effect of re-oxygenation injury on 
these genes within myocardium. Also, it was possible to investigate if chronic ischemic 
damage resulting in cyanosis further modified their expression. 
 
4.4 Differential gene expression in RV myocardium excised from TOF and 
control patient groups exposed to differential oxygen levels  
 
 The main aim of the work within this thesis was to investigate the effect of re-
oxygenation injury on the expression of inflammatory mediators and stress proteins within 
ischemic infant myocardium. Surgical correction on bypass can have adverse effects on post-
operative cardiac output. During such procedures, the myocardium is exposed to high O2 
tensions (Ihnken et al., 1998; reviewed in Allen et al., 2001; reviewed in Morita, 2012). There 
are some concerns that this could cause adverse post-operative complications. When this 
involves patients with TOF, which due to chronic ischemic insult results in cyanosis, it is 
thought a bigger concern as they are thought to have more vulnerable to re-oxygenation injury 
(Modi et al., 2002; Bulutcu et al., 2002). 
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 Therefore, during the surgical correction of congenital heart defects of children from 
both the cyanotic and acyanotic patient groups, ventricular ischemic myocardial tissue was 
removed. This tissue was exposed to differential O2 exposure resulting in a model of localised 
myocardial IR injury. IR injury has been shown to cause inflammation and cellular stress. By 
looking at the affect this had on the expression of both inflammatory mediators and stress 
genes within the myocardium, the molecular mechanisms at play could be investigated. 
Having a better understanding of this would have the potential to help identify new and novel 
methods of myocardial protection. 
 
4.4.1 Experiment 1: exposing myocardial tissue to 2% (hypoxia) and 20% (normoxia) 
O2 
The aim of this experiment was to look at the differential expression of inflammatory 
mediators and stress proteins within ischemic infant myocardium and to see if they are 
affected when exposed to 20% O2 for 1.5 hours (see section 3.3.2.1). This re-enacts re-
oxygenation injury of the myocardium in vitro and allows a better understanding of its affect 
on the molecular mechanisms within the myocardium. Using RNA extracted from the 
ventricular myocardium and appropriate primers, mRNA gene expression was investigated 
using qPCR in all relevant patients for all the genes of interest.  
 
Inflammatory mediators: 
The expression of TLR4, TLR2 and MYD88 were investigated (figure 3-14). Exposure 
of the ischemic myocardium to 2% O2 for 1.5 hours acted as an experimental control. There 
was no significant difference in expression observed for any of these genes. Exposure to 20% 
O2 was performed in order to re-enact re-oxygenation injury i.e. exposure of ischemic tissue to 
20% O2 for 1.5 hours. This did not result in any significant changes in expression. 
 
The original idea had been to expose the tissue to 60% O2, mimicking the hyperoxic 
exposure seen during correction of congenital heart defects. Setting up this experimental 
system was problematic and took several months to achieve as the original incubator bought 
for the experiment did not work and was returned to a company overseas. During this period it 
was decided that exposure to 20% O2 would be investigated as a change from ischemia to 20% 
O2 was still technically a hyperoxic shock. The time period of 1.5 hours was chosen because it 
is the length of time the myocardium is reperfused after ischemia (aortic-clamp release) during 
cardiac surgery on bypass. 
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TLR4 and TLR2 are trans-membrane proteins that once activated by PAMPs or 
DAMPs result in the activation of the innate immune system and the production of pro-
inflammatory cytokines. MYD88 is an adapter protein that is involved in the downstream 
signalling of both TLR4 and TLR2. 20% O2 is approximately the level of O2 in ambient air. It 
could be that this level of O2 exposure for 1.5 hours is not sufficient to cause an inflammatory 
response within the myocardium. This could explain why there was no significant difference 
in the expression of the inflammatory mediators during the work herein, despite the hyperoxic 
shock. It might also be that there was no change in expression at the 1.5 hour timepoint used 
during this experiment. It might have been different if more time points were included in the 
study but this was not possible due to the limited amount of tissue available from each patient. 
Future studies could address this. 
 
The effect of IR injury on the expression of these inflammatory mediators has been 
described in the literature. There are several studies that have used animal models, usually 
involving the occlusion of blood to the heart for a period of time then allowing the flow to 
return. The size of the resulting MI was then measured as an indicator of the level of injury. In 
one study involving knockout TLR4 mice and appropriate controls, a model of IR injury was 
created, with the LV being exposed to 1 hour of ischemia then reperfused for 2 hours. This 
insult resulted in a MI. It was found that infarct size was larger in the wild type mice than in 
the mutant TLR4 mice. This suggested that the lack of TLR4 expression reduced the size of 
infarction (Chong et al., 2004). This reduced size of MI was observed in other similar studies 
involving mutant TLR4 mice and IR injury (Oyama et al., 2005; Shimamoto et al., 2006; Hua 
et al., 2007). In relation to TLR2 expression, several studies showed that TLR2 null mice 
resulted in a reduction in MI formation due to IR injury compared to controls (Favre et al., 
2007; Arslan et al., 2010). For MYD88 expression, a study using MYD88 mutant mice and 
appropriate controls underwent a model of IR injury. They were exposed to 30 minutes of 
ischemia and then 24 hours of reperfusion. MI size was measured in both types of mice, with 
the mutant MYD88 having a smaller infarction size (Feng et al., 2008). This finding was again 
supported in a similar study (Hua et al., 2005).  
 
The fact that a lack of expression of these genes seems to reduce the size of MI 
formation suggested that exposure of the ischemic myocardium to re-oxygenation would cause 
an increase in their expression. This was not the case in the work herein. The work in this 
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thesis involved the isolation of ischemic myocardial tissue that was exposed to differential 
levels of O2 in culture media to determine its effect on gene expression. These animal studies 
removed the expression of these genes then evaluated the end result i.e. MI formation caused. 
It makes the assumption that the difference of MI formation was because of the lack of these 
genes. The methodology is different therefore comparison of these studies to the work within 
this thesis is not appropriate.  
 
A number of studies involving animal models examined TLR4 expression during 
cardiac dysfunction (Tavener et al., 2004; Fallach et al., 2010; Baumgarten et al., 2006; Binck 
et al., 2005). The main question raised was whether it was TLR4 expression on cells of the 
immune system or TLR4 expression within the heart that caused cardiac dysfunction. There 
was no consensus reached as these studies all came to different conclusions. A similar 
problem was raised for TLR2 in relation to IR injury (Favre et al., 2007; Arslan et al., 2010). 
The work herein only looked at expression of defined genes within the myocardium itself. 
Perhaps re-oxygenation injury during corrective surgery causes inflammation within the 
systemic circulation rather than within the myocardium. This could explain the lack of change 
in the inflammatory mediators seen in this thesis. Therefore it suggests it might be worth 
investigating the systemic response in the future. 
 
TLR expression has been investigated during cardiac surgery within the literature. One 
study showed that TLR2 and TLR4 expression on circulating monocytes were elevated after 
adult cardiac surgery with CPB (Dybdahl et al., 2002). This study did not look at the 
myocardial expression of TLR4 or TLR2. Another study was performed that used the TLR4 
inhibitor eritoran. Patients undergoing adult CABG and/or cardiac valvular surgery were 
administered with either eritoran (prevents TLR4 expression) or a placebo pre-operatively. 
There were no significant differences seen when looking at systemic inflammation or organ 
dysfunction. This study will relate more to the damage sustained during CPB as a whole more 
than damage only done locally within the myocardium. Still it suggested that damage 
sustained during cardiac surgery does not cause a TLR4 initiated inflammatory response 
(Bennett-Guerrero et al., 2007). These studies did not investigate the expression of 
inflammatory mediators within the myocardium. Therefore the work of this thesis provided a 
novel opportunity to investigate such expression. Also, the work herein looked at the 
expression of genes within the myocardium in isolation upon re-oxygenation rather than the 
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effect of surgery on bypass as a whole. Therefore methodologies employed were different than 
those used in the above studies (Dybdahl et al., 2002; Bennett-Guerrero et al., 2007).  
 
The use of CPB means that the blood of the patients comes into contact with the extra-
corporeal unit of the CPB machine. This foreign surface initiates the priming of components 
of the immune system within the systemic blood circulation. Once this blood returns to the 
body, it causes a systemic inflammatory response. In this experiment in this thesis, the 
ischemic tissue was exposed to normoxic levels of O2 in media only and therefore the tissue 
was not exposed to an active circulation. The media lacks several of the physiological 
components present within the blood e.g. cells of the immune system. Therefore, the lack of 
expression of these inflammatory mediators in this thesis may have been due to the absence of 
exposure to these factors present during surgery. The work herein highlights that inflammation 
within the myocardium in isolation is not caused by re-oxygenation injury at 20% O2 for 1.5 
hours. As it has been shown in other work that TLR expression within the blood circulation is 
affected by surgery on bypass, investigating expression of these genes within the active 
circulation could be the next logical step. 
 
TLR4, TLR2 and MYD88 expression (see figure 3-14) within the myocardium was not 
changed during the 1.5 hours exposure to either hypoxia or normoxia. This indicates that such 
exposure does not cause an inflammatory response via the TLR mediated signalling pathway. 
This is supported by several studies that have shown normoxic O2 exposure during cardiac 
surgery with CPB is less harmful than using hyperoxic exposure (Ihnken et al., 1998; Caputo 
et al., 2009). The comparison between normoxia and hyperoxia will be discussed in 
experiment 2. 
 
The evidence within the literature, mostly involving animal models, does support the 
role of TLR4, TLR2 and MYD88 in being involved with inflammation caused during IR 
injury. Despite this, the methodology used is different than those used within this thesis. 
Evidence that looked at the expression of these genes during cardiac surgery is sparse and 
inconclusive. Also, such studies do not look at myocardial expression. This experiment 
indicated that normoxic reperfusion of ischemic myocardium does not cause the expression of 
TLR4, TLR2 and MYD88. Therefore, it is quite likely that it is the expression of circulating 
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inflammatory mediators responsible for myocardial inflammation caused during cardiac 
surgery rather than those in the myocardium. These findings are therefore novel. 
 
Stress proteins: 
The expression of HSP20, HSP27, HSP32 (figure 3-15), HSP60, HSP72 and HSP90 
were investigated (figure 3-16). Exposure of the ischemic myocardium to 2% O2 for 1.5 hours 
acted as an experimental control. There was no significant difference seen in the expression of 
the HSPs investigated. This was also true when the ischemic tissue was exposed to 20% for 
1.5 hours.  
 
HSPs are molecular chaperones that help maintain protein conformation and are 
induced by a variety of stressors including IR injury (reviewed in de Jong et al., 2009). The 
lack of HSP expression in the ischemic myocardium after 1.5 hours of 20% O2 exposure 
suggests that exposure to normoxia does not cause enough stress to induce HSP expression. 
Also, the fact that only one time point was looked suggests that expression may have occurred 
at another time. However, 1.5 hours was chosen as it represented the time frame the 
myocardium is exposed to reperfusion (after release of cross-clamp) during surgical repair.  
 
HSP expression during IR injury has been investigated in many studies within the 
literature using a variety of methods. There are several studies that have shown that 
overexpression of both HSP27 and HSP72 in rat cardiac cells reduced damage caused by 
exposure to ischemia and IR injury (Mestril et al., 1984; Liu et al., 2007; Kwon et al., 2007; 
Lu et al., 2008). These studies show prior induction of HSPs protects against IR injury in 
cardiac cells. Similar studies were carried out using animal models. The expression of HSP72 
and HSP27 were induced prior to insult by the creation of a MI in a rat animal model. These 
rats and appropriate wild type controls were exposed to IR injury. When compared, rats with 
prior HSP expression had reduced cardiac dysfunction upon IR injury (Pantos et al., 2007). 
This was demonstrated within the heart in other studies using rat animal models for HSP27, 
HSP20 and HSP32. The only difference was the method of HSP induction prior to injury (Yet 
et al., 2001; Fan et al., 2005; Pachori et al.. 2006; Kwon et al., 2007; Lu et al., 2008). The 
work herein looks at HSP expression as a result of IR injury in the myocardium. This 
methodology is different than used in the examples from the literature described above. 
Therefore it is difficult to compare them to the results in this thesis. We had hoped that if we 
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were able to increase expression of HSPs in ischemic human myocardium upon reperfusion 
we could then determine if this conferred protection to further stresses. No such differences 
were observed. 
 
Other animal models studies have shown that knocking out the expression of HSP32 
and HSP72 can cause more damage by IR injury when compared to wild type controls (Kim et 
al., 2006; Yoshida et al., 2001). This shows that lack of HSP expression is detrimental to the 
heart during IR injury. It would suggest that the presence of HSPs within the myocardium 
promotes cardiac cell survival. The results within this thesis demonstrated the presence of 
HSPs within the myocardium. It just didn’t indicate any statistically significance differences in 
their expression upon varied O2 exposure. Therefore their very presence within the 
myocardium may provide protection without being significantly induced. These studies 
assume that the lack of HSP expression is the cause of more damage by IR injury. They do not 
look at HSP expression as a result of IR injury. Therefore, as with the other animal model 
studies described above, the methodology used is different from the work within this thesis. 
 
There are also examples of HSP expression during cardiac surgery within the 
literature. The expression of HSP27, HSP60, HSP70 and HSC70 was investigated in tissue 
from the RA from patients undergoing surgical repair of congenital heart defects. Tissue was 
removed before the ischemic period i.e. before the aortic-clamp was applied and during the 
ischemic period i.e. after aortic clamping. No tissue was removed during reperfusion i.e. 
removal of aortic-clamp. No significant differences of expression were found but the levels of 
HSP72 increased in 40% of patients and the other HSPs increased in 28% of patients after 
cardioplegic arrest. These patients were associated with a reduction in the level of biomarkers 
of cardiac injury (Giannessi et al., 2003). This study shows an increase (non significant) of 
HSP expression within the heart during surgery and that such expression is associated with 
better post-operative cardiac function. It does not however show the effect of re-oxygenation 
on HSP expression within the myocardium. The methodology used in the work herein was 
different. In this thesis, the affect of re-oxygenation on myocardial gene expression was 
performed in isolation. The lack of HSP expression due to 1.5 hours of 20% O2 exposure 
during this experiment suggests such re-oxygenation is not enough to induce the expression of 
HSPs within myocardium. Such a finding is novel. 
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HSPs are well known for being intracellular molecular chaperones. They are also 
extracellular where they interact with aspects of the immune system (reviewed in Calderwood 
(i) et al, 2007). It was shown in adult patients undergoing CABG with CPB, that HSP72 was 
elevated in patient plasma samples taken after surgery was performed (Dybdahl et al., 2002). 
The same group demonstrated this in a later study but it was shown that the increase in HSP72 
within the plasma was more pronounced after such surgery on bypass in comparison to 
surgery off bypass (Dybdahl et al., 2004). Another study showed HSP70 expression was 
significantly lower in plasma from adult patients that had undergone surgery without bypass 
when compared to surgery with bypass (Lin et al., 2010). A similar increase was seen for the 
expression of HSP27, HSP60, HSP70 and HSP90α in plasma from adult patients undergoing 
CABG on bypass when compared to surgery without bypass (Szerafin et al., 2008). These 
studies show an elevation of HSPs after cardiac surgery with CPB, but this was measured 
within the blood circulation, not the heart tissue. The work herein looked at HSP expression in 
isolated myocardium exposed to re-oxygenation injury in media only. No increase was seen 
after 1.5 hour exposure to 20% O2. The studies described above demonstrate an increase in 
HSPs in the systemic circulation during surgery on bypass. Taken together, the lack of 
exposure of the infant myocardium to an active circulation in the work in this thesis could 
account for the lack of HSP induction within the myocardiym. HSPs are known DAMPs. They 
could be released into the plasma due to cellular injury and initiate inflammation. This work in 
this thesis has shown a lack of induced HSP expression with the myocardium and has 
indicated that it would be of value to measure circulating HSPs in future work. It has 
highlighted the next stage of investigation. 
 
 The expression of HSPs within the myocardium of children undergoing corrective 
surgery for congenital heart defects such as TOF has been previously demonstrated 
(Nakumura et al., 2000; Takeuchi et al., 2003). The presence of HSPs in infant myocardium 
during such procedures has again been shown herein. However, exposure of ischemic tissue to 
20% O2 reperfusion for 1.5 hours did not induce HSP expression.  
 
Within the literature, prior expression of HSPs has been shown to be protective against 
insult such as IR injury in both cardiac cells and animal models. Such evidence used a 
different methodology than the work within this thesis. The studies that looked at HSP 
expression during cardiac surgery focused mostly on extracellular HSP expression within the 
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patient serum. Again this methodology is different than used herein, which should be taken 
into consideration when comparing such studies to the results in this thesis. The work herein 
demonstrated HSP expression within infant myocardium and that it was unaffected by 
normoxic re-oxygenation. It suggests that normoxic exposure for 1.5 hours, which is similar to 
the length of O2 exposure during bypass after removal of the clamp, does not cause cellular 
stress within the myocardium. It also suggested combined with evidence within the literature 
described above, that the lack of exposure to an active blood circulation could be responsible 
for this. Therefore, the next stage in the investigation of cellular stress within the myocardium 
during surgery on bypass has been highlighted. 
 
This experiment had a limited number of clinical samples. This was due to the fact 
they were rare samples that were difficult to obtain. Also, while waiting for the hyperoxic 
reperfusion system to be set up, this experiment allowed the reperfusion system to be 
optimised and properly established. Also, it helped produce pilot data that allowed the 
hyperoxic reperfusion experiment to be improved. 
 
Surgical correction of congenital defects is carried out on bypass using hyperoxic 
levels of O2 (usually 250 to 400 mmHg) (reviewed in Morita, 2012). This experiment only 
exposed the myocardial tissue to normoxic exposure for 1.5 hours. No differences in 
expression were observed for the inflammatory mediators or the stress proteins. The setup of 
the hyperoxic experimental model was problematic but once solved, was the basis of the next 
piece of work within this thesis described below. 
 
4.4.2 Experiment 2: exposing myocardial tissue to 2% (hypoxia), 20% (normoxia) and 
60% (hyperoxia) O2 
 
The aim of this experiment (see section 3.3.2.2) was to look at the differential 
expression of inflammatory mediators and stress proteins within ischemic infant myocardium 
and to determine if they are affected when exposed to 20% and 60% O2 for 4 hours. This re-
enacts re-oxygenation injury of the myocardium in vitro and is an extension of experiment 1 
described above except it incorporated two different levels of O2 exposure. Also, as no 
expression was observed in experiment 1 after only 1.5 hours of exposure, this time period 
was extended to 4 hours. Using RNA extracted from the ventricular myocardium and 
appropriate primers, mRNA gene expression was investigated using qPCR in all relevant 
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patients for all the genes of interest. The effect of chronic ischemic injury that results in 
cyanosis was also investigated in relation to the expression of the genes of interest. 
 
Inflammatory mediators: 
The expression of TLR4 (figure 3-17A), TLR2 (figure 3-17B) and MYD88 (figure 3-
17C) were investigated (figure 3-17). Myocardial tissue was exposed to 2% O2 exposure for 4 
hours, which acted as an experimental control and no significant change in expression were 
observed. Upon exposure to 20% and 60% O2 exposure for 4 hours, no significant changes in 
expression in the myocardial tissue were observed. When looking at the results there was no 
apparent trend of expression that could be expanded on with more patient samples. 
 
This lack of differential expression of TLR4, TLR2 and MYD88 during the 4 hours 
exposure to normoxia (20% O2) also occurred in experiment 1 except exposure was only for 
1.5 hours. This could be because neither 1.5 hours nor 4 hours of normoxic exposure can 
cause inflammation within infant myocardium. Also, the fact no change in expression was 
seen after 4 hours as well as 1.5 hours makes it unlikely a change occurred at another time 
point. This supports that normoxic re-oxygenation of myocardium in isolation does not cause 
inflammation. 
 
Evidence describing TLR4, TLR2 and MYD88 expression during IR injury within the 
literature has been described. Such studies involved animal models (Chong et al., 2004; 
Oyama et al., 2005; Favre et al., 2007; Arslan et al., 2010; Feng et al., 2008) where lack of 
functional forms of these genes reduced the size of MI. These studies make an assumption that 
the lack of these gene results in less IR injury. The work in this thesis looks at the effect of IR 
injury on gene expression therefore uses a different methodology. Also some animal studies 
brought up the question of whether it was the expression of inflammatory mediators within the 
heart or in the blood circulation that were responsible for cardiac damage/ dysfunction 
(Tavener et al., 2004; Fallach et al., 2010; Baumgarten et al., 2006; Binck et al., 2005). No 
clear resolutions were drawn. It suggests that perhaps circulating inflammatory mediators are 
responsible for myocardial inflammation during cardiac surgery. This is supported by the lack 
of their expression within the myocardium in isolation after 1.5 or 4 hours of normoxic 
reperfusion. Despite this, the evidence within these studies is hard to compare to work within 
this thesis (different methodology and studies involving animals rather than human tissue).  
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There was also evidence of TLR expression in the model of cardiac surgery (Dybdahl 
et al., 2002;	  Bennett-Guerrero et al., 2007). The question of whether it was circulating TLR 
expression causing inflammation was again drawn into question (Dybdahl et al., 2002). Also, 
a lack of TLR expression (TLR4 inhibitor) was shown to have no effect on inflammation or 
cardiac function after cardiac surgery on bypass (Bennett-Guerrero et al., 2007). Work herein 
looked at the effect of re-oxygenation in myocardium in isolation. It is again hard to compare 
this work to the work in this thesis, as they did not look at myocardial expression in isolation 
but at the model of cardiac surgery with CPB as a whole. 
Normoxic re-oxygenation at both 1.5 hours and 4 hours did not cause an inflammatory 
response in the myocardium alone. The evidence in the literature was difficult to compare to 
the work in this thesis due to different methodologies. This thesis has highlighted that it is 
unlikely to be myocardial expression of inflammatory mediators that causes myocardial 
inflammation. It is more likely to be caused by circulating immunological factors activated by 
CPB, which would cause inflammation upon myocardial reperfusion.  
Exposure to 60% O2 for 4 hours also did not produce a significant change of expression 
of inflammatory mediators in infant myocardium. This was not looked at in experiment 1. In 
the literature, it was shown by some studies that hyperoxic exposure during cardiac surgery 
with CPB caused more oxidative stress and damage than normoxic O2 exposure (Ihnken et al., 
1998; Caputo et al., 2009). This would suggest that hyperoxic exposure for 4 hours would 
have caused an increase in the expression of inflammatory mediators within this experiment. 
This was not the case. Reasons for this will be similar to the lack of expression upon normoxic 
exposure that is described above. 
 
TLR2 and TLR4 and have been shown to be induced by hyperoxic exposure. However, 
these studies mostly investigated TLR expression within the lungs and involved the use of 
animal models and human epithelial cells (Huang et al., 2011; Zhang et al., 2005; Ogawa et 
al., 2007). Therefore, the methodology used was different and the results therefore are hard to 
compare to work in this thesis. There is also evidence in the literature that hyperoxia can cause 
inflammation during cardiac surgery. It was shown that cardiac surgery with CPB caused an 
increase in pro-inflammatory cytokines within the lungs when using 100% O2 when compared 
to using 50% O2 (Pizov et al., 2000). This suggests that hyperoxia can cause an increase in 
TLR4 and TLR2 expression, as they are often responsible for the production of pro-
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inflammatory cytokines. However, this study involved the lungs and therefore a direct 
comparison cannot be made to the work in this thesis. It does however suggest an avenue for 
future investigation. 
 
Some studies, which used a pig animal model of cyanotic infant myocardium, 
suggested that chronic ischemic exposure resulting in pre-operative cyanosis increased the 
susceptibility of damage caused by hyperoxic exposure (Ihnken (i) et al., 1995; Ihnken (ii) et 
al., 1995; Morita (i) et al., 1995; Morita (ii) et al., 1995). This was also shown during 
paediatric corrective surgery for congenital heart defects (Modi et al., 2002; Bulutcu et al., 
2002). This would suggest that the expression of inflammatory mediators within the 
myocardium from the cyanotic patient group would be higher than in the acyanotic patient 
group when exposed to high levels of O2. In this experiment in this thesis, the expression of 
TLR4 (see figure 3-21A), TLR2 (see figure 3-21B) and MYD88 (see figure 3-21C) after 
exposure to 4 hours of 2%, 20% and 60% O2 was compared between cyanotic and acyanotic 
patients and there was no significant differences seen. This indicated that cyanotic 
myocardium is not more vulnerable to normoxic or hyperoxic IR injury when compared to the 
acyanotic group, at least when assessed by these markers. 
 
The studies within the literature described above indicate that hyperoxic exposure is 
known to cause injury, but there have been several studies that have shown the opposite both 
during cardiac surgery and cardiac arrest (Mariero et al., 2012; Foadoddini et al., 2011; 
Bellomo et al., 2011; Hoedemaekers and van der Hoeven, 2011). Therefore, no hard 
conclusions can be drawn. The lack of TLR4, TLR2 and MYD88 expression during the work 
of this thesis suggests that hyperoxic exposure for 4 hours does not cause inflammation within 
infant myocardium. This could support that the use of hyperoxic levels of O2 to keep patients 
oxygenated during cardiac surgery with CPB does not have any additional detrimental effects. 
Although, this work only shows that hyperoxia does not cause myocardial inflammation after 
4 hours in isolation. As there was no exposure of myocardial tissue to an active circulation, it 
gives no indication of the effect of circulating inflammatory meditators on myocardial 
inflammation. Further experimentation could investigate this. 
 
 Overall, the expression of inflammatory mediators was not initiated within infant 
myocardium undergoing normoxic or hyperoxic exposure for 4 hours. Evidence within the 
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literature, which includes animal models and models of cardiac surgery, all tended to use 
different methodology. Therefore a direct comparison to work in this thesis was not possible. 
This work therefore demonstrates that normoxic and hyperoxic re-oxygenation of the 
myocardium does not initiate a myocardial inflammatory response. Therefore, it suggests, 
along with the body of evidence in the literature that the myocardial inflammation during 
cardiac surgery with CPB is caused by other factors. This is likely the exposure of the 
myocardium to circulating blood factors. Therefore, the next step in this investigation has been 
shown. 
 
Stress proteins: 
The expression of HSP20 (figure 3-18A), HSP27 (figure 3-18B), HSP32, (figure 3-
18C), HSP60 (figure 3-19A), HSP72 (figure 3-19B) and HSP90 (figure 3-19C) were 
investigated. There were no significant changes observed for any HSP upon exposure to 
hypoxia (2% O2) for 4 hours (control). Exposure to normoxia and hyperoxia for 4 hours only 
produced significant changes for HSP32 and HSP72. HSP90 showed an increase when 
exposed to both normoxia and hyperoxia for 4 hours but none reached statistical significance. 
 
HSP32 and HSP72 expression were significantly increased in infant myocardium after 
4 hours of normoxic exposure. This increase in expression was not caused after 1.5 hours in 
experiment 1. It could be that 1.5 hours was not long enough exposure at 20% O2 to cause 
cellular stress. 4 hours is an exaggerated exposure to such O2 levels. The fact that a change in 
expression is seen indicates that the experimental model works. This helps validate the lack of 
expression of inflammatory mediators and stress proteins seen in experiment 1 and 2. 
 
Examples within the literature of HSP expression during IR injury have already been 
discussed in section 4.4.1. These include studies involving cardiac cells (Mestril et al., 1984; 
Fan et al., 2004; Liu et al., 2007’ Kwon et al., 2007; Lu et al., 2008), and animal models (Yet 
et al., 2001; Fan et al., 2005; Pachori et al., 2006; Kwon et al., 2007; Lu et al., 2008). These 
studies mostly involved the overexpression of HSPs prior to insult, which resulted in 
protection against subsequent IR injury. HSP32 and HSP72 were both among the examples of 
HSPs shown to give such protection. Knockout mice were also used, which indicated lack of 
functional HSPs increased the damage done by IR injury (Kim et al., 2006; Yoshida et al., 
2001). It is hard to compare such studies to the evidence in this thesis, as the methods used 
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were different and they involved cardiac cells and animal models. Although they demonstrate 
the protective nature of HSP32 and HSP72, they do not show their response to IR injury 
within myocardium as is demonstrated in the work herein. Therefore, the fact HSP32 and 
HSP72 were shown be induced by normoxic exposure for 4 hours in this thesis is a new 
finding. Also, based on these studies, such expression could be protective against subsequent 
insult. 
 
Several studies involving HSP expression during cardiac surgery were also discussed 
previously (see section 4.4.1). Many showed an increase of extracellular HSP expression i.e. 
within the patient’s plasma (Dybdahl et al., 2002; Dybdahl et al., 2004; Szerafin et al., 2008; 
Lin et al., 2010). Such studies did not look at expression of HSPs within the myocardium. 
They suggested extracellular HSP expression could be increased within the systemic 
circulation in the patients studied herein, which could cause localised myocardial 
inflammation within the myocardium i.e. HSPs acting as DAMPS. The work in this thesis 
only investigated the expression in myocardium exposed to differential levels of O2 in 
isolation. Therefore, other factors must be involved in myocardial insult during cardiac 
surgery. This could be a future investigation. 
 
HSP32 and HSP72 expression were significantly increased in infant myocardium after 
4 hours of hyperoxic exposure. HSP expression and exposure to hyperoxia has been 
investigated in the literature but mostly in studies that involve the lungs. Human respiratory 
epithelial cells that overexpressed HSP72 were shown to have better survival against 
hyperoxic exposure (Wong et al., 1998). A lack of HSP27 expression in lung epithelial cells 
resulted in reduced protection against hyperoxic exposure (Shao et al., 2009). Overexpression 
of HSP32 provided protection against such exposure in human pulmonary epithelial cells (Lee 
et al., 1996). These studies show that HSP expression is important in protecting against 
hyperoxic exposure but not how it affects their expression. Also, these studies do not look at 
expression within the myocardium. Therefore it is not entirely appropriate to compare these 
experiments to the evidence in the work of this thesis. The fact they show that HSPs are 
protective against IR insult suggests that the induced expression of HSP32 and HSP72 shown 
in his thesis during hyperoxic insult could have a protective affect during surgery on bypass. 
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Hyperoxic exposure during cardiac surgery with CPB has been shown to cause more 
damage when compared to normoxic exposure during the same procedure (Ihnken et al., 1998; 
Caputo et al., 2009). Despite this, it has been suggested that the level of O2 used does not 
matter (Mariero et al., 2012). The increase in HSP32 and HSP72 expression in myocardium 
seen herein was seen after both normoxic and hyperoxic exposure for 4 hours. As HSP 
expression occurs in relation to stress, this suggests that the level of O2 tension used during 
cardiac surgery does not affect the degree of cellular stress. This was supported by the fact 
HSP32 expression during the 20% and 60% O2 4 hour exposure was not significantly different 
(figure 3-20A). However, it was demonstrated that the level of HSP72 expression during 20% 
O2 4 hour exposure was significantly higher than the expression seen during the 60% O2 4 
hour exposure (figure 3-20B).  This would indicate that the level of O2 used does make a 
difference in realtion to myocardial IR injury.  
 
In this thesis, the myocardium was exposed to normoxia and hyperoxia for 4 hours 
(reoxygenation of ischemic myocardial tissue), which is longer than would occur during 
cardiac surgery with CPB. Therefore this increase in the expression of HSP32 and HSP72 
within the infant myocardium may be caused by an exaggerated O2 exposure. The fact this 
increase was not seen at 2% O2 for 4 hours (control) helps validate it was the O2 exposure that 
resulted in such cellular stress but whether using 20% or 60% O2 makes a difference still 
remains unclear.  In the case of hyperoxic exposure for 4 hours, as only one time point was 
looked at, the increase in HSP32 and HSP72 expression may have been present before the 4 
hour time point. Also, patients are usually exposed to 100% O2 not 60% O2 during surgery and 
this is a more extreme exposure. Therefore, using higher levels of O2 during surgery with CPB 
may still be of some concern.  
 
HSP32 and HSP72 expression was significantly increased within the myocardium 
upon exposure to normoxia and hyperoxia for 4 hours. Such insult could cause HSP release 
(DAMPs) from cardiac cells that were damaged beyond repair. Extracellular HSPs can interact 
with aspects of the immune system resulting in pro-inflammatory cytokines release (Asea et 
al., 2000; Asea et al., 2002; Basu et al., 2002). They can also cause an anti-inflammatory 
response, with HSP32 being a prime example (Zabalgoitia et al., 2008; Yeh et al., 2009; Wang 
et al., 2009). In the work within this thesis, such release would have been seen within the 
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media the tissue was incubated in. This was not measured for the work in this thesis but could 
be investigated in the future.  
 
HSP32 and HSP72 expression have been demonstrated in RV cyanotic myocardium of 
children undergoing corrective surgery for congenital heart defects (Nakamura et al., 2000; 
Takeuchi et al., 2003). Cyanotic myocardium has been shown to be especially vulnerable to 
hyperoxic exposure (Modi et al., 2002; Bulutcu et al., 2002). As with the inflammatory 
mediators, the expression of HSPs in myocardium exposed to 4 hours of 2%, 20% and 60% O2 
was compared between cyanotic and acyanotic patients. No significant differences in 
expression were seen (figure 3-22 and 3-23). This suggests that cellular stress in myocardium 
from cyanotic patients during re-oxygenation injury is not more exaggerated than within 
myocardium from acyanotic patients but this would require further investigation. 
 
Overall, HSP32 and HSP72 mRNA expression was induced by normoxic or hyperoxic 
exposure for 4 hours. Prior induction of HSPs has been shown to protect against IR injury in 
studies involving both cardiac cells and animal model. Such work provides evidence of the 
protective nature of HSPs. It could be that the increase of HSP32 and HSP72 within the infant 
myocardium shown herein may be an innate mechanism the body employs to provide 
protection against oxidative insult.  
 
The majority of studies that show HSP expression during cardiac surgery focus on 
extracellular HSP expression within patient plasma. They do not investigate myocardial HSP 
expression. They suggest circulating factors may contribute to myocardial cellular stress, 
likely contributing to the HSP induction already caused by high level O2 exposure shown 
herein. This is shown by the fact that the work in this thesis investigated the expression within 
isolated myocardium, which lacks contact with an active circulation, and also by the evidence 
within the literature. 
 
 
4.5 The differential mRNA expression of GRP78 
 
GRP78 is a stress protein located within the ER. Upon cellular stress, such as nutrient 
deprivation, misfolded proteins can accumulate in the ER, which can cause the expression of 
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proteins like GRP78 to accommodate the problem (Shiu et al., 1977; Li et al., 1993; Miles et 
al., 1994; reviewed in Lee, 2001). It has been shown that the expression of GRP78 is up 
regulated in the heart during ischemic insult (Sun et al., 2008; Hardy and Raiter, 2010; Xin et 
al., 2011). It is also increased during IR injury, where it was shown to be cardio-protective 
(Martindale et al., 2006). 
 
4.5.1 Experiment 1: Screening of differential gene expression in ventricular 
myocardium excised from cyanotic and control (acyanotic) patient groups. 
 
The aim of this experiment was to look at the differential mRNA expression of GRP78 
(see section 3.4) and to determine if there was any difference in expression seen between the 
acyanotic and cyanotic patient groups. Using RNA extracted from the ventricular myocardium 
and appropriate primers, qPCR was used to investigate changes in mRNA expression and any 
differences seen in gene expression were calculated using the Comparative Ct method (see 
section 2.9.2) to give RQ of gene expression.  
 
There was no significant change in the expression of GRP78 within the myocardium 
when comparing the cyanotic patient group with the acyanotic patient group (see figure 3-24). 
GRP78 is induced during ischemic insult (Sun et al., 2008; Hardy and Raiter, 2010; Xin et al., 
2011). Cyanotic patients, who include patients with TOF, also have such damage because their 
heart is chronically exposed to low levels of O2 (Apitz et al., 2009). Therefore, it may have 
been expected that the cyanotic group would have a higher expression than the acyanotic 
group. When looking at the results (figure 3-24) it does appear that the level of GRP78 is 
higher in the cyanotic group but this did not reach statistical significance. 
 
4.5.2 Experiment 2: Reperfusion Experiment - exposing myocardial tissue to 2% 
(hypoxia), 20% (normoxia) and 60% (hyperoxia) O2 
 
The aim of this experiment was to look at the differential expression of GRP78 in 
ischemic infant myocardium when exposed to 2% (hypoxia), 20% (normoxia) and 60% 
(hyperoxia) O2 for 4 hours. Therefore, re-oxygenation injury of the myocardium was re-
enacted in vitro. Using RNA extracted from the ventricular myocardium and appropriate 
primers, mRNA gene expression was investigated using qPCR (see section 2.9). RQ of gene 
expression was calculated using the comparative Ct method (see section 2.9.2). The affect of 
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chronic ischemic injury, that results in cyanosis, on the expression of GRP78 during re-
oxygenation injury was also investigated. 
 
Myocardial tissue was exposed to 2% O2 exposure for 4 hours, which acted as an 
experimental control and no significant change in GRP78 expression were observed. There 
were no significant differences seen in GRP78 when infant myocardium was exposed 20% 
(normoxia) and 60% (hyperoxia) O2 for 4 hours (see figure 3-25). It has been shown in a 
mouse animal model that GRP78 expression was increased when exposed to IR injury within 
the heart (Martindale et al., 2006). Therefore it may have been expected to be increased upon 
exposure to either 20% (normoxia) or 60% (hyperoxia) O2 for 4 hours within this thesis. 
Despite this, the study was not performed in the infant myocardium. It was done using an 
animal model and therefore it is hard to compare it to the work herein. 
 
The expression of GRP78 was found to be upregulated in cultured human endothelial 
cells during hyperoxic exposure and conferred protection against the insult. This increase in 
GRP78 expression was due to the knockdown of the ER protein ERp57. When ERp57 
knockdown was removed, expression of GRP78 was reduced and apoptotic cell death was 
increased (Xu et al., 2009). Therefore, upregulation of GRP78 expression seemed to protect 
against hyperoxic exposure. The results presented in this thesis looked at the response of 
GRP78 upon re-oxygenation injury within infant myocardium. It might have been expected 
for GRP78 expression to be increased upon hyperoxic exposure but this was not the case. The 
study described above involved the lungs and the use of a mouse animal model. Therefore 
despite GRP78 providing protection against hyperoxic insult, the results of this study cannot 
be easily compared to the work herein. In another study, the response of GRP78 to cigarette 
smoking was investigated. Smoking cigarettes exposes the lungs to a high level of ROS, which 
is a consequence of hyperoxic exposure. The expression of GRP78 was upregulated in lung 
tissue taken from smokers when compared to non-smokers and ex-smokers. Therefore GRP78 
is increased upon hyperoxic exposure within the lungs (Kelsen et al., 2008). The work herein 
looked at the effect of hyperoxic exposure within the myocardium not the lungs. Also, 
smoking exposes tissue to other damaging factors. Therefore, this study cannot easily be 
compared to the results in this thesis despite it involving human subjects. This is because there 
will be other factors contributing to ER instability other than the ROS. 
 
 
 
266 
 A comparison of GRP78 expression was performed with the tissue exposed to 2% O2 
for 4 hours, 20% O2 for 4 hours and 60% O2 for 4 hours between the cyanotic and acyanotic 
groups. No statistical differences were observed (figure 3-26). Cyanotic patient myocardium 
had been suggested as being more vulnerable than acyanotic patient myocardium but this 
experiment indicates that this is not the case.  
 
 In the literature GRP78 was induced by ischemic insult. Patients with congenital heart 
defects such as TOF are chronically exposed to low O2 tension in their circulation resulting in 
cyanosis. There was no difference seen in GRP78 expression in the acyanotic and cyanotic 
patient groups in experiment 1. In experiment 2, GRP78 expression was unaffected by 4 hour 
exposure to 20% or 60% O2. It has been demonstrated that GRP78 can be induced by 
hyperoxic exposure but this has not been shown within infant myocardium. The results of the 
present work suggest that normoxic and hyperoxic exposure does not cause ER stress and that 
cyanotic patient myocardium in not more vulnerable to IR injury than acyanotic patient 
myocardium. 
 
4.6 The differential mRNA expression of APJ and its endogenous ligand Apelin  
The Apelin receptor (APJ) and its cognate ligand Apelin have been implicated as 
having either a role as a vasodilator (Lee et al., 2000; Tatemoto et al., 2001; Cheng et al., 
2003) or as having a hypothalamic role (De Mota et al., 2000; Reaux et al., 2001; Taheri et al., 
2002; De Mota et al., 2004; Reaux-Le Goazigo et al., 2004). They are expressed in the heart 
where they improve cardiac contractile function (Szokodi et al., 2002; Berry et al., 2004; 
Ashley et al., 2005) and protects against cellular insult (Jia et al., 2006; Atluri et al., 2007). 
 
4.6.1 Experiment 1: Screening of differential gene expression in ventricular 
myocardium excised from cyanotic and control (acyanotic) patient groups 
 
The aim of this experiment was to look at the differential expression of APJ (see 
section 3-5) and to determine if there was any difference in expression seen between the 
acyanotic and cyanotic patient groups. Using RNA extracted from the ventricular myocardium 
and appropriate primers, qPCR was used to investigate changes in mRNA expression and any 
differences seen in gene expression were calculated using the Comparative Ct method (see 
section 2.9.2) to give RQ of gene expression.  
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There was no significant change in the mRNA expression of APJ when comparing the 
cyanotic patient group with the acyanotic patient group (figure 3-27). There was a study that 
looked at the mRNA and protein level of Apelin and APJ in a rat animal model of myocardial 
injury caused by the administration of isoproterenol. In such rats, the mRNA levels of Apelin 
and APJ in the myocardium were noticeably reduced. However the protein level of APJ in the 
myocardium was increased (Jia et al., 2006). Cyanotic patients, who include individuals with 
TOF, are chronically exposed to low O2 tension in the blood. This is a form of myocardial 
injury. Therefore, it might have been expected that the mRNA level of APJ would have been 
reduced in the cyanotic group when compared to the acyanotic group. The mRNA expression 
of Apelin, the ligand of APJ, was found to be decreased in cultured neonatal rat ventricular 
myocytes exposed to mechanical stretch and in two models of chronic ventricular pressure 
overload. These are forms of cellular stress. As the mRNA expression of Apelin was reduced, 
one may have expected that APJ expression would also be lowered (Szokodi et al., 2002). 
Therefore, it may have been expected that APJ mRNA expression would be decreased in the 
cyanotic patient group, which have pre-operative ischemic damage. It was also shown using a 
mouse animal model that in heart and skeletal muscle the expression of Apelin and APJ were 
increased after ischemic myocardial injury. Also, in cultured endothelial cells exposed to 
hypoxia, Apelin mRNA and protein levels were increased by hypoxia (Sheikh et al., 2008). 
This would suggest that APJ mRNA expression would have been expected to be higher in the 
cyanotic patient group. This increase in Apelin and APJ expression after ischemic insult was 
again seen in another study but this was shown at the protein level (Atluri et al., 2007). There 
is therefore contradictory data in the literature as to how the expression of APJ and Apelin are 
affected by cardiac cellular insult. These studies are performed using both cardiac cells and 
animal models and do not look at myocardial APJ expression. As such, comparison to the 
work herein is problematic.  
 
4.6.2 Experiment 2: Reperfusion Experiment - exposing myocardial tissue to 2% 
(hypoxia), 20% (normoxia) and 60% (hyperoxia) O2 
 
The aim of this experiment was to look at the differential expression of APJ in 
ischemic infant myocardium when exposed to 2% (hypoxia), 20% (normoxia) and 60% 
(hyperoxia) O2 for 4 hours. Therefore, re-oxygenation injury of the myocardium was re-
enacted in vitro. Using RNA extracted from the ventricular myocardium and appropriate 
primers, mRNA gene expression was investigated using qPCR (see section 2.9). Relative 
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quantification of gene expression was calculated using the comparative Ct method (see section 
2.9.2). The affect of chronic ischemic injury, that results in cyanosis, on the expression of APJ 
after re-oxygenation injury was also investigated. 
 
Myocardial tissue was exposed to 2% O2 exposure for 4 hours, which acted as an 
experimental control and no significant change in APJ mRNA expression was observed 
(figure 3-28). There were no significant differences seen in APJ when infant myocardium was 
exposed to 20% (normoxia) and 60% (hyperoxia) O2 for 4 hours (figure 3-28). A study was 
performed that looked at the expression of Apelin and APJ during IR injury using a rat animal 
model and cultured myocardial cells from neonatal rats. It was shown that rats exposed to IR 
injury had increased mRNA and protein levels of APJ as well as having a decrease in cardiac 
function. The myocardial cells exposed to IR injury had an increase in the mRNA levels of 
APJ and Apelin as well as an increase in apoptosis (Zeng et al., 2009). This may have 
suggested that exposure to 20% or 60% O2 should have increased the expression of APJ. The 
same study indicated that pre-administration of Apelin improved the resulting cardiac 
dysfunction in the rats and also reduced damage sustained by the myocardial cells when 
exposed to IR injury. Such action of Apelin has been seen in other studies (Jia et al., 2006; 
Atluri et al., 2007). There are numerous studies using animal models that show that 
administration of exogenous Apelin can improve cardiac contractibility function which again 
is an improvement in cardiac function (Szokodi et al., 2002; Berry et al., 2004; Ashley et al., 
2005). Taken together, such evidence suggests cellular insult such as ischemic insult and IR 
injury causes an increase in Apelin and APJ expression, but the pre-administration of 
exogenous Apelin provides cardio-protection by improving cardiac function. There was one 
study that indicated myocardial insult caused a decrease in APJ and Apelin mRNA expression 
within rat myocardium, which would disagree with this. However, the APJ protein expression 
was increased in the rat myocardium during the insult, which would agree with this evidence 
(Jia et al., 2006). Also, APJ mRNA was decreased after mechanical cardiac insult in cultured 
neonatal rat ventricular myocytes (Szokodi et al., 2002).  
 
The results of this experiment indicates that APJ was unaffected by the exposure to 
20% and 60% O2 for 4 hours. The evidence within the literature is confusing therefore the 
results herein are not contradicted. Also, the evidence in the literature was based on work 
involving animal models. This involved different methodology than used within this thesis. 
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Therefore a direct comparison with this work and the studies within the literature is difficult. 
There was only one timepoint used in this experiment therefore changes in expression may be 
seen at other time points.  
 
A comparison of APJ mRNA expression was performed with the tissue exposed to 2% 
O2 for 4 hours, 20% O2 for 4 hours and 60% O2 for 4 hours between the cyanotic and 
acyanotic groups. No statistical differences were observed (figure 3-29). 
 
 Overall, in experiment 1, APJ expression within the myocardium was not different in 
the cyanotic and acyanotic patient groups. There is evidence in the literature that suggests 
cardiac ischemic and myocardial insult results in both a decrease or increase in APJ and 
Apelin expression. Cyanotic patients have pre-operative ischemic damage, which may have 
indicated that a difference in APJ expression would have been expected. In experiment 2, it is 
indicated that IR injury and other types of myocardial insult result in mainly an increase in the 
expression of APJ and Apelin, though some indicate the opposite. This would have again 
suggested that exposure of the infant myocardium to 20% and 60% O2 for 4 hours would have 
produced a change in APJ expression. For both experiments, the evidence in the literature is 
inconclusive. Despite this, most suggest some change in APJ expression upon cardiac insult, 
therefore the lack of change seen in APJ expression in both experiments may not be what was 
expected. Also, these studies use animal models therefore cannot be directly compared to 
evidence within this thesis. There was no apparent difference seen when comparing the 
expression of APJ during varying O2 exposure in the cyanotic patient group compared to the 
acyanotic patient group. It has been shown by others that administration of exogenous Apelin 
has been shown to improve cardiac dysfunction. This would indicate an interesting avenue of 
investigation for the future.  
 
4.7 Decay curve experiments 
The aim of these experiments was to investigate how the expression patterns of genes 
of interest within the infant myocardium were affected by varying incubations times. This 
experiment acted as a control for all other experiments as it showed whether expression seen 
was due to the variable used during the experiment or due to the length of time in the 
incubator. This experiment was very important for any results that demonstrated significant 
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changes in expression. A screening of the literature showed that other investigators have not 
performed these control experiments. 
 
Inflammatory mediators: 
The expression of TLR4, TLR2 and MYD88 was investigated (figure 3-30). Looking 
at the expression at all timepoints for all 3 TOF patients, there was no obvious pattern in 
expression. This mean the expression seen for these genes in the other experiments are due to 
the experimental environment the tissue was exposed to.  
 
Stress proteins: 
HSP20 and HSP27 did not show any particular trends in expression over incubation 
time (figure 3-31). HSP32 (figure 3-31) appeared to have an increase in expression at about 4-
6 hours of incubation. HSP72, HSP60 and HSP90 (figure 3-32) all appeared to have slight 
trend of increase as time of incubation increased. Such changes seen did not appear to be 
significant.  
 
The 6 hour time point relates to the HSP induction experiment 1 when looking at 
mRNA gene expression. HSP32, HSP72 and HSP90 were all induced upon exposure to heavy 
metal for 6 hours. Their induction was also increased in media only for 6 hours (control) but 
the degree by which the heavy metals increased expression was significantly higher than the 
increase in expression caused by the control. HSP32, HSP72 and HSP90 all increase with 
incubation time in this experiment (figure 3-31 and figure 3-32). This would draw into 
question whether or not the change in expression seen was due to the heavy metal exposure. 
The degree by which HSPs are increased by heavy metals compared to the gradual increase 
seen in this experiment by itself suggests that the heavy metal exposure was critical in 
increasing the expression of these HSPs. HSP32 seems to have a more immediate jump in 
expression at 4-6 hours in this experiment. When one compares the difference in RQ values 
seen for heavy metal induction of HSP32 when compared to the increase in RQ value of 
HSP32 in this experiment at 4-6 hours, there is a very distinct difference. This again supports 
that the heavy metals genuinely induced HSP expression in the infant myocardium. Although, 
the incubation time the tissue was exposed to cannot be disregarded as a factor. This is 
supported by the fact that for HSP32, HSP72 and HSP90, the tissue in media only also showed 
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a significant increase in expression after 6 hours. There was no heavy metal exposure of these 
tissues. 
 
Overall, this experiment was a very important control for all other experiments 
performed as it validated others results found in other experiments.  
 
4.8 Association of HSP-27 expression with improved RV function suggests a 
protective effect in cyanotic TOF 
Although TOF (see section 1.1.3) can present with a wide spectrum of clinical and 
anatomical variations, the tetrad of anatomical defects that are prominent in the condition are 
RV outflow tract obstruction, VSD, biventricular origin of the aortic valve and RV 
hypertrophy.  Early and late morbidity is related to the function of the right side of the heart 
which is exposed to increased pressure pre- and post-operatively. A larger VSD and outflow 
tract obstruction subjects the RV to chronic pressure overloading prior to surgery resulting in 
compromised function and slower recovery after repair (Wernovsky et al., 1995). Abnormal 
post-operative load within the ventricle, which can be due to residual lesions or pulmonary 
regurgitation, can lead to RV dilation, right heart failure, conductance disturbance, 
dysrhythmias and sudden death. Therefore, despite surgical repair, the patients may not be 
fully cured. This had led, over the last 50 years, to an expanding adult population with 
compromised right heart function (Davlouros et al., 2006).  
   
This study is important since it is one of few that have investigated HSP levels in 
human infant myocardium. The study was powered based on previous studies from our group 
(Peng et al., 2011). The major finding was that cyanotic TOF myocardium baseline HSP27 
levels (which close as possible represents pre-surgery status) was significantly increased 
compared to the non-cyanotic group and was also associated with better cardiac output/ 
contraction. Thus HSP27 may be important in myocardial protection. The cyanotic group have 
lower oxygen saturations and are more vulnerable than non-cyanotic patients. Interestingly 
this increase in HSP27 was not apparent in the tissue collected and combined after 15 minutes 
until the end of surgery (typically 15- 45 minutes). Whether this relates to protein stability, the 
surgical procedure or some other factor remains to be elucidated. Other possibilities are that as 
surgery time advances other protective mechanisms such as other protective HSPs are 
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increased to maintain protection. Also prior to surgery the myocardium from cyanotic and 
non-cyanotic groups were expose to different conditions (<15 minute group) whereas the >15 
minute group are all now exposed to the same O2 environment. Thus, even though after 15 
minutes the HSP27 levels are reduced, it may be that post-operative function is improved 
because of other protective mechanisms being switched on during the cross clamp time. These 
would include other protective HSPs or it may be that repair mechanisms have been set in 
place by the increase in HSP27 (to repair protein folding) and once this happens the HSP27 
declines. 
 
 An association of HSP27 was found with one out of the three echo ventricular function 
parameters (septal region) but not in the RV or LV free wall. This may be linked to the fact 
that the majority of muscle is removed from the septal area. 
 
 Despite a similar reduction in RV function in both groups the cyanotic group had 
higher troponin levels. Possible explanations are the longer cross-clamp and bypass time, more 
muscle resected, reduced myocardial protection or susceptibility to injury in the cyanotic 
group. Pediatric patients undergoing cardiac surgery have been shown to demonstrate greater 
susceptibility to IR injury and worse clinical outcome when cyanotic. 
 
 HSP27 (see section 1.6) is one of the most widely distributed of the small HSPs 
(Ghayour-Mobarhan et al., 2012).  Animal and cell culture models have shown that the roles 
of HSP27 include protein chaperone function, regulation of glutathione levels and apoptosis 
(Arrigo et al., 2007) and heart tube formation (Brown et al., 2007). Intracellular HSP27 
protects cells against external stress such as heat shock, mechanical and oxidative stress 
(Carper et al., 1997). HSP27 is also thought to be involved in an autoimmune response 
(Ghayour-Mobarhan et al., 2012). Like other small HSPs, HSP27 is regulated at both the 
transcriptional and post-translational level. HSP27 is phosphorylated by MAPKAP kinase 2 as 
a result of the activation of the p38 MAP kinase pathway (Arrigo et al., 2007). Since 
phosphorylated HSP27 is linked to actin-myosin interactions, it would be of interest in future 
studies to assess phosphorylated HSP27 and sarcomere structure in TOF. 
 
 Little is known about the role of HSP27 in the infant human heart. Most of the current 
knowledge has come from animal models or limited studies on adult cardiac disease. HSP27 
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expression has been shown to protect against myocardial infarction (Willis and Patterson, 
2010; Efthymiou et al., 2004) and is increased in rat LV myocardium after coronary ligation 
and in human patients with dilated cardiomyopathy (Knowlton et al., 1998). Studies on HSP27 
knockout mice have shown that, at least in this species, HSP27 is not essential for cardiac 
development but plays a role in the antioxidative response during IR injury (Willis and 
Patterson, 2010). HSP27 delivered with a virus vector into neonatal rat cardiomyoctes was 
shown to protect against apoptosis as well as against hypoxic stress (Brar et al., 1999) and 
modest increases in HSP27 have also been shown to protect against IR injury in dogs (Willis 
and Patterson 2010).  These studies suggest that HSP27 plays a role in antioxidant 
mechanisms during IR injury. 
 
 Studies on the cardio-protective roles of other HSPs in right heart function are limited 
but suggest HSP32 and HSP72 may be cardio-protective in the right heart (Willis and 
Patterson, 2010; Peng et al., 2011; Nakamura et al., 2000). As well as HSPs it may be that 
other mediators of delayed ischemic pre-conditioning may occur in the myocardium and these 
will be the focus of future investigation. These may include investigation of anti-oxidant 
enzymes such as superoxide dismustase, nitric oxide synthase and cyclooxygenase (reviewed 
in Eisen et al., 2004). 
 
 Drugs are now used to increase cellular HSPs as therapy for neurodegenerative 
diseases, which are caused by misfolded proteins (Nakamura et al., 2000). Such drugs, gene 
therapy procedures as well as remote pre-conditioning to increase HSPs prior to surgery may 
one day be used in congenital heart disease in children.  Before this can happen more studies 
such as the one herein are required to fully understand the role of HSPs in TOF. 
 
4.9 Association of APJ expression with improved right ventricle function 
suggests a protective effect in cyanotic TOF 
This is the first study to have shown evidence of APJ receptor expression in the early, 
infant myocardium. There has been extensive study into the expression and function of 
Apelin-APJ in the adult heart and its role in heart failure (Berry et al., 2004; Japp and Newby, 
2008; Chandrasekaran et al., 2010; Falcão-Pires et al., 2010; Japp et al., 2010; Tycinska et al., 
2012), but the characteristics of Apelin-APJ expression and function has never been 
established in the context of paediatric cardiac surgery for congenital heart defect repair. 
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Western blot analysis of the APJ receptor produced evidence that the APJ receptor is 
expressed in the RV of the infant myocardium. This analysis showed two band widths of sizes 
50 and 60kD. These bands correspond to the findings of Atluri et al showing the isolated APJ 
receptor at 50kD and the glycosylated receptor represented at 60kD (Atluri et al., 2007).  
This study has shown not only that the APJ receptor is expressed in the infant 
myocardium but also that expression of the phosphorylated APJ receptor increases as surgery 
progresses and, therefore, as time of cardioplegia and ischemia increases (figure- 3-40). These 
findings tie in with the hypothesis that ischemic conditions upregulate expression of APJ in 
the myocardium as part of a cardio-protective mechanism. Apelin-APJ expression being 
upregulated in this work could be considered part of a cardio-protective mechanism due to the 
physiological effects of Apelin (intropy, peripheral vasodilation and diuresis) taking strain off 
the heart and increasing cardiac output, as well as the known property of Apelin that it 
prevents myocardial damage through ischemia by reducing ER induced apoptosis (Tao et al., 
2011). It has been hypothesized in other studies of Apelin in surgery that it may function to 
restore the epithelium of arteries after cessation of ischemia (Du et al., 2010). This provides 
further evidence that expression of Apelin-APJ is induced by ischemic conditions and 
provides information on the stress the heart is subjected to when undergoing CPB. In future 
studies we will expose myocardium to ischemic stress in vitro and monitor changes on APJ 
expression and Apelin release.  
The rise in APJ expression as time in surgery progresses was not seen when each 
group, cyanotic and non-cyanotic, were looked at individually but was only seen when the 
entire patient pool was analysed together. There may be two reasons for this observation. 
Firstly, the sample size and power of the study may not have been sufficient to detect any 
differences in expression; as when the groups were separated the number of patients used in 
the calculation was smaller. Secondly, it could be hypothesized that the expression of APJ and 
changing expression of APJ is not related to pre-operative cyanotic status and is primarily a 
result of the ischemic stress and myocardial damage sustained by the myocardium during the 
procedure.  
4.9.1 SvO2 
APJ expression in the period of surgery after 10 minutes was correlated to an increased 
SvO2 (figure 3-41). SvO2 is affected by O2 uptake in the periphery, initial oxygenation of 
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blood and cardiac output. It can therefore be hypothesised that the increase in APJ expression 
after 10 minutes of surgery increased post-operative day 1 SvO2 by increasing cardiac output 
in the post-operative recovery. This conclusion can be drawn given that Apelin-APJ function 
increases cardiac contractility and reduces ischemia-induced myocardiocyte damage.  
4.9.2 Limitations 
One of the main limitations of this study is the sample size as it was a pilot study. The 
samples in this study were from the same patient pool that was used in a previous MD study 
(Peng, 2010). The samples of myocardium resected for this project were all from the RV or 
RVOT. It is not known whether the expression of APJ receptor in these areas is representative 
for the rest of the infant heart. It is however the RV which is most at risk of post-operative 
damage in this case and is therefore the most appropriate place of the myocardium to measure 
APJ expression as affected by the surgery.  
4.9.3 Conclusions 
The known physiological functions of Apelin-APJ have made the system a focus for 
exogenous treatment in the context of heart failure since its discovery (Berry et al., 2004; Japp 
and Newby, 2008; Chandrasekaran et al., 2010; Falcão-Pires et al., 2010; Japp et al., 2010; 
Tycinska et al., 2012). Successful clinical trials (Tatemoto et al., 2001) and a new non-peptide 
APJ receptor agonist being described (Iturroiz et al., 2010) suggest that exogenous Apelin 
treatment is a possibility in heart failure. This project, however, presents the new hypothesis 
that, pending further study, Apelin administration could be considered in the context of 
congenital heart defects and prophylactic cardioprotection for surgical repair involving CPB.  
Apelin-13 administration increases cardiac performance and protects the heart from 
damage in severe, end stage heart failure in mice (Koguchi et al., 2012), a time of ischemia 
and strain on the myocardium. CPB during correction of TOF induces comparable, if not 
similar, levels of cardiac stress (Allen et al., 1997). An animal model capable of reproducing 
the conditions of a CPB could further our knowledge of the potential benefit of Apelin-APJ 
function in a procedure of this nature.  
For the first time, this thesis shows evidence that the APJ receptor is expressed in the 
infant human heart. The role of Apelin-APJ function is not fully understood in the context of 
TOF and surgery involving CPB. However, this study has shown that the stress and ischemic 
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conditions of such surgery can increase the expression of phosphorylated APJ receptor in the 
cells of the RV. There is also a correlation between increased levels of phosphorylated APJ 
receptor and a measure of improved clinical post-op recovery (SvO2). There is much study 
needed in the area of Apelin-APJ function, however this project indicates a role for Apelin and 
APJ as a marker of ischemia-induced cardiac damage, as well as a potential therapeutic target 
for improving post-operative cardiac function. This warrants further investigation. 
4.10 Concluding remarks 
The primary aim of this project was to investigate the molecular changes that occur 
within the infant myocardium in the context of congenital heart disease by comparing cyanotic 
and acyanotic myocardium during the ischemic phase. The myocardium of children with 
cyanotic heart defects is exposed to chronic hypoxia whereas those with acyanotic defects are 
not. The study of these molecular mechanisms was also examined in vitro by attempting to 
mimic the re-oxygenation of the myocardium which occurs when the aortic-clamp is removed 
during surgery. In these procedures, the child is often exposed to high levels of O2. The effect 
of these high O2 concentrations on the myocardial molecular mechanisms in both the cyanotic 
and acyanotic patients groups were also looked at. This thesis focused on the expression of 
inflammatory mediators and stress proteins i.e. TLRs (see section 1.4) and HSPs (see section 
1.6). Additional genes were also investigated, including the ER stress protein GRP78 (see 
section 3.4) and APJ (see section 3.5 and 3.6). 
 
 Initially the expression of these genes during the ischemic phase of corrective cardiac 
surgery was examined. This was performed to reflect as near to pre-operative gene expression 
levels as possible. The expression of these genes within myocardium in the two patient groups 
was compared. Expression of TLR4 (p=0.0303), TLR2 (p=0.0177) and HSP27 (0.0303) was 
significantly higher in cyanotic patient myocardium. This could indicate a consequence of the 
hypoxic environment to which the myocardium was exposed. 
 
 With regards to re-oxygenation injury of ischemic myocardium, exposure to 20% and 
60% O2 for 4 hours significantly induced mRNA expression of HSP32 (p=0.0391 and 
p=0.0078 respectively) and HSP72 (p=0.0078 and p=0.0078 respectively). This could indicate 
cellular stress during re-oxygenation of infant myocardium during surgical correction. These 
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changes were seen in both groups and no difference was found between the cyanotic and 
acyanotic patient group.  
 
This project is mainly a scientific investigation. The changes seen are not related to 
any clinical data that describes cardiac function or contraction. Therefore, the molecular 
findings can only be looked at in the context in which the experiments were carried out. This 
is not the case for the investigation of HSP27 and APJ protein expression in TOF myocardium 
over ischemic time (see sections 3.7 and 3.8 respectively), which did relate to findings of 
clinical outcome. 
 
The experiments, within this thesis examined myocardial gene and protein expression 
only. Whether factors within the systemic circulation are altered requires further investigation. 
Therefore, the myocardial inflammation that is seen during cardiac surgery on bypass may be 
caused by exposure to other circulating factors as re-oxygenation in vitro only affected some 
HSPs but not the inflammatory mediators studied.  
 
Therefore it was important to do the work within this thesis in the controlled in vitro 
environment as the results obtained give initial insight into inflammatory changes and 
highlighted the need for future studies to look at the effect of circulating factors on myocardial 
inflammation. Incubating the myocardium with blood from the CPB unit could potentially 
address many of these issues, as this would contain biological factors that could influence the 
activation of certain genes of interest. Also, a comparison between clinical data about cardiac 
function and contraction and the differential expression of our genes of interest would allow 
the scientific findings more clinically relevant. 
 
This project is novel because it looked at the expression of inflammatory mediators 
and stress proteins within the infant myocardium and how these genes were influenced by re-
oxygenation injury. It also examined how such expression was affected by cyanosis. Despite 
the lack of correlation to cardiac functional data, this project allowed a better understanding 
about how these genes are expressed in the myocardium alone and how re-oxygenation can 
affect them. It has also highlighted the best ways in which such investigations could be 
extended. It has contributed important molecular data to the area of research and could 
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potentially help lead to an improvement in myocardial protection during cardiac surgery with 
CPB. 
 
4.11 Plans for the future 
Overall, some general potential future plans for this project include the following:  
• Increase the patient numbers to increase the accuracy of results and look for 
more subtle changes. 
• Include different and more time points of tissue incubation to enhance the data 
already recorded.  
• Include more investigation of differential expression at the protein level to 
enhance the molecular data collected.  
• Using different and more complex media including blood particularly taken 
from the infant during surgery at differing time points. 
Reoxygenation at hyperoxic levels was the main focus and the project. Given more 
time, a bigger sample base would allow a more in depth investigation into the 
differences in expression between cyanotic and acyanotic myocardium than was 
possible during this project.  Also, during these experiments, the ischemic tissue was 
exposed to high levels of O2 in media only and therefore the tissue was not exposed to 
an active circulation. Therefore it would have been interesting to expose tissue to 
media supplemrnted with blood cardioplegia to try and determine if this would 
represent a more physiological state. This project highlighted the likelihood of such 
myocardial exposure as a possible source of inflammation. Therefore investigation into 
measuring circulating inflammaorty factors within the systemic circulation of patients 
(such as pro-inflammatory cytokines and circulating HSPs) that have tissue excised 
would allow the scientific data obtained to be compared to clinical information. 
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Appendices  
1. Information sheets 
1.1 Information sheet for TOF patient group: 
 
PARENT/GUARDIAN INFORMATION SHEET – VERSION 3 (08/10/09) 
 
PART ONE 
1. Study title: 
Myocardial protein expression in children undergoing cardiac surgery (Full title: Myocardial 
cellular adaption to ischemia−reperfusion in children undergoing cardiac surgery: an 
integrated clinical and scientific approach to understand the molecular mechanisms involved). 
 
2. Invitation paragraph 
Your child is being invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
 
• Part 1 tells you the purpose of this study and what will happen during the study   
• Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more information.  Take time 
to decide whether or not you wish to take part. 
 
3. What is the purpose of the research project? 
To investigate how the heart muscle in children with congenital heart disorders functions caused during 
corrective heart surgery by looking at the expression of certain cellular proteins. By understanding 
the possible underlying mechanisms occurring in such children, we hope in the future to 
improve the protective methods employed during surgery and improve post-operative patient 
outcome. 
 
4. Why has my child been chosen? 
Your child has a heart condition called Tetralogy of Fallot (TOF), which is characterised by an 
obstruction to blood flow from the right side of the heart to the lungs (right ventricular outflow 
tract obstruction) and by blood flow between the two main pumping chambers of the heart, 
which is usually absent (ventricular septal defect). Patients with TOF have high pressure and 
low oxygen levels in the blood within the right ventricle of their heart, which can cause an 
impairment of heart contraction. Investigating the underlying mechanisms that occur in TOF 
could help improve our understanding and management of such conditions. 
 
5. Does my child have to take part? 
NO.  It is up to you and your child (wherever possible) to decide whether or not to take part.  
You are both free to withdraw from the research at any time and without giving a reason. 
Your decision about this will not affect the standard of care your child will receive. If you are 
happy for your child to take part, and are satisfied with the explanations, you will be asked to 
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sign a consent form. You will be given a copy of the signed consent form to keep for your 
records.  
 
6. What does my child have to do if we agree to take part? 
This study will not alter the routine care of your child before, during or after the surgery. Your 
child will receive routine tests, which are normally performed prior to surgery, one day post 
surgery and before discharge from hospital. These include a test called an echo, which is a 
type of ultrasound that looks into the heart without using any radiation, similar to an 
ultrasound test which a mum obtains during pregnancy. The echo assessment will be more 
detailed to include a special mode to analyse the heart wall movement. This may take 
approximately 5-10 minutes longer than the usual examination.  Also routine heart tracing will 
be done, where an electrical recording of the heart beat is taken to ensure that the heart is 
working properly. 
During your child’s surgery, removal of heart muscle tissue is routinely undertaken as part of 
the standard procedure to relieve obstruction in the right heart chamber to restore normal 
blood flow to the lungs. Such tissues are not normally retained for laboratory investigation, 
but will be for use in this study. 
Apart from routine blood sampling, additional tests will be performed for cardiac hormone 
analysis. The child will not need an additional needle prick as the samples will be obtained 
during routine blood sampling. At the times when blood will be routinely be taken from your 
child for normal clinical purposes, 2 extra teaspoons of blood will be taken at 4 different times 
over the 48 hours when the surgical/ general patient care of your child takes place. 
Your child will remain part of the study until the day of discharge (5 – 7 days) or up to 1 week 
following the surgery. 
 
7.  What are the possible benefits of taking part? 
A more detailed and more frequent echocardiography assessment of the heart function will 
be performed for every participant. As this study does not alter the surgical or clinical care of 
your child, we do not anticipate any potential complications beyond that expected of the 
normal surgical treatment of your child’s condition.  
 
8.  What happens when the research stops? 
Your child participation ends when the research stops. There is no further responsibility 
involved. It should be noted that the tissue taken from your child may be kept for use in future 
research. 
 
9. Who can I contact for further information? 
If you require any further information on this study or will like to clarify any issues, please do 
not hesitate to contact us. Our contacts are as follows: 
• Mr Mark Danton, Consultant Cardiac Surgeon, Yorkhill (01412010251) 
• Miss Susan Walker, PhD student, University of Glasgow (01412010367) 
• Dr W. B. Knight, Consultant Cardiac Surgeon, Yorkhill 
(brodie.knight@yorkhill.scot.nhs.uk) 
 
This completes Part 1 of the Information Sheet.  If the information in Part 1 has 
interested you and you are considering participation, please continue to read the 
additional information in Part 2 before making any decision. 
 
PART TWO 
1. What if relevant new information becomes available?   
Any new and relevant information that is obtained from this study will be made available to 
the clinicians who are responsible for your child’s routine care. 
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2. What will happen if my child or I don’t want to carry on with the research? 
Your child will still receive the standard, routine clinical care. 
 
3. What if there is a problem? 
Any complaint about the way you or your child have been dealt with during the study or any 
possible harm you might suffer will be addressed. If you have a concern about any aspect of 
this study, you should ask to speak with the researchers who will do their best to answer your 
questions (Department of Cardiac Surgery, phone number: 201 0251 or 201 0090). If you 
remain unhappy and wish to complain formally, you can do this through the normal NHS 
Complaints Procedure that will be available to you.   
In the event that something does go wrong and your child is harmed during the research 
study there are no special compensation arrangements.  If your child is harmed and this is 
due to someone’s negligence then you may have grounds for a legal action for compensation 
but you may have to pay your legal costs. 
 
4. Will my child’s taking part in the research project be kept confidential?  
All personal information which is collected during the study will be kept strictly confidential. 
Your child’s medical records and the data collected for the study will be looked at by 
authorised persons.  We will have a duty to protect your child’s confidentiality as a research 
participant and nothing that could reveal your child identity will be disclosed outside the 
research site. 
 
5. What will happen to any samples my child gives? 
The confidentiality of the sample will be protected.  The heart muscle tissue removed during 
surgery will be analysed in the laboratory for levels of certain cellular proteins which are 
thought to give normal heart tissues protection injury caused during heart surgery.  
 
6. Will any genetic tests be done? No. 
 
7. What will happen to the results of the research study? 
The principal aim of the research is to improve our understanding of how the heart muscle in 
children with congenital heart disorders functions during corrective heart surgery. We plan to 
publish our results in peer-reviewed journal as well as present the findings in local and 
international meetings. Your child’s identity will be protected in any report. 
 
8. Who is organising and funding the research?   
This study received funding from the Yorkhill Hospital Children’s Foundation for a 3 year PhD 
project, conducted in the University of Glasgow. 
 
9. Who has reviewed the study?  
This study was given formal ethical approval by the West of Scotland Research Ethics 
Committee 2 based in Western Infirmary, Glasgow. 
 
Parents of children participating in this study will be given a copy of the information 
sheet and a signed consent form to keep.  
 
Thank you for taking time to read this information sheet.  
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1.2 Information sheet for control patient group: 
 
PARENT/GUARDIAN INFORMATION SHEET – VERSION 4 (08/10/09) 
 
PART ONE 
 
1. Study title: 
Myocardial protein expression in children undergoing cardiac surgery (Full title: Myocardial 
cellular adaption to ischemia−reperfusion in children undergoing cardiac surgery: an 
integrated clinical and scientific approach to understand the molecular mechanisms involved). 
 
2. Invitation paragraph 
Your child is being invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
 
• Part 1 tells you the purpose of this study and what will happen during the study   
• Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more information.  Take time 
to decide whether or not you wish to take part. 
 
3. What is the purpose of the research project? 
To investigate how the heart muscle in children with congenital heart disorders functions 
during corrective heart surgery by looking at the expression of certain cellular proteins. By 
understanding the possible underlying mechanisms occurring in such children, we hope in the 
future to improve the protective methods employed during surgery and improve post-
operative patient outcome. 
 
4. Why has my child been chosen? 
Your child has a heart condition called subaortic stenosis (narrowing of the left ventricular 
outflow tract, which obstructs blood from leaving the heart). As part of the standard surgical 
operation, a piece of muscle is removed to minimise the recurrence of this condition. This 
muscle tissue is not usually kept but we would like to retain this muscle specimen for protein 
analysis as part of a wider clinical investigation. Your child will be part of a control group for 
this study and any tissue you allow to be used will be a gift to others, with no direct benefits to 
your child.  
 
5. Does my child have to take part? 
NO.  It is up to you and your child (wherever possible) to decide whether or not to take part.  
You are both free to withdraw from the research at any time and without giving a reason. 
Your decision about this will not affect the standard of care your child will receive. If you are 
happy for your child to take part, and are satisfied with the explanations, you will be asked to 
sign a consent form. You will be given a copy of the signed consent form to keep for your 
records.  
 
6. What does my child have to do if we agree to take part? 
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This study will not alter the routine care of your child before, during or after the surgery. Your 
child will receive routine tests, which are normally performed prior to surgery, one day post 
surgery and before discharge from hospital. These include a test called an echo, which is a 
type of ultrasound that looks into the heart without using any radiation, similar to an 
ultrasound test which a mum obtains during pregnancy. The echo assessment will be more 
detailed to include a special mode to analyse the heart wall movement. This may take 
approximately 5-10 minutes longer than the usual examination.  Also routine heart tracing will 
be done, where an electrical recording of the heart beat is taken to ensure that the heart is 
working properly. 
During your child’s surgery, removal of heart muscle tissue is routinely undertaken as part of 
the standard procedure to relieve obstruction in the left heart chamber to restore normal 
blood flow to the rest of the body. Such tissues are not normally retained for laboratory 
investigation, but will be for use in this study.  
Apart from routine blood sampling, additional tests will be performed for cardiac hormone 
analysis. The child will not need an additional needle prick as the samples will be obtained 
during routine blood sampling. At the times when blood will be routinely be taken from your 
child for normal clinical purposes, 2 extra teaspoons of blood will be taken at 4 different times 
over the 48 hours when the surgical/ general patient care of your child takes place. 
Your child will remain part of the study until the day of discharge (5 – 7 days) or up to 1 week 
following the surgery. 
 
7.  What are the possible benefits of taking part? 
A more detailed and more frequent echocardiography assessment of the heart function will 
be performed for every participant. As this study does not alter the surgical or clinical care of 
your child, we do not anticipate any potential complications beyond that expected of the 
normal surgical treatment of your child’s condition.  
 
8.  What happens when the research stops? 
Your child participation ends when the research stops. There is no further responsibility 
involved. It should be noted that the tissue taken from your child may be kept for use in future 
research. 
 
9. Who can I contact for further information? 
If you require any further information on this study or will like to clarify any issues, please do 
not hesitate to contact us. Our contacts are as follows: 
• Mr Mark Danton, Consultant Cardiac Surgeon, Yorkhill (01412010251) 
• Miss Susan Walker, PhD student, University of Glasgow (01412010367) 
• Dr W. B. Knight, Consultant Cardiac Surgeon, Yorkhill 
(brodie.knight@yorkhill.scot.nhs.uk) 
 
This completes Part 1 of the Information Sheet.  If the information in Part 1 has 
interested you and you are considering participation, please continue to read the 
additional information in Part 2 before making any decision. 
 
PART TWO 
1. What if relevant new information becomes available?   
Any new and relevant information that is obtained from this study will be made available to 
the clinicians who are responsible for your child’s routine care. 
 
2. What will happen if my child or I don’t want to carry on with the research? 
Your child will still receive the standard, routine clinical care. 
 
3. What if there is a problem? 
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Any complaint about the way you or your child have been dealt with during the study or any 
possible harm you might suffer will be addressed. If you have a concern about any aspect of 
this study, you should ask to speak with the researchers who will do their best to answer your 
questions (Department of Cardiac Surgery, phone number: 80251/80090). If you remain 
unhappy and wish to complain formally, you can do this through the normal NHS Complaints 
Procedure that will be available to you.   
In the event that something does go wrong and your child is harmed during the research 
study there are no special compensation arrangements.  If your child is harmed and this is 
due to someone’s negligence then you may have grounds for a legal action for compensation 
but you may have to pay your legal costs. 
 
4. Will my child’s taking part in the research project be kept confidential?  
All personal information which is collected during the study will be kept strictly confidential. 
Your child’s medical records and the data collected for the study will be looked at by 
authorised persons. We will have a duty to protect your child’s confidentiality as a research 
participant and nothing that could reveal your child identity will be disclosed outside the 
research site. 
 
5. What will happen to any samples my child gives? 
The confidentiality of the sample will be protected.  The heart muscle tissue removed during 
surgery will be analysed in the laboratory for levels of certain cellular proteins which are 
thought to give normal heart tissues protection injury caused during heart surgery.  
 
6. Will any genetic tests be done? No. 
 
7. What will happen to the results of the research study? 
The principal aim of the research is to improve our understanding of how the heart muscle in 
children with congenital heart disorders functions during corrective heart surgery. We plan to 
publish our results in peer-reviewed journal as well as present the findings in local and 
international meetings. Your child’s identity will be protected in any report. 
 
8. Who is organising and funding the research?   
This study received funding from the Yorkhill Hospital Children’s Foundation for a 3 year PhD 
project, conducted in the University of Glasgow. 
 
9. Who has reviewed the study?  
This study was given formal ethical approval by the West of Scotland Research Ethics 
Committee 2 based in Western Infirmary, Glasgow. 
 
Parents of children participating in this study will be given a copy of the information 
sheet and a signed consent form to keep.  
 
Thank your for taking time to read this information sheet.   
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2. Consent form: 
 
Consent form – Version 2 (08/10/09) 
 
 
 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project: Myocardial protein expression in children undergoing cardiac 
surgery 
(Full title: Myocardial cellular adaption to ischemia−reperfusion in children undergoing cardiac surgery: 
an integrated clinical and scientific approach to understand the molecular mechanisms involved). 
 
Name of Researchers: Dr. Mark Danton (CI) and Miss Susan Walker (PI)  
 Please initial box 
1. I confirm that I have read and understand the information sheet dated 08-10-
09 of the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
 
2. I understand that my child’s participation is voluntary and that my child is free 
to withdraw at any time, without giving any reason, without his or her medical 
care or legal rights being affected.  
 
 
3.  I understand that relevant sections of any of my child’s medical notes and 
data collected during the study may be looked at by responsible individuals 
from regulatory authorities, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my 
records.                                       
 
 
4.   I agree to take part in the above study.  
                              
________________________ ________________ ____________________ 
Name of Parent   Date Signature 
 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
(if different from researcher) 
 
_________________________ ________________ ____________________ 
Researcher   Date  Signature 
 
1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes 
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3. Ethical approval 
3.1 Approval from R and D: 
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3.2 REC approval: 
West of Scotland REC 2 
Western Infirmary 
Ground floor, Tennent Institute 
38 Church Street 
Glasgow G11 6NT 
 
Telephone: 0141 211 2123  
Facsimile: 0141 211 1847 
27 October 2009 
 
Dr Mark Danton 
Consultant Cardiac Surgeon 
Royal Sick Children Hospital  
Dept Cardiac Surgery 
Dalnair Street 
Glasgow G3 8SJ 
 
Dear Dr Danton 
 
Full title of study: Myocardial cellular adaption to ischemia-reperfusion in 
children undergoing cardiac surgery: an integrated 
clinical and scientific approach to understand the 
molecular mechanisms involved. 
REC reference number: 09/S0709/61 
Protocol number: 2 
 
Thank you for the email from Susie Walker 12th October. I can confirm the REC has received 
the documents listed below as evidence of compliance with the approval conditions detailed 
in our letter dated 15 September 2009. Please note these documents are for information only 
and have not been reviewed by the committee. 
 
Documents received 
 
The documents received were as follows: 
  
Document    Version    Date      
Protocol  Version 2  12 October 2009    
Covering Letter – by email   12 October 2009    
Participant Information Sheet: Subaortic Stenosis  Version 4  08 October 2009    
Participant Information Sheet: Tetralogy of Fallot (TOF)  Version 3  08 October 2009    
Participant Consent Form  Version 2  08 October 2009    
 
You should ensure that the sponsor has a copy of the final documentation for the study.  It is 
the sponsor's responsibility to ensure that the documentation is made available to R&D 
offices at all participating sites. 
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09/S0709/61 Please quote this number on all correspondence 
Yours sincerely 
 
Liz Jamieson 
Committee Co-ordinator 
E-mail: Liz.Jamieson@ggc.scot.nhs.uk 
Copy to: R&D office for NHS care organisation at lead site] 
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4. List of reagents	  	  
Supplemented media for tissue culture (see section 2.2, 2.3 and 2.4): 
• Medium 199 (With Earle′s salts, L-glutamine and sodium bicarbonate, liquid, sterile-
filtered, cell culture tested) (Sigma, cat. no. M4530-100ML 
• 5% fetal bovine serum (heat inactivated) (Sigma-Aldrich, cat. no. F9665) 
• 1% antibiotic antimycotic solution. (Sigma-Aldrich, cat. no. A5955) 
 
Supplemented media for HSP induction tissue culture (see section 2.4: 
• Medium 199 (With Earle′s salts, L-glutamine and sodium bicarbonate, liquid, sterile-
filtered, cell culture tested) (Sigma, cat. no. M4530-100ML 
• 5% fetal bovine serum (heat inactivated) (Sigma-Aldrich, cat. no. F9665) 
• 1% antibiotic antimycotic solution. (Sigma-Aldrich, cat. no. A5955) 
• 100µM/l of sodium arsenite (NaAsO2) (Sigma, cat. no  35000-1L-R) or 100µM/l of 
cadmium chloride (CdCl2) (Sigma, cat. no. 28811-1ML-F) 
 
Reagents for homogenization of tissue (see section 2.11.1): 
• Homogenising buffer plus protease inhibitor cocktail in 1 litre: 
§ + 500ml H20 
§ + 3.02g Tris (25mM) (121.14g/mol) (Sigma-Aldrich, cat. no. 93352) 
§ + 0.4g EDTA (1mM) (372.24g/mol) (Sigma-Alrich, cat. no. E6758) 
§ 85.6g Sucrose (250mM) (342.3g/mol) (Sigma-Aldrich, cat. no. S9378) 
§ Make up 1 litre with dH2O 
§ Store at 4° C 
o Add 20ml (or 10ml if less samples) of buffer to a sterile universal container. 
o To this add a 250µl (or 125ul) aliquot of protease inhibitor cocktail 
immediately prior to use(Sigma-Aldrich, cat. no. P8340-5ML) 
	  
Reagents for Bradford Assay (see section 2.11.2): 
• Bovine Serum Albumin (BSA) stock standard solution of for Bradford Assay 
o 1mg per ml of BSA (Sigma cat. no. A7906-50G). 
o 10mg BSA in 10ml H2O. 
	  
Reagents for Western blotting (see section 2.12): 
• Sample loading buffer (2x): 
o 1.2ml (1M) Tris (Sigma-Aldrich, cat. no. 93352) 
o 2ml glycerol (Sigma-Aldrich, cat. no. G2025) 
 
 
290 
o 4ml (10% ) sodium dodecyl sulfate (SDS) (Sigma-Aldrich, cat. no. 35000) 
o 2ml (1M) dithiothreitol (Sigma-Aldrich, cat. no. 646563) 
o 0.8ml dH20 
o Bromophenol blue (solid) – add a small amount, add more if needed (Sigma-
Aldrich, cat. no. B0126-25G) 
	  
• Buffer for resolving gel (pH 8.8) (in 1 litre): 
o In a 1litre bottle with stirring bar add 500ml dH20 
o Add 181.65g of Tris (Sigma-Aldrich, cat. no. 93352), shake to dissolve (will 
increase volume) 
o Add 40 ml of 10% SDS (Sigma-Aldrich, cat. no. 35000) (final conc. of 0.4% in 
1litre) slowly, allowing it to dissolve 
o pH buffer (5M HCl) 
o Add dH20 to create a final vol. of 1l (black line) 
	  
• Buffer for stacking gel (pH 6.8) (in 1 litre): 
o In a 1litre bottle with stirring bar add 500ml dH20 
o Add 60.55g of Tris, shake to dissolve (will increase volume) 
o Add 40 ml of 10% SDS solution (final conc. of 0.4% in 1litre) slowly, allowing 
it to dissolve 
o pH buffer (5M HCl) 
o Add dH20 to create a final vol. of 1l (black line) 
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• Composition of resolving and stacking gels: 
	  
Reagent Resolving Gel (2 
gels) (10%) 
Stacking gel (2 
gels) (4%) 
 Volume  2/ 1 gel Volume 
30% acrylamide/ 
bis- acrylamide 
24ml or 12ml 2.7ml 
50% glycerol 4.8ml or 2.4ml n/a 
Buffer A 18ml or 9ml n/a 
Buffer B n/a 5ml 
Distilled water 24.8ml or 12.4ml 12.2ml 
10% APS 360µl or180ul 100µl 
TEMED 36µl or 18ul 20µl 
Total 36x2ml 20ml 
   
• 10% ammonium persulfate (APS) solution (in table above): 
o Measure 1ml of dH20 
o Add 0.1g of ammonium persulpahte (Sigma-Aldrich, cat. no. A3678) 
o Allow to dissolve 
 
• Running buffer (5x) (pH 8.3) (in 4 litre): 
o Get 3litre of dH2O 
o Add 60.4g of Tris 
o Add 288g of glycine  
o Add 200ml of 10% SDS solution 
o pH buffer (5M HCl) 
o Make up final vol. of 4 litres with dH2O 
o Dilute 500ml pf running buffer (5x) in 2 litres of dH2O when using for assay 
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Reagents for transfer of proteins to nitrocellulose (see section 2.12.2) 
• Transfer buffer in 1 litre (pH 7.5): 
o 800ml H20 
o 3g (25mM) Tris 
o 14.4g (190 mM) glycine  
o 200ml (20%) methanol then shake till all has dissolved in solution  
	  
• 0.1% NaOH: 
o 0.1g NaOH (Sigma-Aldrich, cat. no. 655104) in 100ml dH20 
	  
Reagents for immuno-detection of proteins (see section 2.12.3): 
• TBSTB (in 1 litre) (pH 7.5): 
o Retrieve 800ml of dH20. 
o Add 2.4g Tris (20 mM) then shake. 
o pH buffer (Plus 3ml 5M HCl). 
o Add 29.2g  NaCl (0.5 M) then shake. 
o Add 4ml Tween20 (Sigma-Aldrich, cat. no. P1379) 
o Add 2.5g BSA (0.25%) (Sigma-Aldrich, cat. no. A7906) then shake. 
o Add dH2O to make up the final 1 litre volume. 
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